The	O
CD9	O
,	O
CD81	O
,	O
and	O
CD151	O
EC2	O
domains	O
bind	O
to	O
the	O
classical	O
RGD-binding	O
site	O
of	O
integrin	O
αvβ3	O
.	O

Tetraspanins	O
play	O
important	O
roles	O
in	O
normal	O
(	O
e.g.	O
,	O
cell	O
adhesion	O
,	O
motility	O
,	O
activation	O
,	O
and	O
proliferation	O
)	O
,	O
and	O
pathological	O
conditions	O
(	O
e.g.	O
,	O
metastasis	O
and	O
viral	O
infection	O
)	O
.	O

Tetraspanins	O
interact	O
with	O
integrins	O
and	O
regulate	O
integrin	O
functions	O
,	O
but	O
the	O
specifics	O
of	O
tetraspanin	O
-	O
integrin	O
interaction	O
are	O
unclear	O
.	O

Using	O
co-immunoprecipitation	B-P
with	O
integrins	O
as	O
a	O
sole	O
method	O
to	O
detect	O
interaction	O
between	O
integrins	O
and	O
full-length	O
tetraspanins	O
,	O
it	O
has	O
been	O
proposed	O
that	O
the	O
variable	O
region	O
(	O
helices	O
D	O
and	O
E	O
)	O
of	O
the	O
extracellular-2	O
(	O
EC2	O
)	O
of	O
tetraspanins	O
laterally	O
associate	O
with	O
non-ligand-binding	O
site	O
of	O
integrins	O
.	O

We	O
describe	O
that	O
,	O
using	O
adhesion	O
assays	B-P
,	O
the	O
EC2	O
domain	O
of	O
CD81	O
,	O
CD9	O
,	O
and	O
CD151	O
bound	O
to	O
integrin	O
αvβ3	O
and	O
this	O
binding	O
was	O
suppressed	O
by	O
cRGDfV	O
,	O
a	O
specific	O
inhibitor	O
of	O
αvβ3	O
,	O
and	O
antibody	O
7E3	O
that	O
is	O
mapped	O
to	O
the	O
ligand-binding	O
site	O
of	O
β3	O
.	O

We	O
also	O
present	O
evidence	O
that	O
the	O
specificity	O
loop	O
of	O
β3	O
directly	O
bound	O
to	O
the	O
EC2	O
domains	O
.	O

This	O
suggests	O
that	O
the	O
EC2	O
domains	O
specifically	O
binds	O
to	O
the	O
classical	O
ligand-binding	O
site	O
of	O
αvβ3	O
.	O

αvβ3	O
was	O
a	O
more	O
effective	O
receptor	O
for	O
the	O
EC2	O
domains	O
than	O
previously	O
known	O
tetraspanin	O
receptors	O
α3β1	O
,	O
α4β1	O
,	O
and	O
α6β1	O
.	O

Docking	O
simulation	O
predicted	O
that	O
the	O
helices	O
A	O
and	O
B	O
of	O
CD81	O
EC2	O
binds	O
to	O
the	O
RGD-binding	O
site	O
of	O
αvβ3	O
.	O

Substituting	O
Lys	O
residues	O
at	O
position	O
116	O
,	O
144/148	O
of	O
CD81	O
EC2	O
in	O
the	O
predicted	O
integrin	O
-	O
binding	O
interface	O
reduced	O
the	O
binding	O
of	O
CD81	O
EC2	O
to	O
αvβ3	O
,	O
consistent	O
with	O
the	O
docking	O
model	O
.	O

These	O
findings	O
suggest	O
that	O
,	O
in	O
contrast	O
to	O
previous	O
models	O
,	O
the	O
ligand-binding	O
site	O
of	O
integrin	O
αvβ3	O
,	O
a	O
new	O
tetraspanin	O
receptor	O
,	O
binds	O
to	O
the	O
constant	O
region	O
(	O
helices	O
A	O
and	O
B	O
)	O
of	O
the	O
EC2	O
domain	O
.	O

A	O
quantitative	O
method	O
for	O
the	O
assessment	O
of	O
dysarthrophonia	O
in	O
myasthenia	O
gravis	O
.	O

Speech	O
and	O
voice	O
symptomatology	O
(	O
dysarthrophonia	O
)	O
are	O
often	O
reported	O
by	O
patients	O
with	O
myasthenia	O
gravis	O
(	O
MG	O
)	O
.	O

However	O
,	O
they	O
have	O
been	O
poorly	O
investigated	O
despite	O
their	O
significant	O
impact	O
on	O
quality	O
of	O
life	O
.	O

Quantitative	O
methods	O
for	O
the	O
assessment	O
of	O
dysarthrοphonia	O
could	O
facilitate	O
the	O
evaluation	O
of	O
these	O
common	O
MG	O
symptoms	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
phonatory	O
(	O
sustained	O
phonation	O
and	O
reading	O
)	O
and	O
speech	O
(	O
diadochokinesis	O
)	O
function	O
in	O
MG	O
patients	O
using	O
quantitative	O
measures	O
.	O

The	O
voice	O
/	O
speech	O
of	O
12	O
MG	O
patients	O
(	O
7	O
with	O
anti-AchR	O
and	O
5	O
with	O
anti-MuSK	B-P
antibodies	I-P
)	O
and	O
24	O
age-matched	O
healthy	O
controls	O
was	O
recorded	O
and	O
analyzed	O
using	O
electroglottography	B-P
(	O
EGG	B-P
)	O
and	O
speech	O
acoustics	O
.	O

For	O
the	O
analysis	O
of	O
voice	O
,	O
the	O
variables	O
that	O
were	O
found	O
to	O
distinguish	O
MG	O
patients	O
compared	O
to	O
healthy	O
controls	O
were	O
a	O
higher	O
average	O
fundamental	O
frequency	O
(	O
P	O
<	O
0.05	O
)	O
,	O
a	O
higher	O
standard	O
deviation	O
of	O
the	O
average	O
fundamental	O
frequency	O
(	O
P	O
<	O
0.001	O
)	O
,	O
a	O
higher	O
mean	O
fundamental	O
frequency	O
of	O
the	O
vibrating	O
vocal	O
folds	O
(	O
P	O
<	O
0.005	O
)	O
and	O
a	O
higher	O
fundamental	O
frequency	O
range	O
(	O
P	O
<	O
0.005	O
)	O
.	O

The	O
analysis	O
of	O
diadochokinesis	O
showed	O
that	O
MG	O
patients	O
had	O
a	O
higher	O
mean	O
duration	O
of	O
the	O
silent	O
interval	O
between	O
a	O
series	O
of	O
repetitive	O
/pa/	O
syllables	O
(	O
P	O
<	O
0.05	O
)	O
,	O
of	O
the	O
sound	O
/t/	O
(	O
P=0.05	O
)	O
and	O
of	O
the	O
silent	O
interval	O
between	O
a	O
series	O
of	O
repetitive	O
/ka/syllables	O
(	O
P	O
<	O
0.05	O
)	O
.	O

No	O
statistical	O
differences	O
were	O
found	O
in	O
any	O
of	O
these	O
variables	O
between	O
the	O
MG	O
subgroups	O
with	O
anti-AchR	O
or	O
anti-MuSK	B-P
antibodies	I-P
.	O

This	O
study	O
demonstrates	O
that	O
non-invasive	O
physiological	O
methods	O
(	O
EGG	B-P
and	O
speech	O
acoustics	O
)	O
offer	O
essential	O
tools	O
for	O
the	O
assessment	O
of	O
dysarthrophonia	O
in	O
MG	O
patients	O
.	O

Decreased	O
Frequencies	O
of	O
Peripheral	O
Blood	O
CD4+CD25+CD127-Foxp3+	O
in	O
Patients	O
with	O
Graves	O
'	O
Disease	O
and	O
Graves	O
'	O
Orbitopathy	O
:	O
Enhancing	O
Effect	O
of	O
Insulin	O
Growth	O
Factor-1	O
on	O
Treg	O
Cells	O
.	O

Graves	O
'	O
orbitopathy	O
(	O
GO	O
)	O
is	O
characterized	O
by	O
orbital	O
T	O
cell	O
infiltration	O
.	O

We	O
evaluated	O
the	O
regulatory	O
T	O
(	O
Treg	O
)	O
cell	O
fractions	O
induced	O
with	O
IGF-1	O
in	O
Graves	O
'	O
disease	O
(	O
GD	O
)	O
with	O
and	O
without	O
GO	O
.	O

Peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
were	O
obtained	O
from	O
13	O
patients	O
with	O
GD	O
without	O
eye	O
manifestations	O
;	O
10	O
patients	O
with	O
active	O
GO	O
;	O
and	O
12	O
patients	O
with	O
nodular	O
goiter	O
(	O
NG	O
)	O
.	O

All	O
the	O
patients	O
from	O
GD	O
,	O
GO	O
,	O
and	O
NG	O
were	O
subclinical	O
hyperthyroid	O
.	O

We	O
analyzed	O
the	O
expression	B-P
of	I-P
Treg	I-P
cell	I-P
markers	I-P
(	O
CD4	O
,	O
CD25	O
,	O
CD127	O
(	O
-	O
)	O
,	O
Foxp3	O
)	O
on	O
T	O
cells	O
and	O
their	O
ability	O
to	O
respond	O
to	O
IGF-1	O
stimulation	O
.	O

In	O
patients	O
with	O
GD	O
without	O
GO	O
,	O
we	O
found	O
lowered	O
percentages	O
of	O
CD4	O
(	O
+	O
)	O
Foxp3	O
(	O
+	O
)	O
cells	O
,	O
as	O
compared	O
to	O
nodular	O
goiter	O
1.77	O
vs.	O
5.42	O
%	O
(	O
p=0.0276	O
)	O
.	O

Similarly	O
,	O
significantly	O
reduced	O
frequencies	O
of	O
CD4	O
(	O
+	O
)	O
CD25	O
(	O
+	O
)	O
CD127	O
(	O
-	O
)	O
Foxp3	O
(	O
+	O
)	O
and	O
CD4	O
(	O
+	O
)	O
CD25	O
(	O
+	O
)	O
CD127	O
(	O
-	O
)	O
cells	O
were	O
observed	O
in	O
GD	O
patients	O
as	O
compared	O
to	O
nodular	O
goiter	O
patients	O
with	O
hyperthyreosis	O
,	O
(	O
0.7	O
vs.	O
1.48	O
%	O
)	O
(	O
p=0.0071	O
)	O
and	O
(	O
14.5	O
vs.	O
37.2	O
%	O
)	O
(	O
p=0.0051	O
)	O
,	O
respectively	O
.	O

In	O
GO	O
with	O
active	O
GO	O
,	O
only	O
the	O
percentage	O
of	O
CD4	O
(	O
+	O
)	O
CD25	O
(	O
+	O
)	O
CD127	O
(	O
-	O
)	O
cells	O
was	O
found	O
to	O
be	O
decreased	O
versus	O
nodular	O
goiter	O
(	O
9.35	O
vs.	O
37.2	O
)	O
(	O
p=0.0275	O
)	O
.	O

Stimulation	O
of	O
PBMC	O
derived	O
from	O
GO	O
patients	O
with	O
IGF-1	O
resulted	O
in	O
significant	O
increase	O
of	O
frequency	O
of	O
both	O
CD4	O
(	O
+	O
)	O
Foxp3	O
(	O
+	O
)	O
and	O
CD4	O
(	O
+	O
)	O
CD25	O
(	O
+	O
)	O
CD127	O
(	O
-	O
)	O
Foxp3	O
cells	O
.	O

Decreased	O
frequencies	O
of	O
peripheral	O
blood	O
CD4	O
(	O
+	O
)	O
CD25	O
(	O
+	O
)	O
CD127	O
(	O
-	O
)	O
Foxp3	O
(	O
+	O
)	O
in	O
patients	O
with	O
GD	O
and	O
GO	O
could	O
be	O
an	O
useful	O
marker	O
of	O
autoimmune	O
process	O
and	O
perhaps	O
a	O
possible	O
target	O
for	O
future	O
therapies	O
.	O

This	O
is	O
the	O
first	O
study	O
demonstrating	O
Treg	O
-	O
enhancing	O
effects	O
of	O
IGF-1	O
.	O

Thus	O
IGF-1	O
can	O
be	O
accounted	O
for	O
modulating	O
Treg	O
cell	O
-related	O
action	O
in	O
GO	O
.	O

A	O
coarse-grained	O
model	O
for	O
assisting	O
the	O
investigation	O
of	O
structure	O
and	O
dynamics	O
of	O
large	O
nucleic	O
acids	O
by	O
ion	B-P
mobility	I-P
spectrometry-mass	I-P
spectrometry	I-P
.	O

Ion	B-P
Mobility	I-P
Spectrometry-Mass	I-P
Spectrometry	I-P
(	O
IMS-MS	B-P
)	O
is	O
a	O
rapidly	O
emerging	O
tool	O
for	O
the	O
investigation	O
of	O
nucleic	O
acid	O
structure	O
and	O
dynamics	O
.	O

IMS-MS	B-P
determinations	B-P
can	O
provide	O
valuable	O
information	O
regarding	O
alternative	O
topologies	O
,	O
folding	O
intermediates	O
,	O
and	O
conformational	O
heterogeneities	O
,	O
which	O
are	O
not	O
readily	O
accessible	O
to	O
other	O
analytical	B-P
techniques	I-P
.	O

The	O
leading	O
strategies	O
for	O
data	O
interpretation	O
rely	O
on	O
computational	B-P
and	O
experimental	O
approaches	O
to	O
correctly	O
assign	O
experimental	O
observations	O
to	O
putative	O
structures	O
.	O

A	O
very	O
effective	O
strategy	O
involves	O
the	O
application	O
of	O
molecular	O
dynamics	O
(	O
MD	O
)	O
simulations	O
to	O
predict	O
the	O
structure	O
of	O
the	O
analyte	O
molecule	O
,	O
calculate	O
its	O
collision	O
cross	O
section	O
(	O
CCS	O
)	O
,	O
and	O
then	O
compare	O
this	O
computational	O
value	O
with	O
the	O
corresponding	O
experimental	O
data	O
.	O

While	O
this	O
approach	O
works	O
well	O
for	O
small	O
nucleic	O
acid	O
species	O
,	O
analyzing	O
larger	O
nucleic	O
acids	O
of	O
biological	O
interest	O
is	O
hampered	O
by	O
the	O
computational	O
cost	O
associated	O
with	O
capturing	O
their	O
extensive	O
structure	O
and	O
dynamics	O
in	O
all-atom	O
detail	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
the	O
implementation	O
of	O
a	O
coarse	O
graining	O
(	O
CG	O
)	O
approach	O
to	O
reduce	O
the	O
cost	O
of	O
the	O
computational	O
methods	O
employed	O
in	O
the	O
data	O
interpretation	O
workflow	O
.	O

Our	O
framework	O
employs	O
a	O
five-bead	O
model	O
to	O
accurately	O
represent	O
each	O
nucleotide	O
in	O
the	O
nucleic	O
acid	O
structure	O
.	O

The	O
beads	O
are	O
appropriately	O
parameterized	O
to	O
enable	O
the	O
direct	O
calculation	O
of	O
CCS	O
values	O
from	O
CG	O
models	O
,	O
thus	O
affording	O
the	O
ability	O
to	O
pursue	O
the	O
analysis	O
of	O
larger	O
,	O
highly	O
dynamic	O
constructs	O
.	O

The	O
validity	O
of	O
this	O
approach	O
was	O
successfully	O
confirmed	O
by	O
the	O
excellent	O
correlation	O
between	O
the	O
CCS	O
values	O
obtained	O
in	O
parallel	O
by	O
all-atom	O
and	O
CG	O
workflows	O
.	O

Altered	O
Effects	O
of	O
Perspective-Taking	O
on	O
Functional	O
Connectivity	O
during	O
Self-	O
and	O
Other-Referential	O
Processing	O
in	O
Adults	O
with	O
Autism	O
Spectrum	O
Disorder	O
.	O

In	O
interactive	O
social	O
situations	O
,	O
it	O
is	O
often	O
crucial	O
to	O
be	O
able	O
to	O
take	O
another	O
person	O
's	O
perspective	O
when	O
evaluating	O
one	O
's	O
own	O
or	O
another	O
person	O
's	O
specific	O
trait	O
;	O
individuals	O
with	O
ASD	O
critically	O
lack	O
this	O
social	O
skill	O
.	O

To	O
examine	O
how	O
perspective	O
-	O
dependent	O
self-	O
and	O
other-	O
evaluation	O
processes	O
modulate	O
functional	O
connectivity	O
in	O
ASD	O
,	O
we	O
conducted	O
an	O
fMRI	B-P
study	O
in	O
which	O
26	O
high-functioning	O
adults	O
with	O
ASD	O
and	O
24	O
typically	O
developed	O
(	O
TD	O
)	O
controls	O
were	O
asked	O
to	O
decide	O
whether	O
an	O
adjective	O
describing	O
a	O
personality	O
trait	O
correctly	O
described	O
the	O
participant	O
himself/herself	O
(	O
``	O
self	O
``	O
)	O
or	O
the	O
participant	O
's	O
mother	O
(	O
``	O
other	O
''	O
)	O
by	O
taking	O
either	O
the	O
first	O
(	O
1P	O
)	O
or	O
third	O
person	O
(	O
3P	O
)	O
perspective	O
.	O

We	O
observed	O
that	O
functional	O
connectivity	O
between	O
the	O
left	O
sensorimotor	O
cortex	O
and	O
the	O
left	O
middle	O
cingulate	O
cortex	O
was	O
enhanced	O
in	O
TD	O
taking	O
the	O
3P	O
perspective	O
,	O
this	O
enhancement	O
was	O
significantly	O
reduced	O
in	O
ASD	O
,	O
and	O
the	O
degree	O
of	O
reduction	O
was	O
significantly	O
correlated	O
with	O
the	O
severity	O
of	O
autistic	O
traits	O
.	O

Furthermore	O
,	O
the	O
self-reference	O
effect	O
on	O
functional	O
connectivity	O
between	O
the	O
left	O
inferior	O
frontal	O
cortex	O
and	O
frontopolar	O
cortices	O
was	O
significantly	O
enhanced	O
in	O
TD	O
taking	O
the	O
3P	O
perspective	O
,	O
whereas	O
such	O
effect	O
was	O
reversed	O
in	O
ASD	O
.	O

These	O
findings	O
indicate	O
altered	O
effects	O
of	O
perspective	O
on	O
the	O
functional	O
connectivity	O
,	O
which	O
may	O
underlie	O
the	O
deficits	O
in	O
social	O
interaction	O
and	O
communication	O
observed	O
in	O
individuals	O
with	O
ASD	O
.	O

Sonic	O
hedgehog	O
in	O
oral	O
squamous	O
cell	O
carcinoma	O
:	O
An	O
immunohistochemical	B-P
study	O
.	O

Recent	O
studies	O
have	O
revealed	O
the	O
involvement	O
of	O
hedgehog	O
(	O
Hh	O
)	O
signaling	O
component	O
in	O
proliferation	O
and	O
invasive	O
behavior	O
of	O
many	O
carcinomas	O
.	O

This	O
study	O
aims	O
to	O
identify	O
the	O
expression	O
of	O
sonic	O
Hh	O
(	O
SHH	O
)	O
protein	O
of	O
SHH	O
pathway	O
in	O
oral	O
epithelial	O
dysplasia	O
and	O
oral	O
squamous	O
cell	O
carcinoma	O
(	O
OSCC	O
)	O
using	O
SHH	O
(	O
H-160	O
)	O
(	O
Santa	O
Cruz	O
,	O
sc-9042	O
)	O
which	O
could	O
have	O
therapeutic	O
implication	O
in	O
future	O
.	O

A	O
total	O
of	O
250	O
cases	O
comprising	O
50	O
normal	O
oral	O
mucosa	O
,	O
50	O
cases	O
of	O
oral	O
epithelial	O
dysplasia	O
,	O
50	O
well	O
,	O
50	O
moderate	O
and	O
50	O
poorly	O
differentiated	O
OSCCs	O
were	O
included	O
in	O
the	O
study	O
.	O

Immunohistochemical	B-P
evaluation	O
of	O
SHH	O
protein	O
expression	O
was	O
conducted	O
using	O
monoclonal	O
antibody	O
.	O

Interpretation	O
of	O
the	O
expression	O
was	O
done	O
by	O
immunoreactive	O
score	O
of	O
Remmele	O
and	O
Stegner	O
(	O
IRS	O
)	O
scoring	O
method	O
.	O

Chi-Square	O
test	O
was	O
used	O
to	O
analyze	O
the	O
results	O
.	O

The	O
study	O
showed	O
that	O
SHH	O
signaling	O
molecules	O
are	O
highly	O
expressed	O
in	O
OSCC	O
,	O
and	O
their	O
expression	O
was	O
mainly	O
in	O
the	O
cytoplasm	O
of	O
epithelial	O
cells	O
.	O

The	O
SHH	O
signaling	O
component	O
is	O
associated	O
with	O
the	O
pathological	O
parameter	O
in	O
OSCC	O
and	O
oral	O
epithelial	O
dysplasia	O
.	O

New	O
sterols	O
with	O
anti-inflammatory	O
potentials	O
against	O
cyclooxygenase-2	O
and	O
5-lipoxygenase	O
from	O
Paphia	O
malabarica	O
.	O

Marine	O
bivalves	O
occupy	O
a	O
leading	O
share	O
in	O
the	O
total	O
edible	O
molluscs	O
at	O
the	O
coastline	O
regions	O
of	O
south-eastern	O
Asia	O
,	O
and	O
are	O
found	O
to	O
possess	O
significant	O
nutritional	O
and	O
biological	O
potential	O
.	O

Various	O
in	O
vitro	O
evaluation	O
(	O
antioxidant	O
and	O
anti-inflammatory	O
)	O
guided	O
purification	O
of	O
ethyl	O
acetate	O
-	O
methanol	O
(	O
EtOAc	O
-	O
MeOH	O
)	O
extract	O
of	O
bivalve	O
clam	O
,	O
Paphia	O
malabarica	O
characterised	O
two	O
new	O
sterol	O
derivatives	O
as	O
23-gem-dimethylcholesta-5-en-3β-ol	O
(	O
1	O
)	O
and	O
(	O
22E	O
)	O
-24	O
(	O
1	O
)	O
,24	O
(	O
2	O
)	O
-methyldihomocholest-5,22-dien-3β-ol	O
(	O
2	O
)	O
collected	O
from	O
the	O
south-west	O
coast	O
of	O
Arabian	O
Sea	O
.	O

Their	O
structures	O
were	O
unambiguously	O
assigned	O
on	O
the	O
basis	O
of	O
1D	B-P
,	O
2D	B-P
NMR	I-P
spectroscopy	I-P
and	O
mass	B-P
spectrometry	I-P
.	O

The	O
antioxidant	O
and	O
anti-inflammatory	O
activities	O
of	O
2	O
as	O
determined	O
by	O
DPPH	O
/	O
ABTS	O
(	O
+	O
)	O
radical	O
scavenging	O
and	O
anti-	O
cyclooxygenase-2	O
/	O
5-lipoxygenase	O
assays	B-P
were	O
significantly	O
greater	O
(	O
IC50	O
<	O
1	O
mg/mL	O
)	O
than	O
1	O
(	O
IC50	O
>	O
1	O
mg/mL	O
)	O
.	O

Structure-activity	O
relationship	O
analysis	O
revealed	O
that	O
the	O
bioactivities	O
of	O
these	O
compounds	O
were	O
directly	O
proportional	O
to	O
the	O
electronic	O
and	O
lipophilic	O
parameters	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
the	O
occurrence	O
and	O
characterisation	O
of	O
23-gem-dimethyl-3β-hydroxy-Δ	O
(	O
5	O
)	O
-cholestane	O
nucleus	O
and	O
C-30	O
dihomosterol	O
from	O
marine	O
organisms	O
.	O

Association	O
Between	O
Early	O
Lactate	O
Levels	O
and	O
30-	O
Day	O
Mortality	O
in	O
Clinically	O
Suspected	O
Sepsis	O
in	O
Children	O
.	O

Improving	O
emergency	O
care	O
of	O
pediatric	O
sepsis	O
is	O
a	O
public	O
health	O
priority	O
,	O
but	O
optimal	O
early	O
diagnostic	B-P
approaches	I-P
are	O
unclear	O
.	O

Measurement	O
of	O
lactate	O
levels	O
is	O
associated	O
with	O
improved	O
outcomes	O
in	O
adult	O
septic	O
shock	O
,	O
but	O
pediatric	O
guidelines	O
do	O
not	O
endorse	O
its	O
use	O
,	O
in	O
part	O
because	O
the	O
association	O
between	O
early	O
lactate	O
levels	O
and	O
mortality	O
is	O
unknown	O
in	O
pediatric	O
sepsis	O
.	O

To	O
determine	O
whether	O
the	O
initial	O
serum	B-P
lactate	I-P
level	I-P
is	O
associated	O
with	O
30-	O
day	O
mortality	O
in	O
children	O
with	O
suspected	O
sepsis	O
.	O

This	O
observational	O
cohort	O
study	O
of	O
a	O
clinical	O
registry	O
of	O
pediatric	O
patients	O
with	O
suspected	O
sepsis	O
in	O
the	O
emergency	O
department	O
of	O
a	O
tertiary	O
children	O
's	O
hospital	O
from	O
April	O
1	O
,	O
2012	O
,	O
to	O
December	O
31	O
,	O
2015	O
,	O
tested	O
the	O
hypothesis	O
that	O
a	O
serum	B-P
lactate	I-P
level	I-P
of	O
greater	O
than	O
36	O
mg/dL	O
is	O
associated	O
with	O
increased	O
mortality	O
compared	O
with	O
a	O
serum	B-P
lactate	I-P
level	I-P
of	O
36	O
mg/dL	O
or	O
less	O
.	O

Consecutive	O
patients	O
with	O
sepsis	O
were	O
identified	O
and	O
included	O
in	O
the	O
registry	O
following	O
consensus	O
guidelines	O
for	O
clinical	O
recognition	O
(	O
infection	O
and	O
decreased	O
mental	O
status	O
or	O
perfusion	O
)	O
.	O

Among	O
2520	O
registry	O
visits	O
,	O
1221	O
were	O
excluded	O
for	O
transfer	O
from	O
another	O
medical	O
center	O
,	O
no	O
measurement	O
of	O
lactate	O
levels	O
,	O
and	O
patients	O
younger	O
than	O
61	O
days	O
or	O
18	O
years	O
or	O
older	O
,	O
leaving	O
1299	O
visits	O
available	O
for	O
analysis	O
.	O

Lactate	B-P
testing	I-P
is	O
prepopulated	O
in	O
the	O
institutional	O
sepsis	O
order	O
set	O
but	O
may	O
be	O
canceled	O
at	O
clinical	O
discretion	O
.	O

Venous	O
lactate	O
leve	O
l	O
of	O
greater	O
than	O
36	O
mg/dL	O
on	O
the	O
first	O
measurement	O
within	O
the	O
first	O
8	O
hours	O
after	O
arrival	O
.	O

Thirty-	O
day	O
in-	O
hospital	O
mortality	O
was	O
the	O
primary	O
outcome	O
.	O

Odds	O
ratios	O
were	O
calculated	O
using	O
logistic	O
regression	O
to	O
account	O
for	O
potential	O
confounders	O
.	O

Of	O
the	O
1299	O
patients	O
included	O
in	O
the	O
analysis	O
(	O
753	O
boys	O
[	O
58.0	O
%	O
]	O
and	O
546	O
girls	O
[	O
42.0	O
%	O
]	O
;	O
mean	O
[	O
SD	O
]	O
age	O
,	O
7.3	O
[	O
5.3	O
]	O
years	O
)	O
,	O
899	O
(	O
69.2	O
%	O
)	O
had	O
chronic	O
medical	O
conditions	O
and	O
367	O
(	O
28.3	O
%	O
)	O
had	O
acute	O
organ	O
dysfunction	O
.	O

Thirty-	O
day	O
mortality	O
occurred	O
in	O
5	O
of	O
103	O
patients	O
(	O
4.8	O
%	O
)	O
with	O
lactate	O
levels	O
greater	O
than	O
36	O
mg/dL	O
and	O
20	O
of	O
1196	O
patients	O
(	O
1.7	O
%	O
)	O
with	O
lactate	O
levels	O
of	O
36	O
mg/dL	O
or	O
less	O
.	O

Initial	O
lactate	O
levels	O
of	O
greater	O
than	O
36	O
mg/dL	O
were	O
significantly	O
associated	O
with	O
30-	O
day	O
mortality	O
in	O
unadjusted	O
(	O
odds	O
ratio	O
,	O
3.00	O
;	O
95	O
%	O
CI	O
,	O
1.10-8.17	O
)	O
and	O
adjusted	O
(	O
odds	O
ratio	O
,	O
3.26	O
;	O
95	O
%	O
CI	O
,	O
1.16-	O
9.16	O
)	O
analyses	O
.	O

The	O
sensitivity	O
of	O
lactate	O
levels	O
greater	O
than	O
36	O
mg/dL	O
for	O
30-	O
day	O
mortality	O
was	O
20.0	O
%	O
(	O
95	O
%	O
CI	O
,	O
8.9	O
%	O
-39.1	O
%	O
)	O
,	O
and	O
specificity	O
was	O
92.3	O
%	O
(	O
90.7	O
%	O
-93.7	O
%	O
)	O
.	O

In	O
children	O
treated	O
for	O
sepsis	O
in	O
the	O
emergency	O
department	O
,	O
lactate	O
levels	O
greater	O
than	O
36	O
mg/dL	O
were	O
associated	O
with	O
mortality	O
but	O
had	O
a	O
low	O
sensitivity	O
.	O

Measurement	O
of	O
lactate	O
levels	O
may	O
have	O
utility	O
in	O
early	O
risk	O
stratification	O
of	O
pediatric	O
sepsis	O
.	O

Combination	O
of	O
telmisartan	O
with	O
sildenafil	O
ameliorate	O
progression	O
of	O
diabetic	O
nephropathy	O
in	O
streptozotocin	O
-	O
induced	O
diabetic	O
model	O
.	O

Diabetic	O
nephropathy	O
(	O
DN	O
)	O
is	O
a	O
leading	O
cause	O
of	O
end-stage	O
renal	O
disease	O
in	O
the	O
world	O
.	O

Several	O
signaling	O
pathways	O
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
DN	O
including	O
elevation	O
in	O
level	O
of	O
angiotensin	O
II	O
,	O
formation	O
of	O
advanced	O
glycation	O
end	O
products	O
(	O
AGE	O
)	O
,	O
activation	O
of	O
protein	O
kinase	O
c	O
(	O
PKC	O
)	O
,	O
and	O
lipid	O
accumulation	O
.	O

These	O
pathways	O
activate	O
one	O
another	O
mutually	O
leading	O
to	O
oxidative	O
stress	O
,	O
increasing	O
expression	O
of	O
transforming	O
growth	O
factor	O
beta-1	O
(	O
TGF-β	O
1	O
)	O
and	O
release	O
of	O
interleukins	O
and	O
adhesion	O
molecules	O
,	O
so	O
the	O
aim	O
of	O
this	O
study	O
is	O
to	O
interrupt	O
more	O
than	O
pathogenic	O
pathway	O
to	O
ameliorate	O
the	O
progression	O
of	O
DN	O
.	O

In	O
the	O
present	O
study	O
,	O
white	O
male	O
rats	O
(	O
N=48	O
)	O
were	O
divided	O
into	O
six	O
groups	O
(	O
8	O
rats	O
each	O
)	O
,	O
the	O
first	O
two	O
groups	O
served	O
as	O
normal	O
control	O
and	O
a	O
control	O
vehicle	O
group	O
while	O
the	O
remaining	O
four	O
groups	O
were	O
rendered	O
diabetic	O
by	O
a	O
single	O
intraperitoneal	O
injection	O
of	O
Streptozotocin	O
(	O
STZ	O
)	O
and	O
being	O
left	O
for	O
4	O
weeks	O
to	O
develop	O
DN	O
.	O

Thereafter	O
,	O
the	O
rats	O
were	O
divided	O
into	O
DN	O
group	O
,	O
DN	O
group	O
receiving	O
Telmisartan	O
or	O
Sildenafil	O
or	O
Telmisartan	O
Sildenafil	O
combination	O
.	O

After	O
the	O
specified	O
treatment	O
period	O
,	O
urine	O
samples	O
were	O
collected	O
(	O
using	O
metabolic	O
cages	O
)	O
to	O
measure	O
proteinuria	O
,	O
animals	O
were	O
then	O
euthanized	O
,	O
blood	O
and	O
tissue	O
samples	O
were	O
collected	O
for	O
measurement	B-P
of	I-P
Blood	I-P
glucose	I-P
,	O
BUN	B-P
,	O
S.Cr	B-P
,	O
LDL	B-P
,	O
NO	B-P
,	O
TGF-β1	B-P
,	O
IL-1β	B-P
,	O
AGEPs	B-P
,	O
and	O
SOD	B-P
.	O

The	O
combination	O
therapy	O
showed	O
significant	O
decrease	O
in	O
BUN	O
,	O
S.Cr	O
,	O
LDL	O
,	O
TGF-β1	O
,	O
IL-1β	O
,	O
Proteinuria	O
and	O
AGEPs	O
and	O
significant	O
increase	O
in	O
SOD	O
and	O
NO	O
.	O

The	O
findings	O
showed	O
that	O
combination	O
therapy	O
was	O
able	O
to	O
ameliorate	O
DN	O
and	O
that	O
the	O
effects	O
were	O
superior	O
to	O
the	O
single	O
drugs	O
alone	O
.	O

Associations	O
of	O
NEUROD2	O
polymorphisms	O
and	O
change	O
of	O
cognitive	O
dysfunctions	O
in	O
schizophrenia	O
and	O
schizoaffective	O
disorder	O
after	O
eight	O
weeks	O
of	O
antipsychotic	O
treatment	O
.	O

NEUROD2	O
is	O
a	O
neurospecific	O
helix-loop-helix	O
transcription	O
factor	O
which	O
has	O
an	O
impact	O
on	O
the	O
regulation	O
of	O
glutamatergic	O
and	O
GABAergic	O
genes	O
.	O

We	O
investigated	O
an	O
association	O
of	O
NEUROD2	O
with	O
neurocognitive	O
dysfunctions	O
in	O
schizophrenia	O
and	O
schizoaffective	O
disorder	O
patients	O
before	O
and	O
during	O
treatment	O
with	O
different	O
second-generation	O
antipsychotics	O
.	O

Patients	O
were	O
genotyped	O
for	O
four	O
different	O
polymorphisms	O
of	O
the	O
NEUROD2	O
gene	O
(	O
(	O
rs9889354	O
(	O
A/G	O
)	O
,	O
rs1877032	O
(	O
C/T	O
)	O
,	O
rs12453682	O
(	O
C/T	O
)	O
and	O
rs11078918	O
(	O
C/G	O
)	O
)	O
.	O

Cognitive	O
function	O
was	O
assessed	O
at	O
baseline	O
and	O
week	O
8	O
.	O

Results	O
of	O
individual	O
neuropsychological	B-P
tests	I-P
were	O
assigned	O
to	O
six	O
cognitive	O
domains	O
(	O
reaction	O
time	O
and	O
quality	O
;	O
executive	O
function	O
;	O
working	O
,	O
verbal	O
and	O
visual	O
memory	O
)	O
and	O
a	O
general	O
cognitive	O
index	O
.	O

167	O
patients	O
were	O
included	O
in	O
the	O
study	O
.	O

The	O
NEUROD2	O
exonic	O
polymorphism	O
rs11078918	O
showed	O
significant	O
associations	O
with	O
verbal	O
memory	O
and	O
executive	O
functions	O
,	O
whereas	O
the	O
NEUROD2	O
polymorphism	O
rs12453682	O
was	O
significantly	O
associated	O
with	O
working	O
and	O
verbal	O
memory	O
,	O
executive	O
functions	O
and	O
with	O
a	O
cognitive	O
index	O
.	O

Significant	O
associations	O
were	O
found	O
at	O
baseline	O
and	O
after	O
eight	O
weeks	O
.	O

Moreover	O
,	O
significant	O
associations	O
between	O
the	O
change	O
in	O
neuropsychological	B-P
test	I-P
results	O
during	O
antipsychotic	O
treatment	O
and	O
the	O
NEUROD2	O
polymorphisms	O
rs11078918	O
and	O
rs12453682	O
were	O
observed	O
.	O

Our	O
findings	O
suggest	O
that	O
the	O
NEUROD2	O
gene	O
could	O
play	O
a	O
role	O
in	O
the	O
pathophysiology	O
of	O
neurocognitive	O
dysfunctions	O
as	O
well	O
as	O
in	O
the	O
change	O
of	O
cognitive	O
symptoms	O
under	O
antipsychotic	O
treatment	O
in	O
schizophrenia	O
and	O
schizoaffective	O
disorder	O
.	O

Electrospray	O
deposition	O
device	O
used	O
to	O
precisely	O
control	O
the	O
matrix	O
crystal	O
to	O
improve	O
the	O
performance	O
of	O
MALDI	B-P
MSI	I-P
.	O

MALDI	B-P
MSI	I-P
has	O
been	O
recently	O
applied	O
as	O
an	O
innovative	O
tool	O
for	O
detection	O
of	O
molecular	O
distribution	O
within	O
a	O
specific	O
tissue	O
.	O

MALDI	B-P
MSI	I-P
requires	O
deposition	O
of	O
an	O
organic	O
compound	O
,	O
known	O
as	O
matrix	O
,	O
on	O
the	O
tissue	O
of	O
interest	O
to	O
assist	O
analyte	O
desorption	O
and	O
ionization	O
,	O
in	O
which	O
the	O
matrix	O
crystal	O
homogeneity	O
and	O
size	O
greatly	O
influence	O
the	O
imaging	B-P
reproducibility	O
and	O
spatial	O
resolution	O
in	O
MALDI	B-P
MSI	I-P
.	O

In	O
this	O
work	O
,	O
a	O
homemade	O
electrospray	O
deposition	O
device	O
was	O
developed	O
for	O
deposition	O
of	O
matrix	O
in	O
MALDI	B-P
MSI	I-P
.	O

The	O
device	O
could	O
be	O
used	O
to	O
achieve	O
1	O
μm	O
homogeneous	O
matrix	O
crystals	O
in	O
MALDI	B-P
MSI	I-P
analysis	B-P
.	O

Moreover	O
,	O
it	O
was	O
found	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
the	O
electrospray	O
deposition	O
device	O
could	O
be	O
used	O
to	O
precisely	O
control	O
the	O
matrix	O
crystal	O
size	O
,	O
and	O
the	O
imaging	B-P
spatial	O
resolution	O
was	O
increased	O
greatly	O
as	O
the	O
matrix	O
crystals	O
size	O
becoming	O
smaller	O
.	O

In	O
addition	O
,	O
the	O
easily-built	O
electrospray	O
deposition	O
device	O
was	O
durable	O
for	O
acid	O
,	O
base	O
or	O
organic	O
solvent	O
,	O
and	O
even	O
could	O
be	O
used	O
for	O
deposition	O
of	O
nanoparticles	O
matrix	O
,	O
which	O
made	O
it	O
unparalleled	O
for	O
MALDI	B-P
MSI	I-P
analysis	B-P
.	O

The	O
feasibility	O
of	O
the	O
electrospray	O
deposition	O
device	O
was	O
investigated	O
by	O
combination	O
with	O
MALDI	B-P
FTICR	I-P
MSI	I-P
to	O
analyze	O
the	O
distributions	O
of	O
lipids	O
in	O
mouse	O
brain	O
and	O
liver	O
cancer	O
tissue	O
section	O
.	O

Interleukin-1β	O
induced	O
Stress	O
Granules	O
Sequester	O
COX-2	O
mRNA	O
and	O
Regulates	O
its	O
Stability	O
and	O
Translation	O
in	O
Human	O
OA	O
Chondrocytes	O
.	O

Enhanced	O
and	O
immediate	O
expression	O
of	O
cyclooxygenase-2	O
(	O
COX-2	O
)	O
mRNA	O
is	O
observed	O
in	O
IL-1β	O
-	O
stimulated	O
OA	O
chondrocytes	O
but	O
the	O
synthesis	O
of	O
protein	O
found	O
significantly	O
delayed	O
.	O

Here	O
we	O
investigated	O
the	O
role	O
of	O
stress	O
granules	O
(	O
SGs	O
)	O
,	O
ribonucleoprotein	O
complexes	O
that	O
regulate	O
mRNA	O
translation	O
,	O
in	O
the	O
delayed	O
translation	O
of	O
COX-2	O
mRNAs	O
in	O
IL-1β	O
-	O
stimulated	O
OA	O
chondrocytes	O
.	O

Stimulation	O
of	O
human	O
chondrocytes	O
with	O
IL-1β	O
activated	O
the	O
stress	O
response	O
genes	O
and	O
the	O
phosphorylation	O
of	O
eIF2α	O
that	O
triggered	O
the	O
assembly	O
of	O
SGs	O
.	O

Using	O
combined	O
immunofluorescence	B-P
staining	I-P
of	O
SGs	O
markers	O
and	O
COX-2	O
protein	O
,	O
RNA	O
fluorescence	O
in	O
situ	O
hybridization	O
and	O
RNA	O
immunoprecipitation	B-P
,	O
the	O
COX-2	O
mRNAs	O
were	O
found	O
sequestered	O
in	O
SGs	O
in	O
IL-1β	O
-	O
stimulated	O
OA	O
chondrocytes	O
.	O

No	O
increase	O
in	O
COX-2	O
protein	O
expression	O
was	O
observed	O
during	O
the	O
persistence	O
of	O
SGs	O
but	O
enhanced	O
expression	O
of	O
COX-2	O
protein	O
was	O
noted	O
upon	O
clearance	O
of	O
the	O
SGs	O
.	O

Inhibition	O
of	O
SGs	O
clearance	O
blocked	O
COX-2	O
mRNA	O
translation	O
whereas	O
blocking	O
the	O
assembly	O
of	O
SGs	O
by	O
TIA-1	O
depletion	O
resulted	O
in	O
rapid	O
and	O
increased	O
production	O
of	O
COX-2	O
and	O
PGE2	O
.	O

Our	O
findings	O
show	O
for	O
the	O
first	O
time	O
assembly	O
of	O
SGs	O
and	O
sequestration	O
of	O
COX-2	O
mRNAs	O
in	O
human	O
OA	O
chondrocytes	O
under	O
pathological	O
conditions	O
.	O

Post-transcriptional	O
regulation	O
of	O
COX-2	O
mRNAs	O
translation	O
by	O
SGs	O
indicates	O
a	O
role	O
in	O
IL-1β	O
-mediated	O
catabolic	O
response	O
that	O
could	O
be	O
therapeutically	O
targeted	O
in	O
OA	O
.	O

Morphometric	B-P
Study	I-P
of	O
Pancreas	O
in	O
Human	O
Fetuses	O
.	O

The	O
pancreas	O
arises	O
from	O
the	O
endoderm	O
as	O
a	O
dorsal	O
and	O
a	O
ventral	O
bud	O
which	O
fuse	O
together	O
to	O
form	O
the	O
single	O
organ	O
.	O

It	O
extends	O
transversely	O
across	O
the	O
posterior	O
abdominal	O
wall	O
from	O
the	O
duodenum	O
to	O
the	O
spleen	O
.	O

Functionally	O
,	O
it	O
is	O
endocrine	O
and	O
exocrine	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
study	O
the	O
morphometry	B-P
of	O
human	O
pancreas	O
at	O
different	O
gestational	O
age	O
groups	O
of	O
normal	O
,	O
still	O
born	O
fetuses	O
.	O

Forty	O
aborted	O
human	O
fetuses	O
(	O
25	O
male	O
and	O
15	O
female	O
)	O
of	O
12-40	O
weeks	O
gestational	O
age	O
with	O
no	O
obvious	O
congenital	O
abnormality	O
were	O
obtained	O
.	O

The	O
fetuses	O
were	O
dissected	O
and	O
pancreas	O
was	O
removed	O
.	O

The	O
length	O
and	O
weight	O
of	O
the	O
pancreas	O
as	O
well	O
as	O
height	O
of	O
its	O
head	O
were	O
noted	O
.	O

It	O
was	O
observed	O
that	O
there	O
was	O
increase	O
in	O
body	O
weight	O
and	O
crown	O
rump	O
length	O
with	O
increasing	O
gestational	O
age	O
.	O

The	O
average	O
length	O
of	O
pancreas	O
was	O
1.80	O
cm	O
in	O
12	O
(	O
th	O
)	O
week	O
and	O
4.70	O
cm	O
in	O
40	O
(	O
th	O
)	O
week	O
of	O
gestation	O
.	O

The	O
average	O
height	O
of	O
pancreas	O
head	O
was	O
0.80	O
cm	O
in	O
the	O
12	O
(	O
th	O
)	O
and	O
2.70	O
cm	O
in	O
40	O
(	O
th	O
)	O
week	O
of	O
gestation	O
.	O

The	O
knowledge	O
of	O
development	O
of	O
pancreas	O
helps	O
in	O
planning	O
new	O
therapeutic	O
interventions	O
in	O
the	O
treatment	O
of	O
various	O
congenital	O
and	O
functional	O
pancreatic	O
anomalies	O
.	O

Prevalence	O
and	O
Hospital	O
Management	O
of	O
Amphotericin	O
B	O
Deoxycholate	O
-Related	O
Toxicities	O
during	O
Treatment	O
of	O
HIV	O
-	O
Associated	O
Cryptococcal	O
Meningitis	O
in	O
South	O
Africa	O
.	O

We	O
aimed	O
to	O
establish	O
the	O
prevalence	O
of	O
amphotericin	O
B	O
deoxycholate	O
(	O
AmBd	O
)	O
-related	O
toxicities	O
among	O
South	O
African	O
patients	O
with	O
cryptococcosis	O
and	O
determine	O
adherence	O
to	O
international	O
recommendations	O
to	O
prevent	O
,	O
monitor	O
and	O
manage	O
AmBd	O
-related	O
toxicities	O
.	O

Clinical	O
data	O
were	O
collected	O
from	O
cases	O
of	O
laboratory-confirmed	O
cryptococcosis	O
at	O
25	O
hospitals	O
,	O
October	O
2012	O
-February	O
2013	O
.	O

Anemia	O
was	O
defined	O
as	O
hemoglobin	O
(	O
Hb	O
)	O
concentration	O
<	O
10	O
g/dl	O
,	O
hypokalemia	O
as	O
serum	B-P
potassium	I-P
(	O
K	B-P
)	O
<	O
3.4	O
mEq/L	O
and	O
nephrotoxicity	O
as	O
an	O
increase	O
in	O
serum	B-P
creatinine	I-P
(	O
Cr	B-P
)	O
to	O
>	O
1.1	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
.	O

To	O
determine	O
adherence	O
to	O
toxicity	O
prevention	O
recommendations	O
,	O
we	O
documented	O
whether	O
baseline	O
Hb	B-P
,	O
K	B-P
and	O
Cr	B-P
tests	I-P
were	O
performed	O
,	O
whether	O
pre-emptive	O
hydration	O
and	O
IV	O
potassium	O
chloride	O
(	O
KCl	O
)	O
was	O
administered	O
prior	O
to	O
80	O
%	O
and	O
60	O
%	O
of	O
AmBd	O
doses	O
and	O
whether	O
daily	O
oral	O
KCl	O
supplementation	O
was	O
given	O
≥60	O
%	O
of	O
the	O
time	O
.	O

To	O
determine	O
adherence	O
to	O
monitoring	O
recommendations	O
,	O
we	O
ascertained	O
whether	O
a	O
daily	O
fluid	O
chart	O
was	O
completed	O
,	O
Hb	O
was	O
monitored	O
weekly	O
and	O
K	B-P
or	O
Cr	B-P
were	O
monitored	O
bi-weekly	O
.	O

Of	O
846	O
patients	O
,	O
clinical	O
data	O
were	O
available	O
for	O
76	O
%	O
(	O
642/846	O
)	O
,	O
82	O
%	O
(	O
524/642	O
)	O
of	O
whom	O
received	O
AmBd	O
.	O

Sixty-four	O
per	O
cent	O
(	O
n	O
=	O
333	O
)	O
had	O
documented	O
baseline	O
laboratory	B-P
tests	I-P
,	O
40	O
%	O
(	O
n	O
=	O
211	O
)	O
were	O
given	O
pre-emptive	O
hydration	O
and	O
14	O
%	O
(	O
n	O
=	O
72	O
)	O
and	O
19	O
%	O
(	O
n	O
=	O
101	O
)	O
received	O
intravenous	O
and	O
oral	O
KCl	O
.	O

While	O
on	O
AmBd	O
,	O
88	O
%	O
(	O
n	O
=	O
452	O
)	O
had	O
fluid	O
monitoring	O
;	O
27	O
%	O
(	O
n	O
=	O
142	O
)	O
,	O
45	O
%	O
(	O
n	O
=	O
235	O
)	O
and	O
44	O
%	O
(	O
n	O
=	O
232	O
)	O
had	O
Hb	O
,	O
K	O
and	O
Cr	O
levels	O
monitored	O
.	O

Toxicities	O
developed	O
frequently	O
during	O
treatment	O
:	O
anemia	O
,	O
16	O
%	O
(	O
86/524	O
)	O
;	O
hypokalemia	O
,	O
43	O
%	O
(	O
226/524	O
)	O
and	O
nephrotoxicity	O
,	O
32	O
%	O
(	O
169/524	O
)	O
.	O

AmBd	O
-related	O
toxicities	O
occurred	O
frequently	O
but	O
were	O
potentially	O
preventable	O
with	O
adequate	O
monitoring	O
,	O
supplemental	O
fluid	O
and	O
electrolyte	O
therapies	O
.	O

Cell	O
Electrical	O
Impedance	O
as	O
a	O
Novel	O
Approach	O
for	O
Studies	O
on	O
Senescence	O
Not	O
Based	O
on	O
Biomarkers	O
.	O

Senescence	O
of	O
cardiac	O
myocytes	O
is	O
frequently	O
associated	O
with	O
heart	O
diseases	O
.	O

To	O
analyze	O
senescence	O
in	O
cardiac	O
myocytes	O
,	O
a	O
number	O
of	O
biomarkers	O
have	O
been	O
isolated	O
.	O

However	O
,	O
due	O
to	O
the	O
complex	O
nature	O
of	O
senescence	O
,	O
multiple	O
markers	O
are	O
required	O
for	O
a	O
single	O
assay	B-P
to	O
accurately	O
depict	O
complex	O
physiological	O
changes	O
associated	O
with	O
senescence	O
.	O

In	O
single	O
cells	O
,	O
changes	O
in	O
both	O
cytoplasm	O
and	O
cell	O
membrane	O
during	O
senescence	O
can	O
affect	O
the	O
changes	O
in	O
electrical	O
impedance	O
.	O

Based	O
on	O
this	O
phenomenon	O
,	O
we	O
developed	O
MEDoS	B-P
,	O
a	O
novel	O
microelectrochemical	B-P
impedance	I-P
spectroscopy	I-P
for	O
diagnosis	O
of	O
senescence	O
,	O
which	O
allows	O
us	O
to	O
precisely	O
measure	O
quantitative	O
changes	O
in	O
electrical	O
properties	O
of	O
agingf	O
cells	O
.	O

Using	O
cardiac	O
myocytes	O
isolated	O
from	O
3-	O
,	O
6-	O
,	O
and	O
18-month-old	O
isogenic	O
zebrafish	O
,	O
we	O
examined	O
the	O
efficacy	O
of	O
MEDoS	B-P
and	O
showed	O
that	O
MEDoS	B-P
can	O
identify	O
discernible	O
changes	O
in	O
electrical	O
impedance	O
.	O

Taken	O
together	O
,	O
our	O
data	O
demonstrated	O
that	O
electrical	O
impedance	O
in	O
cells	O
at	O
different	O
ages	O
is	O
distinct	O
with	O
quantitative	O
values	O
;	O
these	O
results	O
were	O
comparable	O
with	O
previously	O
reported	O
ones	O
.	O

Therefore	O
,	O
we	O
propose	O
that	O
MEDoS	B-P
be	O
used	O
as	O
a	O
new	O
biomarker	O
-	O
independent	O
methodology	O
to	O
obtain	O
quantitative	O
data	O
on	O
the	O
biological	O
senescence	O
status	O
of	O
individual	O
cells	O
.	O

HERG1	O
potassium	O
channel	O
expression	O
in	O
potentially	O
malignant	O
disorders	O
of	O
the	O
oral	O
mucosa	O
and	O
prognostic	O
relevance	O
in	O
oral	O
squamous	O
cell	O
carcinoma	O
.	O

HERG1	O
potassium	O
channel	O
plays	O
a	O
critical	O
role	O
in	O
the	O
cell	O
proliferation	O
.	O

HERG1	O
protein	O
expression	O
was	O
analyzed	O
by	O
immunohistochemistry	B-P
(	O
IHC	B-P
)	O
in	O
62	O
patients	O
with	O
oral	O
leukoplakias	O
and	O
100	O
patients	O
with	O
oral	O
squamous	O
cell	O
carcinomas	O
(	O
OSCC	O
)	O
.	O

HERG1	O
mRNA	O
levels	O
were	O
assessed	O
by	O
real-time	O
reverse	O
transcriptase-polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
in	O
22	O
patients	O
with	O
primary	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
(	O
HNSCC	O
)	O
.	O

Statistically	O
significant	O
associations	O
were	O
found	O
between	O
HERG1	O
expression	O
and	O
tobacco	O
consumption	O
,	O
disease	B-P
stage	I-P
,	O
tumor	O
differentiation	O
,	O
tumor	O
recurrence	O
,	O
and	O
reduced	O
survival	O
.	O

There	O
was	O
no	O
association	O
between	O
HERG1	O
expression	O
and	O
the	O
risk	O
of	O
progression	O
from	O
oral	O
leukoplakia	O
to	O
OSCC	O
.	O

In	O
addition	O
,	O
a	O
high	O
proportion	O
of	O
tumors	O
(	O
80	O
%	O
)	O
showed	O
increased	O
HERG1	O
mRNA	O
levels	O
compared	O
to	O
normal	O
mucosa	O
from	O
nononcologic	O
patients	O
.	O

Aberrant	O
HERG1	O
expression	O
increases	O
as	O
oral	O
tumorigenesis	O
progresses	O
from	O
oral	O
hyperplasia	O
to	O
OSCC	O
.	O

Increased	O
HERG1	O
mRNA	O
levels	O
were	O
also	O
frequently	O
detected	O
in	O
OSCC	O
and	O
other	O
HNSCC	O
subsites	O
.	O

HERG1	O
expression	O
emerges	O
as	O
a	O
clinically	O
relevant	O
feature	O
during	O
tumor	O
progression	O
and	O
a	O
potential	O
poor	O
prognostic	O
biomarker	O
for	O
OSCC	O
.	O

©	O
2016	O
Wiley	O
Periodicals	O
,	O
Inc.	O
Head	O
Neck	O
38	O
:	O
1708-1716	O
,	O
2016	O
.	O

Expression	O
of	O
WNT10A	O
Gene	O
in	O
Oral	O
Squamous	O
Cell	O
Carcinoma	O
.	O

Oral	O
squamous	O
cell	O
carcinoma	O
(	O
OSCC	O
)	O
constitutes	O
the	O
most	O
frequent	O
malignant	O
tumour	O
of	O
the	O
oral	O
cavity	O
.	O

Considering	O
the	O
significant	O
roles	O
the	O
Wnt	O
family	O
plays	O
in	O
physiological	O
and	O
pathological	O
events	O
,	O
this	O
study	O
aims	O
to	O
investigate	O
WNT10A	O
gene	O
expression	O
in	O
OSCC	O
.	O

The	O
cohort	O
was	O
composed	O
of	O
59	O
specimens	O
:	O
49	O
with	O
OSCC	O
and	O
10	O
controls	O
.	O

Total	O
RNA	O
from	O
the	O
samples	O
was	O
extracted	O
,	O
cDNA	O
was	O
synthesized	O
and	O
Real-time	B-P
PCR	I-P
analyses	I-P
were	O
performed	O
,	O
with	O
β-ACTIN	O
as	O
internal	O
control	O
.	O

The	O
number	O
of	O
OSCC	O
samples	O
for	O
the	O
4	O
TNM	O
stages	O
was	O
:	O
5	O
(	O
10.2	O
%	O
)	O
stage	O
I	O
,	O
10	O
(	O
20.4	O
%	O
)	O
stage	O
II	O
,	O
9	O
(	O
18.3	O
%	O
)	O
stage	O
III	O
,	O
and	O
25	O
(	O
51.1	O
%	O
)	O
stage	O
IV	O
.	O

For	O
Real-Time	B-P
PCR	I-P
analysis	I-P
,	O
significant	O
difference	O
was	O
found	O
between	O
control	O
samples	O
and	O
OSCC	O
stage	O
IV	O
(	O
p	O
<	O
0.01	O
)	O
.	O

Higher	O
levels	O
of	O
WNT10A	O
expression	O
was	O
observed	O
in	O
OSCC	O
stage	O
IV	O
suggesting	O
a	O
potential	O
role	O
in	O
tumour	O
progression	O
.	O

Osteomyelitis	O
of	O
Humerus	O
and	O
Intramuscular	O
Abscess	O
Due	O
to	O
Melioidosis	O
.	O

Melioidosis	O
is	O
a	O
clinically	O
diverse	O
disease	O
caused	O
by	O
gram	O
negative	O
bacterium	O
Burkholderia	O
pseudomallei	O
.	O

It	O
is	O
a	O
potential	O
bioterrorism	O
agent	O
.	O

The	O
high	O
risk	O
group	O
includes	O
the	O
agricultural	O
and	O
construction	O
workers	O
whose	O
contact	O
with	O
contaminated	O
soil	O
and	O
water	O
may	O
expose	O
them	O
to	O
bacteria	O
.	O

The	O
clinical	O
manifestations	O
varies	O
from	O
asymptomatic	O
infection	O
to	O
overwhelming	O
sepsis	O
.	O

To	O
diagnose	O
melioidosis	O
a	O
high	O
index	O
of	O
suspicion	O
along	O
with	O
isolation	O
and	O
identification	O
of	O
the	O
organism	O
from	O
the	O
clinical	O
samples	O
is	O
needed	O
.	O

Early	B-P
diagnosis	I-P
and	O
treatment	O
is	O
essential	O
for	O
better	O
outcome	O
.	O

We	O
are	O
reporting	O
a	O
case	O
of	O
melioidosis	O
which	O
presented	O
as	O
osteomyelitis	O
of	O
humerus	O
with	O
intramuscular	O
abscess	O
.	O

Circulating	O
progenitor	O
cells	O
and	O
coronary	O
microvascular	O
dysfunction	O
:	O
Results	O
from	O
the	O
NHLBI	O
-sponsored	O
Women	O
's	O
Ischemia	O
Syndrome	O
Evaluation	O
-	O
Coronary	O
Vascular	O
Dysfunction	O
Study	O
(	O
WISE-CVD	O
)	O
.	O

Ischemia	O
stimulates	O
a	O
reparative	O
response	O
resulting	O
in	O
mobilization	O
of	O
circulating	O
progenitor	O
cells	O
(	O
CPCs	O
)	O
.	O

We	O
hypothesized	O
that	O
women	O
with	O
chronic	O
myocardial	O
ischemia	O
from	O
coronary	O
microvascular	O
disease	O
(	O
CMD	O
)	O
will	O
mobilize	O
CPCs	O
.	O

In	O
123	O
women	O
with	O
ischemic	O
symptoms	O
and	O
signs	O
but	O
no	O
obstructive	O
coronary	O
artery	O
disease	O
(	O
CAD	O
)	O
enrolled	O
in	O
the	O
Women	O
's	O
Ischemia	O
Syndrome	O
Evaluation	O
-	O
Coronary	O
Vascular	O
Dysfunction	O
Study	O
(	O
WISE-CVD	O
)	O
,	O
we	O
measured	B-P
coronary	I-P
flow	I-P
reserve	I-P
(	O
CFR	B-P
)	O
in	O
response	O
to	O
intracoronary	O
adenosine	O
.	O

Peripheral	O
blood	O
CPCs	O
were	O
measured	O
using	O
flow	B-P
cytometry	I-P
for	O
expression	O
of	O
CD34	O
,	O
CD133	O
,	O
CXCR4	O
,	O
and	O
VEGFR2	O
.	O

Subjects	O
were	O
53	O
±	O
11	O
years	O
,	O
BMI	O
30	O
±	O
8	O
;	O
44	O
%	O
hypertensive	O
,	O
11	O
%	O
diabetic	O
,	O
23	O
%	O
hyperlipidemic	O
and	O
7	O
%	O
smokers	O
.	O

Lower	O
CFR	B-P
correlated	O
inversely	O
with	O
higher	O
levels	O
of	O
hematopoietic	O
-enriched	O
CD34+	O
(	O
r	O
=	O
-0.23	O
,	O
p	O
=	O
0.011	O
)	O
,	O
CD34+	O
/	O
CD133+	O
(	O
r	O
=	O
-0.24	O
,	O
p	O
=	O
0.008	O
)	O
,	O
and	O
CD34+	O
/	O
CXCR4+	O
(	O
r	O
=	O
-0.19	O
,	O
p	O
=	O
0.036	O
)	O
cells	O
.	O

In	O
multivariable	O
regression	O
analyses	O
,	O
after	O
adjusting	O
for	O
traditional	O
cardiovascular	O
risk	O
factors	O
,	O
lower	O
CFR	B-P
remained	O
significantly	O
associated	O
with	O
elevated	O
levels	O
of	O
CD34+	O
(	O
β	O
-0.18	O
,	O
p	O
=	O
0.042	O
)	O
,	O
CD34+	O
/	O
CD133+	O
(	O
β	O
-0.24	O
,	O
p	O
=	O
0.036	O
)	O
,	O
and	O
CD34+	O
/	O
CXCR4+	O
(	O
β	O
-0.22	O
,	O
p	O
=	O
0.050	O
)	O
cells	O
.	O

We	O
found	O
no	O
association	O
between	O
CFR	B-P
and	O
CD34+	O
/	O
VEGFR2+	O
cells	O
.	O

In	O
women	O
with	O
non-obstructive	O
CAD	O
,	O
impaired	O
CFR	B-P
is	O
associated	O
with	O
higher	O
levels	O
of	O
CPCs	O
,	O
suggesting	O
that	O
chronic	O
myocardial	O
ischemia	O
from	O
CMD	O
stimulates	O
CPC	O
mobilization	O
.	O

The	O
functional	O
significance	O
of	O
elevated	O
CPCs	O
in	O
these	O
subjects	O
requires	O
further	O
investigation	O
as	O
a	O
potential	O
biomarker	O
and	O
treatment	O
target	O
.	O

The	O
genetic	O
basis	O
for	O
variation	O
in	O
resistance	O
to	O
infection	O
in	O
the	O
Drosophila	O
melanogaster	O
genetic	O
reference	O
panel	O
.	O

Individuals	O
vary	O
extensively	O
in	O
the	O
way	O
they	O
respond	O
to	O
disease	O
but	O
the	O
genetic	O
basis	O
of	O
this	O
variation	O
is	O
not	O
fully	O
understood	O
.	O

We	O
found	O
substantial	O
individual	O
variation	O
in	O
resistance	O
and	O
tolerance	O
to	O
the	O
fungal	O
pathogen	O
Metarhizium	O
anisopliae	O
Ma549	O
using	O
the	O
Drosophila	O
melanogaster	O
Genetic	O
Reference	O
Panel	O
(	O
DGRP	O
)	O
.	O

In	O
addition	O
,	O
we	O
found	O
that	O
host	O
defense	O
to	O
Ma549	O
was	O
correlated	O
with	O
defense	O
to	O
the	O
bacterium	O
Pseudomonas	O
aeruginosa	O
Pa14	O
,	O
and	O
several	O
previously	O
published	O
DGRP	O
phenotypes	O
including	O
oxidative	O
stress	O
sensitivity	O
,	O
starvation	O
stress	O
resistance	O
,	O
hemolymph	O
glucose	B-P
levels	I-P
,	O
and	O
sleep	O
indices	O
.	O

We	O
identified	O
polymorphisms	O
associated	O
with	O
differences	O
between	O
lines	O
in	O
both	O
their	O
mean	O
survival	O
times	O
and	O
microenvironmental	O
plasticity	O
,	O
suggesting	O
that	O
lines	O
differ	O
in	O
their	O
ability	O
to	O
adapt	O
to	O
variable	O
pathogen	O
exposures	O
.	O

The	O
majority	O
of	O
polymorphisms	O
increasing	O
resistance	O
to	O
Ma549	O
were	O
sex	O
biased	O
,	O
located	O
in	O
non-coding	O
regions	O
,	O
had	O
moderately	O
large	O
effect	O
and	O
were	O
rare	O
,	O
suggesting	O
that	O
there	O
is	O
a	O
general	O
cost	O
to	O
defense	O
.	O

Nevertheless	O
,	O
host	O
defense	O
was	O
not	O
negatively	O
correlated	O
with	O
overall	O
longevity	O
and	O
fecundity	O
.	O

In	O
contrast	O
to	O
Ma549	O
,	O
minor	O
alleles	O
were	O
concentrated	O
in	O
the	O
most	O
Pa14	O
-	O
susceptible	O
as	O
well	O
as	O
the	O
most	O
Pa14	O
-	O
resistant	O
lines	O
.	O

A	O
pathway	O
based	O
analysis	O
revealed	O
a	O
network	O
of	O
Pa14	O
and	O
Ma549	O
-	O
resistance	O
genes	O
that	O
are	O
functionally	O
connected	O
through	O
processes	O
that	O
encompass	O
phagocytosis	O
and	O
engulfment	O
,	O
cell	O
mobility	O
,	O
intermediary	O
metabolism	O
,	O
protein	O
phosphorylation	O
,	O
axon	O
guidance	O
,	O
response	O
to	O
DNA	O
damage	O
,	O
and	O
drug	O
metabolism	O
.	O

Functional	O
testing	O
with	O
insertional	O
mutagenesis	O
lines	O
indicates	O
that	O
12/13	O
candidate	O
genes	O
tested	O
influence	O
susceptibility	O
to	O
Ma549	O
.	O

Many	O
candidate	O
genes	O
have	O
homologs	O
identified	O
in	O
studies	O
of	O
human	O
disease	O
,	O
suggesting	O
that	O
genes	O
affecting	O
variation	O
in	O
susceptibility	O
are	O
conserved	O
across	O
species	O
.	O

Long-term	O
outcomes	O
of	O
stereotactic	O
body	O
radiation	O
therapy	O
(	O
SBRT	O
)	O
with	O
fiducial	O
tracking	O
for	O
inoperable	O
stage	O
I	O
non-small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
.	O

Stereotactic	O
body	O
radiation	O
therapy	O
(	O
SBRT	O
)	O
for	O
stage	O
I	O
non-small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
is	O
considered	O
standard	O
of	O
care	O
in	O
the	O
medically	O
inoperable	O
patient	O
population	O
.	O

Multiple	O
methods	O
of	O
SBRT	O
delivery	O
exist	O
including	O
fiducial	O
-based	O
tumor	O
tracking	O
,	O
which	O
allows	O
for	O
smaller	O
treatment	O
margins	O
and	O
avoidance	O
of	O
patient	O
immobilization	O
devices	O
.	O

We	O
explore	O
the	O
long-term	O
clinical	O
outcomes	O
of	O
this	O
novel	O
fiducial	O
-based	O
SBRT	O
method	O
.	O

In	O
this	O
single	O
institutional	O
retrospective	O
review	O
,	O
we	O
detail	O
the	O
outcomes	O
of	O
medically	O
inoperable	O
pathologically	O
confirmed	O
stage	O
I	O
NSCLC	O
.	O

Patients	O
were	O
treated	O
with	O
the	O
Cyberknife	O
SBRT	O
system	O
using	O
a	O
planning	O
target	O
volume	O
(	O
PTV	O
)	O
defined	O
as	O
a	O
5-mm	O
expansion	O
from	O
gross	O
tumor	O
volume	O
(	O
GTV	O
)	O
without	O
creation	O
of	O
an	O
internal	O
target	O
volume	O
(	O
ITV	O
)	O
.	O

Dose	O
was	O
delivered	O
in	O
three	O
or	O
five	O
equal	O
fractions	O
of	O
10	O
to	O
20	O
Gy	O
.	O

Pretreatment	O
and	O
posttreatment	O
pulmonary	B-P
function	I-P
test	I-P
(	O
PFT	B-P
)	O
changes	O
and	O
evidence	O
of	O
late	O
radiological	B-P
rib	O
fractures	O
were	O
analyzed	O
for	O
the	O
majority	O
of	O
patients	O
.	O

Actuarial	O
local	O
control	O
,	O
locoregional	O
control	O
,	O
distant	O
control	O
,	O
and	O
overall	O
survival	O
were	O
calculated	O
using	O
the	O
Kaplan-Meier	O
method	O
.	O

Sixty-one	O
patients	O
with	O
a	O
median	O
age	O
of	O
75	O
years	O
were	O
available	O
for	O
analysis	O
.	O

The	O
majority	O
(	O
80	O
%	O
)	O
of	O
patients	O
were	O
deemed	O
to	O
be	O
medically	O
inoperable	O
due	O
to	O
underlying	O
pulmonary	O
dysfunction	O
.	O

Eleven	O
patients	O
(	O
18	O
%	O
)	O
developed	O
symptomatic	O
pneumothoraces	O
secondary	O
to	O
fiducial	O
placement	O
under	O
CT	B-P
guidance	I-P
,	O
which	O
precipitously	O
dropped	O
to	O
0	O
%	O
following	O
transition	O
to	O
bronchoscopic	O
fiducial	O
placement	O
.	O

The	O
2-year	O
rib	O
fracture	O
risk	O
was	O
21.4	O
%	O
with	O
a	O
median	O
time	O
to	O
rib	O
fracture	O
of	O
2.9	O
years	O
.	O

PFTs	B-P
averaged	O
over	O
all	O
patients	O
and	O
parameters	O
demonstrated	O
small	O
absolute	O
declines	O
,	O
5.7	O
%	O
averaged	O
PFT	B-P
decline	O
,	O
at	O
approximately	O
1	O
year	O
of	O
follow-up	O
,	O
but	O
only	O
the	O
diffusing	O
capacity	O
of	O
lung	O
for	O
carbon	O
monoxide	O
(	O
DLCO	O
)	O
demonstrated	O
a	O
statistically	O
significant	O
decline	O
(	O
10.29	O
vs.	O
9.01	O
mL/min/mmHg	O
,	O
p	O
=	O
0.01	O
)	O
.	O

Five-year	O
local	O
control	O
,	O
locoregional	O
control	O
,	O
and	O
overall	O
surviva	O
l	O
were	O
87.6	O
,	O
71.8	O
,	O
and	O
39.3	O
%	O
,	O
respectively	O
.	O

Despite	O
reduced	O
treatment	O
margins	O
and	O
lack	O
of	O
patient	O
immobilization	O
,	O
SBRT	O
with	O
fiducial	O
-based	O
tumor	O
tracking	O
achieves	O
clinically	O
comparable	O
long-term	O
outcomes	O
to	O
other	O
linac	O
-based	O
SBRT	O
approaches	O
.	O

The	O
N-Methyl	O
d-Aspartate	O
Glutamate	O
Receptor	O
Antagonist	O
Ketamine	O
Disrupts	O
the	O
Functional	O
State	O
of	O
the	O
Corticothalamic	O
Pathway	O
.	O

The	O
non-competitive	O
N-methyl	O
d-aspartate	O
glutamate	O
receptor	O
(	O
NMDAR	O
)	O
antagonist	O
ketamine	O
elicits	O
a	O
brain	O
state	O
resembling	O
high-risk	O
states	O
for	O
developing	O
psychosis	O
and	O
early	O
stages	O
of	O
schizophrenia	O
characterized	O
by	O
sensory	O
and	O
cognitive	O
deficits	O
and	O
aberrant	O
ongoing	O
gamma	O
oscillations	O
(	O
30-80	O
Hz	O
)	O
in	O
cortical	O
and	O
subcortical	O
structures	O
,	O
including	O
the	O
thalamus	O
.	O

The	O
underlying	O
mechanisms	O
are	O
unknown	O
.	O

The	O
goal	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
whether	O
a	O
ketamine	O
-	O
induced	O
psychotic	O
-	O
relevant	O
state	O
disturbs	O
the	O
functional	O
state	O
of	O
the	O
corticothalamic	O
(	O
CT	O
)	O
pathway	O
.	O

Multisite	B-P
field	I-P
recordings	I-P
were	O
performed	O
in	O
the	O
somatosensory	O
CT	O
system	O
of	O
the	O
sedated	O
rat	O
.	O

Baseline	O
activity	O
was	O
challenged	O
by	O
activation	O
of	O
vibrissa	O
-	O
related	O
prethalamic	O
inputs	O
.	O

The	O
sensory	O
-	O
evoked	O
thalamic	O
response	O
was	O
characterized	O
by	O
a	O
short	O
-	O
latency	O
(	O
∼4	O
ms	O
)	O
prethalamic	O
-mediated	O
negative	O
sharp	O
potential	O
and	O
a	O
longer	O
latency	O
(	O
∼10	O
ms	O
)	O
CT	O
-mediated	O
negative	O
potential	O
.	O

Following	O
a	O
single	O
subcutaneous	O
injection	O
of	O
ketamine	O
(	O
2.5	O
mg/kg	O
)	O
,	O
spontaneously	O
occurring	O
and	O
sensory	O
-	O
evoked	O
thalamic	O
gamma	O
oscillations	O
increased	O
and	O
decreased	O
in	O
power	O
,	O
respectively	O
.	O

The	O
power	O
of	O
the	O
sensory	O
-related	O
gamma	O
oscillations	O
was	O
positively	O
correlated	O
with	O
both	O
the	O
amplitude	O
and	O
the	O
area	O
under	O
the	O
curve	O
of	O
the	O
corresponding	O
CT	O
potential	O
but	O
not	O
with	O
the	O
prethalamic	O
potential	O
.	O

The	O
present	O
results	O
show	O
that	O
the	O
layer	O
VI	O
CT	O
pathway	O
significantly	O
contributes	O
in	O
thalamic	O
gamma	O
oscillations	O
,	O
and	O
they	O
support	O
the	O
hypothesis	O
that	O
reduced	O
NMDAR	O
activation	O
disturbs	O
the	O
functional	O
state	O
of	O
CT	O
and	O
corticocortical	O
networks	O
.	O

Beyond	O
``	O
Median	O
Waiting	O
Time	O
``	O
:	O
Development	O
and	O
Validation	O
of	O
a	O
Competing	O
Risk	O
Model	O
to	O
Predict	O
Outcomes	O
on	O
the	O
Kidney	O
Transplant	O
Waiting	O
List	O
.	O

Median	O
historical	O
time	O
to	O
kidney	O
transplant	O
is	O
misleading	O
because	O
it	O
does	O
not	O
convey	O
the	O
competing	O
risks	O
of	O
death	O
or	O
removal	O
from	O
the	O
waiting	O
list	O
.	O

We	O
developed	O
and	O
validated	O
a	O
competing	O
risk	O
model	O
to	O
calculate	O
likelihood	O
of	O
outcomes	O
for	O
kidney	O
transplant	O
candidates	O
and	O
demonstrate	O
how	O
this	O
information	O
differs	O
from	O
median	O
time	O
to	O
transplant	O
.	O

Data	O
were	O
obtained	O
from	O
the	O
US	O
Scientific	O
Registry	O
of	O
Transplant	O
Recipients	O
.	O

The	O
retrospective	O
cohort	O
included	O
163	O
636	O
adults	O
listed	O
for	O
kidney	O
transplant	O
before	O
December	O
31	O
,	O
2011	O
.	O

Predictors	O
were	O
age	O
,	O
sex	O
,	O
blood	O
type	O
,	O
calculated	B-P
panel-reactive	B-P
antibodies	I-P
,	O
donation	O
service	O
area	O
,	O
dialysis	O
duration	O
,	O
comorbid	O
conditions	O
,	O
and	O
body	O
mass	O
index	O
.	O

Outcomes	O
were	O
deceased	O
or	O
living	O
donor	O
transplant	O
,	O
death	O
or	O
removal	O
from	O
the	O
list	O
due	O
to	O
deteriorating	O
medical	O
condition	O
,	O
or	O
removal	O
due	O
to	O
other	O
reasons	O
.	O

We	O
calculated	O
hazards	O
for	O
the	O
possible	O
outcomes	O
,	O
then	O
the	O
cumulative	O
incidence	O
function	O
for	O
a	O
given	O
candidate	O
using	O
competing	O
risk	O
methodology	O
.	O

Discrimination	O
and	O
calibration	O
were	O
assessed	O
through	O
C	O
statistics	O
and	O
calibration	O
plots	O
for	O
each	O
cause	O
-	O
specific	O
Cox	O
proportional	O
hazard	O
model	O
.	O

C	O
statistics	O
ranged	O
from	O
0.64	O
to	O
0.73	O
.	O

Calibration	O
plots	O
showed	O
good	O
calibration	O
.	O

The	O
competing	O
risk	O
model	O
shows	O
probability	O
of	O
all	O
possible	O
outcomes	O
for	O
up	O
to	O
12	O
years	O
given	O
a	O
candidate	O
's	O
characteristics	O
,	O
contrasted	O
with	O
the	O
median	O
waiting	O
time	O
for	O
that	O
candidate	O
's	O
donation	O
service	O
area	O
.	O

A	O
competing	O
risk	O
model	O
conveys	O
more	O
relevant	O
information	O
than	O
the	O
median	O
waiting	O
time	O
for	O
a	O
given	O
transplant	O
center	O
.	O

This	O
model	O
will	O
be	O
updated	O
to	O
create	O
a	O
calculator	O
reflecting	O
the	O
most	O
recent	O
outcomes	O
and	O
changes	O
in	O
allocation	O
policy	O
.	O

It	O
illustrates	O
the	O
conversations	O
that	O
should	O
be	O
initiated	O
with	O
transplant	O
candidates	O
.	O

N-Terminal	O
Pro-B-Type	O
Natriuretic	O
Peptide	O
as	O
a	O
Biomarker	O
for	O
Loss	O
of	O
Muscle	O
Mass	O
in	O
Prevalent	O
Hemodialysis	O
Patients	O
.	O

Protein-energy	O
wasting	O
(	O
PEW	O
)	O
is	O
common	O
in	O
hemodialysis	O
(	O
HD	O
)	O
patients	O
.	O

A	O
recent	O
study	O
demonstrated	O
that	O
a	O
high	O
level	O
of	O
N-terminal	O
pro-B-type	O
natriuretic	O
peptide	O
(	O
NT-proBNP	O
)	O
may	O
be	O
associated	O
with	O
PEW	O
in	O
those	O
patients	O
.	O

This	O
prospective	O
study	O
aimed	O
to	O
assess	O
the	O
association	O
of	O
NT-proBNP	O
with	O
body	O
composition	O
and	O
muscle	O
loss	O
.	O

A	O
cohort	O
of	O
prevalent	O
HD	O
patients	O
(	O
n	O
=	O
238	O
)	O
was	O
examined	O
.	O

Blood	O
samples	O
were	O
obtained	O
at	O
baseline	O
to	O
measure	O
high-sensitive	O
C-reactive	O
protein	O
(	O
hsCRP	O
)	O
,	O
interleukin-6	O
(	O
IL-6	O
)	O
,	O
adiponectin	O
and	O
NT-proBNP	O
.	O

Nutritional	O
status	O
and	O
changes	O
in	O
muscle	O
mass	O
were	O
assessed	O
by	O
subjective	O
global	O
assessment	O
,	O
percentage	O
creatinine	O
generation	O
rate	O
(	O
%	O
CGR	O
)	O
,	O
creatinine	O
index	O
(	O
CI	O
)	O
and	O
lean	O
body	O
mass	O
(	O
LBM	O
)	O
estimated	O
by	O
dual-energy	B-P
X-ray	I-P
absorptiometry	I-P
(	O
DXA	B-P
)	O
.	O

The	O
%	O
CGR	O
and	O
CI	O
were	O
calculated	O
five	O
times	O
for	O
one	O
year	O
,	O
and	O
DXA	B-P
was	O
performed	O
at	O
baseline	O
and	O
one	O
year	O
later	O
.	O

Cardiac	O
function	O
was	O
estimated	O
by	O
ultrasonography	B-P
at	O
baseline	O
.	O

NT-proBNP	O
was	O
significantly	O
higher	O
in	O
HD	O
patients	O
with	O
PEW	O
.	O

High	O
NT-proBNP	O
was	O
associated	O
with	O
cardiac	O
dysfunction	O
,	O
increased	O
levels	O
of	O
hsCRP	O
and	O
IL-6	O
,	O
and	O
serially	O
decreased	O
levels	O
of	O
the	O
indexes	O
for	O
muscle	O
mass	O
.	O

Multiple	O
regression	O
analysis	O
adjusted	O
with	O
confounders	O
showed	O
that	O
NT-proBNP	O
was	O
an	O
independent	O
predictor	O
for	O
decrease	O
in	O
LBM	O
and	O
serial	O
lower	O
levels	O
of	O
%	O
CGR	O
and	O
CI	O
.	O

In	O
conclusion	O
,	O
the	O
present	O
study	O
demonstrated	O
a	O
novel	O
association	O
between	O
NT-proBNP	O
and	O
muscle	O
loss	O
.	O

NT-proBNP	O
may	O
be	O
an	O
independent	O
biomarker	O
for	O
malnutrition	O
in	O
HD	O
patients	O
,	O
especially	O
in	O
patients	O
with	O
muscles	O
loss	O
,	O
regardless	O
of	O
chronic	O
inflammation	O
,	O
cardiac	O
dysfunction	O
,	O
or	O
overhydration	O
.	O

Spinal	O
load	O
in	O
nurses	O
during	O
emergency	O
lifting	O
of	O
obese	O
patients	O
:	O
preliminary	O
results	O
.	O

Nurses	O
are	O
exposed	O
to	O
the	O
risk	O
of	O
injury	O
while	O
handling	O
patients	O
.	O

This	O
is	O
particularly	O
true	O
for	O
obese	O
patients	O
.	O

The	O
goal	O
of	O
this	O
paper	O
is	O
to	O
estimate	O
the	O
spinal	O
loads	O
and	O
the	O
related	O
risk	O
of	O
injury	O
to	O
nurses	O
while	O
lifting	O
obese	O
patients	O
from	O
the	O
floor	O
with	O
a	O
bariatric	O
sheet	O
during	O
a	O
hospital	O
emergency	O
.	O

Six	O
male	O
nurses	O
participated	O
in	O
this	O
study	O
.	O

The	O
biomechanical	B-P
analysis	I-P
focused	O
on	O
the	O
lifting	O
strategy	O
.	O

Thirty	O
obese	O
in-patients	O
were	O
enrolled	O
to	O
take	O
part	O
in	O
the	O
experimental	O
study	O
and	O
divided	O
into	O
three	O
groups	O
according	O
to	O
their	O
Body	O
Mass	O
Index	O
(	O
BMI	O
)	O
.	O

Three-dimensional	B-P
motion	I-P
analysis	I-P
was	O
conducted	O
using	O
an	O
optoelectronic	O
system	O
.	O

The	O
trunk	O
kinematics	O
and	O
the	O
loading	O
on	O
the	O
spines	O
of	O
the	O
operating	O
nurses	O
were	O
computed	B-P
.	O

Our	O
data	O
showed	O
that	O
when	O
the	O
nurse	O
was	O
operating	O
from	O
the	O
central	O
handle	O
,	O
his	O
trunk	O
was	O
more	O
flexed	O
at	O
the	O
end	O
of	O
the	O
lift	O
with	O
a	O
reduced	O
range	O
of	O
motion	O
.	O

The	O
values	O
were	O
higher	O
when	O
the	O
nurse	O
lifted	O
patients	O
with	O
higher	O
BMIs	O
.	O

All	O
kinetic	O
parameters	O
and	O
tension	O
in	O
the	O
lumbar	O
muscles	O
at	O
the	O
end	O
of	O
the	O
movement	O
were	O
characterised	O
by	O
lower	O
values	O
for	O
the	O
nurse	O
placed	O
beside	O
the	O
patient	O
's	O
head	O
or	O
feet	O
if	O
compared	O
to	O
the	O
operator	O
positioned	O
beside	O
the	O
central	O
handle	O
in	O
all	O
patient	O
groups	O
.	O

Our	O
preliminary	O
data	O
suggest	O
that	O
only	O
the	O
reaction	O
load	O
on	O
the	O
spine	O
of	O
the	O
nurse	O
holding	O
the	O
central	O
handle	O
,	O
closest	O
to	O
the	O
patient	O
's	O
centre	O
of	O
mass	O
,	O
seems	O
to	O
exceed	O
the	O
recommended	O
safety	O
limits	O
.	O

Propensity	O
-	O
matched	O
Analysis	O
of	O
Outcomes	O
and	O
Hospital	O
Charges	O
for	O
Anterior	O
Versus	O
Posterior	O
Cervical	O
Fusion	O
for	O
Cervical	O
Spondylotic	O
Myelopathy	O
.	O

Retrospective	O
analysis	O
of	O
data	O
from	O
the	O
Nationwide	O
Inpatient	O
Sample	O
,	O
a	O
nationally	O
representative	O
,	O
all-payer	O
database	O
of	O
inpatient	O
diagnoses	B-P
and	I-P
procedures	I-P
in	O
the	O
United	O
States	O
.	O

The	O
objective	O
of	O
this	O
study	O
is	O
to	O
compare	O
anterior	O
cervical	O
fusion	O
(	O
ACF	O
)	O
to	O
posterior	O
cervical	O
fusion	O
(	O
PCF	O
)	O
in	O
the	O
treatment	O
of	O
cervical	O
spondylotic	O
myelopathy	O
(	O
CSM	O
)	O
.	O

Previous	O
studies	O
used	O
retrospective	O
single	O
-	O
institution	O
level	O
data	O
to	O
quantify	O
outcomes	O
for	O
CSM	O
patients	O
fusion	O
.	O

It	O
is	O
unclear	O
whether	O
ACF	O
or	O
PCF	O
is	O
superior	O
with	O
regards	O
to	O
charges	O
or	O
outcomes	O
for	O
the	O
treatment	O
of	O
CSM	O
.	O

We	O
used	O
Nationwide	O
Inpatient	O
Sample	O
data	O
to	O
compare	O
ACF	O
to	O
PCF	O
in	O
the	O
management	O
of	O
CSM	O
.	O

All	O
patients	O
18	O
years	O
or	O
older	O
with	O
a	O
diagnosis	B-P
of	O
CSM	O
between	O
1998	O
and	O
2011	O
were	O
included	O
.	O

ACF	O
patients	O
were	O
matched	O
to	O
PCF	O
patients	O
using	O
propensity	O
scores	O
based	O
on	O
patient	O
characteristics	O
(	O
number	O
of	O
levels	O
fused	O
,	O
spine	O
alignment	O
,	O
comorbidities	O
)	O
,	O
hospital	O
characteristics	O
,	O
and	O
patient	O
demographics	O
.	O

Multivariable	O
regression	O
was	O
used	O
to	O
measure	O
the	O
effect	O
of	O
treatment	O
assignment	O
on	O
in-	O
hospital	O
charges	O
,	O
length	O
of	O
hospital	O
stay	O
,	O
in-hospital	O
mortality	O
,	O
discharge	O
disposition	O
,	O
and	O
dysphagia	O
diagnosis	B-P
.	O

From	O
1998	O
to	O
2011	O
,	O
we	O
identified	O
109,728	O
hospitalizations	O
with	O
a	O
CSM	O
diagnosis	B-P
.	O

Of	O
these	O
patients	O
,	O
45,629	O
(	O
41.6	O
%	O
)	O
underwent	O
ACF	O
and	O
14,439	O
(	O
13.2	O
%	O
)	O
underwent	O
PCF	O
.	O

The	O
PCF	O
cohort	O
incurred	O
an	O
average	O
of	O
$	O
41,683	O
more	O
in-hospital	O
charges	O
(	O
P	O
<	O
0.001	O
,	O
inflation	O
adjusted	O
to	O
2011	O
dollars	O
)	O
and	O
remained	O
in	O
hospital	O
an	O
average	O
of	O
2.4	O
days	O
longer	O
(	O
P	O
<	O
0.001	O
)	O
than	O
the	O
ACF	O
cohort	O
.	O

The	O
ACF	O
cohort	O
was	O
just	O
as	O
likely	O
to	O
die	O
in	O
the	O
hospital	O
[	O
odds	O
ratio	O
0.91	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
,	O
0.68-1.2	O
]	O
,	O
3.0	O
times	O
more	O
likely	O
to	O
be	O
discharged	O
to	O
home	O
or	O
self-care	O
(	O
95	O
%	O
CI	O
,	O
2.9-3.2	O
)	O
,	O
and	O
2.5	O
times	O
more	O
likely	O
to	O
experience	O
dysphagia	O
(	O
95	O
%	O
CI	O
,	O
2.0-3.1	O
)	O
than	O
the	O
PCF	O
cohort	O
.	O

In	O
treating	O
CSM	O
,	O
ACF	O
led	O
to	O
lower	O
hospital	O
charges	O
,	O
shorter	O
hospital	O
stays	O
,	O
and	O
an	O
increased	O
likelihood	O
of	O
being	O
discharged	O
to	O
home	O
relative	O
to	O
PCF	O
.	O

Is	O
minimally	O
invasive	O
thoracoscopic	O
surgery	O
the	O
new	O
benchmark	O
for	O
treating	O
mitral	O
valve	O
disease	O
?	O
.	O

The	O
treatment	O
of	O
mitral	O
valve	O
disease	O
remains	O
dynamic	O
;	O
surgeons	O
and	O
patients	O
must	O
now	O
choose	O
between	O
many	O
different	O
surgical	O
options	O
when	O
addressing	O
mitral	O
regurgitation	O
and	O
mitral	O
stenosis	O
.	O

Notably	O
,	O
advances	O
in	O
imaging	B-P
and	O
surgical	O
instrumentation	O
allow	O
surgeons	O
to	O
perform	O
less	O
invasive	O
mitral	O
valve	O
surgery	O
that	O
spares	O
the	O
sternum	O
.	O

With	O
favorable	O
long-term	O
data	O
now	O
emerging	O
,	O
we	O
compare	O
the	O
benefits	O
and	O
risks	O
of	O
thoracoscopic	O
mitral	O
valve	O
surgery	O
with	O
that	O
through	O
conventional	O
sternotomy	O
or	O
surgery	O
that	O
is	O
robot-assisted	O
.	O

Physicochemical	O
characterization	O
of	O
chitosan	O
-	O
hyaluronan	O
-coated	O
solid	O
lipid	O
nanoparticles	O
for	O
the	O
targeted	O
delivery	O
of	O
paclitaxel	O
:	O
a	O
proof-of-concept	O
study	O
in	O
breast	O
cancer	O
cells	O
.	O

To	O
investigate	O
the	O
potential	O
of	O
modified	O
solid	O
lipid	O
nanoparticles	O
(	O
SLN	O
)	O
for	O
the	O
delivery	O
of	O
paclitaxel	O
(	O
PAX	O
)	O
.	O

SLN	O
loaded	O
with	O
PAX	O
were	O
prepared	O
via	O
modified	O
high-pressure	B-P
hot	I-P
homogenization	I-P
.	O

Formulation	O
parameters	O
were	O
optimized	O
to	O
obtain	O
a	O
high-quality	O
delivery	O
system	O
.	O

SLN	O
cores	O
were	O
coated	O
,	O
layer-by-layer	O
,	O
with	O
a	O
chitosan	O
and	O
hyaluronan	O
(	O
HA	O
)	O
shell	O
.	O

Selectivity	O
toward	O
HA	O
receptors	O
was	O
tested	O
in	O
a	O
breast	O
cancer	O
cell	O
line	O
,	O
MCF-7	O
.	O

Stable	O
and	O
reproducible	O
nano-sized	O
and	O
negatively	O
charged	O
nanoparticles	O
resulted	O
.	O

Findings	O
reveal	O
that	O
chitosan	O
-	O
HA	O
-coated	O
SLN	O
facilitated	O
the	O
targeting	O
,	O
cellular	O
uptake	O
and	O
the	O
time-/dose-controlled	O
delivery	O
and	O
release	O
of	O
PAX	O
,	O
enhancing	O
intrinsic	O
chemotherapeutic	O
activities	O
.	O

SLN	O
are	O
suitable	O
carrier	O
candidates	O
for	O
nano-oncology	O
given	O
their	O
localized	O
,	O
and	O
potent	O
cytotoxic	O
potential	O
overcoming	O
multidrug-resistant	O
cancer	O
cells	O
.	O

Appearance	O
Differences	O
Between	O
Lots	O
and	O
Brands	O
of	O
Similar	O
Shade	O
Designations	O
of	O
Dental	O
Composite	O
Resins	O
.	O

The	O
purposes	O
of	O
this	O
study	O
were	O
to	O
investigate	O
differences	O
in	O
two	O
inherent	O
appearance	O
characteristics	O
between	O
lots	O
of	O
an	O
enamel	O
dental	O
composite	O
resin	O
of	O
the	O
same	O
shade	O
and	O
brand	O
,	O
and	O
to	O
further	O
compare	O
these	O
differences	O
to	O
those	O
of	O
similar	O
shade	O
designation	O
of	O
a	O
different	O
brand	O
of	O
dental	O
composite	O
resins	O
.	O

Appearance	O
analyses	O
proceeded	O
for	O
three	O
different	O
lots	O
of	O
shades	O
A1	O
,	O
B2	O
,	O
and	O
D3	O
manufactured	O
by	O
one	O
company	O
and	O
for	O
one	O
lot	O
of	O
shade	O
EA1	O
manufactured	O
by	O
another	O
.	O

Samples	O
were	O
measured	O
on	O
black	O
,	O
white	O
,	O
and	O
gray	O
backings	O
using	O
spectroradiometry	B-P
.	O

Kubelka-Munk	O
theory	O
was	O
used	O
to	O
determine	O
reflectivity	O
of	O
each	O
lot	O
studied	O
.	O

CIELAB	O
values	O
and	O
color	O
differences	O
between	O
shades	O
and	O
lots	O
were	O
analyzed	O
.	O

Translucency	O
indicators	O
were	O
compared	O
between	O
lots	O
over	O
thicknesses	O
from	O
0.5	O
to	O
3.0	O
mm	O
.	O

Differences	O
in	O
inherent	O
color	O
between	O
some	O
lots	O
of	O
same	O
shade	O
designations	O
within	O
a	O
brand	O
were	O
found	O
to	O
be	O
above	O
the	O
acceptability	O
threshold	O
.	O

Color	O
difference	O
between	O
an	O
enamel	O
composite	O
resin	O
of	O
shade	O
A1	O
and	O
a	O
composite	O
resin	O
of	O
shade	O
EA1	O
was	O
also	O
above	O
the	O
acceptability	O
threshold	O
.	O

Statistically	O
significant	O
differences	O
in	O
the	O
translucency	O
were	O
found	O
between	O
some	O
lots	O
of	O
one	O
shade	O
over	O
the	O
entire	O
range	O
of	O
thicknesses	O
studied	O
.	O

Appearance	O
analyses	O
indicate	O
substantial	O
variation	O
between	O
lots	O
of	O
same	O
shade	O
designations	O
as	O
well	O
as	O
between	O
brands	O
of	O
similar	O
shade	O
designations	O
.	O

Optical	O
principles	O
applied	O
to	O
important	O
clinical	O
appearance	O
attributes	O
are	O
described	O
which	O
characterize	O
inherent	O
appearance	O
attributes	O
and	O
provide	O
aid	O
in	O
the	O
appearance	O
matching	O
process	O
for	O
dental	O
composite	O
resins	O
used	O
in	O
restorative	O
and	O
operative	O
dental	O
procedures	O
.	O

(	O
J	O
Esthet	O
Restor	O
Dent	O
29	O
:	O
E6-E14	O
,	O
2017	O
)	O
.	O

Design	O
,	O
synthesis	O
and	O
anti-tumor	O
activity	O
study	O
of	O
novel	O
histone	O
deacetylase	O
inhibitors	O
containing	O
isatin	O
-based	O
caps	O
and	O
o-phenylenediamine	O
-based	O
zinc	O
binding	O
groups	O
.	O

As	O
a	O
hot	O
topic	O
of	O
epigenetic	O
studies	O
,	O
histone	O
deacetylases	O
(	O
HDACs	O
)	O
are	O
related	O
to	O
lots	O
of	O
diseases	O
,	O
especially	O
cancer	O
.	O

Further	O
researches	O
indicated	O
that	O
different	O
HDAC	O
isoforms	O
played	O
various	O
roles	O
in	O
a	O
wide	O
range	O
of	O
tumor	O
types	O
.	O

Herein	O
a	O
novel	O
series	O
of	O
HDAC	O
inhibitors	O
with	O
isatin	O
-based	O
caps	O
and	O
o-phenylenediamine	O
-based	O
zinc	O
binding	O
groups	O
have	O
been	O
designed	O
and	O
synthesized	O
through	O
scaffold	B-P
hopping	I-P
strategy	I-P
.	O

Among	O
these	O
compounds	O
,	O
the	O
most	O
potent	O
compound	O
9n	O
exhibited	O
similar	O
if	O
not	O
better	O
HDAC	O
inhibition	O
and	O
antiproliferative	O
activities	O
against	O
multiple	O
tumor	O
cell	O
lines	O
compared	O
with	O
the	O
positive	O
control	O
entinostat	O
(	O
MS-275	O
)	O
.	O

Additionally	O
,	O
compared	O
with	O
MS-275	O
(	O
IC50	O
values	O
for	O
HDAC1	O
,	O
2	O
and	O
3	O
were	O
0.163	O
,	O
0.396	O
and	O
0.605µM	O
,	O
respectively	O
)	O
,	O
compound	O
9n	O
with	O
IC50	O
values	O
of	O
0.032	O
,	O
0.256	O
and	O
0.311µM	O
for	O
HDAC1	O
,	O
2	O
and	O
3	O
respectively	O
,	O
showed	O
a	O
moderate	O
HDAC1	O
selectivity	O
.	O

Optogenetic	O
Demonstration	O
of	O
Functional	O
Innervation	O
of	O
Mouse	O
Colon	O
by	O
Neurons	O
Derived	O
From	O
Transplanted	O
Neural	O
Cells	O
.	O

Cell	O
therapy	O
offers	O
the	O
potential	O
to	O
treat	O
gastrointestinal	O
motility	O
disorders	O
caused	O
by	O
diseased	O
or	O
absent	O
enteric	O
neurons	O
.	O

We	O
examined	O
whether	O
neurons	O
generated	O
from	O
transplanted	O
enteric	O
neural	O
cells	O
provide	O
a	O
functional	O
innervation	O
of	O
bowel	O
smooth	O
muscle	O
in	O
mice	O
.	O

Enteric	O
neural	O
cells	O
expressing	O
the	O
light-sensitive	O
ion	O
channel	O
,	O
channelrhodopsin	O
,	O
were	O
isolated	O
from	O
the	O
fetal	O
or	O
postnatal	O
mouse	O
bowel	O
and	O
transplanted	O
into	O
the	O
distal	O
colon	O
of	O
3-	O
to	O
4-	O
week	O
-old	O
wild-type	O
recipient	O
mice	O
.	O

Intracellular	O
electrophysiological	B-P
recordings	I-P
of	O
responses	O
to	O
light	O
stimulation	O
of	O
the	O
transplanted	O
cells	O
were	O
made	O
from	O
colonic	O
smooth	O
muscle	O
cells	O
in	O
recipient	O
mice	O
.	O

Electrical	O
stimulation	O
of	O
endogenous	O
enteric	O
neurons	O
was	O
used	O
as	O
a	O
control	O
.	O

The	O
axons	O
of	O
graft	O
-derived	O
neurons	O
formed	O
a	O
plexus	O
in	O
the	O
circular	O
muscle	O
layer	O
.	O

Selective	O
stimulation	O
of	O
graft	O
-derived	O
cells	O
by	O
light	O
resulted	O
in	O
excitatory	O
and	O
inhibitory	O
junction	O
potentials	O
,	O
the	O
electrical	O
events	O
underlying	O
contraction	O
and	O
relaxation	O
,	O
respectively	O
,	O
in	O
colonic	O
muscle	O
cells	O
.	O

Graft	O
-derived	O
excitatory	O
and	O
inhibitory	O
motor	O
neurons	O
released	O
the	O
same	O
neurotransmitters	O
as	O
endogenous	O
motor	O
neurons	O
-	O
acetylcholine	O
and	O
a	O
combination	O
of	O
adenosine	O
triphosphate	O
and	O
nitric	O
oxide	O
,	O
respectively	O
.	O

Graft	O
-derived	O
neurons	O
also	O
included	O
interneurons	O
that	O
provided	O
synaptic	O
inputs	O
to	O
motor	O
neurons	O
,	O
but	O
the	O
pharmacologic	O
properties	O
of	O
interneurons	O
varied	O
with	O
the	O
age	O
of	O
the	O
donors	O
from	O
which	O
enteric	O
neural	O
cells	O
were	O
obtained	O
.	O

Enteric	O
neural	O
cells	O
transplanted	O
into	O
the	O
bowel	O
give	O
rise	O
to	O
multiple	O
functional	O
types	O
of	O
neurons	O
that	O
integrate	O
and	O
provide	O
a	O
functional	O
innervation	O
of	O
the	O
smooth	O
muscle	O
of	O
the	O
bowel	O
wall	O
.	O

Circuits	O
composed	O
of	O
both	O
motor	O
neurons	O
and	O
interneurons	O
were	O
established	O
,	O
but	O
the	O
age	O
at	O
which	O
cells	O
are	O
isolated	O
influences	O
the	O
neurotransmitter	O
phenotype	O
of	O
interneurons	O
that	O
are	O
generated	O
.	O

In	O
vitro	O
screening	B-P
and	O
in	O
silico	O
validation	O
revealed	O
key	O
microbes	O
for	O
higher	O
production	O
of	O
significant	O
therapeutic	O
enzyme	O
l-asparaginase	O
.	O

l-asparaginase	O
is	O
an	O
enzyme	O
of	O
medical	O
prominence	O
and	O
reputable	O
as	O
a	O
chemotherapeutic	O
agent	O
.	O

It	O
also	O
has	O
immense	O
potential	O
to	O
cure	O
autoimmune	O
and	O
infectious	O
diseases	O
.	O

The	O
vast	O
application	O
of	O
this	O
enzyme	O
in	O
healthcare	O
sector	O
increases	O
its	O
market	O
demand	O
.	O

However	O
,	O
presently	O
the	O
huge	O
market	O
demand	O
is	O
not	O
achieved	O
completely	O
.	O

This	O
serves	O
the	O
basis	O
to	O
explore	O
better	O
producer	O
microbial	O
strains	O
to	O
bridge	O
the	O
gap	O
between	O
huge	O
demand	O
and	O
supply	O
of	O
this	O
therapeutic	O
enzyme	O
.	O

The	O
present	O
study	O
deals	O
with	O
the	O
successful	O
screening	B-P
of	O
potent	O
microorganisms	O
producing	O
l-asparaginase	O
.	O

47	O
microorganisms	O
were	O
screened	B-P
including	O
bacteria	O
,	O
fungi	O
,	O
and	O
yeasts	O
.	O

Among	O
all	O
,	O
Penicillium	O
lilacinum	O
showed	O
the	O
highest	O
enzyme	O
activity	O
i.e.	O
,	O
39.67	O
IU/ml	O
.	O

Shigella	O
flexneri	O
has	O
23.21	O
IU/ml	O
of	O
enzyme	O
activity	O
(	O
highest	O
among	O
all	O
the	O
bacterial	O
strain	O
tested	O
)	O
.	O

Further	O
,	O
the	O
3-D	O
structure	O
of	O
l-asparaginase	O
from	O
higher	O
producer	O
strains	O
was	O
developed	O
and	O
validated	O
in	O
silico	O
for	O
its	O
activity	O
.	O

l-asparagine	O
(	O
substrate	O
for	O
l-asparaginase	O
)	O
was	O
docked	O
inside	O
the	O
binding	O
pocket	O
of	O
P.	O
lilacinum	O
and	O
S.	O
flexneri	O
.	O

Docking	O
score	O
for	O
the	O
most	O
common	O
substrate	O
l-asparagine	O
is	O
-6.188	O
(	O
P.	O
lilacinum	O
)	O
,	O
-5.576	O
(	O
S.	O
flexneri	O
)	O
which	O
is	O
quite	O
good	O
.	O

Moreover	O
,	O
the	O
chemical	O
property	O
of	O
the	O
binding	O
pocket	O
revealed	O
that	O
amino	O
acid	O
residues	O
Phe	O
243	O
,	O
Gln	O
260	O
,	O
Gly	O
365	O
,	O
Asp	O
386	O
in	O
P.	O
lilacinum	O
and	O
residues	O
Asp	O
181	O
,	O
Thr	O
318	O
,	O
Asn	O
320	O
in	O
S.	O
flexneri	O
have	O
an	O
important	O
role	O
in	O
H-bonding	O
.	O

The	O
in	O
silico	O
results	O
supports	O
and	O
strengthen	O
the	O
wet	O
lab	O
results	O
.	O

The	O
outcome	O
obtained	O
motivates	O
to	O
take	O
the	O
present	O
study	O
result	O
from	O
lab	O
to	O
industry	O
for	O
the	O
economic	O
/	O
massive	O
production	O
of	O
this	O
enzyme	O
for	O
the	O
diverse	O
therapeutic	O
application	O
.	O

Recurrent	O
noncoding	O
regulatory	O
mutations	O
in	O
pancreatic	O
ductal	O
adenocarcinoma	O
.	O

The	O
contributions	O
of	O
coding	O
mutations	O
to	O
tumorigenesis	O
are	O
relatively	O
well	O
known	O
;	O
however	O
,	O
little	O
is	O
known	O
about	O
somatic	O
alterations	O
in	O
noncoding	O
DNA	O
.	O

Here	O
we	O
describe	O
GECCO	O
(	O
Genomic	O
Enrichment	O
Computational	O
Clustering	O
Operation	O
)	O
to	O
analyze	O
somatic	O
noncoding	O
alterations	O
in	O
308	O
pancreatic	O
ductal	O
adenocarcinomas	O
(	O
PDAs	O
)	O
and	O
identify	O
commonly	O
mutated	O
regulatory	O
regions	O
.	O

We	O
find	O
recurrent	O
noncoding	O
mutations	O
to	O
be	O
enriched	O
in	O
PDA	O
pathways	O
,	O
including	O
axon	O
guidance	O
and	O
cell	O
adhesion	O
,	O
and	O
newly	O
identified	O
processes	O
,	O
including	O
transcription	O
and	O
homeobox	O
genes	O
.	O

We	O
identified	O
mutations	O
in	O
protein	O
binding	O
sites	O
correlating	O
with	O
differential	O
expression	O
of	O
proximal	O
genes	O
and	O
experimentally	O
validated	O
effects	O
of	O
mutations	O
on	O
expression	O
.	O

We	O
developed	O
an	O
expression	O
modulation	O
score	O
that	O
quantifies	O
the	O
strength	O
of	O
gene	O
regulation	O
imposed	O
by	O
each	O
class	O
of	O
regulatory	O
elements	O
,	O
and	O
found	O
the	O
strongest	O
elements	O
were	O
most	O
frequently	O
mutated	O
,	O
suggesting	O
a	O
selective	O
advantage	O
.	O

Our	O
detailed	O
single-cancer	B-P
analysis	I-P
of	O
noncoding	O
alterations	O
identifies	O
regulatory	O
mutations	O
as	O
candidates	O
for	O
diagnostic	O
and	O
prognostic	O
markers	O
,	O
and	O
suggests	O
new	O
mechanisms	O
for	O
tumor	O
evolution	O
.	O

Construction	O
of	O
an	O
Acetylcholinesterase	O
Sensor	O
Based	O
on	O
Synthesized	O
Paramagnetic	O
Nanoparticles	O
,	O
a	O
Simple	O
Tool	O
for	O
Neurotoxic	O
Compounds	O
Assay	B-P
.	O

Magnetic	O
particles	O
(	O
MPs	O
)	O
have	O
been	O
widely	O
used	O
in	O
biological	O
applications	O
in	O
recent	O
years	O
as	O
a	O
carrier	O
for	O
various	O
molecules	O
.	O

Their	O
big	O
advantage	O
is	O
in	O
repeated	O
use	O
of	O
immobilized	O
molecules	O
including	O
enzymes	O
.	O

Acetylcholinesterase	O
(	O
AChE	O
)	O
is	O
an	O
enzyme	O
playing	O
crucial	O
role	O
in	O
neurotransmission	O
and	O
the	O
enzyme	O
is	O
targeted	O
by	O
various	O
molecules	O
like	O
Alzheimer	O
's	O
drugs	O
,	O
pesticides	O
and	O
warfare	O
agents	O
.	O

In	O
this	O
work	O
,	O
an	O
electrochemical	O
biosensor	O
having	O
AChE	O
immobilized	O
onto	O
MPs	O
and	O
stabilized	O
through	O
glutaraldehyde	O
(	O
GA	O
)	O
molecule	O
was	O
proposed	O
for	O
assay	B-P
of	O
the	O
neurotoxic	O
compounds	O
.	O

The	O
prepared	O
nanoparticles	O
were	O
modified	O
by	O
pure	O
AChE	O
and	O
they	O
were	O
used	O
for	O
the	O
measurement	O
anti-Alzheimer	O
's	O
drug	O
galantamine	O
and	O
carbamate	O
pesticide	O
carbofuran	O
with	O
limit	O
of	O
detection	O
1.5	O
µM	O
and	O
20	O
nM	O
,	O
respectively	O
.	O

All	O
measurements	O
were	O
carried	O
out	O
using	O
screen-printed	O
sensor	O
with	O
carbon	O
working	O
,	O
silver	O
reference	O
,	O
and	O
carbon	O
auxiliary	O
electrode	O
.	O

Standard	B-P
Ellman	I-P
's	I-P
assay	I-P
was	O
used	O
for	O
validation	O
measurement	O
of	O
both	O
inhibitors	O
.	O

Part	O
of	O
this	O
work	O
was	O
the	O
elimination	O
of	O
reversible	O
inhibitors	O
represented	O
by	O
galantamine	O
from	O
the	O
active	O
site	O
of	O
AChE	O
.	O

For	O
this	O
purpose	O
,	O
we	O
used	O
a	O
lower	O
pH	O
to	O
get	O
the	O
original	O
activity	O
of	O
AChE	O
after	O
inhibition	O
by	O
galantamine	O
.	O

We	O
also	O
observed	O
decarbamylation	O
of	O
the	O
AChE	O
-	O
carbofuran	O
adduct	O
.	O

Influence	O
of	O
organic	O
solvents	O
to	O
AChE	O
as	O
well	O
as	O
repeatability	O
of	O
measurement	O
with	O
MPs	O
with	O
AChE	O
was	O
also	O
established	O
.	O

A	O
Feasibility	O
Study	O
of	O
Telementoring	O
for	O
Identifying	O
the	O
Appendix	O
Using	O
Smartphone	O
-Based	O
Telesonography	B-P
.	O

We	O
investigated	O
the	O
feasibility	O
of	O
the	O
clinical	O
application	O
of	O
novice	O
-	O
practitioner	O
-	O
performed	O
/	O
offsite	O
-	O
mentor	O
-guided	O
ultrasonography	B-P
for	O
identifying	O
the	O
appendix	O
.	O

A	O
randomized	O
crossover	O
study	O
was	O
conducted	O
using	O
a	O
telesonography	O
system	O
that	O
can	O
transmit	O
the	O
ultrasound	B-P
images	O
displayed	O
on	O
the	O
ultrasound	O
monitor	O
(	O
ultrasound	O
sequence	O
video	O
)	O
and	O
images	O
showing	O
the	O
practitioner	O
's	O
operations	O
(	O
background	O
video	O
)	O
to	O
a	O
smartphone	O
without	O
any	O
interruption	O
in	O
motion	O
over	O
a	O
Long-Term	O
Evolution	O
(	O
LTE	O
)	O
network	O
.	O

Thirty	O
novice	O
practitioners	O
were	O
randomly	O
assigned	O
to	O
two	O
groups	O
.	O

The	O
subjects	O
in	O
group	O
A	O
(	O
n	O
=	O
15	O
)	O
performed	O
ultrasonography	B-P
for	O
the	O
identification	O
of	O
the	O
appendix	O
under	O
mentoring	O
by	O
an	O
onsite	O
expert	O
,	O
whereas	O
those	O
in	O
group	O
B	O
(	O
n	O
=	O
15	O
)	O
performed	O
the	O
same	O
procedure	B-P
under	O
mentoring	O
by	O
an	O
offsite	O
expert	O
.	O

Each	O
subject	O
performed	O
the	O
procedure	B-P
on	O
three	O
simulated	O
patients	O
.	O

After	O
a	O
4-	O
week	O
interval	O
,	O
they	O
performed	O
the	O
procedure	B-P
again	O
under	O
the	O
other	O
type	O
of	O
mentoring	O
.	O

A	O
total	O
of	O
90	O
ultrasound	B-P
examinations	O
were	O
performed	O
in	O
each	O
scenario	O
.	O

The	O
primary	O
outcomes	O
were	O
the	O
success	O
rate	O
for	O
identifying	O
the	O
appendix	O
and	O
the	O
time	O
required	O
to	O
identify	O
the	O
appendix	O
.	O

The	O
success	O
rates	O
for	O
identifying	O
the	O
appendix	O
were	O
91.1	O
%	O
(	O
82/90	O
)	O
in	O
onsite	O
-	O
mentored	O
ultrasonography	B-P
and	O
87.8	O
%	O
(	O
79/90	O
)	O
in	O
offsite	O
-	O
mentored	O
ultrasonography	B-P
;	O
both	O
rates	O
were	O
high	O
,	O
and	O
there	O
was	O
no	O
significant	O
difference	O
(	O
p	O
=	O
0.468	O
)	O
between	O
them	O
.	O

The	O
time	O
required	O
in	O
the	O
case	O
of	O
offsite	O
mentoring	O
(	O
median	O
,	O
242.9	O
s	O
;	O
interquartile	O
range	O
(	O
IQR	O
)	O
,	O
238.2	O
)	O
was	O
longer	O
than	O
that	O
for	O
onsite	O
mentoring	O
(	O
median	O
,	O
291.4	O
s	O
;	O
IQR	O
,	O
200.9	O
)	O
;	O
however	O
,	O
the	O
difference	O
was	O
not	O
significant	O
(	O
p	O
=	O
0.051	O
)	O
.	O

It	O
appears	O
that	O
offsite	O
mentoring	O
can	O
allow	O
novice	O
onsite	O
practitioners	O
to	O
perform	O
ultrasonography	B-P
as	O
effectively	O
as	O
they	O
can	O
under	O
onsite	O
mentoring	O
,	O
even	O
for	O
examinations	O
that	O
require	O
proficiency	O
in	O
rather	O
complex	O
practices	O
,	O
such	O
as	O
identifying	O
the	O
appendix	O
.	O

T2-Imaging	B-P
Changes	O
in	O
the	O
Nigrosome-1	O
Relate	O
to	O
Clinical	O
Measures	O
of	O
Parkinson	O
's	O
Disease	O
.	O

The	O
nigrosome-1	O
region	O
of	O
the	O
substantia	O
nigra	O
(	O
SN	O
)	O
undergoes	O
the	O
greatest	O
and	O
earliest	O
dopaminergic	O
neuron	O
loss	O
in	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
.	O

As	O
T2-weighted	B-P
magnetic	I-P
resonance	I-P
imaging	I-P
(	I-P
MRI	I-P
)	I-P
scans	I-P
are	O
often	O
collected	O
with	O
routine	O
clinical	O
MRI	B-P
protocols	O
,	O
this	O
investigation	O
aims	O
to	O
determine	O
whether	O
T2-imaging	B-P
changes	O
in	O
the	O
nigrosome-1	O
are	O
related	O
to	O
clinical	O
measures	O
of	O
PD	O
and	O
to	O
assess	O
their	O
potential	O
as	O
a	O
more	O
clinically	O
accessible	O
biomarker	O
for	O
PD	O
.	O

Voxel	O
intensity	O
ratios	O
were	O
calculated	O
for	O
T2-weighted	B-P
MRI	I-P
scans	I-P
from	O
47	O
subjects	O
from	O
the	O
Parkinson	O
's	O
Progression	O
Markers	O
Initiative	O
database	O
.	O

Three	O
approaches	O
were	O
used	O
to	O
delineate	O
the	O
SN	O
and	O
nigrosome-1	O
:	O
(	O
1	O
)	O
manual	O
segmentation	B-P
,	O
(	O
2	O
)	O
automated	O
segmentation	B-P
,	O
and	O
(	O
3	O
)	O
area	O
voxel	O
-based	O
morphometry	B-P
.	O

Voxel	O
intensity	O
ratios	O
were	O
calculated	O
from	O
voxel	O
intensity	O
values	O
taken	O
from	O
the	O
nigrosome-1	O
and	O
two	O
areas	O
of	O
the	O
remaining	O
SN	O
.	O

Linear	O
regression	O
analyses	O
were	O
conducted	O
relating	O
voxel	O
intensity	O
ratios	O
with	O
the	O
Movement	O
Disorder	O
Society-Unified	O
Parkinson	O
's	O
Disease	O
Rating	O
Scale	O
(	O
MDS-UPDRS	O
)	O
sub-scores	O
for	O
each	O
subject	O
.	O

For	O
manual	O
segmentation	B-P
,	O
linear	O
regression	O
tests	O
consistently	O
identified	O
the	O
voxel	O
intensity	O
ratio	O
derived	O
from	O
the	O
dorsolateral	O
SN	O
and	O
nigrosome-1	O
(	O
IR2	O
)	O
as	O
predictive	O
of	O
nBehav	O
(	O
p	O
=	O
0.0377	O
)	O
and	O
nExp	O
(	O
p	O
=	O
0.03856	O
)	O
.	O

For	O
automated	O
segmentation	B-P
,	O
linear	O
regression	O
tests	O
identified	O
IR2	O
as	O
predictive	O
of	O
Subscore	O
IA	O
(	O
nBehav	O
)	O
(	O
p	O
=	O
0.01134	O
)	O
,	O
Subscore	O
IB	O
(	O
nExp	O
)	O
(	O
p	O
=	O
0.00336	O
)	O
,	O
Score	O
II	O
(	O
mExp	O
)	O
(	O
p	O
=	O
0.02125	O
)	O
,	O
and	O
Score	O
III	O
(	O
mSign	O
)	O
(	O
p	O
=	O
0.008139	O
)	O
.	O

For	O
the	O
voxel	O
-based	O
morphometric	B-P
approach	I-P
,	O
univariate	O
simple	O
linear	O
regression	O
analysis	O
identified	O
IR2	O
as	O
yielding	O
significant	O
results	O
for	O
nBehav	O
(	O
p	O
=	O
0.003102	O
)	O
,	O
mExp	O
(	O
p	O
=	O
0.0172	O
)	O
,	O
and	O
mSign	O
(	O
p	O
=	O
0.00393	O
)	O
.	O

Neuroimaging	B-P
biomarkers	O
may	O
be	O
used	O
as	O
a	O
proxy	O
of	O
changes	O
in	O
the	O
nigrosome-1	O
,	O
measured	O
by	O
MDS-UPDRS	O
scores	O
as	O
an	O
indicator	O
of	O
the	O
severity	O
of	O
PD	O
.	O

The	O
voxel	O
intensity	O
ratio	O
derived	O
from	O
the	O
dorsolateral	O
SN	O
and	O
nigrosome-1	O
was	O
consistently	O
predictive	O
of	O
non-motor	O
complex	O
behaviors	O
in	O
all	O
three	O
analyses	O
and	O
predictive	O
of	O
non-motor	O
experiences	O
of	O
daily	O
living	O
,	O
motor	O
experiences	O
of	O
daily	O
living	O
,	O
and	O
motor	O
signs	O
of	O
PD	O
in	O
two	O
of	O
the	O
three	O
analyses	O
.	O

These	O
results	O
suggest	O
that	O
T2	O
changes	O
in	O
the	O
nigrosome-1	O
may	O
relate	O
to	O
certain	O
clinical	O
measures	O
of	O
PD	O
.	O

T2	O
changes	O
in	O
the	O
nigrosome-1	O
may	O
be	O
considered	O
when	O
developing	O
a	O
more	O
accessible	O
clinical	O
diagnostic	B-P
tool	I-P
for	O
patients	O
with	O
suspected	O
PD	O
.	O

Espindolol	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
cachexia	O
in	O
patients	O
with	O
stage	O
III/IV	O
non-small	O
cell	O
lung	O
cancer	O
or	O
colorectal	O
cancer	O
:	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
,	O
international	O
multicentre	O
phase	O
II	O
study	O
(	O
the	O
ACT-ONE	O
trial	O
)	O
.	O

Cancer	O
cachexia	O
is	O
a	O
major	O
cause	O
of	O
morbidity	O
and	O
mortality	O
with	O
no	O
widely	O
approved	O
treatment	O
.	O

The	O
ACT-ONE	O
trial	O
is	O
a	O
randomized	O
,	O
double-blind	O
,	O
parallel	O
group	O
,	O
placebo-controlled	O
,	O
phase	O
II	O
multicentre	O
trial	O
in	O
patients	O
(	O
25-80	O
years	O
)	O
with	O
stages	O
III	O
or	O
IV	O
colorectal	O
cancer	O
or	O
non-small	O
cell	O
lung	O
cancer	O
-related	O
cachexia	O
that	O
tested	O
two	O
doses	O
of	O
espindolol	O
(	O
a	O
novel	O
non-selective	O
β	O
blocker	O
with	O
central	O
5-HT1a	O
and	O
partial	O
β2	O
receptor	O
agonist	O
effects	O
)	O
.	O

The	O
primary	O
endpoint	O
was	O
the	O
difference	O
in	O
the	O
rate	O
of	O
weight	O
change	O
over	O
16	O
weeks	O
(	O
linear	O
mixed-effect	O
model	O
for	O
repeated	O
measures	O
)	O
between	O
high-dose	O
espindolol	O
and	O
placebo	O
.	O

Eighty-seven	O
patients	O
were	O
randomized	O
centrally	O
in	O
blocks	O
in	O
a	O
ratio	O
3:2:1	O
[	O
42	O
high	O
dose	O
,	O
10	O
mg	O
twice	O
daily	O
(	O
bd	O
)	O
:31	O
placebo	O
:14	O
low	O
dose	O
,	O
2.5	O
mg	O
bd	O
]	O
.	O

High-dose	O
espindolol	O
produced	O
a	O
statistically	O
and	O
clinically	O
significant	O
weight	O
gain	O
(	O
+0.54	O
kg/4	O
weeks	O
,	O
95	O
%	O
CI	O
0.38-0.70	O
)	O
compared	O
with	O
a	O
weight	O
loss	O
on	O
placebo	O
(	O
-0.21	O
kg/4	O
weeks	O
,	O
95	O
%	O
CI	O
-0.37-0.05	O
)	O
;	O
P	O
<	O
0.0001	O
.	O

High-dose	O
espindolol	O
produced	O
a	O
statistically	O
significant	O
increase	O
in	O
lean	O
body	O
mass	O
,	O
whilst	O
changes	O
in	O
fat	O
mass	O
were	O
neutral	O
.	O

Hand	O
grip	O
strength	O
significantly	O
(	O
high	O
dose	O
-1.15	O
±	O
0.7	O
kg	O
,	O
placebo	O
-3.51	O
±	O
0.8	O
kg	O
change	O
per	O
4	O
weeks	O
;	O
P	O
=	O
0.0134	O
)	O
,	O
stair	O
climbing	O
power	O
,	O
and	O
6-min	B-P
walk	I-P
test	I-P
non-significantly	O
were	O
all	O
directionally	O
in	O
favour	O
of	O
high-dose	O
espindolol	O
.	O

There	O
were	O
no	O
clinically	O
significant	O
differences	O
in	O
safety	O
signals	O
or	O
survival	O
between	O
treatment	O
groups	O
,	O
although	O
a	O
numerical	O
excess	O
of	O
dyspnoea	O
was	O
seen	O
with	O
high-dose	O
espindolol	O
(	O
19.1	O
%	O
)	O
compared	O
with	O
placebo	O
(	O
3.2	O
%	O
)	O
.	O

This	O
positive	O
trial	O
showed	O
that	O
espindolol	O
10	O
mg	O
bd	O
significantly	O
reversed	O
weight	O
loss	O
,	O
improved	O
fat	O
free	O
mass	O
,	O
and	O
maintained	O
fat	O
mass	O
in	O
advanced	O
colorectal	O
cancer	O
and	O
non-small	O
cell	O
lung	O
cancer	O
-related	O
cachexia	O
.	O

This	O
was	O
associated	O
with	O
a	O
significant	O
improvement	O
in	O
handgrip	O
strength	O
,	O
supporting	O
the	O
further	O
investigation	O
of	O
10	O
mg	O
bd	O
espindolol	O
for	O
the	O
treatment	O
of	O
cancer	O
cachexia	O
.	O

Although	O
not	O
powered	O
to	O
look	O
at	O
dose	O
response	O
,	O
most	O
treatment	O
effects	O
for	O
low	O
dose	O
lay	O
between	O
high	O
dose	O
and	O
placebo	O
,	O
suggesting	O
that	O
there	O
may	O
be	O
a	O
dose	O
response	O
in	O
the	O
effects	O
of	O
espindolol	O
.	O

In	O
Vitro	O
Assays	O
for	O
the	O
Discovery	O
of	O
PCSK9	O
Autoprocessing	O
Inhibitors	O
.	O

PCSK9	O
plays	O
a	O
significant	O
role	O
in	O
regulating	O
low-density	B-P
lipoprotein	I-P
(	I-P
LDL	I-P
)	I-P
cholesterol	I-P
levels	I-P
and	O
has	O
become	O
an	O
important	O
drug	O
target	O
for	O
treating	O
hypercholesterolemia	O
.	O

Although	O
a	O
member	O
of	O
the	O
serine	O
protease	O
family	O
,	O
PCSK9	O
only	O
catalyzes	O
a	O
single	O
reaction	O
,	O
the	O
autocleavage	O
of	O
its	O
prodomain	O
.	O

The	O
maturation	O
of	O
the	O
proprotein	O
is	O
an	O
essential	O
prerequisite	O
for	O
the	O
secretion	O
of	O
PCSK9	O
to	O
the	O
extracellular	O
space	O
where	O
it	O
binds	O
the	O
LDL	O
receptor	O
and	O
targets	O
it	O
for	O
degradation	O
.	O

We	O
have	O
found	O
that	O
a	O
construct	O
of	O
proPCSK9	O
where	O
the	O
C-terminal	O
domain	O
has	O
been	O
truncated	O
has	O
sufficient	O
stability	O
to	O
be	O
expressed	O
and	O
purified	O
from	O
Escherichia	O
coli	O
for	O
the	O
in	O
vitro	O
study	O
of	O
autoprocessing	O
.	O

Using	O
automated	O
Western	O
analysis	O
,	O
we	O
demonstrate	O
that	O
autoprocessing	O
exhibits	O
the	O
anticipated	O
first-order	O
kinetics	O
.	O

A	O
high-throughput	B-P
time-resolved	B-P
fluorescence	I-P
resonance	I-P
energy	I-P
transfer	I-P
assay	I-P
for	O
autocleavage	O
has	O
been	O
developed	O
using	O
a	O
PCSK9	O
monoclonal	O
antibody	O
that	O
is	O
sensitive	O
to	O
the	O
conformational	O
changes	O
that	O
occur	O
upon	O
maturation	O
of	O
the	O
proprotein	O
.	O

Kinetic	O
theory	O
has	O
been	O
developed	O
that	O
describes	O
the	O
behavior	O
of	O
both	O
reversible	O
and	O
irreversible	O
inhibitors	O
of	O
autocleavage	O
.	O

The	O
analysis	O
of	O
an	O
irreversible	O
lactone	O
inhibitor	O
validates	O
the	O
expected	O
relationship	O
between	O
potency	O
and	O
the	O
reaction	O
end	O
point	O
.	O

An	O
orthogonal	B-P
liquid	I-P
chromatography-mass	I-P
spectrometry	I-P
assay	I-P
has	O
also	O
been	O
implemented	O
for	O
the	O
confirmation	O
of	O
hits	O
from	O
the	O
antibody-based	B-P
assays	I-P
.	O

Diabetes	O
mellitus	O
and	O
sensorineural	O
hearing	O
loss	O
:	O
is	O
there	O
an	O
association	O
?	O

Baseline	O
of	O
the	O
Brazilian	O
Longitudinal	O
Study	O
of	O
Adult	O
Health	O
(	O
ELSA-Brasil	O
)	O
.	O

Although	O
several	O
studies	O
have	O
investigated	O
the	O
effects	O
of	O
diabetes	O
on	O
hearing	O
loss	O
,	O
the	O
relationship	O
between	O
these	O
two	O
conditions	O
remains	O
unclear	O
.	O

Some	O
studies	O
have	O
suggested	O
that	O
diabetes	O
may	O
cause	O
sensorineural	O
hearing	O
loss	O
,	O
whereas	O
others	O
have	O
failed	O
to	O
find	O
an	O
association	O
.	O

The	O
biggest	O
challenge	O
in	O
investigating	O
the	O
association	O
between	O
diabetes	O
and	O
hearing	O
loss	O
is	O
the	O
presence	O
of	O
confounding	O
variables	O
and	O
the	O
complexity	O
of	O
the	O
auditory	O
system	O
.	O

Our	O
study	O
investigated	O
the	O
association	O
between	O
diabetes	O
and	O
sensorineural	O
hearing	O
loss	O
.	O

We	O
evaluated	O
the	O
influence	O
of	O
time	O
from	O
diabetes	O
diagnosis	O
on	O
this	O
association	O
after	O
controlling	O
for	O
age	O
,	O
gender	O
,	O
and	O
hypertension	O
diagnosis	O
and	O
excluding	O
those	O
subjects	O
with	O
exposure	O
to	O
noise	O
.	O

This	O
cross-sectional	O
study	O
evaluated	O
901	O
adult	O
and	O
elderly	O
Brazilian	O
Longitudinal	O
Study	O
of	O
Adult	O
Health	O
(	O
ELSA-Brasil	O
)	O
participants	O
from	O
São	O
Paulo	O
,	O
Brazil	O
who	O
underwent	O
audiometry	B-P
testing	I-P
as	O
part	O
of	O
ELSA-Brasil	O
's	O
baseline	O
assessment	O
.	O

Hearing	O
thresholds	O
and	O
speech	B-P
test	I-P
results	O
were	O
significantly	O
worse	O
in	O
the	O
group	O
with	O
diabetes	O
than	O
in	O
the	O
group	O
without	O
diabetes	O
.	O

However	O
,	O
no	O
significant	O
differences	O
were	O
found	O
between	O
participants	O
with	O
and	O
without	O
diabetes	O
after	O
adjusting	O
for	O
age	O
,	O
gender	O
,	O
and	O
the	O
presence	O
of	O
hypertension	O
.	O

Hearing	O
thresholds	O
were	O
not	O
affected	O
by	O
occupational	O
noise	O
exposure	O
in	O
the	O
group	O
s	O
with	O
and	O
without	O
diabetes	O
.	O

In	O
addition	O
,	O
no	O
association	O
between	O
the	O
duration	O
of	O
diabetes	O
and	O
hearing	O
thresholds	O
was	O
observed	O
after	O
adjusting	O
for	O
age	O
,	O
gender	O
,	O
and	O
hypertension	O
.	O

We	O
found	O
no	O
association	O
between	O
the	O
duration	O
of	O
diabetes	O
and	O
worse	O
hearing	O
thresholds	O
after	O
models	O
were	O
adjusted	O
for	O
age	O
,	O
gender	O
,	O
and	O
the	O
presence	O
of	O
hypertension	O
.	O

High-fructose	O
diet	O
is	O
as	O
detrimental	O
as	O
high-fat	O
diet	O
in	O
the	O
induction	O
of	O
insulin	O
resistance	O
and	O
diabetes	O
mediated	O
by	O
hepatic	O
/	O
pancreatic	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
stress	O
.	O

In	O
the	O
context	O
of	O
high	O
human	O
consumption	O
of	O
fructose	O
diets	O
,	O
there	O
is	O
an	O
imperative	O
need	O
to	O
understand	O
how	O
dietary	O
fructose	O
intake	O
influence	O
cellular	O
and	O
molecular	O
mechanisms	O
and	O
thereby	O
affect	O
β-cell	O
dysfunction	O
and	O
insulin	O
resistance	O
.	O

While	O
evidence	O
exists	O
for	O
a	O
relationship	O
between	O
high	O
-	O
fat	O
-	O
induced	O
insulin	O
resistance	O
and	O
metabolic	O
disorders	O
,	O
there	O
is	O
lack	O
of	O
studies	O
in	O
relation	O
to	O
high-fructose	O
diet	O
.	O

Therefore	O
,	O
we	O
attempted	O
to	O
study	O
the	O
effect	O
of	O
different	O
diets	O
viz.	O
,	O
high-fat	O
diet	O
(	O
HFD	O
)	O
,	O
high-fructose	O
diet	O
(	O
HFS	O
)	O
,	O
and	O
a	O
combination	O
(	O
HFS	O
+	O
HFD	O
)	O
diet	O
on	O
glucose	O
homeostasis	O
and	O
insulin	O
sensitivity	O
in	O
male	O
Wistar	O
rats	O
compared	O
to	O
control	O
animals	O
fed	O
with	O
normal	O
pellet	O
diet	O
.	O

Investigations	O
include	O
oral	B-P
glucose	I-P
tolerance	I-P
test	I-P
,	O
insulin	B-P
tolerance	I-P
test	I-P
,	O
histopathology	B-P
by	O
H	B-P
&	I-P
E	I-P
and	O
Masson	B-P
's	I-P
trichrome	I-P
staining	I-P
,	O
mRNA	O
expression	O
by	O
real-time	O
PCR	O
,	O
protein	B-P
expression	I-P
by	O
Western	B-P
blot	I-P
,	O
and	O
caspase-3	O
activity	O
by	O
colorimetry	B-P
.	O

Rats	O
subjected	O
to	O
high-fat	O
/	O
fructose	O
diets	O
became	O
glucose	O
intolerant	O
,	O
insulin-resistant	O
,	O
and	O
dyslipidemic	O
.	O

Compared	O
to	O
control	O
animals	O
,	O
rats	O
subjected	O
to	O
different	O
combination	O
of	O
fat	O
/	O
fructose	O
diets	O
showed	O
increased	O
mRNA	O
and	O
protein	O
expression	O
of	O
a	O
battery	O
of	O
ER	O
stress	O
markers	O
both	O
in	O
pancreas	O
and	O
liver	O
.	O

Transcription	O
factors	O
of	O
β-cell	O
function	O
(	O
INSIG1	O
,	O
SREBP1c	O
and	O
PDX1	O
)	O
as	O
well	O
as	O
hepatic	O
gluconeogenesis	O
(	O
FOXO1	O
and	O
PEPCK	O
)	O
were	O
adversely	O
affected	O
in	O
diet	O
-	O
induced	O
insulin-resistant	O
rats	O
.	O

The	O
convergence	O
of	O
chronic	O
ER	O
stress	O
towards	O
apoptosis	O
in	O
pancreas	O
/	O
liver	O
was	O
also	O
indicated	O
by	O
increased	O
levels	O
of	O
CHOP	O
mRNA	O
&	O
increased	O
activity	O
of	O
both	O
JNK	O
and	O
Caspase-3	O
in	O
rats	O
subjected	O
to	O
high-fat	O
/	O
fructose	O
diets	O
.	O

Our	O
study	O
exposes	O
the	O
experimental	O
support	O
in	O
that	O
high-fructose	O
diet	O
is	O
equally	O
detrimental	O
in	O
causing	O
metabolic	O
disorders	O
.	O

Methodology	O
development	O
on	O
aquatic	O
environmental	O
assessment	O
.	O

The	O
Water	O
Framework	O
Directive	O
aims	O
at	O
reaching	O
the	O
good	O
ecological	O
status	O
of	O
the	O
surface	O
and	O
ground	O
water	O
bodies	O
(	O
László	O
et	O
al	O
.	O

Microchem	O
J	O
85	O
(	O
1	O
)	O
:65-71	O
,	O
2007	O
)	O
.	O

The	O
paper	O
deals	O
with	O
quality	O
evaluation	O
of	O
waters	O
with	O
special	O
focus	O
on	O
the	O
water	O
chemistry	O
parameters	O
as	O
defined	O
in	O
the	O
Water	O
Framework	O
Directive	O
and	O
pertaining	O
legal	O
regulations	O
.	O

The	O
purpose	O
of	O
this	O
paper	O
is	O
to	O
devise	O
a	O
quantitative	O
type	O
of	O
water	O
quality	O
assessment	O
method	O
which	O
could	O
provide	O
rapid	O
,	O
accurate	O
,	O
and	O
reliable	O
information	O
on	O
the	O
quality	O
of	O
the	O
surface	O
waters	O
by	O
using	O
water	O
chemistry	O
parameters	O
.	O

Quality	O
classes	O
have	O
been	O
defined	O
for	O
every	O
water	O
chemistry	O
parameter	O
in	O
light	O
of	O
the	O
legal	O
limit	O
values	O
of	O
the	O
water	O
parameters	O
.	O

In	O
addition	O
to	O
this	O
,	O
weight	O
indices	O
were	O
calculated	B-P
on	O
the	O
basis	O
of	O
the	O
outcome	O
of	O
the	O
paired	O
comparison	O
of	O
water	O
chemistry	O
parameters	O
and	O
normalized	O
matrix	O
.	O

This	O
was	O
followed	O
by	O
the	O
parametric	O
level	O
analysis	O
of	O
the	O
water	O
chemistry	O
parameters	O
,	O
and	O
finally	O
,	O
the	O
aquatic	O
environment	O
index	O
(	O
AEI	O
)	O
was	O
calculated	B-P
,	O
which	O
provided	O
general	O
information	O
on	O
the	O
quality	O
of	O
water	O
regarding	O
the	O
water	O
chemistry	O
parameters	O
.	O

The	O
method	O
was	O
illustrated	O
on	O
Lake	O
Balaton	O
,	O
Hungary	O
in	O
which	O
case	O
water	O
samples	O
taken	O
from	O
Balatonfüred	O
City	O
lake	O
area	O
were	O
analyzed	O
and	O
evaluated	O
with	O
the	O
method	O
devised	O
.	O

Association	O
of	O
Fat	O
Mass	O
and	O
Obesity	O
-	O
associated	O
Gene	O
Variant	O
with	O
Lifestyle	O
Factors	O
and	O
Body	O
Fat	O
in	O
Indian	O
Children	O
.	O

Common	O
intronic	O
variants	O
of	O
the	O
fat	O
mass	O
and	O
obesity	O
-	O
associated	O
(	O
FTO	O
)	O
gene	O
have	O
been	O
associated	O
with	O
obesity	O
-related	O
traits	O
in	O
humans	O
.	O

(	O
1	O
)	O
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
study	O
the	O
distribution	O
of	O
FTO	O
gene	O
variants	O
across	O
different	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
categories	O
and	O
(	O
2	O
)	O
to	O
explore	O
the	O
association	O
between	O
FTO	O
gene	O
variants	O
and	O
lifestyle	O
factors	O
in	O
obese	O
and	O
normal	O
weight	O
Indian	O
children	O
.	O

Fifty-six	O
children	O
(	O
26	O
boys	O
,	O
mean	O
age	O
10.3	O
±	O
2.2	O
years	O
)	O
were	O
studied	O
.	O

Height	O
,	O
weight	O
,	O
and	O
waist	O
and	O
hip	O
circumference	O
were	O
measured	O
.	O

Physical	O
activity	O
(	O
questionnaire	O
)	O
and	O
food	O
intake	O
(	O
food	O
frequency	O
questionnaire	O
)	O
were	O
assessed	O
.	O

Body	O
fat	O
percentage	O
(	O
%	O
BF	O
)	O
was	O
measured	O
by	O
dual-energy	B-P
X-ray	I-P
absorptiometry	I-P
.	O

FTO	O
allelic	O
variants	O
at	O
rs9939609	O
site	O
were	O
detected	O
by	O
SYBR	O
Green	O
Amplification	O
Refractory	O
Mutation	O
System	O
real-time	O
polymerase	O
chain	O
reaction	O
using	O
allele	O
-	O
specific	O
primers	O
.	O

Generalized	O
linear	O
model	O
was	O
used	O
to	O
investigate	O
the	O
simultaneous	O
influence	O
of	O
genetic	O
and	O
lifestyle	O
factors	O
on	O
%	O
BF	O
.	O

Mean	O
height	O
,	O
weight	O
,	O
and	O
BMI	O
of	O
normal	O
and	O
obese	O
children	O
were	O
130.6	O
±	O
7.1	O
versus	O
143.2	O
±	O
15.6	O
,	O
24.0	O
±	O
5.2	O
versus	O
53.1	O
±	O
15.8	O
,	O
and	O
13.9	O
±	O
2.1	O
versus	O
25.3	O
±	O
3.2	O
,	O
respectively	O
.	O

The	O
frequency	O
of	O
AA	O
allele	O
was	O
57	O
%	O
among	O
obese	O
children	O
and	O
35	O
%	O
in	O
normal	O
weight	O
children	O
.	O

Children	O
with	O
the	O
AA	O
allele	O
who	O
were	O
obese	O
had	O
least	O
physical	O
activity	O
,	O
whereas	O
children	O
with	O
AT	O
allele	O
and	O
obesity	O
had	O
the	O
highest	O
intake	O
of	O
calories	O
when	O
compared	O
to	O
children	O
who	O
had	O
AT	O
allele	O
and	O
were	O
normal	O
.	O

%	O
BF	O
was	O
positively	O
associated	O
with	O
AA	O
alleles	O
and	O
junk	O
food	O
intake	O
and	O
negatively	O
with	O
healthy	O
food	O
intake	O
and	O
moderate	O
physical	O
activity	O
.	O

Healthy	O
lifestyle	O
with	O
high	O
physical	O
activity	O
and	O
diet	O
low	O
in	O
calories	O
and	O
fat	O
may	O
help	O
in	O
modifying	O
the	O
risk	O
imposed	O
by	O
FTO	O
variants	O
in	O
children	O
.	O

UHPLC-MS/MS	B-P
method	I-P
for	O
the	O
quantitation	O
of	O
penicillin	O
G	O
and	O
metabolites	O
in	O
citrus	O
fruit	O
using	O
internal	O
standards	O
.	O

Penicillin	O
G	O
has	O
been	O
applied	O
to	O
citrus	O
trees	O
as	O
a	O
potential	O
treatment	O
in	O
the	O
fight	O
against	O
Huanglongbing	O
(	O
HLB	O
)	O
.	O

Here	O
,	O
we	O
have	O
developed	O
and	O
validated	O
a	O
method	O
to	O
identify	O
and	O
quantitate	O
penicillin	O
G	O
and	O
two	O
of	O
its	O
metabolites	O
,	O
penillic	O
acid	O
and	O
penilloic	O
acid	O
,	O
in	O
citrus	O
fruit	O
using	O
ultra	B-P
high	I-P
performance	I-P
liquid	I-P
chromatography-tandem	I-P
mass	I-P
spectrometry	I-P
(	O
UHPLC-MS/MS	B-P
)	O
.	O

This	O
method	O
improves	O
upon	O
a	O
previous	O
method	O
by	O
incorporating	O
isotopically	O
labeled	O
internal	O
standards	O
,	O
namely	O
,	O
penillic	O
acid-D5	O
,	O
and	O
penilloic	O
acid-D5	O
.	O

These	O
standards	O
greatly	O
enhanced	O
the	O
accuracy	O
and	O
precision	O
of	O
our	O
measurements	O
by	O
compensating	O
for	O
recovery	O
losses	O
,	O
degradation	O
,	O
and	O
matrix	O
effects	O
.	O

When	O
2g	O
of	O
citrus	O
fruit	O
sample	O
is	O
extracted	O
,	O
the	O
limits	O
of	O
detection	O
(	O
LOD	O
)	O
were	O
determined	O
to	O
be	O
0.1ng/g	O
for	O
penicillin	O
G	O
and	O
penilloic	O
acid	O
,	O
and	O
0.25ng/g	O
for	O
penillic	O
acid	O
.	O

At	O
fortification	O
levels	O
of	O
0.1	O
,	O
0.25	O
,	O
1	O
,	O
and	O
10ng/g	O
,	O
absolute	O
recoveries	O
for	O
penillic	O
and	O
penilloic	O
acids	O
were	O
generally	O
between	O
50-70	O
%	O
.	O

Recoveries	O
corrected	O
with	O
the	O
isotopically	O
labeled	O
standards	O
were	O
approximately	O
90-110	O
%	O
.	O

This	O
method	O
will	O
be	O
useful	O
for	O
the	O
identification	O
and	O
quantitation	O
of	O
drug	O
residues	O
and	O
their	O
degradation	O
products	O
using	O
isotopically	O
labeled	O
standards	O
and	O
UHPLC-MS/MS	B-P
.	O

The	O
EpiDerm™	O
3D	B-P
human	I-P
reconstructed	I-P
skin	I-P
micronucleus	I-P
(	I-P
RSMN	I-P
)	I-P
assay	I-P
:	O
Historical	O
control	O
data	O
and	O
proof	O
of	O
principle	O
studies	O
for	O
mechanistic	B-P
assay	I-P
adaptations	O
.	O

The	O
in	B-P
vitro	I-P
human	I-P
reconstructed	I-P
skin	I-P
micronucleus	I-P
(	I-P
RSMN	I-P
)	I-P
assay	I-P
in	O
EpiDerm™	O
is	O
a	O
promising	O
novel	O
animal	O
alternative	O
for	O
evaluating	O
genotoxicity	O
of	O
topically	O
applied	O
chemicals	O
.	O

It	O
is	O
particularly	O
useful	O
for	O
assessing	O
cosmetic	O
ingredients	O
that	O
can	O
no	O
longer	O
be	O
tested	O
using	O
in	O
vivo	O
assays	B-P
.	O

To	O
advance	O
the	O
use	O
of	O
this	O
test	O
especially	O
for	O
regulatory	O
decision-making	O
,	O
we	O
have	O
established	O
the	O
RSMN	B-P
assay	I-P
in	O
our	O
laboratory	O
according	O
to	O
Good	O
Laboratory	O
Practice	O
and	O
following	O
the	O
principles	O
of	O
the	O
OECD	O
test	O
guideline	O
487	O
in	O
vitro	O
mammalian	O
cell	O
micronucleus	O
test	O
.	O

Proficiency	O
with	O
the	O
assay	B-P
was	O
established	O
by	O
correctly	O
identifying	O
direct-acting	O
genotoxins	O
and	O
genotoxins	O
requiring	O
metabolism	O
,	O
as	O
well	O
as	O
non-genotoxic	O
/	O
non-carcinogenic	O
chemicals	O
.	O

We	O
also	O
report	O
the	O
analysis	O
of	O
our	O
historical	O
control	O
data	O
that	O
demonstrate	O
vehicle	O
control	O
and	O
positive	O
control	O
values	O
for	O
%	O
micronuclei	O
in	O
binucleated	O
cells	O
are	O
in	O
the	O
ranges	O
reported	O
previously	O
.	O

Technical	O
issues	O
including	O
evaluating	O
various	O
solvents	O
with	O
both	O
48h	O
and	O
72h	O
treatment	O
regimens	O
were	O
investigated	O
.	O

For	O
the	O
first	O
time	O
,	O
mechanistic	O
studies	O
using	O
CREST	O
analysis	O
revealed	O
that	O
the	O
RSMN	B-P
assay	I-P
is	O
suitable	O
for	O
distinguishing	O
aneugens	O
and	O
clastogens	O
.	O

Moreover	O
,	O
the	O
assay	B-P
is	O
also	O
suitable	O
for	O
measuring	O
cytokines	O
as	O
markers	O
for	O
proliferative	O
and	O
toxic	O
effects	O
of	O
chemicals	O
.	O

The	O
association	O
between	O
maternal	O
hydronephrosis	O
and	O
acute	O
flank	O
pain	O
during	O
pregnancy	O
:	O
a	O
prospective	O
pilot-study	O
.	O

Maternal	O
hydronephrosis	O
may	O
cause	O
flank	O
pain	O
during	O
pregnancy	O
.	O

We	O
aimed	O
to	O
investigate	O
the	O
association	O
between	O
maternal	O
hydronephrosis	O
and	O
flank	O
pain	O
intensity	O
.	O

From	O
2014	O
to	O
2015	O
,	O
all	O
consecutive	O
women	O
with	O
singleton	O
pregnancies	O
,	O
who	O
presented	O
at	O
our	O
tertiary	O
center	O
due	O
to	O
acute	O
flank	O
pain	O
,	O
were	O
prospectively	O
evaluated	O
by	O
renal	O
ultrasonography	B-P
and	O
pain	O
questionnaires	O
.	O

A	O
visual	B-P
analogue	I-P
scale	I-P
was	O
used	O
to	O
assess	O
pain	O
intensity	O
.	O

The	O
study	O
had	O
90	O
%	O
power	O
to	O
detect	O
a	O
significant	O
correlation	O
between	O
hydronephrosis	O
and	O
flank	O
pain	O
(	O
Spearman	O
's	O
test	O
)	O
.	O

A	O
total	O
of	O
51	O
consecutive	O
women	O
with	O
left-sided	O
(	O
13.7	O
%	O
)	O
,	O
right-sided	O
(	O
64.7	O
%	O
)	O
or	O
bilateral	O
(	O
21.6	O
%	O
)	O
pain	O
were	O
enrolled	O
.	O

The	O
mean	O
gestational	O
age	O
of	O
these	O
women	O
,	O
who	O
presented	O
due	O
to	O
their	O
pain	O
,	O
was	O
27.5	O
±	O
6.8	O
weeks	O
at	O
the	O
time	O
of	O
consultation	O
.	O

The	O
mean	O
VAS	O
score	O
was	O
7.6	O
±	O
2.2	O
.	O

In	O
43/51	O
(	O
84.3	O
%	O
)	O
women	O
,	O
hydronephrosis	O
was	O
found	O
on	O
renal	O
sonograms	O
.	O

No	O
correlation	O
was	O
found	O
between	O
the	O
grade	O
of	O
hydronephrosis	O
and	O
pain	O
intensity	O
(	O
p	O
=	O
0.466	O
;	O
r=	O
-0.28	O
)	O
.	O

Women	O
delivered	O
at	O
a	O
mean	O
gestational	O
age	O
of	O
38.1	O
±	O
2.4	O
weeks	O
and	O
their	O
infants	O
had	O
a	O
mean	O
birthweight	O
of	O
3138	O
±	O
677	O
g.	O
Hydronephrosis	O
is	O
a	O
common	O
finding	O
among	O
pregnant	O
women	O
with	O
acute	O
flank	O
pain	O
.	O

The	O
grade	O
of	O
hydronephrosis	O
does	O
not	O
affect	O
pain	O
intensity	O
.	O

This	O
study	O
suggests	O
normal	O
pregnancy	O
outcomes	O
in	O
these	O
women	O
.	O

Prostate-specific	O
antigen	O
increase	O
during	O
dutasteride	O
to	O
indicate	O
the	O
need	O
for	O
prostate	B-P
biopsy	I-P
:	O
influence	O
of	O
prostatic	O
inflammation	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
significance	O
of	O
an	O
increase	O
in	O
total	B-P
prostate-specific	I-P
antigen	I-P
(	I-P
PSA	I-P
)	I-P
serum	I-P
levels	I-P
despite	O
dutasteride	O
treatment	O
as	O
a	O
predictor	O
of	O
prostate	O
cancer	O
(	O
PC	O
)	O
at	O
biopsy	B-P
.	O

We	O
focused	O
our	O
attention	O
on	O
the	O
rate	O
of	O
the	O
first	O
PSA	O
increase	O
and	O
on	O
the	O
influence	O
of	O
prostatic	O
inflammation	O
.	O

From	O
2011	O
to	O
2016	O
,	O
365	O
men	O
with	O
a	O
previous	O
negative	O
prostate	B-P
biopsy	I-P
and	O
persistent	O
elevated	O
PSA	B-P
levels	I-P
received	O
dutasteride	O
treatment	O
.	O

The	O
population	O
was	O
followed	O
for	O
a	O
range	O
of	O
12-48	O
months	O
.	O

One	O
hundred	O
twelve	O
cases	O
with	O
a	O
confirmed	O
PSA	O
increase	O
>	O
0.5	O
ng/ml	O
over	O
the	O
nadir	O
value	O
during	O
the	O
follow-up	O
were	O
included	O
in	O
Group	O
A	O
and	O
underwent	O
a	O
new	O
prostate	B-P
biopsy	I-P
.	O

In	O
Group	O
A	O
,	O
the	O
PSA	O
increase	O
was	O
associated	O
with	O
PC	O
at	O
the	O
re-biopsy	B-P
in	O
66	O
%	O
of	O
cases	O
.	O

The	O
percentage	O
of	O
PSA	O
reduction	O
after	O
6	O
months	O
of	O
treatment	O
was	O
not	O
a	O
significant	O
indicator	O
of	O
the	O
risk	O
for	O
PC	O
.	O

The	O
distribution	O
of	O
inflammatory	O
infiltrates	O
significantly	O
(	O
p	O
<	O
00.01	O
)	O
varied	O
from	O
positive	O
to	O
negative	O
prostate	B-P
biopsies	I-P
.	O

The	O
relative	O
risk	O
for	O
PC	O
at	O
biopsy	B-P
significantly	O
increase	O
d	O
according	O
to	O
PSA	B-P
level	I-P
during	O
dutasteride	O
.	O

Treatment	O
with	O
dutasteride	O
can	O
help	O
to	O
analyze	O
PSA	O
kinetic	O
.	O

A	O
persistent	O
prostatic	O
inflammation	O
is	O
a	O
factor	O
able	O
to	O
reduce	O
the	O
performance	O
of	O
PSA	O
kinetic	O
during	O
dutasteride	O
treatment	O
.	O

Dupuytren	O
in	O
a	O
Child	O
:	O
Rare	O
Presentation	O
of	O
a	O
Rare	O
Clinical	O
Entity	O
.	O

Dupuytren	O
disease	O
in	O
children	O
younger	O
than	O
10	O
years	O
is	O
rare	O
and	O
only	O
8	O
histologically	O
proven	O
cases	O
have	O
been	O
reported	O
.	O

A	O
histologically	O
proven	O
Dupuytren	O
disease	O
in	O
a	O
10-year-old	O
with	O
an	O
uncommon	O
clinical	O
presentation	O
as	O
a	O
nodule	O
on	O
the	O
radial	O
side	O
of	O
the	O
middle	O
phalanx	O
of	O
the	O
little	O
finger	O
is	O
documented	O
.	O

Dupuytren	O
's	O
disease	O
should	O
be	O
in	O
the	O
differential	B-P
diagnosis	I-P
in	O
cases	O
of	O
nodules	O
and	O
contractures	O
in	O
the	O
palm	O
and	O
fingers	O
of	O
children	O
.	O

Mesenchymal	O
stem	O
cells	O
enhance	O
the	O
oncolytic	O
effect	O
of	O
Newcastle	O
disease	O
virus	O
in	O
glioma	O
cells	O
and	O
glioma	O
stem	O
cells	O
via	O
the	O
secretion	O
of	O
TRAIL	O
.	O

Newcastle	O
disease	O
virus	O
(	O
NDV	O
)	O
is	O
an	O
avian	O
paramyxovirus	O
,	O
which	O
selectively	O
exerts	O
oncolytic	O
effects	O
in	O
cancer	O
cells	O
.	O

Mesenchymal	O
stem	O
cells	O
(	O
MSCs	O
)	O
have	O
been	O
reported	O
to	O
affect	O
tumor	O
growth	O
and	O
deliver	O
anti-tumor	O
agents	O
to	O
experimental	O
glioblastoma	O
(	O
GBM	O
)	O
.	O

Here	O
,	O
we	O
explored	O
the	O
effects	O
of	O
NDV	O
-	O
infected	O
MSCs	O
derived	O
from	O
different	O
sources	O
,	O
on	O
glioma	O
cells	O
and	O
glioma	O
stem	O
cells	O
(	O
GSCs	O
)	O
and	O
the	O
mechanisms	O
involved	O
in	O
their	O
effects	O
.	O

The	O
glioma	O
cell	O
lines	O
(	O
A172	O
and	O
U87	O
)	O
and	O
primary	O
GSCs	O
that	O
were	O
generated	O
from	O
GBM	O
tumors	O
were	O
used	O
in	O
this	O
study	O
.	O

MSCs	O
derived	O
from	O
bone	O
marrow	O
,	O
adipose	O
tissue	O
or	O
umbilical	O
cord	O
were	O
infected	O
with	O
NDV	O
(	O
MTH-68/H	O
)	O
.	O

The	O
ability	O
of	O
these	O
cells	O
to	O
deliver	O
the	O
virus	O
to	O
glioma	O
cell	O
lines	O
and	O
GSCs	O
and	O
the	O
effects	O
of	O
NDV	O
-	O
infected	O
MSCs	O
on	O
cell	O
death	O
and	O
on	O
the	O
stemness	O
and	O
self-renewal	O
of	O
GSCs	O
were	O
examined	O
.	O

The	O
mechanisms	O
involved	O
in	O
the	O
cytotoxic	O
effects	O
of	O
the	O
NDV	O
-	O
infected	O
MSCs	O
and	O
their	O
influence	O
on	O
the	O
radiation	O
sensitivity	O
of	O
GSCs	O
were	O
examined	O
as	O
well	O
.	O

NDV	O
induced	O
a	O
dose-dependent	O
cell	O
death	O
in	O
glioma	O
cells	O
and	O
a	O
low	O
level	O
of	O
apoptosis	O
and	O
inhibition	O
of	O
self-renewal	O
in	O
GSCs	O
.	O

MSCs	O
derived	O
from	O
bone	O
marrow	O
,	O
adipose	O
and	O
umbilical	O
cord	O
that	O
were	O
infected	O
with	O
NDV	O
delivered	O
the	O
virus	O
to	O
co-cultured	B-P
glioma	O
cells	O
and	O
GSCs	O
.	O

Conditioned	O
medium	O
of	O
NDV	O
-	O
infected	O
MSCs	O
induced	O
higher	O
level	O
of	O
apoptosis	O
in	O
the	O
tumor	O
cells	O
compared	O
with	O
the	O
apoptosis	O
induced	O
by	O
their	O
direct	O
infection	O
with	O
similar	O
virus	O
titers	O
.	O

These	O
results	O
suggest	O
that	O
factor	O
(	O
s	O
)	O
secreted	O
by	O
the	O
infected	O
MSCs	O
sensitized	O
the	O
glioma	O
cells	O
to	O
the	O
cytotoxic	O
effects	O
of	O
NDV	O
.	O

We	O
identified	O
TRAIL	O
as	O
a	O
mediator	O
of	O
the	O
cytotoxic	O
effects	O
of	O
the	O
infected	O
MSCs	O
and	O
demonstrated	O
that	O
TRAIL	O
synergized	O
with	O
NDV	O
in	O
the	O
induction	O
of	O
cell	O
death	O
in	O
glioma	O
cells	O
and	O
GSCs	O
.	O

Moreover	O
,	O
conditioned	O
medium	O
of	O
infected	O
MSCs	O
enhanced	O
the	O
sensitivity	O
of	O
GSCs	O
to	O
γ-radiation	O
.	O

NDV	O
-	O
infected	O
umbilical	O
cord	O
-	O
derived	O
MSCs	O
may	O
provide	O
a	O
novel	O
effective	O
therapeutic	O
approach	O
for	O
targeting	O
GSCs	O
and	O
GBM	O
and	O
for	O
sensitizing	O
these	O
tumors	O
to	O
γ-radiation	O
.	O

Prevalence	O
of	O
high	O
fractional	O
exhaled	O
nitric	O
oxide	O
among	O
US	O
youth	O
with	O
asthma	O
.	O

High	O
fractional	O
exhaled	O
nitric	O
oxide	O
(	O
FeNO	O
)	O
is	O
an	O
indicator	O
of	O
poor	O
asthma	O
control	O
and	O
has	O
been	O
proposed	O
as	O
a	O
non-invasive	O
assessment	O
tool	O
to	O
guide	O
asthma	O
management	O
.	O

We	O
aimed	O
to	O
describe	O
the	O
prevalence	O
of	O
and	O
factors	O
associated	O
with	O
high	O
FeNO	O
among	O
US	O
youth	O
with	O
asthma	O
.	O

Data	O
from	O
716	O
children	O
and	O
adolescents	O
with	O
asthma	O
ages	O
6-19	O
years	O
who	O
participated	O
in	O
the	O
2007-2012	O
National	O
Health	O
and	O
Nutrition	O
Examination	O
Survey	O
were	O
analyzed	O
.	O

Using	O
American	O
Thoracic	O
Society	O
guidelines	O
,	O
high	O
FeNO	O
was	O
defined	O
as	O
>	O
50	O
ppb	O
for	O
ages	O
12-19	O
years	O
and	O
>	O
35	O
ppb	O
for	O
ages	O
6-11	O
years	O
.	O

Multivariate	O
logistic	O
regression	O
examined	O
associations	O
between	O
high	O
FeNO	O
and	O
age	O
,	O
sex	O
,	O
race	O
/	O
Hispanic	O
origin	O
,	O
income	O
status	O
,	O
weight	O
status	O
,	O
tobacco	O
smoke	O
exposure	O
,	O
and	O
other	O
factors	O
associated	O
with	O
asthma	O
control	O
(	O
recent	O
use	O
of	O
inhaled	O
corticosteroids	O
,	O
recent	O
respiratory	O
illness	O
,	O
asthma	O
-related	O
respiratory	O
signs/symptoms	O
,	O
and	O
spirometry	B-P
)	O
.	O

About	O
16.5	O
%	O
of	O
youth	O
with	O
asthma	O
had	O
high	O
FeNO	O
.	O

The	O
prevalence	O
of	O
high	O
FeNO	O
was	O
higher	O
among	O
non-Hispanic	O
black	O
(	O
27	O
%	O
,	O
P	O
<	O
0.001	O
)	O
and	O
Hispanic	O
(	O
20.2	O
%	O
,	O
P	O
=	O
0.002	O
)	O
youth	O
than	O
non-Hispanic	O
white	O
(	O
9.7	O
%	O
)	O
youth	O
.	O

Differences	O
in	O
high	O
FeNO	O
prevalence	O
by	O
sex	O
(	O
girls	O
<	O
boys	O
)	O
,	O
weight	O
status	O
(	O
obese	O
<	O
normal	O
weight	O
)	O
,	O
tobacco	O
smoke	O
exposure	O
(	O
smokers	O
<	O
home	O
exposure	O
<	O
no	O
exposure	O
)	O
,	O
and	O
FEV1/FVC	O
(	O
normal	O
<	O
abnormal	O
)	O
were	O
also	O
observed	O
.	O

No	O
differences	O
were	O
noted	O
between	O
categories	O
for	O
the	O
remaining	O
covariates	O
.	O

High	O
FeNO	O
was	O
observed	O
to	O
be	O
associated	O
with	O
sex	O
,	O
race	O
/	O
Hispanic	O
origin	O
,	O
weight	O
status	O
,	O
tobacco	O
smoke	O
exposure	O
,	O
and	O
abnormal	O
FEV1/FVC	O
,	O
but	O
was	O
not	O
associated	O
with	O
asthma	O
-related	O
respiratory	O
symptoms	O
.	O

These	O
findings	O
may	O
help	O
inform	O
future	O
research	O
and	O
clinical	O
practice	O
guidelines	O
on	O
the	O
use	O
of	O
high	O
FeNO	O
in	O
the	O
assessment	O
of	O
asthma	O
control	O
.	O

The	O
Correlation	O
of	O
Arterial	O
Stiffness	O
with	O
Biophysical	O
Parameters	O
and	O
Blood	O
Biochemistry	O
.	O

Type	O
2	O
diabetes	O
presents	O
with	O
numerous	O
macrovascular	O
and	O
microvascular	O
impairments	O
,	O
which	O
in	O
turn	O
lead	O
to	O
various	O
co-morbidities	O
.	O

Vascular	O
co-morbidities	O
can	O
be	O
seen	O
when	O
examining	O
arterial	O
stiffness	O
(	O
AS	O
)	O
,	O
which	O
is	O
a	O
predictor	O
for	O
endothelial	O
health	O
and	O
cardiovascular	O
disease	O
risk	O
.	O

Pulse	B-P
wave	I-P
analysis	I-P
(	O
PWA	B-P
)	O
and	O
pulse	O
wave	O
velocity	O
(	O
PWV	O
)	O
are	O
two	O
tests	O
that	O
are	O
commonly	O
used	O
to	O
measure	O
AS	O
.	O

Currently	O
,	O
disease	O
states	O
and	O
progression	O
are	O
tracked	O
via	O
blood	O
biochemistry	O
.	O

These	O
gold	O
standards	O
in	O
monitoring	O
diabetes	O
are	O
expensive	O
and	O
need	O
optimization	O
.	O

To	O
investigate	O
which	O
biophysical	O
and	O
biochemical	O
parameters	O
correlated	O
best	O
with	O
AS	O
,	O
which	O
may	O
reduce	O
the	O
number	O
of	O
biochemical	B-P
tests	I-P
and	O
biophysical	O
parameter	O
measurements	O
needed	O
to	O
track	O
disease	O
progression	O
.	O

Data	O
from	O
42	O
subjects	O
with	O
type	O
2	O
diabetes	O
mellitus	O
for	O
≤10	O
years	O
,	O
aged	O
40-70	O
years	O
,	O
were	O
analyzed	O
at	O
a	O
single	O
time	O
point	O
.	O

We	O
investigated	O
various	O
blood	O
biochemistry	O
,	O
body	O
composition	O
,	O
and	O
AS	O
parameters	O
.	O

A	O
combination	O
of	O
fat	O
mass	O
and	O
fat-free	O
mass	O
was	O
most	O
associated	O
with	O
PWA	B-P
over	O
any	O
other	O
parameters	O
.	O

Leptin	O
and	O
high-sensitivity	O
C-reactive	O
protein	O
seem	O
to	O
be	O
the	O
next	O
two	O
parameters	O
that	O
correlate	O
with	O
augmentation	O
index	O
.	O

No	O
other	O
parameters	O
had	O
strong	O
correlations	O
to	O
either	O
PWA	B-P
or	O
PWV	O
values	O
.	O

Body	B-P
composition	I-P
methods	I-P
seemed	O
to	O
be	O
better	O
predictors	O
of	O
type	O
2	O
diabetes	O
mellitus	O
patient	O
's	O
vascular	O
disease	O
progression	O
.	O

Our	O
study	O
indicates	O
that	O
body	O
composition	O
measurements	O
may	O
help	O
replace	O
expensive	B-P
tests	I-P
.	O

This	O
may	O
have	O
public	O
health	O
and	O
health	O
surveillance	O
implications	O
in	O
countries	O
facing	O
financial	O
challenges	O
.	O

Bone	O
-	O
Albumin	O
filling	O
decreases	O
donor	O
site	O
morbidity	O
and	O
enhances	O
bone	O
formation	O
after	O
anterior	O
cruciate	O
ligament	O
reconstruction	O
with	O
bone-patellar	O
tendon-bone	O
autografts	O
.	O

Donor	O
site	O
pain	O
affects	O
32-43	O
%	O
of	O
patients	O
after	O
anterior	O
cruciate	O
ligament	O
surgery	O
when	O
the	O
autograft	O
is	O
freshly	O
harvested	O
bone-patellar	O
tendon-bone	O
tissue	O
.	O

Our	O
aim	O
was	O
to	O
compare	O
functional	O
and	O
morphological	O
differences	O
between	O
donor	O
sites	O
with	O
and	O
without	O
serum	O
albumin	O
-	O
coated	O
bone	O
allograft	O
filling	O
.	O

After	O
harvesting	O
and	O
implanting	O
the	O
graft	O
,	O
the	O
tibia	O
site	O
was	O
filled	O
with	O
either	O
fresh	O
autologous	O
cancellous	O
bone	O
enhanced	O
with	O
albumin	O
-	O
coated	O
allograft	O
or	O
autologous	O
bone	O
alone	O
.	O

The	O
patella	O
site	O
was	O
filled	O
either	O
with	O
albumin	O
-	O
coated	O
allograft	O
or	O
with	O
blood	O
clot	O
.	O

Knee	O
function	O
was	O
evaluated	O
by	O
the	O
VISA	O
,	O
Lysholm	O
and	O
IKDC	O
scores	O
and	O
a	O
visual	B-P
analog	I-P
scale	I-P
of	I-P
pain	I-P
during	O
standing	O
,	O
kneeling	O
and	O
crouching	O
after	O
six	O
weeks	O
and	O
six	O
months	O
.	O

Computed	B-P
tomography	I-P
was	O
performed	O
at	O
six	O
months	O
for	O
morphological	O
evaluation	O
.	O

At	O
six	O
weeks	O
,	O
both	O
groups	O
were	O
still	O
recovering	O
from	O
surgery	O
and	O
the	O
overall	O
knee	O
function	O
was	O
still	O
impaired	O
but	O
the	O
functional	O
scores	O
were	O
significantly	O
higher	O
in	O
the	O
Bone	O
-	O
Albumin	O
group	O
.	O

The	O
pain	O
with	O
crouching	O
and	O
kneeling	O
was	O
also	O
lower	O
as	O
compared	O
to	O
controls	O
.	O

At	O
six	O
months	O
,	O
the	O
knee	O
function	O
scores	O
were	O
close	O
to	O
normal	O
,	O
with	O
a	O
slight	O
decrease	O
in	O
the	O
controls	O
.	O

Pain	O
at	O
kneeling	O
was	O
still	O
prominent	O
in	O
the	O
controls	O
,	O
but	O
significantly	O
lower	O
in	O
the	O
Bone	O
-	O
Albumin	O
group	O
.	O

Computed	B-P
tomography	I-P
showed	O
significantly	O
smaller	O
bone	O
defects	O
and	O
higher	O
bone	O
density	O
in	O
the	O
Bone	O
-	O
Albumin	O
group	O
.	O

Results	O
from	O
the	O
present	O
study	O
indicate	O
that	O
donor	O
site	O
pain	O
,	O
a	O
disturbing	O
long-term	O
side	O
effect	O
of	O
bone-patellar	O
tendon-bone	O
surgery	O
,	O
is	O
significantly	O
reduced	O
if	O
bone	O
buildup	O
in	O
the	O
patella	O
and	O
the	O
tibia	O
is	O
augmented	O
by	O
serum	O
albumin	O
-	O
coated	O
bone	O
allografts	O
.	O

Artemisinin	O
loaded	O
chitosan	O
magnetic	O
nanoparticles	O
for	O
the	O
efficient	O
targeting	O
to	O
the	O
breast	O
cancer	O
.	O

Artemisinin	O
,	O
a	O
natural	O
anti-malarial	O
agent	O
,	O
also	O
possesses	O
anti-proliferative	O
and	O
anti-angiogenic	O
activity	O
in	O
cancer	O
cells	O
with	O
very	O
low	O
toxicity	O
to	O
normal	O
healthy	O
cells	O
.	O

Drug	O
loaded	O
magnetic	O
nanoparticles	O
by	O
using	O
external	O
magnetic	O
field	O
could	O
selectively	O
accumulate	O
the	O
drug	O
at	O
the	O
target	O
site	O
and	O
thereby	O
reduce	O
the	O
doses	O
required	O
to	O
achieve	O
therapeutic	O
concentration	O
which	O
may	O
otherwise	O
produce	O
serious	O
side	O
effects	O
on	O
healthy	O
cells	O
.	O

In	O
the	O
present	O
study	O
the	O
artemisinin	O
magnetic	O
nanoparticles	O
were	O
successfully	O
formulated	O
using	O
chitosan	O
by	O
ionic-gelation	B-P
method	I-P
.	O

The	O
developed	O
magnetic	O
nanoparticles	O
of	O
artemisinin	O
were	O
smooth	O
and	O
spherical	O
in	O
nature	O
and	O
their	O
size	O
was	O
in	O
the	O
range	O
of	O
349-445nm	O
.	O

The	O
polydispersity	O
index	O
(	O
PDI	O
)	O
and	O
zeta	O
potential	O
of	O
the	O
formulated	O
nanoparticles	O
were	O
in	O
the	O
range	O
of	O
0.373-0.908	O
and	O
-9.34	O
to	O
-33.3	O
respectively	O
.	O

They	O
showed	O
55	O
%	O
to	O
62.5	O
%	O
of	O
drug	O
encapsulation	O
efficiency	O
and	O
20	O
%	O
to	O
25	O
%	O
drug	O
loading	O
capacity	O
.	O

Around	O
62	O
%	O
to	O
78	O
%	O
of	O
artemisinin	O
was	O
released	O
from	O
the	O
artemisinin	O
magnetic	O
nanoparticles	O
over	O
the	O
period	O
of	O
48h	O
.	O

On	O
application	O
of	O
physiologically	O
acceptable	O
external	O
magnetic	O
field	O
,	O
FITC	O
conjugated	O
artemisinin	O
magnetic	O
nanoparticles	O
showed	O
an	O
enhanced	O
accumulation	O
of	O
nanoparticles	O
in	O
the	O
4T1	O
breast	O
tumour	O
tissues	O
of	O
BALB/c	O
mice	O
model	O
.	O

Granulomatous	O
prostatitis	O
:	O
clinical	O
and	O
histomorphologic	O
survey	O
of	O
the	O
disease	O
in	O
a	O
tertiary	O
care	O
hospital	O
.	O

Granulomatous	O
prostatitis	O
is	O
an	O
uncommon	O
entity	O
that	O
is	O
diagnosed	O
incidentally	O
on	O
histopathology	O
and	O
is	O
broadly	O
classified	O
as	O
nonspecific	O
,	O
specific	O
,	O
postsurgical	O
(	O
post-transurethral	O
resection	O
)	O
,	O
or	O
secondary	O
to	O
other	O
rare	O
systemic	O
granulomatous	O
diseases	O
.	O

Only	O
very	O
few	O
studies	O
are	O
available	O
in	O
the	O
literature	O
that	O
describe	O
the	O
clinical	O
and	O
histomorphological	B-P
spectrum	I-P
of	O
the	O
disease	O
.	O

A	O
retrospective	O
analysis	O
of	O
histopathological	O
records	O
of	O
1,181	O
prostatic	O
specimens	O
received	O
in	O
the	O
pathology	O
department	O
was	O
done	O
over	O
a	O
period	O
of	O
13	O
years	O
(	O
January	O
2003	O
to	O
January	O
2016	O
)	O
.	O

All	O
histologically	B-P
proven	O
cases	O
of	O
granulomatous	O
prostatitis	O
were	O
retrieved	O
,	O
and	O
relevant	O
clinical	O
data	O
were	O
collected	O
from	O
patients	O
'	O
records	O
.	O

Epstein	O
and	O
Hutchins	O
classification	O
was	O
used	O
to	O
categorize	O
these	O
cases	O
.	O

Twenty-two	O
cases	O
of	O
granulomatous	O
prostatitis	O
were	O
identified	O
,	O
accounting	O
for	O
an	O
incidence	O
of	O
1.86	O
%	O
.	O

Among	O
these	O
,	O
nonspecific	O
granulomatous	O
prostatitis	O
(	O
n	O
=	O
10	O
)	O
was	O
the	O
most	O
common	O
followed	O
by	O
tubercular	O
prostatitis	O
(	O
n	O
=	O
5	O
)	O
,	O
posttransurethral	O
resection	O
of	O
the	O
prostate	O
(	O
n	O
=	O
3	O
)	O
,	O
allergic	O
(	O
n	O
=	O
2	O
)	O
,	O
and	O
xanthogranulomatous	O
prostatitis	O
(	O
n	O
=	O
2	O
)	O
.	O

The	O
age	O
range	O
of	O
these	O
patients	O
was	O
between	O
41	O
and	O
75	O
years	O
,	O
with	O
the	O
majority	O
of	O
patients	O
in	O
their	O
7	O
(	O
th	O
)	O
decade	O
.	O

Serum	B-P
prostate-specific	I-P
antigen	I-P
levels	I-P
ranged	O
between	O
0.88	O
ng/mL	O
and	O
19.22	O
ng/mL	O
.	O

Hard	O
and	O
fixed	O
nodules	O
were	O
observed	O
on	O
digital	B-P
rectal	I-P
examination	I-P
in	O
14	O
cases	O
.	O

Transrectal	B-P
ultrasound	I-P
revealed	O
hypoechoic	O
shadows	O
in	O
five	O
cases	O
.	O

Despite	O
present-day	O
advances	O
in	O
imaging	O
modalities	O
and	O
serological	B-P
investigations	I-P
,	O
it	O
is	O
virtually	O
impossible	O
to	O
identify	O
granulomatous	O
prostatitis	O
clinically	O
.	O

Histopathology	O
remains	O
the	O
gold	O
standard	O
in	O
diagnosing	O
the	O
disease	O
.	O

However	O
,	O
assigning	O
an	O
etiologic	O
cause	O
to	O
the	O
wide	O
spectrum	O
of	O
granulomas	O
in	O
granulomatous	O
prostatitis	O
requires	O
a	O
pathologist	O
's	O
expertise	O
and	O
proper	O
clinical	O
correlation	O
for	O
appropriate	O
patient	O
management	O
.	O

Comparison	O
of	O
the	O
Effects	O
of	O
Subcutaneous	O
Versus	O
Continuous	O
Infusion	O
of	O
Heparin	O
on	O
Key	O
Inflammatory	O
Parameters	O
Following	O
Sepsis	O
.	O

Sepsis	O
is	O
the	O
result	O
of	O
the	O
interaction	O
between	O
inflammatory	O
mediators	O
and	O
coagulation	O
pathway	O
.	O

Unfractionated	O
heparin	O
may	O
play	O
a	O
role	O
as	O
an	O
anti-inflammatory	O
agent	O
beyond	O
its	O
anticoagulatory	O
effect	O
in	O
sepsis	O
.	O

As	O
a	O
result	O
,	O
it	O
may	O
cause	O
reduction	O
in	O
organ	O
failure	O
rate	O
in	O
patients	O
with	O
sepsis	O
due	O
to	O
its	O
impact	O
on	O
both	O
inflammatory	O
and	O
coagulation	O
process	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
anti-inflammatory	O
effects	O
of	O
heparin	O
in	O
sepsis	O
.	O

Plasma	O
plasminogen	O
activator	O
inhibitor-1	O
(	O
PAI-1	O
)	O
as	O
an	O
inflammatory	O
mediator	O
and	O
urinary	O
necoutrophil	O
gelatinase-associated	O
lipocalin	O
(	O
NGAL	O
)	O
as	O
a	O
marker	O
of	O
kidney	O
injury	O
were	O
investigated	O
.	O

This	O
prospective	O
,	O
randomized	O
controlled	O
trial	O
was	O
conducted	O
in	O
a	O
32-	O
bed	O
intensive	O
care	O
unit	O
.	O

Thirty	O
patients	O
with	O
sepsis	O
were	O
randomized	O
to	O
receive	O
heparin	O
infusion	O
of	O
500	O
units/hour	O
or	O
5000	O
units	O
of	O
heparin	O
three	O
times	O
a	O
day	O
,	O
subcutaneously	O
.	O

The	O
plasma	O
level	O
of	O
PAI-1	O
and	O
urinary	O
level	O
of	O
NGAL	O
were	O
determined	O
at	O
day	O
0	O
,	O
2	O
and	O
7	O
.	O

The	O
infusion	O
group	O
had	O
a	O
lower	O
plasma	O
PAI-1	O
level	O
compared	O
to	O
the	O
subcutaneous	O
group	O
at	O
day	O
7	O
(	O
11.3	O
±	O
1.6	O
vs.	O
16.5	O
±	O
4.2	O
;	O
P	O
=	O
0.003	O
)	O
.	O

The	O
urinary	O
NGAL	O
level	O
was	O
lower	O
in	O
the	O
infusion	O
group	O
at	O
day	O
2	O
(	O
131.3	O
±	O
11.9	O
vs.	O
151.2	O
±	O
20.6	O
;	O
P	O
=	O
0.014	O
)	O
;	O
however	O
,	O
at	O
day	O
7	O
the	O
NGAL	O
level	O
was	O
decreased	O
in	O
the	O
subcutaneous	O
group	O
as	O
much	O
as	O
the	O
infusion	O
group	O
and	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
two	O
groups	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
acute	B-P
physiology	I-P
and	I-P
chronic	I-P
health	I-P
evaluation	I-P
(	I-P
APACHE	I-P
)	I-P
II	I-P
and	O
sequential	O
organ	O
failure	O
assessment	O
(	O
SOFA	O
)	O
scores	O
between	O
the	O
two	O
groups	O
at	O
day	O
0	O
,	O
2	O
and	O
7	O
.	O

Low-dose	O
heparin	O
infusion	O
compared	O
to	O
subcutaneous	O
heparin	O
can	O
decrease	O
the	O
plasma	O
PAI-1	O
and	O
urinary	O
NGAL	O
levels	O
more	O
rapidly	O
.	O

It	O
can	O
be	O
related	O
to	O
anti-inflammatory	O
effects	O
of	O
heparin	O
,	O
which	O
may	O
be	O
more	O
prominent	O
in	O
infusion	O
route	O
.	O

Using	O
melanopsin	O
to	O
study	O
G	O
protein	O
signaling	O
in	O
cortical	O
neurons	O
.	O

Our	O
understanding	O
of	O
G	O
protein-coupled	O
receptors	O
(	O
GPCRs	O
)	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
has	O
been	O
hampered	O
by	O
the	O
limited	O
availability	O
of	O
tools	O
allowing	O
for	O
the	O
study	O
of	O
their	O
signaling	O
with	O
precise	O
temporal	O
control	O
.	O

To	O
overcome	O
this	O
,	O
we	O
tested	O
the	O
utility	O
of	O
the	O
bistable	O
mammalian	O
opsin	O
melanopsin	O
to	O
examine	O
G	O
protein	O
signaling	O
in	O
CNS	O
neurons	O
.	O

Specifically	O
,	O
we	O
used	O
biolistic	O
(	O
gene	O
gun	O
)	O
approaches	O
to	O
transfect	O
melanopsin	O
into	O
cortical	O
pyramidal	O
cells	O
maintained	O
in	O
organotypic	B-P
slice	I-P
culture	I-P
.	O

Whole	O
cell	O
recordings	O
from	O
transfected	O
neurons	O
indicated	O
that	O
application	O
of	O
blue	O
light	O
effectively	O
activated	O
the	O
transfected	O
melanopsin	O
to	O
elicit	O
the	O
canonical	O
biphasic	O
modulation	O
of	O
membrane	O
excitability	O
previously	O
associated	O
with	O
the	O
activation	O
of	O
GPCRs	O
coupling	O
to	O
Gαq-11	O
Remarkably	O
,	O
full	O
mimicry	O
of	O
exogenous	O
agonist	O
concentration	O
could	O
be	O
obtained	O
with	O
pulses	O
as	O
short	O
as	O
a	O
few	O
milliseconds	O
,	O
suggesting	O
that	O
their	O
triggering	O
required	O
a	O
single	O
melanopsin	O
activation-deactivation	O
cycle	O
.	O

The	O
resulting	O
temporal	O
control	O
over	O
melanopsin	O
activation	O
allowed	O
us	O
to	O
compare	O
the	O
activation	O
kinetics	O
of	O
different	O
components	O
of	O
the	O
electrophysiological	O
response	O
.	O

We	O
also	O
replaced	O
the	O
intracellular	O
loops	O
of	O
melanopsin	O
with	O
those	O
of	O
the	O
5-HT2A	O
receptor	O
to	O
create	O
a	O
light-activated	O
GPCR	O
capable	O
of	O
interacting	O
with	O
the	O
5-HT2A	O
receptor	O
interacting	O
proteins	O
.	O

The	O
resulting	O
chimera	O
expressed	O
weak	O
activity	O
but	O
validated	O
the	O
potential	O
usefulness	O
of	O
melanopsin	O
as	O
a	O
tool	O
for	O
the	O
study	O
of	O
G	O
protein	O
signaling	O
in	O
CNS	O
neurons	O
.	O

Reducing	O
neuroinflammation	O
by	O
delivery	O
of	O
IL-10	O
encoding	O
lentivirus	O
from	O
multiple-channel	O
bridges	O
.	O

The	O
spinal	O
cord	O
is	O
unable	O
to	O
regenerate	O
after	O
injury	O
largely	O
due	O
to	O
growth-inhibition	O
by	O
an	O
inflammatory	O
response	O
to	O
the	O
injury	O
that	O
fails	O
to	O
resolve	O
,	O
resulting	O
in	O
secondary	O
damage	O
and	O
cell	O
death	O
.	O

An	O
approach	O
that	O
prevents	O
inhibition	O
by	O
attenuating	O
the	O
inflammatory	O
response	O
and	O
promoting	O
its	O
resolution	O
through	O
the	O
transition	O
of	O
macrophages	O
to	O
anti-inflammatory	O
phenotypes	O
is	O
essential	O
for	O
the	O
creation	O
of	O
a	O
growth	O
permissive	O
microenvironment	O
.	O

Viral	O
gene	O
delivery	O
to	O
induce	O
the	O
expression	O
of	O
anti-inflammatory	O
factors	O
provides	O
the	O
potential	O
to	O
provide	O
localized	O
delivery	O
to	O
alter	O
the	O
host	O
inflammatory	O
response	O
.	O

Initially	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
the	O
biomaterial	O
and	O
viral	O
components	O
of	O
the	O
delivery	O
system	O
to	O
influence	O
the	O
extent	O
of	O
cell	O
infiltration	O
and	O
the	O
phenotype	O
of	O
these	O
cells	O
.	O

Bridge	O
implantation	O
reduces	O
antigen	O
-presenting	O
cell	O
infiltration	O
at	O
day	O
7	O
,	O
and	O
lentivirus	O
addition	O
to	O
the	O
bridge	O
induces	O
a	O
transient	O
increase	O
in	O
neutrophils	O
in	O
the	O
spinal	O
cord	O
at	O
day	O
7	O
and	O
macrophages	O
at	O
day	O
14	O
.	O

Delivery	O
of	O
a	O
lentivirus	O
encoding	O
IL-10	O
,	O
an	O
anti-inflammatory	O
factor	O
that	O
inhibits	O
immune	O
cell	O
activation	O
and	O
polarizes	O
the	O
macrophage	B-P
population	I-P
towards	O
anti-inflammatory	O
phenotypes	O
,	O
reduced	O
neutrophil	O
infiltration	O
at	O
both	O
day	O
7	O
and	O
day	O
28	O
.	O

Though	O
IL-10	O
lentivirus	O
did	O
not	O
affect	O
macrophages	B-P
number	I-P
,	O
it	O
skewed	O
the	O
macrophage	B-P
population	I-P
toward	O
an	O
anti-inflammatory	O
M2	O
phenotype	O
and	O
altered	O
macrophage	O
morphology	O
.	O

Additionally	O
,	O
IL-10	O
delivery	O
resulted	O
in	O
improved	O
motor	O
function	O
,	O
suggesting	O
reduced	O
secondary	O
damage	O
and	O
increased	O
sparing	O
.	O

Taken	O
together	O
,	O
these	O
results	O
indicate	O
that	O
localized	O
expression	O
of	O
anti-inflammatory	O
factors	O
,	O
such	O
as	O
IL-10	O
,	O
can	O
modulate	O
the	O
inflammatory	O
response	O
following	O
spinal	O
cord	O
injury	O
,	O
and	O
may	O
be	O
a	O
key	O
component	O
of	O
a	O
combinatorial	O
approach	O
that	O
targets	O
the	O
multiple	O
barriers	O
to	O
regeneration	O
and	O
functional	O
recovery	O
.	O

Iron	O
Deficiency	O
Is	O
Common	O
During	O
Remission	O
in	O
Children	O
With	O
Inflammatory	O
Bowel	O
Disease	O
.	O

The	O
aim	O
was	O
to	O
study	O
prevalence	O
of	O
iron	O
deficiency	O
in	O
children	O
with	O
inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
during	O
remission	O
.	O

In	O
addition	O
,	O
there	O
was	O
an	O
observational	O
evaluation	O
of	O
hematological	B-P
response	O
to	O
oral	O
iron	O
.	O

A	O
population-based	O
retrospective	O
study	O
including	O
90	O
Swedish	O
children	O
(	O
median	O
13	O
years	O
)	O
with	O
IBD	O
was	O
performed	O
.	O

Patient	O
records	O
covered	O
in	O
median	O
25	O
months	O
.	O

Iron	O
deficiency	O
was	O
present	O
in	O
70/77	O
children	O
(	O
91	O
%	O
)	O
in	O
which	O
iron	B-P
status	I-P
could	O
be	O
assessed	O
.	O

In	O
clinical	O
and	O
biochemical	O
remission	O
,	O
iron	O
deficiency	O
was	O
found	O
in	O
57/67	O
(	O
85	O
%	O
)	O
of	O
children	O
,	O
and	O
23	O
(	O
34	O
%	O
)	O
of	O
them	O
had	O
iron	O
deficiency	O
anemia	O
.	O

Thirty-six	O
iron-deficient	O
children	O
were	O
prescribed	O
oral	O
iron	O
supplementation	O
and	O
32	O
(	O
89	O
%	O
)	O
improved	O
hemoglobin	O
levels	O
over	O
6	O
months	O
.	O

In	O
conclusion	O
,	O
iron	O
deficiency	O
is	O
common	O
during	O
clinical	O
remission	O
in	O
children	O
with	O
IBD	O
,	O
even	O
in	O
cohorts	O
with	O
low	O
prevalence	O
of	O
anemia	O
.	O

Therefore	O
,	O
regular	O
biochemical	B-P
screening	I-P
for	O
iron	O
deficiency	O
is	O
warranted	O
during	O
all	O
stages	O
of	O
disease	O
,	O
irrespective	O
of	O
symptoms	O
and	O
inflammatory	O
blood	O
markers	O
.	O

Utility	O
of	O
an	O
Ultrasonic	O
Aspirator	O
in	O
Transcanal	O
Endoscopic	O
Resection	O
of	O
Temporal	O
Bone	O
Paraganglioma	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
role	O
of	O
removing	O
middle	O
ear	O
paragangliomas	O
using	O
an	O
ultrasonic	O
aspirator	O
(	O
UA	O
)	O
through	O
a	O
transcanal	O
,	O
exclusively	O
endoscopic	O
approach	O
.	O

Three	O
consecutive	O
patients	O
undergoing	O
transcanal	O
endoscopic	O
resection	O
of	O
middle	O
ear	O
paragangliomas	O
using	O
an	O
UA	O
were	O
retrospectively	O
studied	O
.	O

The	O
primary	O
outcome	O
measure	O
was	O
achieving	O
gross	O
total	O
tumor	O
resection	O
.	O

Secondary	O
outcomes	O
included	O
postoperative	O
hearing	O
and	O
early	O
convalescence	O
.	O

Two	O
glomus	O
tympanicum	O
tumors	O
and	O
one	O
small	O
glomus	O
jugulare	O
were	O
included	O
,	O
and	O
complete	O
tumor	O
resection	O
was	O
achieved	O
endoscopically	B-P
in	O
all	O
cases	O
.	O

All	O
patients	O
demonstrated	O
intact	O
tympanic	O
membranes	O
and	O
normal	O
facial	O
nerve	O
function	O
at	O
the	O
initial	O
postoperative	O
visit	O
.	O

There	O
were	O
no	O
cases	O
of	O
bone-conduction	O
pure	O
tone	O
threshold	O
increases	O
of	O
more	O
than	O
15	O
dB	O
.	O

The	O
UA	O
was	O
helpful	O
when	O
performing	O
exclusively	O
endoscopic	O
transcanal	O
resection	O
of	O
middle	O
ear	O
paraganglioma	O
given	O
its	O
simultaneous	O
suction-aspiration	O
capability	O
.	O

Complete	O
Genome	B-P
Sequences	I-P
of	O
the	O
Endophytic	O
Streptomyces	O
Strains	O
EN16	O
,	O
EN23	O
,	O
and	O
EN27	O
,	O
Isolated	O
from	O
Wheat	O
Plants	O
.	O

The	O
complete	O
genome	B-P
sequences	I-P
of	O
three	O
endophytic	O
Streptomyces	O
species	O
were	O
compared	O
.	O

Strains	O
EN16	O
,	O
EN23	O
,	O
and	O
EN27	O
were	O
isolated	O
from	O
surface-	O
sterilized	O
roots	O
of	O
wheat	O
plants	O
from	O
South	O
Australia	O
.	O

In	O
field	O
trials	O
,	O
these	O
strains	O
are	O
effective	O
in	O
suppressing	O
fungal	O
root	O
diseases	O
of	O
wheat	O
when	O
added	O
as	O
spore	O
coatings	O
to	O
wheat	O
seed	O
.	O

Pembrolizumab	O
for	O
the	O
treatment	O
of	O
non-small	O
cell	O
lung	O
cancer	O
.	O

In	O
the	O
last	O
years	O
,	O
a	O
spectacular	O
development	O
of	O
immunotherapeutic	O
agents	O
aimed	O
at	O
the	O
PD-1	O
/	O
PD-L1	O
axis	O
has	O
taken	O
place	O
.	O

This	O
development	O
of	O
these	O
checkpoint	O
inhibitors	O
has	O
greatly	O
influenced	O
our	O
approach	O
to	O
the	O
treatment	O
of	O
lung	O
cancer	O
in	O
first	O
and	O
second	O
line	O
.	O

The	O
limited	O
toxicity	O
profile	O
and	O
the	O
ability	O
to	O
treat	O
for	O
prolonged	O
periods	O
,	O
even	O
in	O
smokers	O
,	O
is	O
a	O
welcome	O
expansion	O
of	O
the	O
therapeutic	O
arsenal	O
of	O
the	O
oncologist	O
.	O

Areas	O
covered	O
:	O
This	O
review	O
highlights	O
the	O
results	O
of	O
recent	O
clinical	O
trials	O
on	O
pembrolizumab	O
for	O
the	O
treatment	O
of	O
non-small	O
cell	O
lung	O
cancer	O
.	O

The	O
authors	O
discuss	O
both	O
first	O
and	O
second	O
line	O
treatment	O
with	O
pembrolizumab	O
as	O
monotherapy	O
and	O
in	O
combination	O
therapies	O
.	O

Additionally	O
,	O
implications	O
of	O
the	O
PD-L1	O
immunohistochemistry	B-P
assay	I-P
with	O
the	O
22C3	O
antibody	O
and	O
its	O
use	O
in	O
clinical	O
practice	O
and	O
trials	O
is	O
discussed	O
.	O

Expert	O
commentary	O
:	O
A	O
higher	O
overall	O
response	O
,	O
overall	O
survival	O
and	O
a	O
moderate	O
toxicity	O
profile	O
is	O
observed	O
with	O
the	O
use	O
of	O
pembrolizumab	O
,	O
compared	O
to	O
chemotherapy	O
,	O
in	O
both	O
first	O
and	O
second	O
line	O
.	O

These	O
promising	O
results	O
have	O
already	O
translated	O
into	O
the	O
registration	O
of	O
pembrolizumab	O
in	O
first	O
and	O
second	O
line	O
in	O
patients	O
with	O
a	O
high	O
expression	O
of	O
PD-L1	O
.	O

However	O
,	O
as	O
PD-L1	O
staining	B-P
does	O
not	O
sufficiently	O
discriminate	O
responders	O
from	O
non-responders	O
for	O
all	O
checkpoint	O
inhibitors	O
,	O
there	O
still	O
is	O
a	O
need	O
for	O
a	O
better	O
predictive	O
biomarker	O
.	O

Early	O
assessment	O
of	O
bilateral	O
inguinal	O
hernia	O
repair	O
:	O
A	O
comparison	O
between	O
the	O
laparoscopic	O
total	O
extraperitoneal	O
and	O
Stoppa	O
approaches	O
.	O

The	O
present	O
clinical	O
trial	O
was	O
designed	O
to	O
compare	O
the	O
results	O
of	O
bilateral	O
inguinal	O
hernia	O
repair	O
between	O
patients	O
who	O
underwent	O
the	O
conventional	O
Stoppa	O
technique	O
and	O
laparoscopic	O
total	O
extraperitoneal	O
repair	O
(	O
LTE	O
)	O
with	O
a	O
single	O
mesh	O
and	O
without	O
staple	O
fixation	O
.	O

This	O
controlled	O
,	O
randomised	O
clinical	O
trial	O
was	O
conducted	O
at	O
General	O
Surgery	O
and	O
Trauma	O
of	O
the	O
Clinics	O
Hospital	O
,	O
Medical	O
School	O
,	O
the	O
University	O
of	O
Sγo	O
Paulo	O
between	O
September	O
2010	O
and	O
February	O
2011	O
.	O

Totally	O
,	O
50	O
male	O
patients	O
,	O
with	O
a	O
bilateral	O
inguinal	O
hernia	O
,	O
older	O
than	O
25	O
years	O
were	O
considered	O
eligible	O
for	O
the	O
study	O
.	O

The	O
following	O
parameters	O
were	O
analysed	O
during	O
the	O
early	O
post-operative	O
period	O
:	O
(	O
1	O
)	O
The	O
intensity	O
of	O
surgical	O
trauma	O
,	O
operation	O
time	O
,	O
C-reactive	O
protein	O
(	O
CRP	O
)	O
levels	O
,	O
white	B-P
blood	I-P
cell	I-P
count	I-P
,	O
bleeding	O
and	O
pain	O
intensity	O
;	O
(	O
2	O
)	O
quality	O
of	O
life	O
assessment	O
;	O
and	O
(	O
3	O
)	O
post-operative	O
complications	O
.	O

LTE	O
procedure	O
was	O
longer	O
than	O
the	O
Stoppa	O
procedure	O
(	O
134.6	O
min	O
΁	O
38.3	O
vs.	O
90.6	O
min	O
΁	O
41.3	O
;	O
P	O
<	O
0.05	O
)	O
.	O

The	O
levels	O
of	O
CRP	O
were	O
higher	O
in	O
the	O
Stoppa	O
group	O
(	O
P	O
<	O
0.05	O
)	O
but	O
the	O
number	O
of	O
leucocytes	O
,	O
haematocrit	O
,	O
and	O
haemoglobin	O
were	O
similar	O
between	O
the	O
groups	O
(	O
P	O
>	O
0.05	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
pain	O
during	O
the	O
1	O
st	O
and	O
7	O
th	O
post-operative	O
,	O
physical	O
functioning	O
,	O
physical	O
limitation	O
,	O
the	O
impact	O
of	O
pain	O
on	O
daily	O
activities	O
,	O
and	O
the	O
Carolinas	O
Comfort	O
Scale	O
during	O
the	O
7	O
th	O
and	O
15	O
th	O
post-operative	O
(	O
P	O
>	O
0.05	O
)	O
.	O

Complications	O
occurred	O
in	O
88	O
%	O
of	O
Stoppa	O
group	O
(	O
22	O
patients	O
)	O
and	O
64	O
%	O
in	O
LTE	O
group	O
(	O
16	O
patients	O
)	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
comparative	O
study	O
between	O
the	O
Stoppa	O
and	O
LTE	O
approaches	O
for	O
the	O
bilateral	O
inguinal	O
hernia	O
repair	O
demonstrated	O
that	O
:	O
(	O
1	O
)	O
The	O
LTE	O
approach	O
showed	O
less	O
surgical	O
trauma	O
despite	O
the	O
longer	O
operation	O
time	O
;	O
(	O
2	O
)	O
Quality	O
of	O
life	O
during	O
the	O
early	O
post-operative	O
period	O
were	O
similar	O
;	O
and	O
(	O
3	O
)	O
Complication	O
rates	O
were	O
higher	O
in	O
the	O
Stoppa	O
group	O
.	O

Sleep	O
characteristics	O
in	O
type	O
1	O
diabetes	O
and	O
associations	O
with	O
glycemic	O
control	O
:	O
systematic	O
review	O
and	O
meta-analysis	O
.	O

The	O
association	O
between	O
inadequate	O
sleep	O
and	O
type	O
2	O
diabetes	O
has	O
garnered	O
much	O
attention	O
,	O
but	O
little	O
is	O
known	O
about	O
sleep	O
and	O
type	O
1	O
diabetes	O
(	O
T1D	O
)	O
.	O

Our	O
objectives	O
were	O
to	O
conduct	O
a	O
systematic	O
review	O
and	O
meta-analysis	O
comparing	O
sleep	O
in	O
persons	O
with	O
and	O
without	O
T1D	O
,	O
and	O
to	O
explore	O
relationships	O
between	O
sleep	O
and	O
glycemic	O
control	O
in	O
T1D	O
.	O

Studies	O
were	O
identified	O
from	O
Medline	O
and	O
Scopus	O
.	O

Studies	O
reporting	O
measures	O
of	O
sleep	O
in	O
T1D	O
patients	O
and	O
controls	O
,	O
and/or	O
associations	O
between	O
sleep	O
and	O
glycemic	O
control	O
,	O
were	O
selected	O
.	O

A	O
total	O
of	O
22	O
studies	O
were	O
eligible	O
for	O
the	O
meta-analysis	O
.	O

Children	O
with	O
T1D	O
had	O
shorter	O
sleep	O
duration	O
(	O
mean	O
difference	O
[	O
MD	O
]	O
=	O
-26.4	O
minutes	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
=	O
-35.4	O
,	O
-17.7	O
)	O
than	O
controls	O
.	O

Adults	O
with	O
T1D	O
reported	O
poorer	O
sleep	O
quality	O
(	O
MD	O
in	O
standardized	O
sleep	O
quality	O
score	O
=	O
0.51	O
;	O
95	O
%	O
CI	O
=	O
0.33	O
,	O
0.70	O
)	O
,	O
with	O
higher	O
scores	O
reflecting	O
worse	O
sleep	O
quality	O
)	O
than	O
controls	O
,	O
but	O
there	O
was	O
no	O
difference	O
in	O
self	O
-	O
reported	O
sleep	O
duration	O
.	O

Adults	O
with	O
TID	O
who	O
reported	O
sleeping	O
>	O
6	O
hours	O
had	O
lower	O
hemoglobin	B-P
A1c	I-P
(	I-P
HbA1c	I-P
)	I-P
levels	I-P
than	O
those	O
sleeping	O
≤6	O
hours	O
(	O
MD	O
=	O
-0.24	O
%	O
;	O
95	O
%	O
CI	O
=	O
-0.47	O
,	O
-0.02	O
)	O
,	O
and	O
participants	O
reporting	O
good	O
sleep	O
quality	O
had	O
lower	O
HbA1c	O
than	O
those	O
with	O
poor	O
sleep	O
quality	O
(	O
MD	O
=	O
-0.19	O
%	O
;	O
95	O
%	O
CI	O
=	O
-0.30	O
,	O
-0.08	O
)	O
.	O

The	O
estimated	O
prevalence	O
of	O
obstructive	O
sleep	O
apnea	O
(	O
OSA	O
)	O
in	O
adults	O
with	O
TID	O
was	O
51.9	O
%	O
(	O
95	O
%	O
CI	O
=	O
31.2	O
,	O
72.6	O
)	O
.	O

Patients	O
with	O
moderate-to-severe	O
OSA	O
had	O
a	O
trend	O
toward	O
higher	O
HbA1c	O
(	O
MD	O
=	O
0.39	O
%	O
,	O
95	O
%	O
CI	O
=	O
-0.08	O
,	O
0.87	O
)	O
.	O

T1D	O
was	O
associated	O
with	O
poorer	O
sleep	O
and	O
high	O
prevalence	O
of	O
OSA	O
.	O

Poor	O
sleep	O
quality	O
,	O
shorter	O
sleep	O
duration	O
,	O
and	O
OSA	O
were	O
associated	O
with	O
suboptimal	O
glycemic	O
control	O
in	O
T1D	O
patients	O
.	O

Common	O
and	O
Uncommon	O
Anatomical	O
Variants	O
of	O
Intrahepatic	O
Bile	O
Ducts	O
in	O
Magnetic	B-P
Resonance	I-P
Cholangiopancreatography	I-P
and	O
its	O
Clinical	O
Implication	O
.	O

Preoperative	O
knowledge	O
of	O
intrahepatic	O
bile	O
duct	O
(	O
IHD	O
)	O
anatomy	O
is	O
critical	O
for	O
planning	O
liver	O
resections	O
,	O
liver	O
transplantations	O
and	O
complex	O
biliary	O
reconstructive	O
surgery	O
.	O

The	O
purpose	O
of	O
our	O
study	O
was	O
to	O
demonstrate	O
the	O
imaging	O
features	O
of	O
various	O
anatomical	O
variants	O
of	O
IHD	O
using	O
magnetic	B-P
resonance	I-P
cholangio-pancreatography	I-P
(	O
MRCP	B-P
)	O
and	O
their	O
prevalence	O
in	O
our	O
population	O
.	O

This	O
observational	O
clinical	O
evaluation	O
study	O
included	O
224	O
patients	O
who	O
were	O
referred	O
for	O
MRCP	B-P
.	O

MRCP	B-P
was	O
performed	O
in	O
a	O
1.5-Tesla	O
magnet	O
(	O
Philips	O
)	O
with	O
SSH	B-P
MRCP	I-P
3DHR	O
and	O
SSHMRCP	B-P
rad	O
protocol	O
.	O

A	O
senior	O
radiologist	O
assessed	O
the	O
biliary	O
passage	O
for	O
anatomical	O
variations	O
.	O

The	O
branching	O
pattern	O
of	O
the	O
right	O
hepatic	O
duct	O
(	O
RHD	O
)	O
was	O
typical	O
in	O
55.3	O
%	O
of	O
subjects	O
.	O

The	O
most	O
common	O
variant	O
was	O
right	O
posterior	O
sectoral	O
duct	O
(	O
RPSD	O
)	O
draining	O
into	O
the	O
left	O
hepatic	O
duct	O
(	O
LHD	O
)	O
in	O
27.6	O
%	O
of	O
subjects	O
.	O

Trifurcation	O
pattern	O
was	O
noted	O
in	O
9.3	O
%	O
of	O
subjects	O
.	O

In	O
4	O
%	O
of	O
subjects	O
,	O
RPSD	O
was	O
draining	O
into	O
the	O
common	O
hepatic	O
duct	O
(	O
CHD	O
)	O
and	O
in	O
0.8	O
%	O
of	O
subjects	O
into	O
the	O
cystic	O
duct	O
.	O

Other	O
variants	O
were	O
noted	O
in	O
2.6	O
%	O
of	O
subjects	O
.	O

In	O
4.9	O
%	O
of	O
cases	O
there	O
was	O
an	O
accessory	O
duct	O
.	O

The	O
most	O
common	O
type	O
of	O
LHD	O
branching	O
pattern	O
was	O
a	O
common	O
trunk	O
of	O
segment	O
2	O
and	O
3	O
ducts	O
joining	O
the	O
segment	O
4	O
duct	O
in	O
67.8	O
%	O
of	O
subjects	O
.	O

In	O
23.2	O
%	O
of	O
subjects	O
,	O
segment	O
2	O
duct	O
united	O
with	O
the	O
common	O
trunk	O
of	O
segment	O
3	O
and	O
4	O
and	O
in	O
3.4	O
%	O
of	O
subjects	O
segment	O
2	O
,	O
3	O
,	O
and	O
4	O
ducts	O
united	O
together	O
to	O
form	O
LHD	O
.	O

Other	O
uncommon	O
branching	O
patterns	O
of	O
LHD	O
were	O
seen	O
in	O
4.9	O
%	O
of	O
subjects	O
.	O

Intrahepatic	O
bile	O
duct	O
anatomy	O
is	O
complex	O
with	O
many	O
common	O
and	O
uncommon	O
variations	O
.	O

MRCP	B-P
is	O
a	O
reliable	O
non-invasive	O
imaging	B-P
method	I-P
for	O
demonstration	O
of	O
bile	O
duct	O
morpholog	O
y	O
,	O
which	O
is	O
useful	O
to	O
plan	O
complex	O
surgeries	O
and	O
to	O
prevent	O
iatrogenic	O
injuries	O
.	O

How	O
Integrated	B-P
Management	I-P
Strategies	I-P
Promote	O
Protein	O
Quality	O
of	O
Cotton	O
Embryos	O
:	O
High	O
Levels	O
of	O
Soil	O
Available	O
N	O
,	O
N	O
Assimilation	O
and	O
Protein	O
Accumulation	O
Rate	O
.	O

Cottonseed	O
is	O
widely	O
used	O
as	O
a	O
source	O
of	O
ruminant	O
feed	O
and	O
for	O
industrial	O
purposes	O
.	O

Therefore	O
,	O
there	O
is	O
a	O
tremendous	O
need	O
to	O
improve	O
the	O
nutritional	O
value	O
of	O
cotton	O
embryos	O
.	O

In	O
this	O
study	O
,	O
a	O
conventional	B-P
management	I-P
(	O
CM	B-P
)	O
and	O
two	O
integrated	O
cotton	O
management	B-P
strategies	I-P
(	O
IMS1	B-P
,	O
IMS2	B-P
)	O
were	O
performed	O
at	O
two	O
soil	O
fertility	O
levels	O
to	O
study	O
the	O
relationships	O
among	O
soil	O
N	O
,	O
N	O
assimilation	O
,	O
embryonic	O
protein	O
accumulation	O
and	O
protein	O
quality	O
.	O

The	O
levels	B-P
of	I-P
proteins	I-P
,	O
essential	B-P
amino	I-P
acids	I-P
,	O
and	O
semi-essential	B-P
amino	I-P
acids	I-P
,	O
especially	O
those	O
of	O
glutamate	B-P
,	O
lysine	B-P
,	O
and	O
methionine	B-P
,	O
were	O
higher	O
in	O
IMS1	B-P
and	O
IMS2	B-P
embryos	O
than	O
in	O
CM	B-P
embryos	O
.	O

These	O
changes	O
were	O
significantly	O
positively	O
correlated	O
with	O
the	O
soil	O
-	O
available	O
N	B-P
content	I-P
,	O
glutamine	O
synthetase	O
activity	O
and	O
peak	O
value	O
of	O
protein	O
accumulation	O
rate	O
and	O
were	O
negatively	O
correlated	O
with	O
the	O
free	O
amino	B-P
acid	I-P
level	I-P
.	O

These	O
results	O
illustrated	O
that	O
integrated	B-P
management	I-P
strategies	I-P
,	O
especially	O
the	O
rates	O
and	O
timing	O
of	O
N	O
application	O
,	O
raise	O
the	O
level	O
of	O
soil	O
available	O
N	O
,	O
which	O
is	O
beneficial	O
for	O
N	O
assimilation	O
in	O
developing	O
cotton	O
embryos	O
.	O

The	O
protein	B-P
content	I-P
was	O
limited	O
by	O
the	O
rate	O
of	O
protein	O
accumulation	O
rather	O
than	O
by	O
the	O
free	O
amino	B-P
acid	I-P
content	I-P
.	O

The	O
combination	O
of	O
target	O
yield	O
fertilization	O
,	O
a	O
growth	O
-driven	O
N	O
application	O
schedule	O
,	O
a	O
high	O
plant	O
density	O
and	O
the	O
seedling	O
raising	O
with	O
bio-organic	O
fertilizer	O
can	O
substantially	O
improve	O
protein	O
quality	O
in	O
cotton	O
embryos	O
,	O
especially	O
at	O
a	O
soil	O
with	O
low	O
soil	O
organic	O
matter	O
and	O
total	O
nitrogen	O
.	O

Electrocardiographic	O
appearance	O
of	O
aortic	O
stenosis	O
before	O
and	O
after	O
aortic	O
valve	O
replacement	O
.	O

So	O
far	O
,	O
the	O
specific	O
appearance	O
of	O
QRS	O
complex	O
,	O
ST-segment	O
,	O
and	O
T	O
wave	O
was	O
observed	O
in	O
aortic	O
stenosis	O
(	O
AS	O
)	O
.	O

S-wave	O
dynamic	O
change	O
in	O
leads	O
V1	O
-	O
V3	O
was	O
not	O
reported	O
in	O
AS	O
.	O

In	O
a	O
single-center	O
,	O
prospective	O
study	O
,	O
we	O
included	O
a	O
total	O
number	O
of	O
1.175	O
patients	O
who	O
underwent	O
surgical	O
aortic	O
valve	O
replacement	O
(	O
AVR	O
)	O
.	O

We	O
conducted	O
3-year	O
gathering	O
of	O
patients	O
with	O
symptomatic	O
and	O
asymptomatic	O
severe	O
AS	O
,	O
and	O
separated	O
them	O
by	O
hemodynamic	O
stability	O
into	O
groups	O
A	O
and	O
B	O
,	O
through	O
EFLV	O
(	O
of	O
more	O
or	O
less	O
than	O
50	O
%	O
)	O
,	O
AVA	O
(	O
of	O
more	O
or	O
less	O
than	O
0.9	O
cm	O
(	O
2	O
)	O
)	O
,	O
PG	O
(	O
between	O
55	O
and	O
75	O
mm	O
Hg	O
or	O
over	O
75	O
mm	O
Hg	O
)	O
,	O
and	O
end-diastolic	O
LV	O
dimension	O
(	O
of	O
more	O
or	O
less	O
than	O
56	O
mm	O
)	O
.	O

We	O
evaluated	O
the	O
impact	O
of	O
S-wave	O
magnitude	O
in	O
right	O
precordial	O
leads	O
before	O
and	O
after	O
AVR	O
in	O
all	O
patients	O
.	O

We	O
followed	O
S-wave	O
changes	O
in	O
electrocardiogram	O
altogether	O
with	O
hemodynamic	O
measurements	O
derived	O
from	O
echocardiography	B-P
.	O

Analysis	O
of	O
echocardiographic	B-P
parameters	O
,	O
measured	O
in	O
patients	O
before	O
surgery	O
,	O
did	O
not	O
show	O
statistical	O
significance	O
between	O
asymptomatic	O
and	O
symptomatic	O
group	O
.	O

The	O
statistical	O
significance	O
was	O
observed	O
in	O
the	O
change	O
in	O
S-wave	O
magnitude	O
in	O
the	O
right	O
precordial	O
leads	O
in	O
both	O
subsets	O
of	O
patients	O
before	O
AVR	O
.	O

We	O
found	O
statistically	O
significant	O
predictive	O
value	O
of	O
S-wave	O
magnitude	O
in	O
leads	O
V2	O
-	O
V3	O
for	O
dependent	O
variables	O
PG	O
and	O
end-diastolic	O
LV	O
dimension	O
.	O

S-wave	O
changes	O
in	O
right	O
precordial	O
leads	O
can	O
predict	O
increase	O
in	O
PG	O
and	O
critical	O
narrowing	O
of	O
AVA	O
,	O
suggestive	O
of	O
timely	O
referral	O
for	O
AVR	O
.	O

Construction	O
of	O
recombinant	O
adenovirus	O
Ad-rat	O
PLCγ2	O
and	O
its	O
effects	O
on	O
apoptosis	O
of	O
rat	O
liver	O
cell	O
BRL-3A	O
in	O
vitro	O
.	O

Although	O
the	O
role	O
of	O
PLCγ2	O
in	O
apoptotic	O
response	O
has	O
been	O
reported	O
,	O
too	O
little	O
is	O
known	O
about	O
whether	O
PLCγ2	O
induces	O
liver	O
cell	O
apoptosis	O
during	O
liver	O
regeneration	O
.	O

Therefore	O
,	O
this	O
study	O
firstly	O
packaged	O
Ad-PLCγ2	O
recombinant	O
adenovirus	O
and	O
primarily	O
evaluated	O
its	O
effect	O
on	O
apoptosis	O
of	O
rat	O
liver	O
cell	O
BRL-3A	O
in	O
vitro	O
.	O

Following	O
ten	O
days	O
of	O
co-transfection	O
of	O
pHBAd-MCMV-GFP-PLCγ2	O
and	O
pHBAd-BHG	O
into	O
HEK293	O
cells	O
,	O
viral	O
cytopathic	O
effect	O
(	O
CPE	O
)	O
was	O
apparent	O
.	O

Following	O
three	O
rounds	O
of	O
amplification	O
,	O
tissue	O
culture	O
infectious	O
dose	O
50	O
(	O
TCID50	O
)	O
assay	B-P
showed	O
that	O
the	O
titer	O
value	O
reached	O
1×1010	O
PFU/mL	O
.	O

After	O
24	O
h	O
of	O
transfection	O
of	O
recombinant	O
adenovirus	O
into	O
BRL-3A	O
cells	O
,	O
transfection	O
efficiency	O
of	O
adenovirus	O
into	O
BRL-3A	O
cells	O
was	O
above	O
90	O
%	O
when	O
obsereved	O
under	O
fluorescent	B-P
microscopy	I-P
.	O

qRT-PCR	O
and	O
Western	O
blot	O
assays	O
showed	O
mRNA	O
and	O
protein	O
levels	O
of	O
PLCγ2	O
were	O
significantly	O
elevated	O
in	O
the	O
transfected	O
BRL-3A	O
cells	O
.	O

Flow	B-P
cytometric	I-P
analysis	I-P
showed	O
that	O
,	O
compared	O
with	O
the	O
control	O
and	O
Ad-GFP	O
groups	O
,	O
cell	O
apoptosis	O
rate	O
of	O
Ad-PLCγ2	O
group	O
were	O
significantly	O
increased	O
(	O
P	O
<	O
0.01	O
)	O
,	O
and	O
the	O
cell	O
cycle	O
in	O
Ad-PLCγ2	O
group	O
was	O
arrested	O
at	O
G1	O
phase	O
which	O
was	O
manifested	O
by	O
a	O
marked	O
increase	O
(	O
P	O
<	O
0.01	O
)	O
in	O
the	O
percentage	O
of	O
G1	O
phase	O
cells	O
and	O
a	O
great	O
decrease	O
(	O
P	O
<	O
0.01	O
)	O
in	O
the	O
percentage	O
of	O
S	O
and	O
G2	O
/	O
M	O
phase	O
cells	O
.	O

It	O
was	O
concluded	O
from	O
above	O
results	O
that	O
recombinant	O
adenovirus	O
Ad-PLCγ2	O
was	O
packaged	O
successfully	O
,	O
and	O
could	O
promote	O
cell	O
apoptosis	O
by	O
arresting	O
the	O
transition	O
from	O
G1	O
to	O
S	O
phase	O
of	O
BRL-3A	O
cells	O
.	O

Performance	O
of	O
Debaryomyces	O
hansenii	O
as	O
a	O
Diet	O
for	O
Rotifers	O
for	O
Feeding	O
Zebrafish	O
Larvae	O
.	O

The	O
zebrafish	O
larval	O
stage	O
is	O
a	O
critical	O
moment	O
due	O
to	O
high	O
mortality	O
rates	O
associated	O
with	O
inadequate	O
supplies	O
of	O
nutritional	O
requirements	O
.	O

Larval	O
feeding	O
has	O
important	O
challenges	O
associated	O
with	O
such	O
factors	O
as	O
small	O
mouth	O
gape	O
(	O
≈100	O
μm	O
)	O
,	O
the	O
low	O
activity	O
of	O
digestive	O
enzymes	O
,	O
and	O
the	O
intake	O
of	O
live	O
food	O
.	O

A	O
common	O
zebrafish	O
live	O
food	O
at	O
the	O
onset	O
of	O
exogenous	O
feeding	O
is	O
rotifers	O
,	O
mainly	O
Brachionus	O
plicatilis	O
.	O

These	O
rotifers	O
should	O
be	O
fed	O
with	O
other	O
microorganisms	O
such	O
as	O
microalgae	O
or	O
yeast	O
,	O
mostly	O
from	O
the	O
Saccharomyces	O
genus	O
.	O

In	O
the	O
laboratory	O
,	O
the	O
culture	B-P
of	O
microalgae	O
is	O
more	O
expensive	O
than	O
the	O
culture	B-P
of	O
yeast	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
performance	O
of	O
Debaryomyces	O
hansenii	O
as	O
a	O
diet	O
for	O
rotifers	O
in	O
comparison	O
to	O
a	O
microalgae	O
-based	O
diet	O
(	O
Rotigrow	O
(	O
®	O
)	O
)	O
.	O

To	O
achieve	O
this	O
aim	O
,	O
we	O
assessed	O
the	O
rotifer	O
total	B-P
protein	I-P
content	I-P
,	O
the	O
rotifers	O
fatty	B-P
acid	I-P
profile	I-P
,	O
zebrafish	O
larval	O
growth	O
performance	O
,	O
the	O
expression	O
of	O
key	O
growth	O
,	O
and	O
endocrine	O
appetite	O
regulation	O
genes	O
.	O

The	O
total	B-P
protein	I-P
and	O
fatty	B-P
acids	I-P
content	I-P
were	O
similar	O
in	O
both	O
rotifer	O
cultures	B-P
,	O
averaging	O
35	O
%	O
of	O
dry	O
matter	O
(	O
DM	O
)	O
and	O
18	O
%	O
of	O
DM	O
,	O
respectively	O
.	O

Interestingly	O
,	O
the	O
fatty	B-P
acids	I-P
profile	I-P
showed	O
differences	O
between	O
the	O
two	O
rotifer	O
cultures	B-P
:	O
omega-3	O
fatty	O
acids	O
were	O
only	O
observed	O
in	O
the	O
Microalgae	O
/	O
rotifer	O
,	O
whereas	O
,	O
omega-6	O
fatty	O
acids	O
presented	O
similar	O
levels	O
in	O
both	O
rotifer	O
cultures	B-P
.	O

No	O
differences	O
were	O
observed	O
in	O
the	O
larval	O
body	O
length	O
distribution	O
or	O
mortalities	O
between	O
the	O
rotifer	O
cultures	B-P
.	O

However	O
,	O
gh	O
,	O
igf-1	O
,	O
and	O
cck	O
gene	O
expression	O
showed	O
significantly	O
higher	O
upregulation	O
in	O
zebrafish	O
fed	O
the	O
Microalgae	O
/	O
rotifer	O
diet	O
compared	O
with	O
those	O
fed	O
the	O
Debaryomyces	O
/	O
rotifer	O
diet	O
.	O

In	O
conclusion	O
,	O
D.	O
hansenii	O
could	O
be	O
an	O
alternative	O
diet	O
for	O
rotifer	O
used	O
as	O
a	O
live	O
food	O
in	O
zebrafish	O
larvae	O
at	O
the	O
onset	O
of	O
exogenous	O
feeding	O
.	O

The	O
gene	O
responses	O
observed	O
in	O
this	O
work	O
open	O
up	O
the	O
opportunity	O
to	O
study	O
the	O
effect	O
of	O
omega-3	O
supply	O
on	O
growth	O
regulation	O
in	O
zebrafish	O
.	O

Thixotropic	O
injectable	O
hydrogel	O
using	O
a	O
polyampholyte	O
and	O
nanosilicate	O
prepared	O
directly	O
after	O
cryopreservation	B-P
.	O

Success	O
of	O
tissue	O
engineering	O
applications	O
in	O
regenerative	O
medicine	O
requires	O
the	O
preservation	O
of	O
tissue-engineered	O
products	O
at	O
a	O
low	O
temperature	O
.	O

This	O
can	O
be	O
successfully	O
achieved	O
by	O
the	O
use	O
of	O
cryoprotective	O
agent	O
(	O
CPA	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
formulated	O
a	O
unique	O
injectable	O
hydrogel	O
for	O
the	O
purpose	O
of	O
cell	O
delivery	O
after	O
cryopreservation	B-P
by	O
using	O
polyampholyte	O
CPA	O
.	O

The	O
polyampholyte	O
showed	O
excellent	O
post-thaw	O
cell	O
survival	O
,	O
and	O
after	O
thawing	B-P
,	O
the	O
polymeric	O
CPA	O
did	O
not	O
have	O
to	O
be	O
removed	O
because	O
of	O
its	O
low	O
cytotoxicity	O
.	O

The	O
polyampholyte	O
could	O
be	O
transformed	O
into	O
a	O
hydrogel	O
by	O
mixing	O
with	O
nanosilicates	O
.	O

Previously	O
,	O
nanosilicates	O
were	O
used	O
to	O
improve	O
mechanical	O
properties	O
,	O
but	O
this	O
is	O
the	O
first	O
report	O
of	O
the	O
use	O
of	O
a	O
nanosilicate	O
together	O
with	O
CPA	O
to	O
formulate	O
hydrogels	O
.	O

Inclusion	O
of	O
the	O
nanosilicate	O
led	O
to	O
the	O
formation	O
of	O
thixotropic	O
hydrogels	O
,	O
which	O
can	O
be	O
injected	O
using	O
fine	O
needles	O
.	O

These	O
gels	O
with	O
tunable	O
mechanical	O
properties	O
can	O
be	O
injected	O
into	O
defect	O
sites	O
to	O
form	O
scaffolds	O
for	O
cell	O
growth	O
and	O
tissue	O
repair	O
,	O
and	O
they	O
do	O
not	O
require	O
any	O
separate	O
seeding	O
of	O
cells	O
before	O
injection	O
,	O
thus	O
eliminating	O
the	O
need	O
for	O
cell	O
harvesting	O
and	O
cell	O
maintenance	O
.	O

This	O
is	O
a	O
distinct	O
system	O
in	O
which	O
cells	O
can	O
be	O
cryopreserved	O
until	O
before	O
usage	O
;	O
when	O
required	O
,	O
the	O
cells	O
in	O
the	O
polyampholyte	O
can	O
be	O
revived	O
to	O
their	O
original	O
state	O
and	O
the	O
thixotropic	O
hydrogel	O
can	O
be	O
formed	O
.	O

The	O
combination	O
of	O
thixotropy	O
and	O
cytocompatibility	O
of	O
the	O
gels	O
could	O
enable	O
a	O
wide	O
range	O
of	O
biomedical	O
applications	O
such	O
as	O
cell	O
delivery	O
and	O
orthopedic	O
repair	O
.	O

Performance	O
of	O
loop-mediated	B-P
isothermal	I-P
amplification	I-P
(	O
LAMP	B-P
)	O
for	O
the	O
diagnosis	O
of	O
malaria	O
among	O
malaria	O
suspected	O
pregnant	O
women	O
in	O
Northwest	O
Ethiopia	O
.	O

Malaria	O
is	O
a	O
major	O
public	O
health	O
problem	O
and	O
an	O
important	O
cause	O
of	O
maternal	O
and	O
infant	O
morbidity	O
in	O
sub-Saharan	O
Africa	O
,	O
including	O
Ethiopia	O
.	O

Early	B-P
and	O
accurate	O
diagnosis	O
of	O
malaria	O
with	O
effective	O
treatment	O
is	O
the	O
best	O
strategy	O
for	O
prevention	O
and	O
control	O
of	O
complications	O
during	O
pregnancy	O
and	O
infant	O
morbidity	O
and	O
mortality	O
.	O

However	O
,	O
laboratory	B-P
diagnosis	I-P
has	O
relied	O
on	O
the	O
identification	O
of	O
malaria	O
parasites	O
and	O
parasite	O
antigens	O
in	O
peripheral	O
blood	O
using	O
Giemsa-stained	B-P
microscopy	I-P
or	O
rapid	B-P
diagnostic	I-P
tests	I-P
(	O
RDTs	B-P
)	O
which	O
lack	O
analytical	O
and	O
clinical	O
sensitivity	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
performance	O
of	O
loop-mediated	B-P
isothermal	I-P
amplification	I-P
(	O
LAMP	B-P
)	O
for	O
the	O
diagnosis	O
of	O
malaria	O
among	O
malaria	O
suspected	O
pregnant	O
women	O
in	O
Northwest	O
Ethiopia	O
.	O

A	O
cross	O
sectional	O
study	O
was	O
conducted	O
from	O
January	O
to	O
April	O
2016	O
.	O

Pregnant	O
women	O
(	O
n	O
=	O
87	O
)	O
suspected	O
of	O
having	O
malaria	O
at	O
six	O
health	O
centres	O
were	O
enrolled	O
.	O

A	O
venous	O
blood	O
sample	O
was	O
collected	O
from	O
each	O
study	O
subject	O
,	O
and	O
analysed	O
for	O
Plasmodium	O
parasites	O
by	O
microscopy	B-P
,	O
RDT	B-P
,	O
and	O
LAMP	B-P
.	O

Diagnostic	O
accuracy	O
outcome	O
measures	O
(	O
sensitivity	O
,	O
specificity	O
,	O
predictive	O
values	O
,	O
and	O
Kappa	O
scores	O
)	O
of	O
microscopy	B-P
,	O
RDT	B-P
and	O
LAMP	B-P
were	O
compared	O
to	O
nested	O
polymerase	O
chain	O
reaction	O
(	O
nPCR	O
)	O
as	O
the	O
gold	O
standard	O
.	O

Specimen	B-P
processing	I-P
and	O
reporting	O
times	O
were	O
documented	O
.	O

Using	O
nPCR	O
as	O
the	O
gold	O
standard	O
technique	O
,	O
the	O
sensitivity	O
of	O
microscopy	B-P
and	O
RDT	B-P
was	O
90	O
and	O
70	O
%	O
,	O
and	O
the	O
specificity	O
was	O
98.7	O
and	O
97.4	O
%	O
,	O
respectively	O
.	O

LAMP	B-P
assay	B-P
was	O
100	O
%	O
sensitive	O
and	O
93.5	O
%	O
specific	O
compared	O
to	O
nPCR	O
.	O

This	O
study	O
showed	O
higher	O
sensitivity	O
of	O
LAMP	B-P
compared	O
to	O
microscopy	B-P
and	O
RDT	B-P
for	O
the	O
detection	O
of	O
malaria	O
in	O
pregnancy	O
.	O

Increased	O
sensitivity	O
and	O
ease	O
of	O
use	O
with	O
LAMP	B-P
in	O
point-of-care	O
testing	O
for	O
malaria	O
in	O
pregnancy	O
was	O
noted	O
.	O

LAMP	B-P
warrants	O
further	O
evaluation	O
in	O
intermittent	O
screening	O
and	O
treatment	O
programmes	O
in	O
pregnancy	O
.	O

When	O
water	O
is	O
thicker	O
than	O
blood	O
:	O
recognising	O
a	O
systemic	O
cause	O
of	O
haemoptysis	O
.	O

The	O
case	O
of	O
an	O
11-	O
year-old	O
child	O
presenting	O
with	O
acute	O
haemoptysis	O
and	O
breathlessness	O
is	O
described	O
.	O

The	O
girl	O
was	O
Malaysian	O
and	O
had	O
recently	O
arrived	O
in	O
the	O
UK	O
.	O

She	O
subsequently	O
deteriorated	O
,	O
developing	O
respiratory	O
failure	O
.	O

The	O
course	O
of	O
the	O
illness	O
is	O
described	O
,	O
with	O
reference	O
to	O
the	O
diagnostic	B-P
process	I-P
at	O
each	O
stage	O
.	O

The	O
case	O
demonstrates	O
the	O
importance	O
of	O
having	O
a	O
broad	O
investigatory	O
approach	O
in	O
acute	O
haemoptysis	O
.	O

Aberrant	O
LncRNA	O
Expression	O
Profile	O
in	O
a	O
Contusion	O
Spinal	O
Cord	O
Injury	O
Mouse	O
Model	O
.	O

Long	O
noncoding	O
RNAs	O
(	O
LncRNAs	O
)	O
play	O
a	O
crucial	O
role	O
in	O
cell	O
growth	O
,	O
development	O
,	O
and	O
various	O
diseases	O
related	O
to	O
the	O
central	O
nervous	O
system	O
.	O

However	O
,	O
LncRNA	O
differential	O
expression	O
profiles	O
in	O
spinal	O
cord	O
injury	O
are	O
yet	O
to	O
be	O
reported	O
.	O

In	O
this	O
study	O
,	O
we	O
profiled	O
the	O
expression	O
pattern	O
of	O
LncRNAs	O
using	O
a	O
microarray	B-P
method	I-P
in	O
a	O
contusion	O
spinal	O
cord	O
injury	O
(	O
SCI	O
)	O
mouse	O
model	O
.	O

Compared	O
with	O
a	O
spinal	O
cord	O
without	O
injury	O
,	O
few	O
changes	O
in	O
LncRNA	O
expression	O
levels	O
were	O
noted	O
1	O
day	O
after	O
injury	O
.	O

The	O
differential	O
changes	O
in	O
LncRNA	O
expression	O
peaked	O
1	O
week	O
after	O
SCI	O
and	O
subsequently	O
declined	O
until	O
3	O
weeks	O
after	O
injury	O
.	O

Quantitative	O
real-time	O
polymerase	O
chain	O
reaction	O
(	O
qRT-PCR	O
)	O
was	O
used	O
to	O
validate	O
the	O
reliability	O
of	O
the	O
microarray	O
,	O
demonstrating	O
that	O
the	O
results	O
were	O
reliable	O
.	O

Gene	O
ontology	O
(	O
GO	O
)	O
analysis	O
indicated	O
that	O
differentially	O
expressed	O
mRNAs	O
were	O
involved	O
in	O
transport	O
,	O
cell	O
adhesion	O
,	O
ion	O
transport	O
,	O
and	O
metabolic	O
processes	O
,	O
among	O
others	O
.	O

Kyoto	O
Encyclopedia	O
of	O
Genes	O
and	O
Genomes	O
(	O
KEGG	O
)	O
enrichment	O
analysis	O
showed	O
that	O
the	O
neuroactive	O
ligand-receptor	O
interaction	O
,	O
the	O
PI3K	O
-	O
Akt	O
signaling	O
pathway	O
,	O
and	O
focal	O
adhesions	O
were	O
potentially	O
implicated	O
in	O
SCI	O
pathology	O
.	O

We	O
constructed	O
a	O
dynamic	O
LncRNA	O
-	O
mRNA	O
network	O
containing	O
264	O
LncRNAs	O
and	O
949	O
mRNAs	O
to	O
elucidate	O
the	O
interactions	O
between	O
the	O
LncRNAs	O
and	O
mRNAs	O
.	O

Overall	O
,	O
the	O
results	O
from	O
this	O
study	O
indicate	O
for	O
the	O
first	O
time	O
that	O
LncRNAs	O
are	O
differentially	O
expressed	O
in	O
a	O
contusion	O
SCI	O
mouse	O
model	O
.	O

An	O
innovative	O
method	O
of	O
ocular	O
prosthesis	O
fabrication	O
by	O
bio-CAD	O
and	O
rapid	O
3-D	O
printing	O
technology	O
:	O
A	O
pilot	O
study	O
.	O

Ocular	O
prosthesis	O
is	O
either	O
a	O
readymade	O
stock	O
shell	O
or	O
custom	O
made	O
prosthesis	O
(	O
CMP	O
)	O
.	O

Presently	O
,	O
there	O
is	O
no	O
other	O
technology	O
available	O
,	O
which	O
is	O
either	O
superior	O
or	O
even	O
comparable	O
to	O
the	O
conventional	O
CMP	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
fabricate	O
ocular	O
prosthesis	O
using	O
computer	O
aided	O
design	O
(	O
CAD	O
)	O
and	O
rapid	O
manufacturing	O
(	O
RM	O
)	O
technology	O
and	O
to	O
compare	O
it	O
with	O
custom	O
made	O
prosthesis	O
(	O
CMP	O
)	O
.	O

The	O
ocular	O
prosthesis	O
prepared	O
by	O
CAD	O
was	O
compared	O
with	O
conventional	O
CMP	O
in	O
terms	O
of	O
time	O
taken	O
for	O
fabrication	O
,	O
weight	O
,	O
cosmesis	O
,	O
comfort	O
,	O
and	O
motility	O
.	O

Two	O
eyes	O
of	O
two	O
patients	O
were	O
included	O
.	O

Computerized	B-P
tomography	I-P
scan	I-P
of	O
wax	O
model	O
of	O
socket	O
was	O
converted	O
into	O
three	O
dimensional	O
format	O
using	O
Materialize	O
Interactive	O
Medical	O
Image	O
Control	O
System	O
(	O
MIMICS	O
)	O
software	O
and	O
further	O
refined	O
.	O

This	O
was	O
given	O
as	O
an	O
input	O
to	O
rapid	O
manufacturing	O
machine	O
(	O
Polyjet	O
3-D	O
printer	O
)	O
.	O

The	O
final	O
painting	O
on	O
prototype	O
was	O
done	O
by	O
an	O
ocularist	O
.	O

The	O
average	O
effective	O
time	O
required	O
for	O
fabrication	O
of	O
CAD	O
prosthesis	O
was	O
2.5	O
hours	O
;	O
and	O
weight	O
2.9	O
grams	O
.	O

The	O
same	O
for	O
CMP	O
were	O
10	O
hours	O
;	O
and	O
4.4	O
grams	O
.	O

CAD	O
prosthesis	O
was	O
more	O
comfortable	O
for	O
both	O
the	O
patients	O
.	O

The	O
study	O
demonstrates	O
the	O
first	O
ever	O
attempt	O
of	O
fabricating	O
a	O
complete	O
ocular	O
prosthesis	O
using	O
CAD	O
and	O
rapid	O
manufacturing	O
and	O
comparing	O
it	O
with	O
conventional	O
CMP	O
.	O

This	O
prosthesis	O
takes	O
lesser	O
time	O
for	O
fabrication	O
,	O
and	O
is	O
more	O
comfortable	O
.	O

Studies	O
with	O
larger	O
sample	O
size	O
will	O
be	O
required	O
to	O
further	O
validate	O
this	O
technique	O
.	O

Unusual	O
axillary	O
metastasis	O
of	O
recurrent	O
nasopharyngeal	O
cancer	O
:	O
A	O
case	O
report	O
.	O

Nasopharyngeal	O
carcinoma	O
(	O
NPC	O
)	O
has	O
a	O
high	O
propensity	O
of	O
metastasis	O
.	O

The	O
most	O
commonly	O
described	O
sites	O
of	O
distant	O
metastasis	O
are	O
the	O
bones	O
,	O
lungs	O
,	O
and	O
liver	O
,	O
whereas	O
axillary	O
metastasis	O
is	O
seldom	O
reported	O
.	O

We	O
hereby	O
present	O
the	O
case	O
of	O
a	O
66-year-old	O
man	O
with	O
NPC	O
,	O
cT2N2M0	O
,	O
at	O
diagnosis	O
.	O

He	O
had	O
completed	O
chemoradiotherapy	O
and	O
been	O
disease-free	O
for	O
7	O
years	O
.	O

After	O
that	O
period	O
,	O
late	O
recurrence	O
in	O
the	O
form	O
of	O
a	O
solitary	O
axillary	O
lymph	O
node	O
metastasis	O
was	O
detected	O
and	O
confirmed	O
by	O
core-needle	B-P
biopsy	I-P
.	O

The	O
lesion	O
was	O
chemoresistant	O
but	O
responded	O
to	O
salvage	O
radiotherapy	O
at	O
a	O
dose	O
of	O
65	O
Gy	O
in	O
21	O
fractions	O
.	O

Post-radiotherapy	O
positron	B-P
emission	I-P
tomography	I-P
scan	I-P
showed	O
no	O
evidence	O
of	O
disease	O
.	O

We	O
suggested	O
that	O
long-term	O
follow-up	O
of	O
NPC	O
patients	O
is	O
important	O
because	O
a	O
late	O
relapse	O
may	O
occur	O
at	O
an	O
unusual	O
site	O
.	O

Aggressive	O
management	O
of	O
solitary	O
metastasis	O
may	O
achieve	O
good	O
outcome	O
.	O

Zebrafish	O
adult	O
pigment	O
stem	O
cells	O
are	O
multipotent	O
and	O
form	O
pigment	O
cells	O
by	O
a	O
progressive	O
fate	O
restriction	O
process	O
:	O
Clonal	B-P
analysis	I-P
identifies	O
shared	O
origin	O
of	O
all	O
pigment	O
cell	O
types	O
.	O

Skin	O
pigment	O
pattern	O
formation	O
is	O
a	O
paradigmatic	O
example	O
of	O
pattern	O
formation	O
.	O

In	O
zebrafish	O
,	O
the	O
adult	O
body	O
stripes	O
are	O
generated	O
by	O
coordinated	O
rearrangement	O
of	O
three	O
distinct	O
pigment	O
cell-types	O
,	O
black	O
melanocytes	O
,	O
shiny	O
iridophores	O
and	O
yellow	O
xanthophores	O
.	O

A	O
stem	O
cell	O
origin	O
of	O
melanocytes	O
and	O
iridophores	O
has	O
been	O
proposed	O
although	O
the	O
potency	O
of	O
those	O
stem	O
cells	O
has	O
remained	O
unclear	O
.	O

Xanthophores	O
,	O
however	O
,	O
seemed	O
to	O
originate	O
predominantly	O
from	O
proliferation	O
of	O
embryonic	O
xanthophores	O
.	O

Now	O
,	O
data	O
from	O
Singh	O
et	O
al	O
.	O

shows	O
that	O
all	O
three	O
cell-types	O
derive	O
from	O
shared	O
stem	O
cells	O
,	O
and	O
that	O
these	O
cells	O
generate	O
peripheral	O
neural	O
cell-types	O
too	O
.	O

Furthermore	O
,	O
clonal	O
compositions	O
are	O
best	O
explained	O
by	O
a	O
progressive	O
fate	O
restriction	O
model	O
generating	O
the	O
individual	O
cell-types	O
.	O

The	O
numbers	O
of	O
adult	O
pigment	O
stem	O
cells	O
associated	O
with	O
the	O
dorsal	O
root	O
ganglia	O
remain	O
low	O
,	O
but	O
progenitor	O
numbers	O
increase	O
significantly	O
during	O
larval	O
development	O
up	O
to	O
metamorphosis	O
,	O
likely	O
via	O
production	O
of	O
partially	O
restricted	O
progenitors	O
on	O
the	O
spinal	O
nerves	O
.	O

Low	O
Cytochrome	O
Oxidase	O
1	O
Links	O
Mitochondrial	O
Dysfunction	O
to	O
Atherosclerosis	O
in	O
Mice	O
and	O
Pigs	O
.	O

Cytochrome	O
oxidase	O
IV	O
complex	O
regulates	O
energy	O
production	O
in	O
mitochondria	O
.	O

Therefore	O
,	O
we	O
determined	O
the	O
relation	O
of	O
COX	O
genes	O
with	O
atherosclerosis	O
in	O
mice	O
and	O
pigs	O
.	O

First	O
,	O
we	O
compared	O
atherosclerosis	O
in	O
the	O
aortic	O
arch	O
of	O
age-matched	O
(	O
24	O
weeks	O
)	O
C57BL/6J	O
control	O
(	O
n	O
=	O
10	O
)	O
,	O
LDL-receptor	O
deficient	O
(	O
n	O
=	O
8	O
)	O
,	O
leptin	O
-	O
deficient	O
ob/ob	O
(	O
n	O
=	O
10	O
)	O
,	O
and	O
double	O
knock-out	O
(	O
lacking	O
LDL-receptor	O
and	O
leptin	O
)	O
mice	O
(	O
n	O
=	O
12	O
)	O
.	O

Low	O
aortic	O
mitochondria	O
-encoded	O
cytochrome	O
oxidase	O
1	O
in	O
obese	O
diabetic	O
double	O
knock-out	O
mice	O
was	O
associated	O
with	O
a	O
larger	O
plaque	O
area	O
and	O
higher	O
propensity	O
of	O
M1	O
macrophages	O
and	O
oxidized	O
LDL	O
.	O

Caloric	O
restriction	O
increased	O
mitochondria	O
-encoded	O
cytochrome	O
oxidase	O
1	O
and	O
reduced	O
plaque	O
area	O
and	O
oxidized	O
LDL	O
.	O

This	O
was	O
associated	O
with	O
a	O
reduction	O
of	O
titer	B-P
of	I-P
anti-oxidized	I-P
LDL	I-P
antibodies	I-P
,	O
a	O
proxy	O
of	O
systemic	O
oxidative	O
stress	O
.	O

Low	O
of	O
mitochondria	O
-encoded	O
cytochrome	O
oxidase	O
1	O
was	O
related	O
to	O
low	O
expression	O
of	O
peroxisome	O
proliferative	O
activated	O
receptors	O
α	O
,	O
δ	O
,	O
and	O
γ	O
and	O
of	O
peroxisome	O
proliferative	O
activated	O
receptor	O
,	O
gamma	O
,	O
co-activator	O
1	O
alpha	O
reflecting	O
mitochondrial	O
dysfunction	O
.	O

Caloric	O
restriction	O
increased	O
them	O
.	O

To	O
investigate	O
if	O
there	O
was	O
a	O
diabetic	O
/	O
obesity	O
requirement	O
for	O
mitochondria	O
-encoded	O
cytochrome	O
oxidase	O
1	O
to	O
be	O
down-regulated	O
,	O
we	O
then	O
studied	O
atherosclerosis	O
in	O
LAD	O
of	O
hypercholesterolemic	O
pigs	O
(	O
n	O
=	O
37	O
)	O
.	O

Pigs	O
at	O
the	O
end	O
of	O
the	O
study	O
were	O
divided	O
in	O
three	O
groups	O
based	O
on	O
increasing	O
LAD	O
plaque	O
complexity	O
according	O
to	O
Stary	O
(	O
Stary	O
I	O
:	O
n	O
=	O
12	O
;	O
Stary	O
II	O
:	O
n	O
=	O
13	O
;	O
Stary	O
III	O
:	O
n	O
=	O
12	O
)	O
.	O

Low	O
mitochondria	O
-encoded	O
cytochrome	O
oxidase	O
1	O
in	O
isolated	O
plaque	O
macrophages	O
was	O
associated	O
with	O
more	O
complex	O
coronary	O
plaques	O
and	O
oxidized	O
LDL	O
.	O

Nucleus	O
-encoded	O
cytochrome	O
oxidase	O
4I1	O
and	O
cytochrome	O
oxidase	O
10	O
did	O
not	O
correlate	O
with	O
plaque	O
complexity	O
and	O
oxidative	O
stress	O
.	O

In	O
mice	O
and	O
pigs	O
,	O
MT-COI	O
was	O
inversely	O
related	O
to	O
insulin	O
resistance	O
.	O

Low	O
MT-COI	O
is	O
related	O
to	O
mitochondrial	O
dysfunction	O
,	O
oxidative	O
stress	O
and	O
atherosclerosis	O
and	O
plaque	O
complexity	O
.	O

Prevalence	O
of	O
depression	O
in	O
patients	O
of	O
type	O
2	O
diabetes	O
mellitus	O
:	O
A	O
cross	O
sectional	O
study	O
in	O
a	O
tertiary	O
care	O
centre	O
.	O

The	O
present	O
study	O
aims	O
to	O
study	O
the	O
prevalence	O
of	O
depression	O
in	O
patients	O
with	O
uncomplicated	O
type	O
II	O
diabetes	O
mellitus	O
and	O
to	O
find	O
its	O
association	O
with	O
various	O
socio-demographic	O
factors	O
in	O
the	O
same	O
.	O

A	O
cross-sectional	O
,	O
single	O
interview	O
study	O
was	O
performed	O
in	O
an	O
outpatient	O
department	O
of	O
an	O
endocrinology	O
institute	O
.	O

Total	O
80	O
type	O
II	O
DM	O
patients	O
without	O
any	O
associated	O
complications	O
of	O
diabetes	O
were	O
included	O
in	O
this	O
study	O
.	O

To	O
diagnose	O
Depressive	O
Episode	O
,	O
structured	B-P
clinical	I-P
interview	I-P
for	O
DSM	O
V	O
was	O
applied	O
.	O

Severity	O
of	O
depression	O
was	O
assessed	O
by	O
Hamilton	O
Rating	O
Scale	O
for	O
Depression	O
(	O
HAM-D	O
)	O
.	O

To	O
assess	O
socio-demographic	O
characteristics	O
of	O
the	O
patients	O
,	O
all	O
of	O
them	O
were	O
evaluated	O
with	O
a	O
semi-structured	O
socio-demographic	O
performa	O
.	O

38.75	O
%	O
patients	O
(	O
N=31	O
)	O
were	O
found	O
to	O
be	O
suffering	O
from	O
depression	O
.	O

Among	O
them	O
48.38	O
%	O
were	O
moderately	O
depressed	O
and	O
none	O
were	O
suffering	O
from	O
very	O
severe	O
depression	O
.	O

Significant	O
association	O
was	O
not	O
found	O
between	O
depression	O
and	O
socio-demographic	O
factors	O
of	O
age	O
(	O
p=0.920	O
)	O
,	O
gender	O
(	O
p=0.251	O
)	O
,	O
economic	O
profile	O
(	O
p=0.583	O
)	O
,	O
local	O
background	O
of	O
the	O
patient	O
(	O
p=0.646	O
)	O
,	O
educational	O
qualification	O
(	O
p=0.935	O
)	O
and	O
marital	O
status	O
(	O
p=0.644	O
)	O
.	O

Similarly	O
no	O
association	O
was	O
found	O
with	O
duration	O
of	O
diabetes	O
,	O
HbA1c	O
and	O
BMI	O
.	O

Exclusion	O
of	O
complicated	O
cases	O
did	O
n't	O
seem	O
to	O
influence	O
overall	O
prevalence	O
of	O
depression	O
,	O
although	O
reduction	O
in	O
severity	O
was	O
apparent	O
.	O

Thus	O
even	O
in	O
those	O
diabetic	O
patients	O
who	O
are	O
leading	O
a	O
complication	O
free	O
life	O
,	O
a	O
detailed	O
psychiatric	O
analysis	O
to	O
rule	O
out	O
depression	O
is	O
mandatory	O
.	O

From	O
chemotherapy	O
to	O
target	O
therapies	O
associated	O
with	O
radiation	O
in	O
the	O
treatment	O
of	O
NSCLC	O
:	O
a	O
durable	O
marriage	O
?	O
.	O

The	O
integration	O
between	O
radiotherapy	O
and	O
drugs	O
,	O
from	O
chemotherapy	O
to	O
recently	O
available	O
target	O
therapies	O
,	O
continues	O
to	O
have	O
a	O
relevant	O
role	O
in	O
the	O
treatment	O
of	O
locally	O
advanced	O
and	O
metastatic	O
Non-small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
.	O

Aim	O
of	O
the	O
present	O
review	O
is	O
to	O
evaluate	O
the	O
promising	O
and	O
emerging	O
application	O
of	O
the	O
best	O
interaction	O
between	O
new	O
drugs	O
and	O
new	O
modalities	O
of	O
radiotherapy	O
.	O

Areas	O
covered	O
:	O
We	O
searched	O
Medline	O
,	O
Google	O
Scholar	O
,	O
PubMed	O
,	O
ProQuest	O
Dissertation	O
,	O
and	O
Theses	O
databases	O
for	O
reports	O
published	O
in	O
English	O
.	O

A	O
study	O
was	O
included	O
when	O
it	O
reported	O
on	O
cancer-related	O
radiotherapy	O
and	O
included	O
patients	O
with	O
NSCLC	O
treated	O
with	O
chemo	O
and/or	O
target	O
therapies	O
.	O

Review	O
articles	O
were	O
excluded	O
from	O
the	O
analysis	O
.	O

Expert	O
commentary	O
:	O
Chemo-radiotherapy	O
still	O
represents	O
the	O
standard	O
of	O
choice	O
in	O
locally	O
advanced	O
NSCLC	O
,	O
while	O
to	O
date	O
the	O
addition	O
of	O
target	O
therapies	O
to	O
chemo-radiotherapy	O
did	O
not	O
demonstrate	O
any	O
robust	O
advantage	O
in	O
this	O
stage	B-P
of	I-P
disease	I-P
.	O

Considering	O
the	O
absence	O
of	O
randomized	O
controlled	O
trials	O
,	O
the	O
role	O
of	O
target	O
therapies	O
in	O
early	O
stage	O
adjuvant	O
NSCLC	O
is	O
not	O
yet	O
recommended	O
in	O
clinical	O
practice	O
.	O

On	O
the	O
contrary	O
,	O
in	O
the	O
setting	O
of	O
oligometastatic	O
and	O
oligoprogressive	O
disease	O
,	O
new	O
molecules	O
demonstrated	O
to	O
be	O
safe	O
and	O
effective	O
,	O
opening	O
to	O
a	O
promising	O
and	O
emerging	O
application	O
of	O
the	O
best	O
interaction	O
between	O
new	O
drugs	O
and	O
new	O
modalities	O
of	O
radiotherapy	O
.	O

Association	O
between	O
neutrophil	O
-to-	O
lymphocyte	O
ratio	O
and	O
differentiated	O
thyroid	O
cancer	O
:	O
a	O
meta-analysis	O
.	O

The	O
association	O
between	O
neutrophil	O
-to-	O
lymphocyte	O
ratio	O
(	O
NLR	O
)	O
and	O
differentiated	O
thyroid	O
cancer	O
(	O
DTC	O
)	O
is	O
undecided	O
.	O

To	O
rectify	O
this	O
question	O
,	O
we	O
conducted	O
a	O
systematic	O
meta-analysis	O
based	O
on	O
7	O
prospective	O
cohort	O
studies	O
published	O
between	O
2013	O
and	O
2015	O
,	O
comprising	O
7349	O
patients	O
.	O

Six	O
of	O
these	O
cohorts	O
included	O
pretreatment	O
(	O
baseline	O
)	O
NLR	O
data	O
for	O
patients	O
with	O
thyroid	O
nodules	O
.	O

The	O
meta-analysis	O
of	O
these	O
6	O
cohorts	O
showed	O
that	O
the	O
NLR	O
of	O
patients	O
with	O
DTC	O
(	O
4617	O
cases	O
)	O
was	O
statistically	O
similar	O
to	O
patients	O
with	O
benign	O
nodules	O
only	O
(	O
1666	O
cases	O
)	O
,	O
with	O
a	O
mean	O
difference	O
(	O
MD	O
)	O
of	O
0.19	O
(	O
95	O
%	O
CI	O
:	O
-0.09	O
to	O
0.46	O
;	O
I	O
(	O
2	O
)	O
=	O
93	O
%	O
;	O
P	O
<	O
0.001	O
)	O
.	O

No	O
significant	O
difference	O
in	O
NLR	O
was	O
found	O
between	O
patients	O
with	O
DTC	O
and	O
patients	O
with	O
benign	O
nodules	O
.	O

Two	O
studies	B-P
addressed	O
an	O
association	O
between	O
NLR	O
and	O
papillary	O
thyroid	O
carcinoma	O
in	O
patients	O
stratified	O
by	O
age	O
<	O
45	O
and	O
≥45	O
years	O
(	O
496	O
and	O
891	O
cases	O
,	O
respectively	O
)	O
;	O
the	O
pooled	O
MD	O
was	O
0.09	O
(	O
95	O
%	O
CI	O
:	O
-0.37	O
to	O
0.55	O
;	O
I	O
(	O
2	O
)	O
=	O
92.2	O
%	O
,	O
P	O
<	O
0.001	O
)	O
.	O

An	O
elevated	O
NLR	O
seems	O
not	O
a	O
reliable	O
indicator	O
of	O
progressing	O
DTC	O
in	O
patients	O
with	O
goiters	O
,	O
and	O
there	O
was	O
no	O
difference	O
in	O
NLR	O
between	O
patients	O
aged	O
<	O
45	O
years	O
and	O
those	O
aged	O
≥45	O
years	O
.	O

Well-designed	O
and	O
large-scale	O
investigations	O
are	O
warranted	O
to	O
understand	O
the	O
value	O
of	O
NLR	O
in	O
the	O
prognosis	O
of	O
DTC	O
.	O

Antimicrobial	O
and	O
antioxidant	O
activities	O
of	O
a	O
new	O
metabolite	O
from	O
Quercus	O
incana	O
.	O

Phytochemical	O
investigations	O
of	O
Quercus	O
incana	O
led	O
to	O
the	O
isolation	O
of	O
a	O
new	O
catechin	O
derivative	O
quercuschin	O
(	O
1	O
)	O
,	O
along	O
with	O
six	O
known	O
compounds	O
:	O
quercetin	O
(	O
2	O
)	O
,	O
methyl	O
gallate	O
(	O
3	O
)	O
,	O
gallic	O
acid	O
(	O
4	O
)	O
,	O
betulinic	O
acid	O
(	O
5	O
)	O
,	O
(	O
Z	O
)	O
-9-octadecenoic	O
acid	O
methyl	O
ester	O
(	O
6	O
)	O
and	O
β-sitosterol	O
glucoside	O
(	O
7	O
)	O
from	O
the	O
ethyl	O
acetate	O
fraction	O
of	O
methanolic	O
extract	O
of	O
the	O
bark	O
.	O

Compound	O
1	O
was	O
screened	O
for	O
its	O
antibacterial	O
,	O
antifungal	O
and	O
antioxidant	O
potential	O
.	O

Antibacterial	O
and	O
antifungal	O
activities	O
of	O
the	O
compound	O
were	O
tested	O
against	O
different	O
bacterial	O
and	O
fungal	O
strains	O
,	O
employing	O
the	O
agar	B-P
well	I-P
diffusion	I-P
methods	I-P
.	O

The	O
antibacterial	O
activity	O
was	O
the	O
highest	O
against	O
Streptococcus	O
pyogenes	O
with	O
80.0	O
%	O
inhibition	O
,	O
while	O
the	O
antifungal	O
activity	O
of	O
the	O
compound	O
was	O
the	O
highest	O
against	O
Candida	O
glabrata	O
with	O
80.5	O
%	O
inhibition	O
.	O

The	O
results	O
of	O
the	O
antioxidant	O
activity	O
indicated	O
that	O
the	O
compound	O
exhibited	O
antioxidant	O
activity	O
comparable	O
to	O
that	O
of	O
standard	O
,	O
butylated	O
hydroxyanisole	O
(	O
51.2	O
μg/10	O
μl	O
versus	O
45.9	O
μg/10	O
μl	O
)	O
.	O

Green	O
and	O
rapid	O
synthesis	O
of	O
silver	O
nanoparticles	O
using	O
Borago	O
officinalis	O
leaf	O
extract	O
:	O
anticancer	O
and	O
antibacterial	O
activities	O
.	O

This	O
study	O
highlights	O
the	O
facile	O
,	O
reliable	O
,	O
cost	O
effective	O
,	O
and	O
ecofriendly	O
synthesis	O
of	O
silver	O
nanoparticles	O
(	O
AgNPs	O
)	O
using	O
Borago	O
officinalis	O
leaves	O
extract	O
efficiently	O
.	O

The	O
biosynthesis	O
of	O
AgNPs	O
was	O
verified	O
by	O
UV-Vis	O
spectrum	O
which	O
showed	O
the	O
surface	O
plasmon	O
resonance	O
(	O
SPR	O
)	O
band	O
at	O
422	O
nm	O
.	O

Transmission	B-P
electron	I-P
microscope	I-P
(	I-P
TEM	I-P
)	I-P
analysis	I-P
revealed	O
that	O
the	O
particles	O
were	O
spherical	O
,	O
hexagonal	O
,	O
and	O
irregular	O
in	O
shape	O
and	O
had	O
size	O
ranging	O
from	O
30	O
to	O
80	O
nm	O
.	O

The	O
energy	B-P
dispersive	I-P
X-ray	I-P
spectroscopy	I-P
(	O
EDX	B-P
)	O
and	O
elemental	B-P
mapping	I-P
have	O
displayed	O
the	O
purity	O
and	O
maximum	O
distribution	O
of	O
silver	O
in	O
the	O
AgNPs	O
.	O

The	O
crystalline	O
nature	O
of	O
AgNPs	O
had	O
been	O
identified	O
using	O
X-ray	B-P
diffraction	I-P
(	O
XRD	B-P
)	O
and	O
selected	B-P
area	I-P
diffraction	I-P
pattern	I-P
(	O
SAED	O
)	O
.	O

The	O
particle	O
size	O
analysis	O
revealed	O
that	O
the	O
Z-average	O
diameter	O
of	O
the	O
AgNPs	O
was	O
50.86	O
nm	O
with	O
polydispersity	O
index	O
(	O
PDI	O
)	O
0.136	O
.	O

Zeta	O
potential	O
analysis	O
displayed	O
the	O
colloidal	O
stability	O
of	O
AgNPs	O
.	O

This	O
work	O
also	O
showed	O
the	O
efficacy	O
of	O
AgNPs	O
against	O
lung	O
cancer	O
cell	O
lines	O
(	O
A549	O
)	O
and	O
cervical	O
cancer	O
cell	O
line	O
(	O
HeLa	O
)	O
,	O
in	O
vitro	O
.	O

The	O
AgNPs	O
showed	O
cytotoxicity	O
to	O
the	O
A549	O
and	O
HeLa	O
cancer	O
cell	O
line	O
at	O
the	O
concentrations	O
5	O
and	O
2	O
μg/ml	O
.	O

The	O
AgNPs	O
were	O
also	O
explored	O
for	O
the	O
antibacterial	O
activity	O
including	O
biofilm	O
inhibition	O
against	O
pathogenic	O
bacteria	O
.	O

The	O
B.	O
officinalis	O
leaves	O
extract	O
can	O
be	O
used	O
efficiently	O
for	O
green	O
synthesis	O
AgNPs	O
.	O

The	O
biosynthesized	O
AgNPs	O
demonstrated	O
potentials	O
as	O
anticancer	O
and	O
antibacterial	O
agents	O
.	O

This	O
work	O
provides	O
helpful	O
insight	O
into	O
the	O
development	O
of	O
new	O
anticancer	O
and	O
antimicrobial	O
agents	O
.	O

Pitfalls	O
in	O
interpretation	O
of	O
FDG	O
PET/CT	B-P
:	O
Septic	O
pulmonary	O
emboli	O
mimicking	O
metastases	O
in	O
a	O
case	O
of	O
gastric	O
carcinoma	O
.	O

Inflammatory	O
lesions	O
may	O
sometimes	O
show	O
intense	O
tracer	O
uptake	O
and	O
mimic	O
neoplastic	O
lesions	O
on	O
(	O
18	O
)	O
F-fluoro-deoxyglucose	O
(	O
FDG	O
)	O
positron	B-P
emission	I-P
tomography/computed	I-P
tomography	I-P
(	O
PET/CT	B-P
)	O
.	O

We	O
report	O
one	O
such	O
false	O
positive	O
case	O
on	O
FDG	O
PET/CT	B-P
,	O
where	O
septic	O
pulmonary	O
emboli	O
(	O
SPE	O
)	O
mimicked	O
pulmonary	O
metastases	O
.	O

A	O
45-	O
year-old	O
man	O
with	O
stomach	O
cancer	O
had	O
an	O
indwelling	O
central	O
venous	O
catheter	O
(	O
CVC	O
)	O
in	O
situ	O
while	O
on	O
neoadjuvant	O
chemotherapy	O
.	O

He	O
underwent	O
FDG	O
PET/CT	B-P
scan	I-P
for	O
response	O
assessment	O
and	O
the	O
images	O
revealed	O
multiple	O
,	O
intensely	O
FDG	O
avid	O
,	O
peripheral	O
,	O
lung	O
nodules	O
with	O
feeding	O
vessels	O
,	O
which	O
were	O
suspicious	O
for	O
pulmonary	O
metastases	O
.	O

A	O
day	O
later	O
,	O
the	O
patient	O
developed	O
fever	O
with	O
chills	O
and	O
his	O
blood	B-P
culture	I-P
showed	O
bacterial	O
growth	O
(	O
Enterobacter	O
cloacae	O
)	O
.	O

A	O
provisional	O
diagnosis	O
of	O
SPE	O
from	O
an	O
infected	O
CVC	O
was	O
made	O
.	O

Chemotherapy	O
was	O
withheld	O
,	O
CVC	O
removed	O
,	O
and	O
the	O
catheter	O
tip	O
was	O
sent	O
for	O
bacterial	B-P
culture	I-P
.	O

Following	O
a	O
4-week	O
course	O
of	O
antibiotic	O
treatment	O
,	O
the	O
patient	O
became	O
afebrile	O
.	O

Culture	B-P
from	O
the	O
CVC	O
tip	O
grew	O
the	O
same	O
organism	O
,	O
as	O
was	O
seen	O
earlier	O
in	O
the	O
patient	O
's	O
blood	B-P
culture	I-P
,	O
thus	O
pin-pointing	O
the	O
source	O
of	O
infection	O
in	O
our	O
case	O
.	O

Diagnosis	O
of	O
SPE	O
was	O
clinched	O
when	O
follow-up	O
CT	B-P
chest	O
done	O
after	O
completion	O
of	O
antibiotic	O
course	O
showed	O
complete	O
resolution	O
of	O
the	O
lung	O
lesions	O
.	O

Human	O
Umbilical	O
Cord	O
Blood	O
-	O
Derived	O
Neural	O
Stem	O
Cell	O
Line	O
as	O
a	O
Screening	O
Model	O
for	O
Toxicity	O
.	O

The	O
aim	O
was	O
to	O
investigate	O
whether	O
a	O
human	O
neural	O
stem	O
cell	O
(	O
NSC	O
)	O
line	O
derived	O
from	O
human	O
umbilical	O
cord	O
blood	O
(	O
hUCB	O
)	O
can	O
be	O
used	O
for	O
toxicity	O
study	O
.	O

Toxicity	O
of	O
both	O
neurotoxic	O
environmental	O
xenobiotics	O
,	O
methyl	O
mercury	O
chloride	O
(	O
CH3HgCl	O
)	O
,	O
lead	O
acetate	O
(	O
CH3COOPb	O
)	O
,	O
and	O
chlorpyrifos	O
(	O
CP	O
)	O
,	O
and	O
non-neurotoxic	O
insecticide	O
,	O
dichlorvos	O
,	O
as	O
well	O
as	O
non-neurotoxic	O
drugs	O
,	O
theophylline	O
and	O
acetaminophen	O
were	O
assessed	O
.	O

Additionally	O
,	O
differentiation	O
of	O
neuronal	O
and	O
glial	O
cell	O
lines	O
derived	O
from	O
hUCB	O
was	O
elucidated	O
.	O

It	O
was	O
observed	O
that	O
CH3HgCl	O
was	O
more	O
toxic	O
to	O
human	O
NSCs	O
in	O
comparison	O
to	O
CH3COOPb	O
and	O
CP	O
.	O

The	O
minimum	O
inhibitory	O
concentration	O
(	O
MIC	O
)	O
value	O
against	O
NSCs	O
was	O
3	O
,	O
10	O
,	O
and	O
300	O
mg/L	O
,	O
in	O
each	O
staining	B-P
process	I-P
,	O
acridine	O
orange	O
/	O
ethidium	O
bromide	O
(	O
AO	O
/	O
EB	O
)	O
staining	B-P
,	O
3-	O
(	O
4,5-dimethylthiazol-2-yl	O
)	O
2,5-diphenyl	O
tetrazolium	O
bromide	O
(	O
MTT	O
)	O
assay	B-P
,	O
and	O
Hoechst	B-P
staining	I-P
,	O
for	O
CH3HgCl	O
,	O
CP	O
,	O
and	O
CH3COOPb	O
,	O
respectively	O
.	O

CH3HgCl	O
had	O
the	O
LC25	O
value	O
as	O
10.0	O
,	O
14.4	O
,	O
and	O
12.7	O
mg/L	O
,	O
by	O
staining	B-P
method	I-P
mentioned	O
in	O
succession	O
.	O

CP	O
had	O
the	O
LC25	O
value	O
as	O
21.9	O
,	O
23.7	O
,	O
and	O
18.4	O
mg/L	O
;	O
similarly	O
,	O
CH3COOPb	O
had	O
LC25	O
values	O
,	O
successively	O
as	O
616.9	O
,	O
719.2	O
,	O
and	O
890.3	O
mg/L	O
.	O

LC50	O
values	O
ranged	O
from	O
18.2	O
to	O
21.7	O
mg/L	O
for	O
CH3HgCl	O
,	O
56.4	O
to	O
60.2	O
mg/L	O
for	O
CP	O
,	O
and	O
1000	O
to	O
1460.1	O
for	O
CH3COOPb	O
.	O

Theophylline	O
,	O
acetaminophen	O
,	O
and	O
dichlorvos	O
had	O
no	O
impact	O
on	O
the	O
viability	O
of	O
NSCs	O
.	O

This	O
work	O
justified	O
that	O
hUCB	O
-	O
NSC	O
model	O
can	O
be	O
used	O
for	O
toxicity	O
study	O
.	O

Neutrophil	O
and	O
Monocyte	O
Function	O
in	O
Patients	O
with	O
Chronic	O
Hepatitis	O
C	O
Undergoing	O
Antiviral	O
Therapy	O
with	O
Regimens	O
Containing	O
Protease	O
Inhibitors	O
with	O
and	O
without	O
Interferon	O
.	O

Real-life	O
data	O
showed	O
an	O
increased	O
incidence	O
of	O
bacterial	O
infections	O
in	O
patients	O
with	O
advanced	O
liver	O
disease	O
receiving	O
a	O
protease	O
inhibitor	O
(	O
PI	O
)	O
-containing	O
antiviral	O
regimen	O
against	O
hepatitis	O
C	O
(	O
HCV	O
)	O
.	O

However	O
,	O
the	O
causes	O
of	O
this	O
event	O
are	O
unknown	O
.	O

We	O
hypothesized	O
that	O
PIs	O
might	O
impair	O
innate	O
immune	O
responses	O
through	O
the	O
inhibition	O
of	O
proteases	O
participating	O
in	O
the	O
anti-bacterial	O
functions	O
of	O
neutrophils	O
and	O
monocytes	O
.	O

The	O
aims	O
of	O
the	O
study	O
were	O
to	O
assess	O
phagocytic	O
and	O
oxidative	O
burst	O
capacity	O
in	O
neutrophils	O
and	O
monocytes	O
obtained	O
from	O
patients	O
receiving	O
a	O
PI	O
containing-	O
antiviral	O
regimen	O
,	O
and	O
to	O
determine	O
cytokine	O
secretion	O
after	O
neutrophil	O
stimulation	O
with	O
flagellin	O
.	O

Forty	O
patients	O
with	O
chronic	O
HCV	O
(	O
80	O
%	O
with	O
cirrhosis	O
)	O
were	O
enrolled	O
in	O
the	O
study	O
,	O
28	O
received	O
triple	O
therapy	O
(	O
Group	O
A	O
)	O
with	O
pegylated-interferon	O
and	O
ribavirin	O
for	O
4	O
weeks	O
followed	O
by	O
the	O
addition	O
of	O
a	O
PI	O
(	O
telaprevir	O
,	O
boceprevir	O
or	O
simeprevir	O
)	O
,	O
and	O
12	O
patients	O
received	O
an	O
interferon	O
-free	O
regimen	O
(	O
Group	O
B	O
)	O
with	O
simeprevir	O
and	O
sofosbuvir	O
.	O

Phagocytosis	O
and	O
oxidative	O
burst	O
capacity	O
were	O
analyzed	O
by	O
flow	B-P
cytometry	I-P
at	O
baseline	O
,	O
week	O
4	O
,	O
and	O
week	O
8	O
of	O
therapy	O
.	O

In	O
neutrophils	O
from	O
Group	O
A	O
patients	O
,	O
oxidative	O
burst	O
rate	O
and	O
oxidative	O
enzymatic	O
activity	O
per	O
cell	O
significantly	O
decreased	O
throughout	O
the	O
study	O
period	O
(	O
p	O
=	O
0.014	O
and	O
p	O
=	O
0.010	O
,	O
respectively	O
)	O
.	O

Pairwise	O
comparisons	O
showed	O
a	O
decrease	O
between	O
baseline	O
and	O
week	O
4	O
and	O
8	O
of	O
therapy	O
.	O

No	O
differences	O
were	O
observed	O
after	O
the	O
introduction	O
of	O
the	O
PI	O
.	O

The	O
oxidative	O
enzymatic	O
activity	O
per	O
cell	O
in	O
monocytes	O
significantly	O
decrease	O
during	O
the	O
study	O
period	O
(	O
p	O
=	O
0.042	O
)	O
due	O
to	O
a	O
decrease	O
from	O
baseline	O
to	O
week	O
8	O
of	O
therapy	O
(	O
p	O
=	O
0.037	O
)	O
in	O
patients	O
from	O
Group	O
A	O
.	O

None	O
of	O
these	O
findings	O
were	O
observed	O
in	O
Group	O
B	O
patients	O
.	O

Cytokine	O
secretion	O
did	O
not	O
significantly	O
change	O
during	O
the	O
study	O
in	O
both	O
groups	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
the	O
use	O
interferon	O
(	O
rather	O
than	O
the	O
PI	O
)	O
has	O
a	O
deleterious	O
effect	O
on	O
neutrophil	O
and	O
monocyte	O
phagocytic	O
and	O
oxidative	O
burst	O
capacity	O
in	O
this	O
cohort	O
of	O
patients	O
with	O
HCV	O
-related	O
advanced	O
liver	O
fibrosis	O
.	O

Long	O
noncoding	O
RNA	O
XIST	O
acts	O
as	O
an	O
oncogene	O
in	O
non-small	O
cell	O
lung	O
cancer	O
by	O
epigenetically	O
repressing	O
KLF2	O
expression	O
.	O

Recently	O
,	O
long	O
noncoding	O
RNAs	O
(	O
lncRNAs	O
)	O
have	O
been	O
identified	O
as	O
critical	O
regulators	O
in	O
numerous	O
types	O
of	O
cancers	O
,	O
including	O
non-small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
.	O

X	O
inactivate-specific	O
transcript	O
(	O
XIST	O
)	O
has	O
been	O
found	O
to	O
be	O
up-regulated	O
and	O
acts	O
as	O
an	O
oncogene	O
in	O
gastric	O
cancer	O
and	O
hepatocellular	O
carcinoma	O
,	O
but	O
little	O
is	O
known	O
about	O
its	O
expression	O
pattern	O
,	O
biological	O
function	O
and	O
underlying	O
mechanism	O
in	O
NSCLC	O
.	O

Here	O
,	O
we	O
identified	O
XIST	O
as	O
an	O
oncogenic	O
lncRNA	O
by	O
driving	O
tumorigenesis	O
in	O
NSCLC	O
.	O

We	O
found	O
that	O
XIST	O
is	O
over-	O
expressed	O
in	O
NSCLC	O
,	O
and	O
its	O
increased	O
level	O
is	O
associated	O
with	O
shorter	O
survival	O
and	O
poorer	O
prognosis	O
.	O

Knockdown	O
of	O
XIST	O
impaired	O
NSCLC	O
cells	O
proliferation	O
,	O
migration	O
and	O
invasion	O
in	O
vitro	O
,	O
and	O
repressed	O
the	O
tumorigenicity	O
of	O
NSCLC	O
cells	O
in	O
vivo	O
.	O

Mechanistically	O
,	O
RNA	O
immune-precipitation	B-P
(	O
RIP	B-P
)	O
and	O
RNA	O
pull-down	O
experiment	O
demonstrated	O
that	O
XIST	O
could	O
simultaneously	O
interact	O
with	O
EZH2	O
to	O
suppress	O
transcription	O
of	O
its	O
potential	O
target	O
KLF2	O
.	O

Additionally	O
,	O
rescue	O
experiments	O
revealed	O
that	O
XIST	O
's	O
oncogenic	O
functions	O
were	O
partly	O
depending	O
on	O
silencing	O
KLF2	O
expression	O
.	O

Collectively	O
,	O
our	O
findings	O
expound	O
how	O
XIST	O
over-	O
expression	O
endows	O
an	O
oncogenic	O
function	O
in	O
NSCLC	O
.	O

Tuning	O
cell	O
adhesive	O
properties	O
via	O
layer-by-layer	O
assembly	O
of	O
chitosan	O
and	O
alginate	O
.	O

Understanding	O
the	O
mechanisms	O
controlling	O
cell	O
-	O
multilayer	O
film	O
interactions	O
is	O
crucial	O
to	O
the	O
successful	O
engineering	O
of	O
these	O
coatings	O
for	O
biotechnological	O
and	O
biomedical	O
applications	O
.	O

Herein	O
,	O
we	O
present	O
a	O
strategy	O
to	O
tune	O
the	O
cell	O
adhesive	O
properties	O
of	O
multilayers	O
based	O
on	O
marine	O
polysaccharides	O
with	O
and	O
without	O
cross-linking	O
and/or	O
coating	O
with	O
extracellular	O
matrix	O
proteins	O
.	O

Chemical	O
cross-linking	O
of	O
multilayers	O
improved	O
mechanical	O
properties	O
of	O
the	O
coatings	O
but	O
also	O
elicited	O
changes	O
in	O
surface	O
chemistry	O
that	O
alter	O
the	O
adhesion	O
of	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
.	O

We	O
evaluated	O
a	O
strategy	O
to	O
decouple	O
the	O
mechanical	O
and	O
chemical	O
properties	O
of	O
these	O
films	O
,	O
enabling	O
the	O
transition	O
from	O
cell	O
-	O
adhesive	O
to	O
cell	O
-	O
resistant	O
multilayers	O
.	O

Addition	O
of	O
chitosan	O
/	O
alginate	O
multilayers	O
on	O
top	O
of	O
cross-linked	O
films	O
decreased	O
endothelial	O
cell	O
adhesion	O
,	O
spreading	O
,	O
and	O
proliferation	O
to	O
similar	O
levels	O
as	O
uncross-linked	O
films	O
.	O

Our	O
findings	O
highlight	O
the	O
key	O
role	O
of	O
surface	O
chemistry	O
in	O
cell	O
-	O
multilayer	O
film	O
interactions	O
,	O
and	O
these	O
engineered	O
nanocoatings	O
represent	O
a	O
tunable	O
model	O
of	O
cell	O
adhesive	O
and	O
non-adhesive	O
multilayered	O
films	O
.	O

Multilayered	O
films	O
based	O
on	O
marine-derived	O
polysaccharides	O
were	O
obtained	O
by	O
layer-by-layer	O
(	O
LbL	O
)	O
.	O

Biological	B-P
tests	I-P
with	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
showed	O
the	O
potential	O
of	O
these	O
films	O
to	O
tailor	O
cell	O
adhesion	O
,	O
spreading	O
and	O
proliferation	O
.	O

These	O
multilayered	O
films	O
promise	O
to	O
be	O
versatile	O
and	O
tunable	O
model	O
of	O
cell	O
adhesive	O
and	O
non-adhesive	O
films	O
.	O

Molar	O
loss	O
and	O
powder	O
diet	O
leads	O
to	O
memory	O
deficit	O
and	O
modifies	O
the	O
mRNA	O
expression	O
of	O
brain-derived	O
neurotrophic	O
factor	O
in	O
the	O
hippocampus	O
of	O
adult	O
mice	O
.	O

It	O
is	O
known	O
that	O
tooth	O
loss	O
is	O
known	O
to	O
be	O
a	O
risk	O
factor	O
for	O
Alzheimer	O
's	O
disease	O
and	O
soft	O
diet	O
feeding	O
induces	O
memory	O
impairment	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
brain-derived	O
neurotrophic	O
factor	O
(	O
BDNF	O
)	O
is	O
associated	O
with	O
tooth	O
loss	O
or	O
soft	O
diet	O
in	O
young	O
animal	O
model	O
,	O
and	O
that	O
BDNF	O
expression	O
is	O
decreased	O
in	O
patients	O
with	O
Alzheimer	O
's	O
disease	O
.	O

However	O
,	O
single	O
or	O
combined	O
effect	O
of	O
tooth	O
loss	O
and/or	O
soft	O
diet	O
on	O
brain	O
function	O
has	O
not	O
fully	O
understood	O
.	O

Here	O
we	O
examined	O
the	O
effect	O
of	O
molar	O
loss	O
and	O
powder	O
diet	O
on	O
memory	O
ability	O
and	O
the	O
expression	O
of	O
BDNF	O
mRNA	O
in	O
the	O
hippocampus	O
of	O
adult	O
C57BL/6J	O
mice	O
.	O

Twenty	O
eight-weeks-old	O
C57BL/6J	O
mice	O
were	O
divided	O
into	O
intact	O
molar	O
group	O
and	O
extracted	O
molar	O
group	O
.	O

They	O
were	O
randomly	O
divided	O
into	O
the	O
I/S	O
group	O
(	O
Intact	O
upper	O
molar	O
teeth	O
/	O
Solid	O
diet	O
feeding	O
)	O
,	O
the	O
E/S	O
group	O
(	O
Extracted	O
upper	O
molar	O
teeth	O
/	O
Solid	O
diet	O
feeding	O
)	O
,	O
the	O
I/P	O
group	O
(	O
Intact	O
upper	O
molar	O
teeth	O
/	O
Powder	O
diet	O
feeding	O
)	O
,	O
and	O
the	O
E/P	O
group	O
(	O
Extracted	O
upper	O
molar	O
teeth	O
/	O
Powder	O
diet	O
feeding	O
)	O
.	O

The	O
observation	O
periods	O
were	O
4	O
and	O
16-week	O
.	O

To	O
analyze	O
the	O
memory	O
ability	O
,	O
the	O
step-through	O
passive	O
avoidance	O
test	O
was	O
conducted	O
.	O

BDNF-related	O
mRNA	O
in	O
the	O
hippocampus	O
was	O
analyzed	O
by	O
real-time	O
polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
.	O

At	O
4	O
weeks	O
later	O
,	O
we	O
performed	O
memory	B-P
test	I-P
and	O
isolated	O
brains	O
to	O
analyze	O
.	O

There	O
were	O
no	O
differences	O
in	O
memory	O
function	O
and	O
BDNF	O
mRNA	O
level	O
between	O
these	O
four	O
groups	O
.	O

However	O
,	O
at	O
16	O
weeks	O
later	O
,	O
E/S	O
and	O
E/P	O
group	O
showed	O
memory	O
impairment	O
,	O
and	O
decreased	O
level	O
of	O
BDNF	O
mRNA	O
.	O

Whereas	O
,	O
the	O
powder	O
diet	O
had	O
no	O
effect	O
on	O
memory	O
function	O
and	O
BDNF	O
mRNA	O
level	O
even	O
at	O
16	O
weeks	O
later	O
.	O

These	O
results	O
suggest	O
that	O
the	O
effect	O
of	O
molar	O
loss	O
and	O
powder	O
diet	O
on	O
memory	O
function	O
and	O
BDNF	O
mRNA	O
levels	O
were	O
different	O
,	O
molar	O
loss	O
may	O
have	O
a	O
greater	O
long-term	O
effect	O
on	O
memory	O
ability	O
than	O
powder	O
diet	O
does	O
.	O

Novel	O
biomarkers	O
in	O
primary	O
breast	B-P
core	I-P
biopsies	I-P
to	O
predict	O
poor	O
response	O
to	O
neoadjuvant	O
chemotherapy	O
and	O
appearance	O
of	O
metastases	O
.	O

Drug	O
resistance	O
has	O
been	O
one	O
of	O
the	O
major	O
obstacles	O
limiting	O
the	O
success	O
of	O
cancer	O
chemotherapy	O
.	O

In	O
two	O
thirds	O
of	O
breast	O
cancer	O
patients	O
,	O
large	O
(	O
>	O
1cm	O
)	O
residual	O
tumors	O
are	O
present	O
after	O
neoadjuvant	O
chemotherapy	O
(	O
NCT	O
)	O
.	O

The	O
residual	O
tumor	O
and	O
involved	O
nodes	O
have	O
been	O
indicators	O
of	O
relapse	O
and	O
survival	O
very	O
important	O
in	O
breast	O
cancer	O
.	O

The	O
goal	O
of	O
this	O
preliminary	O
study	O
was	O
to	O
assess	O
the	O
predictive	O
significance	O
of	O
a	O
panel	O
of	O
molecular	O
biomarkers	O
,	O
related	O
with	O
the	O
response	O
to	O
treatment	O
or	O
drug	O
resistance	O
to	O
NCT	O
,	O
as	O
determined	O
on	O
the	O
diagnostic	O
tumor	O
.	O

The	O
expression	O
of	O
22	O
proteins	O
was	O
examined	O
using	O
immunohistochemistry	B-P
in	O
tissue	O
microarrays	O
(	O
TMA	O
)	O
from	O
115	O
patients	O
of	O
stage	O
II	O
-	O
III	O
breast	O
cancer	O
,	O
treated	O
with	O
NCT	O
.	O

Among	O
studied	O
proteins	O
,	O
there	O
are	O
some	O
that	O
are	O
anti-apoptotic	O
,	O
pro-proliferative	O
,	O
cancer	O
stem	O
cell	O
markers	O
and	O
the	O
Vitamin	O
D	O
Receptor	O
.	O

Other	O
proteins	O
are	O
involved	O
in	O
the	O
identification	O
of	O
molecular	O
subtype	O
,	O
cell	O
cycle	O
regulation	O
or	O
DNA	O
repair	O
.	O

Next	O
,	O
a	O
predictive	O
signature	O
of	O
poor	O
response	O
was	O
generated	O
from	O
independent	O
markers	O
of	O
predictive	O
value	O
.	O

Tumors	O
that	O
expressed	O
four	O
or	O
five	O
conditions	O
(	O
biomarkers	O
of	O
chemoresistance	O
with	O
a	O
determinated	O
cutoff	O
)	O
were	O
associated	O
with	O
a	O
9-fold	O
increase	O
in	O
the	O
chances	O
of	O
these	O
patients	O
of	O
having	O
a	O
poor	O
response	O
to	O
NCT	O
.	O

Additionally	O
,	O
we	O
also	O
found	O
a	O
worse	O
prognostic	O
signature	O
,	O
generated	O
from	O
independent	O
markers	O
of	O
prognostic	O
value	O
.	O

Tumors	O
which	O
expressed	O
two	O
or	O
three	O
conditions	O
of	O
worst	O
prognostic	O
,	O
were	O
associated	O
with	O
a	O
6-fold	O
reduction	O
in	O
Distant	O
Disease	O
Free	O
Survival	O
.	O

In	O
conclusion	O
,	O
finding	O
biomarkers	O
of	O
chemoresitance	O
(	O
ypTNM	O
II-III	O
)	O
and	O
metastases	O
can	O
become	O
a	O
stepping	O
stone	O
for	O
future	O
studies	O
that	O
will	O
need	O
to	O
be	O
assessed	O
in	O
a	O
bigger	O
scale	O
.	O

A	O
helical	O
segment	O
makes	O
potassium	O
channels	O
go-go	O
.	O

More	O
than	O
500	O
variants	O
in	O
the	O
KCNH2	O
gene	O
,	O
which	O
encodes	O
the	O
cardiac	O
human	O
ether-a-go-go	O
(	O
hERG	O
)	O
ion	O
channel	O
,	O
have	O
been	O
associated	O
with	O
sudden	O
cardiac	O
death	O
,	O
but	O
only	O
a	O
subset	O
of	O
these	O
variants	O
have	O
been	O
investigated	O
.	O

Matthew	O
D.	O
Perry	O
and	O
colleagues	O
now	O
combine	O
NMR	B-P
spectroscopy	I-P
and	O
electrophysiological	B-P
experiments	I-P
to	O
explore	O
the	O
functional	O
properties	O
of	O
mutations	O
within	O
an	O
overlooked	O
hERG	O
helix	O
,	O
finding	O
important	O
contributions	O
to	O
channel	O
function	O
.	O

Quadrilateral	O
Space	O
Syndrome	O
:	O
A	O
Case	O
Report	O
.	O

We	O
present	O
a	O
case	O
of	O
quadrilateral	O
space	O
syndrome	O
(	O
QSS	O
)	O
in	O
a	O
patient	O
with	O
left	O
arm	O
pain	O
.	O

The	O
patient	O
sustained	O
a	O
trauma	O
to	O
his	O
left	O
arm	O
,	O
and	O
QSS	O
was	O
successfully	O
diagnosed	O
by	O
physical	O
examination	O
,	O
magnetic	B-P
resonance	I-P
image	I-P
,	O
electromyographic	B-P
evaluation	I-P
,	O
and	O
nerve	B-P
conduction	I-P
studies	I-P
.	O

Surgery	O
was	O
performed	O
to	O
decompress	O
the	O
axillary	O
nerve	O
and	O
the	O
patient	O
recovered	O
fully	O
with	O
minimal	O
residual	O
symptoms	O
.	O

Can	O
Sergentomyia	O
(	O
Diptera	O
,	O
Psychodidae	O
)	O
play	O
a	O
role	O
in	O
the	O
transmission	O
of	O
mammal	O
-	O
infecting	O
Leishmania	O
?	O
.	O

Leishmaniases	O
are	O
parasitic	O
diseases	O
caused	O
by	O
protozoa	O
of	O
the	O
genus	O
Leishmania	O
.	O

The	O
parasites	O
,	O
which	O
infect	O
various	O
wild	O
and	O
domestic	O
mammals	O
,	O
including	O
humans	O
,	O
are	O
transmitted	O
by	O
the	O
bite	O
of	O
phlebotomine	O
sand	O
flies	O
belonging	O
to	O
the	O
Phlebotomus	O
genus	O
in	O
the	O
Old	O
World	O
and	O
to	O
several	O
genera	O
(	O
including	O
Lutzomyia	O
,	O
Psychodopygus	O
and	O
Nyssomyia	O
)	O
in	O
the	O
New	O
World	O
.	O

In	O
this	O
paper	O
,	O
we	O
consider	O
the	O
genus	O
Sergentomyia	O
as	O
divided	O
into	O
seven	O
subgenera	O
,	O
mainly	O
based	O
on	O
spermathecal	O
morphology	O
:	O
Sergentomyia	O
,	O
Sintonius	O
,	O
Parrotomyia	O
,	O
Rondanomyia	O
,	O
Capensomyia	O
,	O
Vattieromyia	O
and	O
Trouilletomyia	O
.	O

We	O
also	O
include	O
the	O
groups	O
Grassomyia	O
and	O
Demeillonius	O
but	O
exclude	O
the	O
genera	O
Spelaeomyia	O
and	O
Parvidens	O
.	O

The	O
possible	O
role	O
of	O
Sergentomyia	O
in	O
the	O
circulation	O
of	O
mammalian	O
leishmaniases	O
in	O
the	O
Old	O
World	O
has	O
been	O
considered	O
as	O
Leishmania	O
DNA	O
and/or	O
parasites	O
have	O
been	O
identified	O
in	O
several	O
species	O
.	O

However	O
,	O
several	O
criteria	O
must	O
be	O
fulfilled	O
to	O
incriminate	O
an	O
arthropod	O
as	O
a	O
biological	O
vector	O
of	O
leishmaniasis	O
,	O
namely	O
:	O
it	O
must	O
be	O
attracted	O
to	O
and	O
willing	O
to	O
feed	O
on	O
humans	O
and	O
any	O
reservoir	O
host	O
,	O
and	O
be	O
present	O
in	O
the	O
same	O
environment	O
;	O
several	O
unambiguously	O
identified	O
wild	O
female	O
flies	O
not	O
containing	O
blood	O
meals	O
have	O
to	O
be	O
found	O
infected	O
(	O
through	O
isolation	B-P
and/or	O
typing	B-P
of	O
parasites	O
)	O
with	O
the	O
same	O
strain	O
of	O
Leishmania	O
as	O
occurs	O
in	O
humans	O
or	O
any	O
reservoir	O
host	O
;	O
the	O
presence	O
of	O
infective	O
forms	O
of	O
Leishmania	O
on	O
naturally	O
infected	O
females	O
and/or	O
on	O
colonized	O
sand	O
flies	O
infected	O
experimentally	O
should	O
be	O
observed	O
;	O
and	O
finally	O
,	O
the	O
vector	O
has	O
to	O
be	O
able	O
to	O
transmit	O
parasites	O
as	O
a	O
result	O
of	O
blood	O
-	O
feeding	O
on	O
a	O
susceptible	O
mammal	O
.	O

FGF21	O
is	O
a	O
biomarker	O
for	O
mitochondrial	O
translation	O
and	O
mtDNA	O
maintenance	O
disorders	O
.	O

To	O
validate	O
new	O
mitochondrial	O
myopathy	O
serum	O
biomarkers	O
for	O
diagnostic	B-P
use	I-P
.	O

We	O
analyzed	O
serum	O
FGF21	O
(	O
S-FGF21	O
)	O
and	O
GDF15	O
from	O
patients	O
with	O
(	O
1	O
)	O
mitochondrial	O
diseases	O
and	O
(	O
2	O
)	O
nonmitochondrial	O
disorders	O
partially	O
overlapping	O
with	O
mitochondrial	O
disorder	O
phenotypes	O
.	O

We	O
(	O
3	O
)	O
did	O
a	O
meta-analysis	O
of	O
S-FGF21	O
in	O
mitochondrial	O
disease	O
and	O
(	O
4	O
)	O
analyzed	O
S-Fgf21	O
and	O
skeletal	O
muscle	O
Fgf21	O
expression	O
in	O
6	O
mouse	O
models	O
with	O
different	O
muscle	O
-	O
manifesting	O
mitochondrial	O
dysfunctions	O
.	O

We	O
report	O
that	O
S-FGF21	O
consistently	O
increases	O
in	O
primary	O
mitochondrial	O
myopathy	O
,	O
especially	O
in	O
patients	O
with	O
mitochondrial	O
translation	O
defects	O
or	O
mitochondrial	O
DNA	O
(	O
mtDNA	O
)	O
deletions	O
(	O
675	O
and	O
347	O
pg/mL	O
,	O
respectively	O
;	O
controls	O
:	O
66	O
pg/mL	O
,	O
p	O
<	O
0.0001	O
for	O
both	O
)	O
.	O

This	O
is	O
corroborated	O
in	O
mice	O
(	O
mtDNA	O
deletions	O
1,163	O
vs	O
379	O
pg/mL	O
,	O
p	O
<	O
0.0001	O
)	O
.	O

However	O
,	O
patients	O
and	O
mice	O
with	O
structural	O
respiratory	O
chain	O
subunit	O
or	O
assembly	O
factor	O
defects	O
showed	O
low	O
induction	O
(	O
human	O
335	O
pg/mL	O
,	O
p	O
<	O
0.05	O
;	O
mice	O
335	O
pg/mL	O
,	O
not	O
significant	O
)	O
.	O

Overall	O
specificities	O
of	O
FGF21	O
and	O
GDF15	O
to	O
find	O
patients	O
with	O
mitochondrial	O
myopathy	O
were	O
89.3	O
%	O
vs	O
86.4	O
%	O
,	O
and	O
sensitivities	O
67.3	O
%	O
and	O
76.0	O
%	O
,	O
respectively	O
.	O

However	O
,	O
GDF15	O
was	O
increased	O
also	O
in	O
a	O
wide	O
range	O
of	O
nonmitochondrial	O
conditions	O
.	O

S-FGF21	O
is	O
a	O
specific	O
biomarker	O
for	O
muscle	O
-	O
manifesting	O
defects	O
of	O
mitochondrial	O
translation	O
,	O
including	O
mitochondrial	O
transfer-RNA	O
mutations	O
and	O
primary	O
and	O
secondary	O
mtDNA	O
deletions	O
,	O
the	O
most	O
common	O
causes	O
of	O
mitochondrial	O
disease	O
.	O

However	O
,	O
normal	O
S-FGF21	O
does	O
not	O
exclude	O
structural	O
respiratory	O
chain	O
complex	O
or	O
assembly	O
factor	O
defects	O
,	O
important	O
to	O
acknowledge	O
in	O
diagnostics	B-P
.	O

This	O
study	O
provides	O
Class	O
III	O
evidence	O
that	O
elevated	O
S-FGF21	O
accurately	O
distinguishes	O
patients	O
with	O
mitochondrial	O
myopathies	O
from	O
patients	O
with	O
other	O
conditions	O
,	O
and	O
FGF21	O
and	O
GDF15	O
mitochondrial	O
myopathy	O
from	O
other	O
myopathies	O
.	O

Biochemical	O
and	O
molecular	O
characterization	O
of	O
a	O
lipase	O
from	O
an	O
Algerian	O
isolated	O
Staphylococcus	O
aureus	O
strain	O
.	O

A	O
Staphylococcus	O
aureus	O
strain	O
,	O
isolated	O
from	O
an	O
Algerian	O
biotope	O
,	O
secretes	O
a	O
non-induced	O
lipase	O
in	O
the	O
culture	O
medium	O
.	O

The	O
S.	O
aureus	O
lipase	O
(	O
SAL	O
)	O
was	O
purified	O
to	O
homogeneity	O
.	O

Pure	O
SAL	O
is	O
a	O
monomeric	O
protein	O
(	O
43	O
kDa	O
)	O
.	O

The	O
20	O
N-terminal	O
amino	O
acid	O
residues	O
showed	O
a	O
high	O
degree	O
of	O
homology	O
with	O
other	O
staphylococcal	O
lipase	O
sequences	O
.	O

SAL	O
presents	O
specific	O
activities	O
of	O
about	O
1600	O
and	O
555	O
U	O
mg	O
(	O
-1	O
)	O
using	O
tributyrin	O
and	O
olive	O
oil	O
emulsion	O
as	O
substrates	O
,	O
respectively	O
.	O

In	O
contrast	O
to	O
other	O
staphylococcal	O
lipases	O
previously	O
characterized	O
,	O
SAL	O
was	O
stable	O
at	O
a	O
pH	O
range	O
from	O
6	O
to	O
9	O
after	O
1	O
h	O
incubation	O
,	O
and	O
retained	O
50	O
%	O
of	O
its	O
activity	O
after	O
10	O
min	O
incubation	O
at	O
50	O
°C	O
.	O

The	O
purified	O
enzyme	O
was	O
also	O
characterized	O
using	O
monolayer	B-P
technique	I-P
.	O

Lipase	O
activity	O
can	O
be	O
measured	O
only	O
when	O
the	O
surface	O
pressure	O
exceeds	O
15	O
mN	O
m	O
(	O
-1	O
)	O
.	O

The	O
critical	O
surface	O
pressure	O
(	O
πc	O
)	O
measured	O
with	O
egg-PC	O
films	O
was	O
estimated	O
at	O
33	O
mN	O
m	O
(	O
-1	O
)	O
.	O

SAL	O
showed	O
a	O
preference	O
for	O
the	O
distal	O
ester	O
groups	O
of	O
the	O
diglyceride	O
isomers	O
at	O
low	O
surface	O
pressure	O
,	O
for	O
the	O
adjacent	O
ester	O
groups	O
at	O
high	O
surface	O
pressure	O
and	O
a	O
preference	O
for	O
the	O
sn-3	O
position	O
of	O
the	O
2,3-sn-enantiomer	O
of	O
dicaprin	O
.	O

Cloned	O
and	O
sequenced	O
gene	O
part	O
,	O
encoding	O
the	O
mature	O
lipase	O
shows	O
,	O
in	O
comparison	O
with	O
S.	O
aureus	O
lipase	O
3	O
(	O
SAL3	O
)	O
,	O
a	O
deletion	O
of	O
three	O
residues	O
(	O
LKA	O
)	O
at	O
the	O
N-terminal	O
extremity	O
and	O
a	O
substitution	O
of	O
glycine	O
208	O
and	O
isoleucine	O
226	O
with	O
an	O
arginine	O
and	O
leucine	O
,	O
respectively	O
.	O

5-Bromo-2-aryl	O
benzimidazole	O
derivatives	O
as	O
non-cytotoxic	O
potential	O
dual	O
inhibitors	O
of	O
α-glucosidase	O
and	O
urease	O
enzymes	O
.	O

On	O
the	O
basis	O
of	O
previous	O
report	O
on	O
promising	O
α-glucosidase	O
inhibitory	O
activity	O
of	O
5-bromo-2-aryl	O
benzimidazole	O
derivatives	O
,	O
these	O
derivatives	O
were	O
further	O
screened	B-P
for	O
urease	O
inhibitory	O
and	O
cytotoxicity	B-P
activity	I-P
in	O
order	O
to	O
get	O
more	O
potent	O
and	O
non-cytotoxic	O
potential	O
dual	O
inhibitor	O
for	O
the	O
patients	O
suffering	O
from	O
diabetes	O
as	O
well	O
as	O
peptic	O
ulcer	O
.	O

In	O
this	O
study	O
,	O
all	O
compounds	O
showed	O
varying	O
degree	O
of	O
potency	O
in	O
the	O
range	O
of	O
(	O
IC50	O
=8.15±0.03-354.67±0.19μM	O
)	O
as	O
compared	O
to	O
standard	O
thiourea	O
(	O
IC50	O
=21.25±0.15μM	O
)	O
.	O

It	O
is	O
worth	O
mentioning	O
that	O
derivatives	O
7	O
(	O
IC50	O
=12.07±0.05μM	O
)	O
,	O
8	O
(	O
IC50	O
=10.57±0.12μM	O
)	O
,	O
11	O
(	O
IC50	O
=13.76±0.02μM	O
)	O
,	O
14	O
(	O
IC50	O
=15.70±0.12μM	O
)	O
and	O
22	O
(	O
IC50	O
=8.15±0.03μM	O
)	O
were	O
found	O
to	O
be	O
more	O
potent	O
inhibitors	O
than	O
standard	O
.	O

All	O
compounds	O
were	O
also	O
evaluated	O
for	O
cytotoxicity	B-P
towards	O
3T3	O
mouse	O
fibroblast	O
cell	O
line	O
and	O
found	O
to	O
be	O
completely	O
non-toxic	O
.	O

Previously	O
benzimidazole	O
1-25	O
were	O
also	O
showed	O
α-glucosidase	O
inhibitory	O
potential	O
.	O

In	O
silico	O
studies	O
were	O
performed	O
on	O
the	O
lead	O
molecules	O
i.e	O
.	O

2	O
,	O
7	O
,	O
8	O
,	O
11	O
,	O
14	O
,	O
and	O
22	O
,	O
in	O
order	O
to	O
rationalize	O
the	O
binding	O
interaction	O
of	O
compounds	O
with	O
the	O
active	O
site	O
of	O
urease	O
enzyme	O
.	O

Peripheral	O
interactions	O
between	O
cannabinoid	O
and	O
opioid	O
receptor	O
agonists	O
in	O
a	O
model	O
of	O
inflammatory	O
mechanical	O
hyperalgesia	O
.	O

Activation	O
of	O
opioid	O
and	O
cannabinoid	O
receptors	O
expressed	O
in	O
nociceptors	O
induces	O
effective	O
antihyperalgesia	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
whether	O
combinations	O
of	O
opioid	O
and	O
cannabinoid	O
receptor	O
agonists	O
directed	O
at	O
the	O
injured	O
site	O
would	O
enhance	O
therapeutic	O
effectiveness	O
.	O

Behavioral	O
pharmacology	O
experiments	O
were	O
performed	O
to	O
compare	O
the	O
effects	O
of	O
DAMGO	O
,	O
a	O
selective	O
agonist	O
for	O
μ-opioid	O
receptor	O
(	O
MOR	O
)	O
,	O
ACPA	O
,	O
a	O
specific	O
agonist	O
for	O
CB1	O
,	O
and	O
combinations	O
of	O
DAMGO	O
and	O
ACPA	O
in	O
attenuating	O
complete	O
Freund	O
's	O
adjuvant	O
(	O
CFA	O
)	O
-induced	O
mechanical	O
hyperalgesia	O
in	O
the	O
rat	O
hindpaw	O
.	O

DAMGO	O
(	O
1μg-1mg	O
)	O
or	O
ACPA	O
(	O
1μg-2mg	O
)	O
was	O
administered	O
into	O
the	O
inflamed	O
paw	O
when	O
mechanical	O
hyperalgesia	O
was	O
fully	O
developed	O
.	O

When	O
administered	O
individually	O
,	O
DAMGO	O
and	O
ACPA	O
dose	O
-dependently	O
reversed	O
the	O
mechanical	O
hyperalgesia	O
.	O

DAMGO	O
displayed	O
a	O
lower	O
ED50	O
value	O
(	O
57.4±2.49μg	O
)	O
than	O
ACPA	O
(	O
111.6±2.18μg	O
)	O
,	O
but	O
ACPA	O
produced	O
longer	O
lasting	O
antihyperalgesic	O
effects	O
.	O

Combinations	O
of	O
DAMGO	O
and	O
ACPA	O
also	O
dose	O
-dependently	O
attenuated	O
mechanical	O
hyperalgesia	O
,	O
but	O
the	O
antihyperalgesic	O
effects	O
were	O
partial	O
and	O
transient	O
even	O
at	O
high	O
doses	O
.	O

Using	O
isobolographic	B-P
analysis	I-P
,	O
we	O
determined	O
that	O
combined	O
treatment	O
with	O
DAMGO	O
and	O
ACPA	O
produced	O
antagonistic	O
effects	O
with	O
the	O
observed	O
ED50	O
of	O
128.4±2.28μg	O
.	O

Our	O
findings	O
showed	O
that	O
MOR	O
and	O
CB1	O
agonists	O
directed	O
at	O
the	O
inflamed	O
site	O
effectively	O
attenuate	O
mechanical	O
hyperalgesia	O
when	O
administered	O
individually	O
,	O
but	O
exert	O
opposing	O
effects	O
when	O
administered	O
together	O
.	O

The	O
antagonistic	O
interactions	O
between	O
the	O
two	O
classes	O
of	O
drugs	O
at	O
the	O
inflamed	O
site	O
suggest	O
distinct	O
mechanisms	O
unique	O
to	O
peripheral	O
nociceptors	O
or	O
inflamed	O
tissue	O
,	O
and	O
therefore	O
require	O
further	O
studies	O
to	O
investigate	O
whether	O
the	O
therapeutic	O
utility	O
of	O
the	O
combined	O
drug	O
treatments	O
in	O
chronic	O
pain	O
conditions	O
can	O
be	O
optimized	O
.	O

Regulatory	O
role	O
of	O
cytosolic	O
phospholipase	O
A2	O
alpha	O
in	O
the	O
induction	O
of	O
CD40	O
in	O
microglia	O
.	O

The	O
aberrant	O
expression	O
of	O
CD40	O
,	O
a	O
co-stimulatory	O
receptor	O
found	O
on	O
the	O
antigen-presenting	O
cells	O
,	O
is	O
involved	O
in	O
the	O
pathogenesis	O
of	O
various	O
degenerative	O
diseases	O
.	O

Our	O
previous	O
study	O
demonstrated	O
that	O
the	O
reduction	O
of	O
cytosolic	O
phospholipase	O
A2	O
alpha	O
(	O
cPLA2α	O
)	O
protein	O
overexpression	O
and	O
activation	O
in	O
the	O
spinal	O
cord	O
of	O
a	O
mouse	O
model	O
of	O
ALS	O
,	O
hmSOD1	O
G93A	O
,	O
inhibited	O
CD40	O
upregulation	O
in	O
microglia	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
determine	O
whether	O
cPLA2α	O
has	O
a	O
direct	O
,	O
participatory	O
role	O
in	O
the	O
molecular	O
events	O
leading	O
to	O
CD40	O
induction	O
.	O

Cultures	B-P
of	O
primary	O
mouse	O
microglia	O
or	O
BV-2	O
microglia	O
cell	O
line	O
exposed	O
to	O
lipopolysaccharide	O
(	O
LPS	O
)	O
or	O
interferon	O
gamma	O
(	O
IFNγ	O
)	O
for	O
different	O
periods	O
of	O
time	O
,	O
in	O
order	O
to	O
study	O
the	O
role	O
of	O
cPLA2α	O
in	O
the	O
events	O
leading	O
to	O
CD40	O
protein	O
induction	O
.	O

Addition	O
of	O
LPS	O
or	O
IFNγ	O
caused	O
a	O
significant	O
upregulation	O
of	O
cPLA2α	O
and	O
of	O
CD40	O
,	O
while	O
prevention	O
of	O
cPLA2α	O
upregulation	O
by	O
a	O
specific	O
oligonucleotide	O
antisense	O
(	O
AS	O
)	O
prevented	O
the	O
induction	O
of	O
CD40	O
,	O
suggesting	O
a	O
role	O
of	O
cPLA2α	O
in	O
the	O
induction	O
of	O
CD40	O
.	O

Addition	O
of	O
LPS	O
to	O
microglia	O
caused	O
an	O
immediate	O
activation	O
of	O
cPLA2α	O
detected	O
by	O
its	O
phosphorylated	O
form	O
,	O
while	O
addition	O
of	O
IFNγ	O
induced	O
cPLA2α	O
activation	O
at	O
a	O
later	O
time	O
scale	O
(	O
4	O
h	O
)	O
.	O

The	O
activation	O
of	O
cPLA2α	O
is	O
mediated	O
by	O
ERK	O
activity	O
.	O

Suppression	O
of	O
cPLA2α	O
activity	O
inhibited	O
superoxide	O
production	O
by	O
NOX2-NADPH	O
oxidase	O
and	O
activation	O
of	O
NF-κB	O
detected	O
by	O
the	O
phosphorylation	O
of	O
p65	O
on	O
serine	O
536	O
at	O
15	O
min	O
by	O
LPS	O
and	O
at	O
4	O
h	O
by	O
IFNγ	O
.	O

Inhibition	O
of	O
NOX2	O
prevented	O
NF-κB	O
activation	O
and	O
CD40	O
induction	O
but	O
did	O
not	O
affect	O
cPLA2α	O
activation	O
,	O
suggesting	O
cPLA2α	O
is	O
located	O
upstream	O
to	O
NOX2	O
and	O
NF-κB	O
.	O

The	O
activation	O
of	O
cPLA2	O
by	O
LPS	O
was	O
mediated	O
by	O
both	O
adaptor	O
proteins	O
downstream	O
to	O
LPS	O
receptor	O
;	O
TRIF	O
and	O
MyD88	O
,	O
while	O
the	O
activation	O
of	O
cPLA2α	O
by	O
IFNγ	O
was	O
mediated	O
by	O
the	O
secreted	O
TNF-α	O
at	O
4	O
h.	O
The	O
early	O
activation	O
of	O
STAT1α	O
(	O
detected	O
by	O
phospho-serine727	O
and	O
phoshpo-tyrosine701	O
)	O
by	O
IFNγ	O
and	O
the	O
late	O
activation	O
of	O
STAT1α	O
by	O
LPS	O
were	O
not	O
affected	O
in	O
the	O
presence	O
of	O
cPLA2α	O
inhibitors	O
,	O
indicating	O
that	O
STAT1α	O
is	O
not	O
under	O
cPLA2α	O
regulation	O
.	O

Our	O
results	O
show	O
for	O
the	O
first	O
time	O
that	O
cPLA2	O
upregulates	O
CD40	O
protein	O
expression	O
induced	O
by	O
either	O
LPS	O
or	O
IFNγ	O
,	O
and	O
this	O
regulatory	O
effect	O
is	O
mediated	O
via	O
the	O
activation	O
of	O
NOX2-NADPH	O
oxidase	O
and	O
NF-κB	O
.	O

Cumulatively	O
,	O
our	O
results	O
indicate	O
that	O
cPLA2α	O
may	O
serve	O
as	O
a	O
pivotal	O
amplifier	O
of	O
the	O
inflammatory	O
response	O
in	O
the	O
CNS	O
.	O

The	O
Usefulness	O
of	O
Employing	O
an	O
Electronic	O
Traction	O
Table	O
to	O
Determine	O
Flexibility	O
in	O
Adolescent	O
Idiopathic	O
Scoliosis	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
develop	O
new	O
equipment	O
for	O
the	O
assessment	O
of	O
the	O
flexibility	O
of	O
the	O
spine	O
with	O
different	O
forces	O
.	O

This	O
new	O
system	O
should	O
provide	O
a	O
different	O
perspective	O
to	O
adolescent	O
idiopathic	O
scoliosis	O
(	O
AIS	O
)	O
for	O
the	O
selection	O
of	O
fusion	O
levels	O
and	O
surgical	O
success	O
.	O

Eighteen	O
patients	O
suffering	O
from	O
AIS	O
who	O
were	O
scheduled	O
to	O
undergo	O
posterior	O
instrumented	O
spinal	O
fusion	O
in	O
our	O
clinic	O
were	O
recruited	O
in	O
this	O
study	O
.	O

The	O
Electronic	O
Traction	O
Table	O
(	O
ETT	O
)	O
that	O
was	O
designed	O
in	O
our	O
clinic	O
was	O
used	O
to	O
evaluate	O
the	O
radiogical	O
and	O
clinical	O
parameters	O
of	O
the	O
spine	O
.	O

The	O
significant	O
prescriptive	O
angle	O
of	O
major	O
Cobb	O
angles	O
between	O
postoperative	O
angles	O
were	O
longitudinal	O
traction	O
and	O
lateral	O
pushing	O
Cobb	O
angles	O
.	O

Longitudinal	O
traction	O
and	O
lateral	O
pushing	O
angles	O
were	O
more	O
correlated	O
with	O
correction	O
ratios	O
.	O

There	O
was	O
a	O
significant	O
difference	O
between	O
longitudinal	O
traction	O
minor	O
Cobb	O
angle	O
,	O
longitudinal	O
traction	O
lateral	O
pushing	O
minor	O
Cobb	O
angle	O
and	O
postoperative	O
minor	O
Cobb	O
angles	O
.	O

The	O
deformity	O
is	O
needed	O
to	O
balance	O
both	O
tractional	O
and	O
rotational	O
forces	O
and	O
useful	O
technique	O
to	O
evaluate	O
curve	O
flexibility	O
before	O
the	O
operation	O
.	O

Electronic	O
traction	O
table	O
is	O
a	O
new	O
device	O
for	O
determining	O
preoperative	O
flexibility	O
with	O
longitudinal	O
traction	O
and	O
lateral	B-P
pushing	I-P
radiographs	I-P
.	O

It	O
can	O
be	O
useful	O
for	O
choosing	O
selective	O
fusion	O
levels	O
at	O
the	O
proximal	O
and	O
distal	O
end	O
of	O
the	O
vertebral	O
column	O
.	O

Perfusion	O
deconvolution	O
in	O
DSC-MRI	B-P
with	O
dispersion-compliant	O
bases	O
.	O

Perfusion	B-P
imaging	I-P
of	O
the	O
brain	O
via	O
Dynamic	B-P
Susceptibility	I-P
Contrast	I-P
MRI	I-P
(	O
DSC-MRI	B-P
)	O
allows	O
tissue	O
perfusion	O
characterization	O
by	O
recovering	O
the	O
tissue	O
impulse	O
response	O
function	O
and	O
scalar	O
parameters	O
such	O
as	O
the	O
cerebral	O
blood	O
flow	O
(	O
CBF	O
)	O
,	O
blood	O
volume	O
(	O
CBV	O
)	O
,	O
and	O
mean	O
transit	O
time	O
(	O
MTT	O
)	O
.	O

However	O
,	O
the	O
presence	O
of	O
bolus	O
dispersion	O
causes	O
the	O
data	O
to	O
reflect	O
macrovascular	O
properties	O
,	O
in	O
addition	O
to	O
tissue	O
perfusion	O
.	O

In	O
this	O
case	O
,	O
when	O
performing	O
deconvolution	O
of	O
the	O
measured	O
arterial	O
and	O
tissue	O
concentration	O
time-curves	O
it	O
is	O
only	O
possible	O
to	O
recover	O
the	O
effective	O
,	O
i.e	O
.	O

dispersed	O
,	O
response	O
function	O
and	O
parameters	O
.	O

We	O
introduce	O
Dispersion-Compliant	O
Bases	O
(	O
DCB	O
)	O
to	O
represent	O
the	O
response	O
function	O
in	O
the	O
presence	O
and	O
absence	O
of	O
dispersion	O
.	O

We	O
perform	O
in	O
silico	O
and	O
in	O
vivo	O
experiments	O
,	O
and	O
show	O
that	O
DCB	O
deconvolution	O
outperforms	O
oSVD	O
and	O
the	O
state-of-the-art	O
CPI+VTF	O
techniques	O
in	O
the	O
estimation	O
of	O
effective	O
perfusion	O
parameters	O
,	O
regardless	O
of	O
the	O
presence	O
and	O
amount	O
of	O
dispersion	O
.	O

We	O
also	O
show	O
that	O
DCB	O
deconvolution	O
can	O
be	O
used	O
as	O
a	O
pre-processing	O
step	O
to	O
improve	O
the	O
estimation	O
of	O
dispersion	O
-free	O
parameters	O
computed	B-P
with	O
CPI+VTF	O
,	O
which	O
employs	O
a	O
model	O
of	O
the	O
vascular	O
transport	O
function	O
to	O
characterize	O
dispersion	O
.	O

Indeed	O
,	O
in	O
silico	O
results	O
show	O
a	O
reduction	O
of	O
relative	O
errors	O
up	O
to	O
50	O
%	O
for	O
dispersion	O
-free	O
CBF	O
and	O
MTT	O
.	O

Moreover	O
,	O
the	O
DCB	O
method	O
recovers	O
effective	O
response	O
functions	O
that	O
comply	O
with	O
healthy	O
and	O
pathological	O
scenarios	O
,	O
and	O
offers	O
the	O
advantage	O
of	O
making	O
no	O
assumptions	O
about	O
the	O
presence	O
,	O
amount	O
,	O
and	O
nature	O
of	O
dispersion	O
.	O

Silent	O
strain	O
of	O
caregiving	O
:	O
exploring	O
the	O
best	O
predictors	O
of	O
distress	O
in	O
family	O
carers	O
of	O
geriatric	O
patients	O
.	O

The	O
aim	O
of	O
this	O
article	O
was	O
to	O
identify	O
the	O
best	O
predictors	O
of	O
distress	O
suffered	O
by	O
family	O
carers	O
(	O
FCs	O
)	O
of	O
geriatric	O
patients	O
.	O

A	O
cross-sectional	O
study	O
of	O
100	O
FC	O
-	O
geriatric	O
patient	O
dyads	O
was	O
conducted	O
.	O

The	O
negative	O
impact	O
of	O
care	O
(	O
NIoC	O
)	O
subscale	O
of	O
the	O
COPE	O
index	O
was	O
dichotomized	O
to	O
identify	O
lower	O
stress	O
(	O
score	O
of	O
≤15	O
on	O
the	O
scale	O
)	O
and	O
higher	O
stress	O
(	O
score	O
of	O
≥16	O
on	O
the	O
scale	O
)	O
exerted	O
on	O
FCs	O
by	O
the	O
process	O
of	O
providing	O
care	O
.	O

The	O
set	O
of	O
explanatory	O
variables	O
comprised	O
a	O
wide	O
range	O
of	O
sociodemographic	O
and	O
care-related	O
attributes	O
,	O
including	O
patient-related	O
results	O
from	O
comprehensive	O
geriatric	O
assessments	O
and	O
disease	O
profiles	O
.	O

The	O
best	O
combination	O
of	O
explanatory	O
variables	O
that	O
provided	O
the	O
highest	O
predictive	O
powe	O
r	O
for	O
distress	O
among	O
FCs	O
in	O
the	O
multiple	O
logistic	O
regression	O
(	O
LR	O
)	O
model	O
was	O
determined	O
according	O
to	O
statistical	O
information	O
criteria	O
.	O

The	O
statistical	O
robustness	O
of	O
the	O
observed	O
relationships	O
and	O
the	O
discriminative	O
power	O
of	O
the	O
model	O
were	O
verified	O
with	O
the	O
cross-validation	O
method	O
.	O

The	O
mean	O
age	O
of	O
FCs	O
was	O
57.2	O
(	O
±10.6	O
)	O
years	O
,	O
whereas	O
that	O
of	O
geriatric	O
patients	O
was	O
81.7	O
(	O
±6.4	O
)	O
years	O
.	O

Despite	O
the	O
broad	O
initial	O
set	O
of	O
potential	O
explanatory	O
variables	O
,	O
only	O
five	O
predictors	O
were	O
jointly	O
selected	O
for	O
the	O
best	O
statistical	O
model	O
.	O

A	O
higher	O
level	O
of	O
distress	O
was	O
independently	O
predicted	O
by	O
lower	O
self-evaluation	O
of	O
health	O
;	O
worse	O
self-appraisal	O
of	O
coping	O
well	O
as	O
a	O
caregiver	O
;	O
lower	O
sense	O
of	O
general	O
support	O
;	O
more	O
hours	O
of	O
care	O
per	O
week	O
;	O
and	O
the	O
motor	O
retardation	O
of	O
the	O
cared	O
-for	O
person	O
measured	O
with	O
the	O
speed	O
of	O
the	O
Timed	B-P
Up	I-P
and	I-P
Go	I-P
(	I-P
TUG	I-P
)	I-P
test	I-P
.	O

Worse	O
performance	O
on	O
the	O
TUG	B-P
test	I-P
was	O
only	O
the	O
patient	O
-related	O
predictor	O
of	O
distress	O
among	O
the	O
variables	O
examined	O
as	O
contributors	O
to	O
the	O
higher	O
NIoC	O
.	O

Enhancing	O
the	O
mobility	O
of	O
geriatric	O
patients	O
through	O
suitably	O
tailored	O
kinesitherapeutic	O
methods	O
during	O
their	O
hospital	O
stay	O
may	O
mitigate	O
the	O
burden	O
endured	O
by	O
FCs	O
.	O

Chronic	O
adiponectin	O
deficiency	O
leads	O
to	O
Alzheimer	O
's	O
disease	O
-like	O
cognitive	O
impairments	O
and	O
pathologies	O
through	O
AMPK	O
inactivation	O
and	O
cerebral	O
insulin	O
resistance	O
in	O
aged	O
mice	O
.	O

Insulin	O
resistance	O
is	O
the	O
major	O
pathogenesis	O
underlying	O
type	O
2	O
diabetes	O
mellitus	O
(	O
T2DM	O
)	O
and	O
these	O
patients	O
have	O
doubled	O
risk	O
of	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O

Increasing	O
evidence	O
suggests	O
that	O
insulin	O
resistance	O
plays	O
an	O
important	O
role	O
in	O
AD	O
pathogenesis	O
,	O
possibly	O
due	O
to	O
abnormal	O
GSK3β	O
activation	O
,	O
causing	O
intra-	O
and	O
extracellular	O
amyloid-beta	O
(	O
Aβ	O
)	O
accumulation	O
.	O

Adiponectin	O
(	O
APN	O
)	O
is	O
an	O
adipokine	O
with	O
insulin-sensitizing	O
and	O
anti-inflammatory	O
effects	O
.	O

Reduced	O
circulatory	O
APN	O
level	O
is	O
associated	O
with	O
insulin	O
resistance	O
and	O
T2DM	O
.	O

The	O
role	O
of	O
APN	O
in	O
AD	O
has	O
not	O
been	O
elucidated	O
.	O

In	O
this	O
study	O
,	O
we	O
aim	O
to	O
examine	O
if	O
adiponectin	O
deficiency	O
would	O
lead	O
to	O
cerebral	O
insulin	O
resistance	O
,	O
cognitive	O
decline	O
and	O
Alzheimer's-like	O
pathology	O
in	O
mice	O
.	O

To	O
study	O
the	O
role	O
of	O
adiponectin	O
in	O
cognitive	O
functions	O
,	O
we	O
employed	O
adiponectin-knockout	O
(	O
APN-KO	O
)	O
mice	O
and	O
demonstrated	O
chronic	O
APN	O
deficiency	O
in	O
their	O
CNS	O
.	O

Behavioral	B-P
tests	I-P
were	O
performed	O
to	O
study	O
the	O
cognitions	O
of	O
male	O
APN-KO	O
mice	O
.	O

Brains	O
and	O
tissue	O
lysates	O
were	O
collected	O
to	O
study	O
the	O
pathophysiological	O
and	O
molecular	O
changes	O
in	O
the	O
brain	O
of	O
APN-KO	O
mice	O
.	O

SH-SY5Y	O
neuroblastoma	O
cell	O
line	O
was	O
used	O
to	O
study	O
the	O
molecular	O
mechanism	O
upon	O
APN	O
and	O
insulin	O
treatment	O
.	O

Aged	O
APN	O
-deficient	O
mice	O
displayed	O
spatial	O
memory	O
and	O
learning	O
impairments	O
,	O
fear-conditioned	O
memory	O
deficit	O
as	O
well	O
as	O
anxiety	O
.	O

These	O
mice	O
also	O
developed	O
AD	O
pathologies	O
including	O
increased	O
cerebral	O
Aβ42	O
level	O
,	O
Aβ	O
deposition	O
,	O
hyperphosphorylated	O
Tau	O
proteins	O
,	O
microgliosis	O
and	O
astrogliosis	O
with	O
increased	O
cerebral	O
IL-1β	O
and	O
TNFα	O
levels	O
that	O
associated	O
with	O
increased	O
neuronal	O
apoptosis	O
and	O
reduced	O
synaptic	O
proteins	O
levels	O
,	O
suggesting	O
APN	O
deficiency	O
may	O
lead	O
to	O
neuronal	O
and	O
synaptic	O
loss	O
in	O
the	O
brain	O
.	O

AD	O
pathologies	O
-associated	O
APN	O
-	O
KO	O
mice	O
displayed	O
attenuated	O
AMPK	O
phosphorylation	O
and	O
impaired	O
insulin	O
signaling	O
including	O
decreased	O
Akt	O
induction	O
and	O
increased	O
GSK3β	O
activation	O
in	O
the	O
hippocampus	O
and	O
frontal	O
cortex	O
.	O

Aged	O
APN	O
-KO	O
mice	O
developed	O
hippocampal	O
insulin	O
resistance	O
with	O
reduced	O
pAkt	O
induction	O
upon	O
intracerebral	O
insulin	O
injection	O
.	O

Consistently	O
,	O
APN	O
treatment	O
in	O
SH-SY5Y	O
cells	O
with	O
insulin	O
resistance	O
and	O
overexpressing	O
Aβ	O
induce	O
higher	O
pAkt	O
levels	O
through	O
AdipoR1	O
upon	O
insulin	O
treatment	O
whereas	O
the	O
induction	O
was	O
blocked	O
by	O
compound	O
C	O
,	O
indicating	O
APN	O
can	O
enhance	O
neuronal	O
insulin	O
sensitivity	O
through	O
AMPK	O
activation	O
.	O

Our	O
results	O
indicated	O
that	O
chronic	O
APN	O
deficiency	O
inactivated	O
AMPK	O
causing	O
insulin	O
desensitization	O
and	O
elicited	O
AD-like	O
pathogenesis	O
in	O
aged	O
mice	O
which	O
also	O
developed	O
significant	O
cognitive	O
impairments	O
and	O
psychiatric	O
symptoms	O
.	O

Intranasal	O
Insulin	O
Prevents	O
Anesthesia	O
-	O
Induced	O
Cognitive	O
Impairment	O
and	O
Chronic	O
Neurobehavioral	O
Changes	O
.	O

General	O
anesthesia	O
increases	O
the	O
risk	O
for	O
cognitive	O
impairment	O
post	O
operation	O
,	O
especially	O
in	O
the	O
elderly	O
and	O
vulnerable	O
individuals	O
.	O

Recent	O
animal	O
studies	O
on	O
the	O
impact	O
of	O
anesthesia	O
on	O
postoperative	O
cognitive	O
impairment	O
have	O
provided	O
some	O
valuable	O
insights	O
,	O
but	O
much	O
remains	O
to	O
be	O
understood	O
.	O

Here	O
,	O
by	O
using	O
mice	O
of	O
various	O
ages	O
and	O
conditions	O
,	O
we	O
found	O
that	O
anesthesia	O
with	O
propofol	O
and	O
sevoflurane	O
caused	O
significant	O
deficits	O
in	O
spatial	O
learning	O
and	O
memory	O
,	O
as	O
tested	O
using	O
Morris	B-P
Water	I-P
Maze	I-P
(	O
MWM	B-P
)	O
2-6	O
days	O
after	O
anesthesia	O
exposure	O
,	O
in	O
aged	O
(	O
17-18	O
months	O
old	O
)	O
wild-type	O
(	O
WT	O
)	O
mice	O
and	O
in	O
adult	O
(	O
7-8	O
months	O
old	O
)	O
3xTg-AD	O
mice	O
(	O
a	O
triple	O
transgenic	O
mouse	O
model	O
of	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
)	O
,	O
but	O
not	O
in	O
adult	O
WT	O
mice	O
.	O

Anesthesia	O
resulted	O
in	O
long-term	O
neurobehavioral	O
changes	O
in	O
the	O
fear	O
conditioning	O
task	O
carried	O
out	O
65	O
days	O
after	O
exposure	O
to	O
anesthesia	O
in	O
3xTg-AD	O
mice	O
.	O

Importantly	O
,	O
daily	O
intranasal	O
administration	O
of	O
insulin	O
(	O
1.75	O
U/	O
mouse	O
/	O
day	O
)	O
for	O
only	O
3	O
days	O
prior	O
to	O
anesthesia	O
completely	O
prevented	O
the	O
anesthesia	O
-	O
induced	O
deficits	O
in	O
spatial	O
learning	O
and	O
memory	O
and	O
the	O
long-term	O
neurobehavioral	O
changes	O
tested	O
65	O
days	O
after	O
exposure	O
to	O
anesthesia	O
in	O
3xTg-AD	O
mice	O
.	O

These	O
results	O
indicate	O
that	O
aging	O
and	O
AD	O
-like	O
brain	O
pathology	O
increase	O
the	O
vulnerability	O
to	O
cognitive	O
impairment	O
after	O
anesthesia	O
and	O
that	O
intranasal	O
treatment	O
with	O
insulin	O
can	O
prevent	O
anesthesia	O
-	O
induced	O
cognitive	O
impairment	O
.	O

Assessment	O
of	O
periodontal	O
bone	O
level	O
revisited	O
:	O
a	O
controlled	O
study	O
on	O
the	O
diagnostic	O
accuracy	O
of	O
clinical	O
evaluation	O
methods	O
and	O
intra-oral	B-P
radiography	I-P
.	O

The	O
accuracy	O
of	O
analogue	B-P
and	O
especially	O
digital	B-P
intra-oral	I-P
radiography	I-P
in	O
assessing	O
interdental	O
bone	O
level	O
needs	O
further	O
documentation	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
clinical	O
and	O
radiographic	B-P
bone	O
level	O
assessment	O
to	O
intra-surgical	O
bone	O
level	O
registration	O
(	O
1	O
)	O
and	O
to	O
identify	O
the	O
clinical	O
variables	O
rendering	O
interdental	O
bone	O
level	O
assessment	O
inaccurate	O
(	O
2	O
)	O
.	O

The	O
study	O
sample	O
included	O
49	O
interdental	O
sites	O
in	O
17	O
periodontitis	O
patients	O
.	O

Evaluation	O
methods	O
included	O
vertical	O
relative	O
probing	O
attachment	O
level	O
(	O
RAL-V	O
)	O
,	O
analogue	B-P
and	O
digital	B-P
intra-oral	I-P
radiography	I-P
and	O
bone	B-P
sounding	I-P
without	O
and	O
with	O
flap	O
elevation	O
.	O

The	O
latter	O
was	O
considered	O
the	O
true	O
bone	O
level	O
.	O

Five	O
examiners	O
evaluated	O
all	O
radiographs	B-P
.	O

Significant	O
underestimation	O
of	O
the	O
true	O
bone	O
level	O
was	O
observed	O
for	O
all	O
evaluation	O
methods	O
pointing	O
to	O
2.7	O
mm	O
on	O
average	O
for	O
analogue	B-P
radiography	I-P
,	O
2.5	O
mm	O
for	O
digital	B-P
radiography	I-P
,	O
1.8	O
mm	O
for	O
RAL-V	O
and	O
0.6	O
mm	O
for	O
bone	B-P
sounding	I-P
without	O
flap	O
elevation	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Radiographic	B-P
underestimation	O
of	O
the	O
true	O
bone	O
level	O
was	O
higher	O
in	O
the	O
(	O
pre	O
)	O
molar	O
region	O
(	O
p	O
≤	O
0.047	O
)	O
and	O
increased	O
with	O
defect	O
depth	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Variation	O
between	O
clinicians	O
was	O
huge	O
(	O
range	O
analogue	B-P
radiography	I-P
2.2-3.2	O
mm	O
;	O
range	O
digital	B-P
radiography	I-P
2.1-3.0	O
mm	O
)	O
.	O

All	O
evaluation	O
methods	O
significantly	O
underestimated	O
the	O
true	O
bone	O
level	O
.	O

Bone	B-P
sounding	I-P
was	O
most	O
accurate	O
,	O
whereas	O
intra-oral	B-P
radiographs	I-P
were	O
least	O
accurate	O
.	O

Deep	O
periodontal	O
defects	O
in	O
the	O
(	O
pre	O
)	O
molar	O
region	O
were	O
most	O
underrated	O
by	O
intra-oral	B-P
radiography	I-P
.	O

Bone	B-P
sounding	I-P
had	O
the	O
highest	O
accuracy	O
in	O
assessing	O
interdental	O
bone	O
level	O
.	O

Determination	O
of	O
volatile	O
organic	O
compounds	O
exhaled	O
by	O
cell	O
lines	O
derived	O
from	O
hematological	O
malignancies	O
.	O

Background	O
:	O
The	O
gas	O
human	O
exhaled	O
contains	O
many	O
volatile	O
organic	O
compounds	O
(	O
VOCs	O
)	O
,	O
which	O
is	O
related	O
to	O
the	O
health	O
status	O
of	O
body	O
.	O

Analysis	O
of	O
VOCs	O
has	O
been	O
proposed	O
as	O
a	O
noninvasive	O
diagnostic	B-P
tool	I-P
for	O
certain	O
cancers	O
.	O

Detailed	O
research	O
on	O
the	O
VOCs	O
in	O
gas	O
exhaled	O
by	O
cell	O
can	O
characterize	O
cell	O
type	O
specific	O
metabolites	O
and	O
may	O
be	O
helpful	O
to	O
detect	O
the	O
cancer	O
markers	O
in	O
clinical	O
practice	O
.	O

Methods	O
:	O
Solid	B-P
phase	I-P
microextraction	I-P
-	O
gas	B-P
chromatography	I-P
-	O
mass	B-P
spectrometry	I-P
was	O
used	O
to	O
detect	O
VOCs	O
in	O
the	O
headspace	O
of	O
tissue	O
culture	O
flask	O
in	O
non-Hodgkin	O
's	O
lymphoma	O
cell	O
line	O
JEKO	O
and	O
acute	O
mononuclear	O
leukemia	O
cell	O
line	O
SHI-1	O
,	O
to	O
elaborate	O
the	O
characteristic	O
gaseous	O
biomarkers	O
of	O
hematological	O
malignancies	O
.	O

While	O
macrophage	O
cells	O
and	O
lymphocytic	O
cells	O
were	O
acted	O
as	O
control	O
.	O

The	O
blank	O
group	O
was	O
only	O
the	O
RPMI	O
1640	O
medium	O
containing	O
10	O
%	O
fetal	O
calf	O
serum	O
that	O
without	O
cells	O
.	O

Results	O
:	O
Comparing	O
to	O
control	O
group	O
,	O
the	O
concentration	O
of	O
dimethyl	O
sulphide	O
,	O
2,4-dimethyl-heptane	O
,	O
methylbenzene	O
,	O
o-xylene	O
,	O
dodecane	O
and	O
1,3-ditert-butylbenzene	O
in	O
JEKO	O
cells	O
were	O
relatively	O
higher	O
,	O
while	O
the	O
concentration	O
of	O
ethanol	O
,	O
hexanal	O
and	O
benzaldehyde	O
was	O
lower	O
.	O

In	O
SHI-1	O
cells	O
,	O
the	O
levels	O
of	O
2,4-dimethyl-heptane	O
,	O
benzene	O
,	O
4-methyldecane	O
,	O
chloroform	O
,	O
3,7-dimethyl	O
dodecane	O
and	O
hexadecane	O
were	O
significantly	O
elevated	O
,	O
but	O
the	O
levels	O
of	O
hexanol	O
and	O
cyclohexanol	O
were	O
distinctly	O
reduced	O
.	O

Conclusions	O
:	O
This	O
pilot	O
study	O
revealed	O
that	O
the	O
malignant	O
hematological	O
cells	O
could	O
change	O
the	O
components	O
of	O
VOCs	O
in	O
the	O
cell	B-P
culture	I-P
flask	I-P
in	O
a	O
cell	O
type	O
specific	O
pattern	O
.	O

The	O
traits	O
of	O
VOCs	O
in	O
our	O
setting	O
offered	O
new	O
strategy	O
for	O
hematological	O
malignancies	O
tracing	O
,	O
and	O
would	O
act	O
as	O
potential	O
biomarkers	O
in	O
diagnosis	O
of	O
malignant	O
hematological	O
diseases	O
.	O

Design	O
and	O
synthesis	O
of	O
pH	O
-	O
sensitive	O
polymeric	O
micelles	O
for	O
oral	O
delivery	O
of	O
poorly	O
water	O
-	O
soluble	O
drugs	O
.	O

pH	O
-	O
sensitive	O
polymer	O
poly	O
(	O
polylactide-co-methacrylic	O
acid	O
)	O
-b-poly	O
(	O
acrylic	O
acid	O
)	O
was	O
synthesized	O
using	O
atom	O
transfer	O
radical	O
polymerization	O
and	O
ring-opening	O
polymerization	O
and	O
characterized	O
by	O
gel	B-P
permeation	I-P
chromatography	I-P
and	O
(	B-P
1	I-P
)	I-P
H	I-P
NMR	I-P
.	O

The	O
polymers	O
can	O
self-assemble	O
to	O
form	O
micelles	O
in	O
aqueous	O
medium	O
,	O
which	O
respond	O
rapidly	O
to	O
pH	O
change	O
within	O
the	O
gastrointestinal	O
relevant	O
pH	O
range	O
.	O

Critical	O
micelle	O
concentrations	O
and	O
pH	O
response	O
behavior	O
of	O
the	O
polymeri	O
c	O
micelle	O
were	O
investigated	O
.	O

Water	O
-	O
insoluble	O
drug	O
nifedipine	O
was	O
loaded	O
and	O
the	O
drug	O
-	O
loading	O
content	O
can	O
be	O
controlled	O
by	O
tuning	O
the	O
composition	O
of	O
the	O
polymers	O
.	O

The	O
in	O
vitro	O
release	O
studies	O
indicate	O
pH	O
sensitivity	O
enabled	O
rapid	O
drug	O
release	O
at	O
the	O
environment	O
of	O
simulated	O
intestinal	O
fluid	O
(	O
pH	O
7.36	O
)	O
,	O
the	O
cumulative	O
released	O
amount	O
of	O
NFD	O
reached	O
more	O
than	O
80	O
%	O
within	O
24	O
h	O
,	O
while	O
only	O
35	O
%	O
in	O
the	O
simulated	O
gastric	O
fluid	O
(	O
pH	O
1.35	O
)	O
.	O

All	O
the	O
results	O
showed	O
that	O
the	O
pH	O
-	O
sensitive	O
P	O
(	O
PLAMA-co-MAA	O
)	O
-b-PAA	O
micelle	O
may	O
be	O
a	O
prospective	O
candidate	O
as	O
oral	O
drug	O
delivery	O
carrier	O
for	O
hydrophobic	O
drugs	O
with	O
controlled	O
release	O
behavior	O
.	O

Macrophages	O
modulate	O
the	O
growth	O
and	O
differentiation	O
of	O
rhesus	O
monkey	O
embryonic	O
trophoblasts	O
.	O

Immune	O
cells	O
within	O
the	O
endometrium	O
at	O
implantation	O
are	O
thought	O
to	O
play	O
an	O
important	O
role	O
in	O
implantation	O
,	O
although	O
their	O
exact	O
role	O
is	O
not	O
well	O
understood	O
.	O

A	O
co-culture	B-P
system	I-P
of	O
rhesus	O
monkey	O
embryos	O
and	O
maternal	O
immune	O
cells	O
was	O
established	O
.	O

Blastocysts	O
obtained	O
by	O
in	O
vitro	O
fertilization	O
were	O
co-cultured	B-P
with	O
peripheral	O
blood	O
cells	O
or	O
decidual	O
macrophages	O
.	O

Culture	O
media	O
were	O
collected	O
to	O
assess	O
secretions	O
.	O

Embryo	O
growth	O
was	O
monitored	O
,	O
and	O
trophoblasts	O
were	O
evaluated	O
for	O
proliferation	O
,	O
apoptosis	O
,	O
and	O
differentiation	O
.	O

Embryonic	O
trophoblast	O
outgrowths	O
were	O
visible	O
within	O
6	O
days	O
of	O
culture	B-P
,	O
and	O
the	O
area	O
of	O
embryo	O
outgrowth	O
was	O
reduced	O
when	O
blastocysts	O
were	O
cultured	B-P
with	O
peripheral	O
-	O
derived	O
or	O
decidual	O
macrophages	O
.	O

Trophoblast	O
proliferation	O
was	O
not	O
significantly	O
affected	O
with	O
macrophage	O
co-culture	B-P
while	O
chorionic	O
gonadotropin	O
secretion	O
was	O
increased	O
.	O

Trophoblast	O
expression	O
of	O
CDH	O
11	O
and	O
GJA1	O
was	O
increased	O
,	O
suggesting	O
that	O
macrophages	O
accelerate	O
differentiation	O
of	O
peri-implantation	O
trophoblasts	O
.	O

These	O
results	O
indicate	O
an	O
important	O
role	O
of	O
macrophages	O
in	O
placentation	O
and	O
pregnancy	O
success	O
.	O

Episomal	O
Nonviral	O
Gene	O
Therapy	O
Vectors	O
Slow	O
Progression	O
of	O
Atherosclerosis	O
in	O
a	O
Model	O
of	O
Familial	O
Hypercholesterolemia	O
.	O

Familial	O
hypercholesterolemia	O
(	O
FH	O
)	O
is	O
a	O
life-threatening	O
genetic	O
disorder	O
characterized	O
by	O
elevated	O
levels	B-P
of	I-P
plasma	I-P
low-density	I-P
lipoprotein	I-P
cholesterol	I-P
(	O
LDL-cholesterol	O
)	O
.	O

Current	O
attempts	O
at	O
gene	O
therapy	O
for	O
FH	O
have	O
been	O
limited	O
by	O
the	O
use	O
of	O
strong	O
heterologous	O
promoters	O
which	O
lack	O
genomic	O
DNA	O
elements	O
essential	O
for	O
regulated	O
expression	O
.	O

Here	O
,	O
we	O
have	O
combined	O
a	O
mini-gene	O
vector	O
expressing	O
the	O
human	O
LDLR	O
cDNA	O
from	O
a	O
10	O
kb	O
native	O
human	O
LDLR	O
locus	O
genomic	O
DNA	O
promoter	O
element	O
,	O
with	O
an	O
efficient	O
miRNA	O
targeting	O
3-hydroxy-3-methylgutaryl-coenzyme	O
A	O
reductase	O
(	O
Hmgcr	O
)	O
,	O
to	O
further	O
enhance	O
LDLR	O
expression	O
.	O

We	O
show	O
that	O
the	O
combined	O
vector	O
suppresses	O
endogenous	O
Hmgcr	O
transcripts	O
in	O
vivo	O
,	O
leading	O
to	O
an	O
increase	O
in	O
LDLR	O
transgene	O
expression	O
.	O

In	O
a	O
diet-induced	O
Ldlr	O
(	O
-/-	O
)	O
mouse	O
model	O
of	O
FH	O
,	O
we	O
show	O
that	O
administration	O
of	O
the	O
combined	O
vector	O
reduces	O
atherogenic	B-P
plasma	I-P
lipids	I-P
by	O
~32	O
%	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
our	O
episomal	O
nonviral	O
vectors	O
are	O
able	O
to	O
reduce	O
atherosclerosis	O
by	O
~40	O
%	O
after	O
12	O
weeks	O
in	O
vivo	O
.	O

Taken	O
together	O
,	O
the	O
vector	O
system	O
we	O
describe	O
exploits	O
the	O
normal	O
cellular	O
regulation	O
of	O
the	O
LDLR	O
to	O
provide	O
prolonged	O
expression	O
of	O
LDLR	O
through	O
targeted	O
knockdown	O
of	O
Hmgcr	O
.	O

This	O
novel	O
gene	O
therapy	O
system	O
could	O
act	O
alone	O
,	O
or	O
in	O
synergy	O
with	O
current	O
therapies	O
that	O
modulate	O
intracellular	O
cholesterol	O
,	O
such	O
as	O
statins	O
,	O
greatly	O
enhancing	O
its	O
therapeutic	O
application	O
for	O
FH	O
.	O

Pulmonary	O
function	O
and	O
health-related	O
quality	O
of	O
life	O
1-	O
year	O
follow	O
up	O
after	O
cardiac	O
surgery	O
.	O

Pulmonary	O
function	O
is	O
severely	O
reduced	O
in	O
the	O
early	O
period	O
after	O
cardiac	O
surgery	O
,	O
and	O
impairments	O
have	O
been	O
described	O
up	O
to	O
4-6	O
months	O
after	O
surgery	O
.	O

Evaluation	O
of	O
pulmonary	O
function	O
in	O
a	O
longer	O
perspective	O
is	O
lacking	O
.	O

In	O
this	O
prospective	O
study	O
pulmonary	O
function	O
and	O
health-related	O
quality	O
of	O
life	O
were	O
investigated	O
1	O
year	O
after	O
cardiac	O
surgery	O
.	O

Pulmonary	O
function	O
measurements	O
,	O
health-related	O
quality	O
of	O
life	O
(	O
SF-36	O
)	O
,	O
dyspnoea	O
,	O
subjective	O
breathing	O
and	O
coughing	O
ability	O
and	O
pain	O
were	O
evaluated	O
before	O
and	O
1	O
year	O
after	O
surgery	O
in	O
150	O
patients	O
undergoing	O
coronary	O
artery	O
bypass	O
grafting	O
,	O
valve	O
surgery	O
or	O
combined	O
surgery	O
.	O

One	O
year	O
after	O
surgery	O
the	O
forced	O
vital	O
capacity	O
and	O
forced	O
expiratory	O
volume	O
in	O
1	O
s	O
were	O
significantly	O
decreased	O
(	O
by	O
4-5	O
%	O
)	O
compared	O
to	O
preoperative	O
values	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Saturation	O
of	O
peripheral	O
oxygen	O
was	O
unchanged	O
1	O
year	O
postoperatively	O
compared	O
to	O
baseline	O
.	O

A	O
significantly	O
improved	O
health-related	O
quality	O
of	O
life	O
was	O
found	O
1	O
year	O
after	O
surgery	O
,	O
with	O
improvements	O
in	O
all	O
eight	O
aspects	O
of	O
SF-36	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Sternotomy	O
-related	O
pain	O
was	O
low	O
1	O
year	O
postoperatively	O
at	O
rest	O
(	O
median	O
0	O
[	O
min-max	O
;	O
0-7	O
]	O
)	O
,	O
while	O
taking	O
a	O
deep	O
breath	O
(	O
0	O
[	O
0-4	O
]	O
)	O
and	O
while	O
coughing	O
(	O
0	O
[	O
0-8	O
]	O
)	O
.	O

A	O
more	O
pronounced	O
decrease	O
in	O
pulmonary	O
function	O
was	O
associated	O
with	O
dyspnoea	O
limitations	O
and	O
impaired	O
subjective	O
breathing	O
and	O
coughing	O
ability	O
.	O

One	O
year	O
after	O
cardiac	O
surgery	O
static	O
and	O
dynamic	O
lung	B-P
function	I-P
measurements	I-P
were	O
slightly	O
decreased	O
,	O
while	O
health-related	O
quality	O
of	O
life	O
was	O
improved	O
in	O
comparison	O
to	O
preoperative	O
values	O
.	O

Measured	O
levels	O
of	O
pain	O
were	O
low	O
and	O
saturation	O
of	O
peripheral	O
oxygen	O
was	O
same	O
as	O
preoperatively	O
.	O

Utility	O
of	O
Post-Mortem	B-P
Genetic	O
Testing	O
in	O
Cases	O
of	O
Sudden	O
Arrhythmic	O
Death	O
Syndrome	O
.	O

Sudden	O
arrhythmic	O
death	O
syndrome	O
(	O
SADS	O
)	O
describes	O
a	O
sudden	O
death	O
with	O
negative	O
autopsy	B-P
and	O
toxicological	O
analysis	O
.	O

Cardiac	O
genetic	O
disease	O
is	O
a	O
likely	O
etiology	O
.	O

This	O
study	O
investigated	O
the	O
clinical	O
utility	O
and	O
combined	O
yield	O
of	O
post-mortem	B-P
genetic	O
testing	O
(	O
molecular	B-P
autopsy	I-P
)	O
in	O
cases	O
of	O
SADS	O
and	O
comprehensive	O
clinical	O
evaluation	O
of	O
surviving	O
relatives	O
.	O

We	O
evaluated	O
302	O
expertly	O
validated	O
SADS	O
cases	O
with	O
suitable	O
DNA	O
(	O
median	O
age	O
:	O
24	O
years	O
;	O
65	O
%	O
males	O
)	O
who	O
underwent	O
next-generation	O
sequencing	B-P
using	O
an	O
extended	O
panel	O
of	O
77	O
primary	O
electrical	O
disorder	O
and	O
cardiomyopathy	O
genes	O
.	O

Pathogenic	O
and	O
likely	O
pathogenic	O
variants	O
were	O
classified	O
using	O
American	O
College	O
of	O
Medical	O
Genetics	O
(	O
ACMG	O
)	O
consensus	O
guidelines	O
.	O

The	O
yield	O
of	O
combined	O
molecular	B-P
autopsy	I-P
and	O
clinical	O
evaluation	O
in	O
82	O
surviving	O
families	O
was	O
evaluated	O
.	O

A	O
gene-level	O
rare	O
variant	O
association	O
analysis	O
was	O
conducted	O
in	O
SADS	O
cases	O
versus	O
controls	O
.	O

A	O
clinically	O
actionable	O
pathogenic	O
or	O
likely	O
pathogenic	O
variant	O
was	O
identified	O
in	O
40	O
of	O
302	O
cases	O
(	O
13	O
%	O
)	O
.	O

The	O
main	O
etiologies	O
established	O
were	O
catecholaminergic	O
polymorphic	O
ventricular	O
tachycardia	O
and	O
long	O
QT	O
syndrome	O
(	O
17	O
[	O
6	O
%	O
]	O
and	O
11	O
[	O
4	O
%	O
]	O
,	O
respectively	O
)	O
.	O

Gene-based	O
rare	O
variants	O
association	O
analysis	O
showed	O
enrichment	O
of	O
rare	O
predicted	O
deleterious	O
variants	O
in	O
RYR2	O
(	O
p	O
=	O
5	O
×	O
10	O
(	O
-5	O
)	O
)	O
.	O

Combining	O
molecular	B-P
autopsy	I-P
with	O
clinical	O
evaluation	O
in	O
surviving	O
families	O
increased	O
diagnostic	O
yield	O
from	O
26	O
%	O
to	O
39	O
%	O
.	O

Molecular	B-P
autopsy	I-P
for	O
electrical	O
disorder	O
and	O
cardiomyopathy	O
genes	O
,	O
using	O
ACMG	O
guidelines	O
for	O
variant	O
classification	O
,	O
identified	O
a	O
modest	O
but	O
realistic	O
yield	O
in	O
SADS	O
.	O

Our	O
data	O
highlighted	O
the	O
predominant	O
role	O
of	O
catecholaminergic	O
polymorphic	O
ventricular	O
tachycardia	O
and	O
long	O
QT	O
syndrome	O
,	O
especially	O
the	O
RYR2	O
gene	O
,	O
as	O
well	O
as	O
the	O
minimal	O
yield	O
from	O
other	O
genes	O
.	O

Furthermore	O
,	O
we	O
showed	O
the	O
enhanced	O
utility	O
of	O
combined	O
clinical	O
and	O
genetic	O
evaluation	O
.	O

How	O
does	O
the	O
body	O
representation	O
system	O
develop	O
in	O
the	O
human	O
brain	O
?	O
.	O

Exploration	O
of	O
the	O
body	O
representation	O
system	O
(	O
BRS	O
)	O
from	O
kinaesthetic	O
illusions	O
in	O
fMRI	B-P
has	O
revealed	O
a	O
complex	O
network	O
composed	O
of	O
sensorimotor	O
and	O
frontoparietal	O
components	O
.	O

Here	O
,	O
we	O
evaluated	O
the	O
degree	O
of	O
maturity	O
of	O
this	O
network	O
in	O
children	O
aged	O
7-11	O
years	O
,	O
and	O
the	O
extent	O
to	O
which	O
structural	O
factors	O
account	O
for	O
network	O
differences	O
with	O
adults	O
.	O

Brain	O
activation	O
following	O
tendon	O
vibration	O
at	O
100Hz	O
(	O
'illusion	O
'	O
)	O
and	O
30Hz	O
(	O
'	O
no	O
illusion	O
'	O
)	O
were	O
analysed	O
using	O
the	O
two-stage	O
random	O
effects	O
model	O
,	O
with	O
or	O
without	O
white	O
and	O
grey	O
matter	O
covariates	O
.	O

The	O
BRS	O
was	O
already	O
well	O
established	O
in	O
children	O
as	O
revealed	O
by	O
the	O
contrast	O
'illusion	O
'	O
vs	O
'	O
no	O
illusion	O
'	O
,	O
although	O
still	O
immature	O
in	O
some	O
aspects	O
.	O

This	O
included	O
a	O
lower	O
level	O
of	O
activation	O
in	O
primary	O
somatosensory	O
and	O
posterior	O
parietal	O
regions	O
,	O
and	O
the	O
exclusive	O
activation	O
of	O
the	O
frontopolar	O
cortex	O
(	O
FPC	O
)	O
in	O
children	O
compared	O
to	O
adults	O
.	O

The	O
former	O
differences	O
were	O
related	O
to	O
structure	O
,	O
while	O
the	O
latter	O
difference	O
reflected	O
a	O
functional	O
strategy	O
where	O
the	O
FPC	O
may	O
serve	O
as	O
the	O
'top	O
'	O
in	O
top-down	O
modulation	O
of	O
the	O
activity	O
of	O
the	O
other	O
BRS	O
regions	O
to	O
facilitate	O
the	O
establishment	O
of	O
body	O
representations	O
.	O

Hence	O
,	O
the	O
development	O
of	O
the	O
BRS	O
not	O
only	O
relies	O
on	O
structural	O
maturation	O
,	O
but	O
also	O
involves	O
the	O
disengagement	O
of	O
an	O
executive	O
region	O
not	O
classically	O
involved	O
in	O
body	O
processing	O
.	O

Predicting	O
MEK	O
Inhibitor	O
Response	O
in	O
Lung	O
Cancer	O
:	O
A	O
Proper	O
Signature	O
Is	O
Required	O
.	O

The	O
ERK	O
signaling	O
pathway	O
is	O
one	O
of	O
the	O
most	O
commonly	O
deregulated	O
pathways	O
in	O
cancer	O
.	O

Assays	B-P
that	O
accurately	O
measure	O
ERK	O
signaling	O
output	O
in	O
clinical	O
specimens	O
would	O
be	O
extremely	O
helpfu	O
l	O
not	O
only	O
in	O
determining	O
the	O
pharmacodynamic	O
effects	O
of	O
drug	O
treatment	O
but	O
also	O
in	O
selecting	O
those	O
patients	O
most	O
likely	O
to	O
respond	O
to	O
therapy	O
.	O

Clin	O
Cancer	O
Res	O
;	O
23	O
(	O
6	O
)	O
;	O
1365-7	O
.	O

©2016	O
AACRSee	O
related	O
article	O
by	O
Brant	O
et	O
al.	O
,	O
p.	O
1471	O
.	O

Size	O
effect	O
of	O
Au	O
/	O
PAMAM	O
contrast	O
agent	O
on	O
CT	B-P
imaging	I-P
of	O
reticuloendothelial	O
system	O
and	O
tumor	O
tissue	O
.	O

Polyamidoamine	O
(	O
PAMAM	O
)	O
-entrapped	O
Au	O
nanoparticles	O
were	O
synthesized	O
with	O
distinct	O
sizes	O
to	O
figure	O
out	O
the	O
size	O
effect	O
of	O
Au	O
-based	O
contrast	O
agent	O
on	O
CT	B-P
imaging	I-P
of	O
passively	O
targeted	O
tissues	O
.	O

Au	O
/	O
PAMAM	O
nanoparticles	O
were	O
first	O
synthesized	O
with	O
narrow	O
distribution	O
of	O
particles	O
size	O
of	O
22.2	O
±	O
3.1	O
,	O
54.2	O
±	O
3.7	O
,	O
and	O
104.9	O
±	O
4.7	O
nm	O
in	O
diameters	O
.	O

Size	O
effect	O
leads	O
no	O
significant	O
difference	O
on	O
X-ray	B-P
attenuation	O
when	O
Au	O
/	O
PAMAM	O
was	O
≤0.05	O
mol/L	O
.	O

For	O
CT	B-P
imaging	I-P
of	O
a	O
tumor	O
model	O
,	O
small	O
Au	O
/	O
PAMAM	O
were	O
more	O
easily	O
internalized	O
via	O
endocytosis	O
in	O
the	O
liver	O
,	O
leading	O
to	O
more	O
obviously	O
enhanced	B-P
contrast	I-P
.	O

Similarly	O
,	O
contrast	O
agents	O
with	O
small	O
sizes	O
were	O
more	O
effective	O
in	O
tumor	O
imaging	B-P
because	O
of	O
the	O
enhanced	O
permeability	O
and	O
retention	O
effect	O
.	O

Overall	O
,	O
the	O
particle	O
size	O
of	O
Au	O
/	O
PAMAM	O
heavily	O
affected	O
the	O
efficiency	O
of	O
CT	O
enhancement	O
in	O
imaging	B-P
RES	O
and	O
tumors	O
.	O

Child	O
death	O
and	O
maternal	O
psychosis-like	O
experiences	O
in	O
44	O
low-	O
and	O
middle-income	O
countries	O
:	O
The	O
role	O
of	O
depression	O
.	O

Studies	O
on	O
the	O
effect	O
of	O
child	O
death	O
on	O
the	O
mental	O
wellbeing	O
of	O
women	O
in	O
low-	O
and	O
middle-income	O
countries	O
(	O
LMICs	O
)	O
are	O
scarce	O
despite	O
the	O
high	O
child	O
mortality	O
rates	O
.	O

Thus	O
,	O
the	O
aim	O
of	O
the	O
current	O
study	O
was	O
to	O
assess	O
the	O
association	O
between	O
child	O
death	O
and	O
psychosis-like	O
experiences	O
(	O
PLEs	O
)	O
,	O
as	O
well	O
as	O
the	O
role	O
of	O
depression	O
in	O
this	O
association	O
.	O

Data	O
from	O
44	O
LMICs	O
which	O
participated	O
in	O
the	O
World	O
Health	O
Survey	O
(	O
WHS	O
)	O
were	O
analyzed	O
.	O

A	O
total	O
of	O
59,444	O
women	O
who	O
ever	O
gave	O
birth	O
,	O
aged	O
18-49	O
years	O
,	O
without	O
a	O
self-reported	O
lifetime	O
psychosis	B-P
diagnosis	I-P
,	O
were	O
included	O
in	O
the	O
analysis	O
.	O

The	O
World	O
Mental	O
Health	O
Survey	O
version	O
of	O
the	O
Composite	O
International	O
Diagnostic	O
Interview	O
(	O
CIDI	O
)	O
was	O
used	O
to	O
establish	O
the	O
diagnosis	O
of	O
past	O
12-	O
month	O
DSM-IV	O
depression	O
,	O
and	O
assess	O
four	O
positive	O
psychotic	O
symptoms	O
.	O

Depression	O
was	O
defined	O
as	O
self-reported	O
lifetime	O
depression	B-P
diagnosis	I-P
and/or	O
past	O
12-	O
month	O
depression	O
.	O

Multivariable	O
logistic	O
regression	O
analyses	O
were	O
performed	O
.	O

After	O
adjustment	O
for	O
potential	O
confounders	O
,	O
women	O
who	O
experienced	O
child	O
death	O
had	O
higher	O
odds	O
for	O
all	O
types	O
of	O
PLEs	O
(	O
when	O
unadjusted	O
for	O
depression	O
)	O
(	O
OR	O
1.20-1.71	O
;	O
p	O
<	O
0.05	O
)	O
and	O
depression	O
(	O
OR	O
=1.64	O
;	O
95	O
%	O
CI	O
=1.39-1.93	O
)	O
.	O

When	O
adjusted	O
for	O
depression	O
,	O
only	O
delusion	O
of	O
control	O
was	O
strongly	O
associated	O
with	O
child	O
death	O
(	O
OR	O
=1.54	O
;	O
95	O
%	O
CI	O
=1.20-1.97	O
)	O
.	O

Child	O
death	O
may	O
be	O
an	O
important	O
determinant	O
of	O
mental	O
wellbeing	O
among	O
women	O
in	O
LMICs	O
.	O

Given	O
the	O
known	O
adverse	O
health	O
outcomes	O
associated	O
with	O
PLEs	O
and	O
depression	O
,	O
as	O
well	O
as	O
the	O
co-occurrence	O
of	O
these	O
symptoms	O
,	O
mental	O
health	O
care	O
may	O
be	O
particularly	O
important	O
for	O
mothers	O
who	O
have	O
experienced	O
child	O
loss	O
in	O
LMICs	O
.	O

Correlation	O
of	O
the	O
Lipid	O
Profile	B-P
,	O
BMI	O
and	O
Bone	O
Mineral	O
Density	O
in	O
Postmenopausal	O
Women	O
.	O

To	O
the	O
reduction	O
of	O
bone	O
density	O
and	O
osteoporosis	O
in	O
postmenopausal	O
women	O
contribute	O
elevated	O
lipid	O
parameters	O
and	O
Body	O
Mass	O
Index	O
(	O
BMI	O
)	O
.	O

The	O
goal	O
of	O
our	O
study	O
was	O
to	O
determine	O
the	O
correlation	O
between	O
lipid	O
parameters	O
,	O
BMI	O
and	O
osteoporosis	O
in	O
postmenopausal	O
women	O
.	O

The	O
study	O
was	O
carried	O
out	O
by	O
matched	O
type	O
between	O
experimental	O
group	O
and	O
controls	O
.	O

The	O
experimental	O
group	O
consisted	O
of	O
100	O
females	O
at	O
postmenopausal	O
age	O
,	O
in	O
which	O
by	O
the	O
DEXA	B-P
method	I-P
was	O
diagnosed	O
osteoporosis	O
at	O
the	O
Department	O
of	O
Endocrinology	O
,	O
Diabetes	O
and	O
Metabolic	O
Diseases	O
,	O
University	O
Medical	O
Center	O
of	O
RS	O
during	O
2015-2016	O
,	O
while	O
the	O
control	O
group	O
consisted	O
of	O
100	O
females	O
in	O
a	O
postmenopausal	O
age	O
but	O
without	O
diagnosed	O
osteoporosis	O
.	O

The	O
groups	O
were	O
matched	O
by	O
age	O
(	O
±	O
2	O
years	O
)	O
.	O

To	O
all	O
participants	O
of	O
the	O
study	O
were	O
carried	O
out	O
biochemical	B-P
analysis	I-P
of	I-P
blood	I-P
,	O
or	O
the	O
analysis	O
of	O
the	O
lipid	O
profile	B-P
that	O
included	O
total	O
cholesterol	O
,	O
LDL	O
cholesterol	O
,	O
triglycerides	O
(	O
TG	O
)	O
and	O
HDL	O
cholesterol	O
,	O
and	O
was	O
determined	O
the	O
values	O
of	O
BMI	O
and	O
waist	O
circumference	O
(	O
WC	O
)	O
.	O

Analysis	O
of	O
the	O
data	O
of	O
our	O
research	O
shows	O
that	O
by	O
the	O
univariate	O
logistic	O
regression	O
the	O
values	O
of	O
lipid	O
parameters	O
total	O
cholesterol	O
(	O
p=0.000	O
)	O
,	O
LDL	O
(	O
p=0.005	O
)	O
and	O
TG	O
(	O
p=0.033	O
)	O
were	O
significantly	O
associated	O
with	O
osteoporosis	O
,	O
while	O
in	O
multivariate	O
logistic	O
model	O
only	O
total	O
cholesterol	O
(	O
p=	O
0.018	O
)	O
was	O
found	O
as	O
an	O
independent	O
risk	O
factor	O
for	O
osteoporosis	O
in	O
postmenopausal	O
women	O
.	O

BMI	O
values	O
were	O
not	O
statistically	O
significantly	O
associated	O
with	O
osteoporosis	O
(	O
p=0.727	O
)	O
.	O

On	O
the	O
decrease	O
in	O
bone	O
mineral	O
density	O
and	O
osteoporosis	O
in	O
postmenopausal	O
women	O
influence	O
many	O
risk	O
factors	O
whose	O
identification	O
has	O
the	O
aim	O
to	O
develop	O
more	O
effective	O
prevention	O
of	O
this	O
disease	O
in	O
the	O
elderly	O
.	O

Maturational	O
Patterns	O
of	O
Systolic	O
Ventricular	O
Deformation	O
Mechanics	O
by	O
Two-Dimensional	B-P
Speckle-Tracking	I-P
Echocardiography	I-P
in	O
Preterm	O
Infants	O
over	O
the	O
First	O
Year	O
of	O
Age	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
maturational	O
changes	O
in	O
systolic	O
ventricular	O
strain	O
mechanics	O
by	O
two-dimensional	B-P
speckle-tracking	I-P
echocardiography	I-P
in	O
extremely	O
preterm	O
neonates	O
from	O
birth	O
to	O
1	O
year	O
of	O
age	O
and	O
discern	O
the	O
impact	O
of	O
common	O
cardiopulmonary	O
abnormalities	O
on	O
the	O
deformation	O
measures	O
.	O

In	O
a	O
prospective	O
multicenter	O
study	O
of	O
239	O
extremely	O
preterm	O
infants	O
(	O
<	O
29	O
weeks	O
gestation	O
at	O
birth	O
)	O
,	O
left	O
ventricular	O
(	O
LV	O
)	O
global	O
longitudinal	O
strain	O
(	O
GLS	O
)	O
and	O
global	O
longitudinal	O
systolic	O
strain	O
rate	O
(	O
GLSRs	O
)	O
,	O
interventricular	O
septal	O
wall	O
(	O
IVS	O
)	O
GLS	O
and	O
GLSRs	O
,	O
(	O
RV	O
)	O
free	O
wall	O
longitudinal	O
strain	O
and	O
strain	O
rate	O
,	O
and	O
segmental	O
longitudinal	O
strain	O
in	O
the	O
RV	O
free	O
wall	O
,	O
LV	O
free	O
wall	O
,	O
and	O
IVS	O
were	O
serially	O
measured	O
on	O
days	O
1	O
,	O
2	O
,	O
and	O
5	O
to	O
7	O
,	O
at	O
32	O
and	O
36	O
weeks	O
postmenstrual	O
age	O
,	O
and	O
at	O
1	O
year	O
corrected	O
age	O
(	O
CA	O
)	O
.	O

Premature	O
infants	O
who	O
developed	O
bronchopulmonary	O
dysplasia	O
or	O
had	O
echocardiographic	B-P
findings	O
of	O
pulmonary	O
hypertension	O
were	O
analyzed	O
separately	O
.	O

In	O
uncomplicated	O
preterm	O
infants	O
(	O
n	O
=	O
103	O
[	O
48	O
%	O
]	O
)	O
,	O
LV	O
GLS	O
and	O
GLSRs	O
remained	O
unchanged	O
from	O
days	O
5	O
to	O
7	O
to	O
1	O
year	O
CA	O
(	O
P	O
=	O
.60	O
and	O
P	O
=	O
.59	O
)	O
.	O

RV	O
free	O
wall	O
longitudinal	O
strain	O
,	O
RV	O
free	O
wall	O
longitudinal	O
strain	O
rate	O
,	O
and	O
IVS	O
GLS	O
and	O
GLSRs	O
significantly	O
increased	O
over	O
the	O
same	O
time	O
period	O
(	O
P	O
<	O
.01	O
for	O
all	O
measures	O
)	O
.	O

A	O
significant	O
base-to-apex	O
(	O
highest	O
to	O
lowest	O
)	O
segmental	O
longitudinal	O
strain	O
gradient	O
(	O
P	O
<	O
.01	O
)	O
was	O
seen	O
in	O
the	O
RV	O
free	O
wall	O
and	O
a	O
reverse	O
apex-to-base	O
gradient	O
(	O
P	O
<	O
.01	O
)	O
in	O
the	O
LV	O
free	O
wall	O
.	O

In	O
infants	O
with	O
bronchopulmonary	O
dysplasia	O
and/or	O
pulmonary	O
hypertension	O
(	O
n	O
=	O
119	O
[	O
51	O
%	O
]	O
)	O
,	O
RV	O
free	O
wall	O
longitudinal	O
strain	O
and	O
IVS	O
GLS	O
were	O
significantly	O
lower	O
(	O
P	O
<	O
.01	O
)	O
,	O
LV	O
GLS	O
and	O
GLSRs	O
were	O
similar	O
(	O
P	O
=	O
.56	O
)	O
,	O
and	O
IVS	O
segmental	O
longitudinal	O
strain	O
persisted	O
as	O
an	O
RV	O
-	O
dominant	O
base-to-apex	O
gradient	O
from	O
32	O
weeks	O
postmenstrual	O
age	O
to	O
1	O
year	O
CA	O
.	O

This	O
study	O
tracks	O
the	O
maturational	O
patterns	O
of	O
global	O
and	O
regional	O
deformation	O
by	O
two-dimensional	B-P
speckle-tracking	I-P
echocardiography	I-P
in	O
extremely	O
preterm	O
infants	O
from	O
birth	O
to	O
1	O
year	O
CA	O
.	O

The	O
maturational	O
patterns	O
are	O
ventricular	O
specific	O
.	O

Bronchopulmonary	O
dysplasia	O
and	O
pulmonary	O
hypertension	O
leave	O
a	O
negative	O
impact	O
on	O
RV	O
and	O
IVS	O
strain	O
,	O
while	O
LV	O
strain	O
remains	O
stable	O
.	O

Self	O
-	O
assembled	O
nanocomplex	O
between	O
polymerized	O
phenylboronic	O
acid	O
and	O
doxorubicin	O
for	O
efficient	O
tumor	O
-	O
targeted	O
chemotherapy	O
.	O

Since	O
the	O
discovery	O
that	O
nano-scaled	O
particulates	O
can	O
easily	O
be	O
incorporated	O
into	O
tumors	O
via	O
the	O
enhanced	O
permeability	O
and	O
retention	O
(	O
EPR	O
)	O
effect	O
,	O
such	O
nanostructures	O
have	O
been	O
exploited	O
as	O
therapeutic	O
small	O
molecule	O
delivery	O
systems	O
.	O

However	O
,	O
the	O
convoluted	O
synthetic	O
process	O
of	O
conventional	O
nanostructures	O
has	O
impeded	O
their	O
feasibility	O
and	O
reproducibility	O
in	O
clinical	O
applications	O
.	O

Herein	O
,	O
we	O
report	O
an	O
easily	O
prepared	O
formulation	O
of	O
self	O
-	O
assembled	O
nanostructures	O
for	O
systemic	O
delivery	O
of	O
the	O
anti-cancer	O
drug	O
doxorubicin	O
(	O
DOX	O
)	O
.	O

Phenylboronic	O
acid	O
(	O
PBA	O
)	O
was	O
grafted	O
onto	O
the	O
polymeric	O
backbone	O
of	O
poly	O
(	O
maleic	O
anhydride	O
)	O
.	O

pPBA-DOX	O
nanocomplexes	O
were	O
prepared	O
by	O
simple	O
mixing	O
,	O
on	O
the	O
basis	O
of	O
the	O
strong	O
interaction	O
between	O
the	O
1,3-diol	O
of	O
DOX	O
and	O
the	O
PBA	O
moiety	O
on	O
pPBA	O
.	O

Three	O
nanocomplexes	O
(	O
1	O
,	O
2	O
,	O
4	O
)	O
were	O
designed	O
on	O
the	O
basis	O
of	O
[	O
PBA	O
]	O
:	O
[	O
DOX	O
]	O
molar	O
ratios	O
of	O
1:1	O
,	O
2:1	O
,	O
and	O
4:1	O
,	O
respectively	O
,	O
to	O
investigate	O
the	O
function	O
of	O
the	O
residual	O
PBA	O
moiety	O
as	O
a	O
targeting	O
ligand	O
.	O

An	O
acid-labile	O
drug	O
release	O
profile	O
was	O
observed	O
,	O
owing	O
to	O
the	O
intrinsic	O
properties	O
of	O
the	O
phenylboronic	O
ester	O
.	O

Moreover	O
,	O
the	O
tumor	O
-	O
targeting	O
ability	O
of	O
the	O
nanocomplexes	O
was	O
demonstrated	O
,	O
both	O
in	O
vitro	O
by	O
confocal	B-P
microscopy	I-P
and	O
in	O
vivo	O
by	O
fluorescence	B-P
imaging	I-P
,	O
to	O
be	O
driven	O
by	O
an	O
inherent	O
property	O
of	O
the	O
residual	O
PBA	O
.	O

Ligand	B-P
competition	I-P
assays	I-P
with	O
free	O
PBA	O
pre-treatment	O
demonstrated	O
the	O
targeting	O
effect	O
of	O
the	O
residual	O
PBA	O
from	O
the	O
nanocomplexes	O
2	O
and	O
4	O
.	O

Finally	O
,	O
the	O
nanocomplexes	O
2	O
and	O
4	O
,	O
compared	O
with	O
the	O
free	O
DOX	O
,	O
exhibited	O
significantly	O
greater	O
anti-cancer	O
effects	O
in	O
vitro	O
and	O
even	O
in	O
vivo	O
.	O

Our	O
pPBA-DOX	O
nanocomplex	O
enables	O
a	O
new	O
paradigm	O
for	O
self	O
-	O
assembled	O
nanostructures	O
with	O
potential	O
biomedical	O
applications	O
.	O

Asymmetry	O
of	O
lumbopelvic	O
movement	O
patterns	O
during	O
active	O
hip	O
abduction	B-P
is	O
a	O
risk	O
factor	O
for	O
low	O
back	O
pain	O
development	O
during	O
standing	O
.	O

An	O
induced-pain	O
paradigm	O
has	O
been	O
used	O
in	O
back	O
-	O
healthy	O
people	O
to	O
understand	O
risk	O
factors	O
for	O
developing	O
low	O
back	O
pain	O
(	O
LBP	O
)	O
during	O
prolonged	O
standing	O
.	O

We	O
examined	O
asymmetry	O
of	O
lumbopelvic	O
movement	O
timing	O
during	O
a	O
clinical	O
test	O
of	O
active	O
hip	O
abduction	O
in	O
back-healthy	O
people	O
who	O
developed	O
LBP	O
symptoms	O
during	O
standing	O
(	O
Pain	O
Developers	O
;	O
PDs	O
)	O
compared	O
to	O
back-healthy	O
people	O
who	O
did	O
not	O
develop	O
LBP	O
symptoms	O
during	O
standing	O
(	O
Non	O
Pain	O
Developers	O
,	O
NPDs	O
)	O
.	O

Participants	O
completed	O
the	O
hip	O
abduction	B-P
test	I-P
while	O
movement	O
was	O
recorded	O
with	O
a	O
motion	O
capture	O
system	O
.	O

Difference	O
in	O
time	O
between	O
start	O
of	O
hip	O
and	O
lumbopelvic	O
movement	O
was	O
calculated	B-P
(	O
startdiff	O
)	O
.	O

PDs	O
moved	O
the	O
lumbopelvic	O
region	O
earlier	O
during	O
left	O
hip	O
abduction	O
than	O
right	O
hip	O
abduction	O
.	O

There	O
was	O
no	O
difference	O
between	O
sides	O
in	O
NPDs	O
.	O

In	O
PDs	O
,	O
the	O
amount	O
of	O
asymmetry	O
was	O
related	O
to	O
average	O
symptom	O
intensity	O
during	O
standing	O
.	O

Asymmetric	O
lumbopelvic	O
movement	O
patterns	O
may	O
be	O
a	O
risk	O
factor	O
for	O
LBP	O
development	O
during	O
prolonged	O
standing	O
.	O

Embryonic	O
Mutant	O
Huntingtin	O
Aggregate	O
Formation	O
in	O
Mouse	O
Models	O
of	O
Huntington	O
's	O
Disease	O
.	O

The	O
role	O
of	O
aggregate	O
formation	O
in	O
the	O
pathophysiology	O
of	O
Huntington	O
's	O
disease	O
(	O
HD	O
)	O
remains	O
uncertain	O
.	O

However	O
,	O
the	O
temporal	O
appearance	O
of	O
aggregates	O
tends	O
to	O
correlate	O
with	O
the	O
onset	O
of	O
symptoms	O
and	O
the	O
numbers	O
of	O
neuropil	O
aggregates	O
correlate	O
with	O
the	O
progression	O
of	O
clinical	O
disease	O
.	O

Using	O
highly	O
sensitive	O
immunohistochemical	B-P
methods	I-P
we	O
have	O
detected	O
the	O
appearance	O
of	O
diffuse	O
aggregates	O
during	O
embryonic	O
development	O
in	O
the	O
R6/2	O
and	O
YAC128	O
mouse	O
models	O
of	O
HD	O
.	O

These	O
are	O
initially	O
seen	O
in	O
developing	O
axonal	O
tracts	O
and	O
appear	O
to	O
spread	O
throughout	O
the	O
cerebrum	O
in	O
the	O
early	O
neonate	O
.	O

Prevalence	O
and	O
presentation	O
of	O
tuberculosis	O
among	O
hemodialysis	O
patients	O
in	O
Khartoum	O
,	O
Sudan	O
.	O

Tuberculosis	O
(	O
TB	O
)	O
is	O
a	O
major	O
health	O
problem	O
in	O
the	O
developing	O
countries	O
.	O

There	O
are	O
limited	O
data	O
about	O
the	O
prevalence	O
of	O
TB	O
patients	O
on	O
maintenance	O
hemodialysis	O
(	O
HD	O
)	O
in	O
Sudan	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
identify	O
the	O
prevalence	O
and	O
presentation	O
of	O
TB	O
among	O
Sudanese	O
maintenance	O
HD	O
patients	O
.	O

This	O
is	O
a	O
hospital	O
-based	O
descriptive	O
study	O
.	O

The	O
participants	O
of	O
the	O
study	O
are	O
all	O
HD	O
patients	O
distributed	O
in	O
13	O
HD	O
centers	O
in	O
Khartoum	O
and	O
Khartoum	O
North	O
Provinces	O
in	O
Sudan	O
.	O

All	O
patients	O
attended	O
the	O
HD	O
centers	O
from	O
November	O
1	O
,	O
2014	O
to	O
February	O
1	O
,	O
2015	O
,	O
were	O
interviewed	O
by	O
a	O
questionnaire	O
focused	O
on	O
personal	O
and	O
clinical	O
data	O
.	O

Those	O
who	O
were	O
diagnosed	O
as	O
having	O
active	O
TB	O
were	O
studied	O
regarding	O
their	O
clinical	O
presentation	O
,	O
presence	O
of	O
comorbidities	O
,	O
site	O
of	O
TB	O
,	O
and	O
methods	O
used	O
on	O
diagnosis	O
.	O

The	O
total	O
number	O
of	O
HD	O
patients	O
during	O
the	O
study	O
period	O
was	O
1328	O
patients	O
.	O

We	O
found	O
19	O
patients	O
who	O
already	O
diagnosed	O
and	O
treated	O
for	O
TB	O
infection	O
.	O

The	O
prevalence	O
rate	O
of	O
TB	O
among	O
HD	O
patients	O
is	O
1.4	O
%	O
.	O

The	O
mean	O
age	O
of	O
patient	O
was	O
44.53±8.69	O
years	O
,	O
89.5	O
%	O
of	O
them	O
were	O
males	O
.	O

The	O
majority	O
of	O
them	O
have	O
comorbidities	O
:	O
31.6	O
%	O
%	O
have	O
hypertension	O
and	O
21.1	O
%	O
have	O
diabetes	O
.	O

Extrapulmonary	O
TB	O
was	O
the	O
major	O
presentation	O
(	O
57.9	O
%	O
)	O
mainly	O
tuberculous	O
lymphadenitis	O
(	O
26.3	O
%	O
)	O
.	O

The	O
pulmonary	O
presentation	O
was	O
found	O
to	O
be	O
42.1	O
%	O
.	O

The	O
diagnosis	O
of	O
TB	O
was	O
supported	O
by	O
microbiological	O
evidence	O
of	O
alcohol	O
acid-fast	O
Bacilli	O
present	O
in	O
sputum	O
smear	O
(	O
21	O
%	O
)	O
,	O
histological	O
diagnosis	O
(	O
31.6	O
%	O
)	O
,	O
polymerase	O
chain	O
reaction	O
(	O
21	O
%	O
)	O
,	O
and	O
imaging	B-P
in	I-P
(	O
26.3	O
%	O
)	O
.	O

Patients	O
on	O
maintenance	O
HD	O
are	O
at	O
an	O
increased	O
risk	O
of	O
TB	O
and	O
diagnosis	O
of	O
TB	O
among	O
HD	O
patients	O
need	O
a	O
high	O
index	O
of	O
suspicion	O
.	O

There	O
is	O
a	O
great	O
need	O
for	O
establishing	O
a	O
screening	O
scheme	O
for	O
TB	O
among	O
HD	O
patients	O
and	O
further	O
epidemiological	O
studies	O
are	O
needed	O
to	O
fully	O
evaluate	O
this	O
problem	O
.	O

Ideal	O
cardiovascular	O
health	O
and	O
inflammation	O
in	O
European	O
adolescents	O
:	O
The	O
HELENA	O
study	O
.	O

Inflammation	O
plays	O
a	O
key	O
role	O
in	O
atherosclerosis	O
and	O
this	O
process	O
seems	O
to	O
appear	O
in	O
childhood	O
.	O

The	O
ideal	O
cardiovascular	O
health	O
index	O
(	O
ICHI	O
)	O
has	O
been	O
inversely	O
related	O
to	O
atherosclerotic	O
plaque	O
in	O
adults	O
.	O

However	O
,	O
evidence	O
regarding	O
inflammation	O
and	O
ICHI	O
in	O
adolescents	O
is	O
scarce	O
.	O

The	O
aim	O
is	O
to	O
assess	O
the	O
association	O
between	O
ICHI	O
and	O
inflammation	O
in	O
European	O
adolescents	O
.	O

As	O
many	O
as	O
543	O
adolescents	O
(	O
251	O
boys	O
and	O
292	O
girls	O
)	O
from	O
the	O
Healthy	O
Lifestyle	O
in	O
Europe	O
by	O
Nutrition	O
in	O
Adolescence	O
(	O
HELENA	O
)	O
study	O
,	O
a	O
cross-sectional	O
multi-center	O
study	O
including	O
9	O
European	O
countries	O
,	O
were	O
measured	O
.	O

C-reactive	O
protein	O
(	O
CRP	O
)	O
,	O
complement	O
factors	O
C3	O
and	O
C4	O
,	O
leptin	O
and	O
white	O
blood	O
cell	O
counts	O
were	O
used	O
to	O
compute	O
an	O
inflammatory	O
score	O
.	O

Multilevel	O
linear	O
models	O
and	O
multilevel	O
logistic	O
regression	O
were	O
used	O
to	O
assess	O
the	O
association	O
between	O
ICHI	O
and	O
inflammation	O
controlling	O
by	O
covariates	O
.	O

Higher	O
ICHI	O
was	O
associated	O
with	O
a	O
lower	O
inflammatory	O
score	O
,	O
as	O
well	O
as	O
with	O
several	O
individual	O
components	O
,	O
both	O
in	O
boys	O
and	O
girls	O
(	O
p	O
<	O
0.01	O
)	O
.	O

In	O
addition	O
,	O
adolescents	O
with	O
at	O
least	O
4	O
ideal	O
components	O
of	O
the	O
ICHI	O
had	O
significantly	O
lower	O
inflammatory	O
score	O
and	O
lower	O
levels	O
of	O
the	O
study	O
biomarkers	O
,	O
except	O
CRP	O
.	O

Finally	O
,	O
the	O
multilevel	O
logistic	O
regression	O
showed	O
that	O
for	O
every	O
unit	O
increase	O
in	O
the	O
ICHI	O
,	O
the	O
probability	O
of	O
having	O
an	O
inflammatory	O
profile	B-P
decreased	O
by	O
28.1	O
%	O
in	O
girls	O
.	O

Results	O
from	O
this	O
study	O
suggest	O
that	O
a	O
better	O
ICHI	O
is	O
associated	O
with	O
a	O
lower	O
inflammatory	O
profile	B-P
already	O
in	O
adolescence	O
.	O

Improving	O
these	O
health	O
behaviors	O
,	O
and	O
health	O
factors	O
included	O
in	O
the	O
ICHI	O
,	O
could	O
play	O
an	O
important	O
role	O
in	O
CVD	O
prevention	O
.	O

A	O
framework	O
for	O
automatic	O
creation	O
of	O
gold	O
-	O
standard	O
rigid	O
3D-2D	O
registration	O
datasets	O
.	O

Advanced	O
image-guided	O
medical	O
procedures	O
incorporate	O
2D	O
intra-interventional	O
information	O
into	O
pre-interventional	O
3D	O
image	O
and	O
plan	O
of	O
the	O
procedure	O
through	O
3D	O
/	O
2D	O
image	O
registration	O
(	O
32R	O
)	O
.	O

To	O
enter	O
clinical	O
use	O
,	O
and	O
even	O
for	O
publication	O
purposes	O
,	O
novel	O
and	O
existing	O
32R	O
methods	O
have	O
to	O
be	O
rigorously	O
validated	O
.	O

The	O
performance	O
of	O
a	O
32R	O
method	O
can	O
be	O
estimated	O
by	O
comparing	O
it	O
to	O
an	O
accurate	O
reference	O
or	O
gold	B-P
standard	I-P
method	I-P
(	O
usually	O
based	O
on	O
fiducial	O
markers	O
)	O
on	O
the	O
same	O
set	O
of	O
images	O
(	O
gold	O
standard	O
dataset	O
)	O
.	O

Objective	O
validation	O
and	O
comparison	O
of	O
methods	O
are	O
possible	O
only	O
if	O
evaluation	O
methodology	O
is	O
standardized	O
,	O
and	O
the	O
gold	O
standard	O
dataset	O
is	O
made	O
publicly	O
available	O
.	O

Currently	O
,	O
very	O
few	O
such	O
datasets	O
exist	O
and	O
only	O
one	O
contains	O
images	O
of	O
multiple	O
patients	O
acquired	O
during	O
a	O
procedure	B-P
.	O

To	O
encourage	O
the	O
creation	O
of	O
gold	O
standard	O
32R	O
datasets	O
,	O
we	O
propose	O
an	O
automatic	O
framework	O
.	O

The	O
framework	O
is	O
based	O
on	O
rigid	O
registration	O
of	O
fiducial	O
markers	O
.	O

The	O
main	O
novelty	O
is	O
spatial	O
grouping	O
of	O
fiducial	O
markers	O
on	O
the	O
carrier	O
device	O
,	O
which	O
enables	O
automatic	O
marker	O
localization	O
and	O
identification	O
across	O
the	O
3D	O
and	O
2D	O
images	O
.	O

The	O
proposed	O
framework	O
was	O
demonstrated	O
on	O
clinical	O
angiograms	B-P
of	O
20	O
patients	O
.	O

Rigid	O
32R	O
computed	B-P
by	O
the	O
framework	O
was	O
more	O
accurate	O
than	O
that	O
obtained	O
manually	O
,	O
with	O
the	O
respective	O
target	O
registration	O
error	O
below	O
0.027	O
mm	O
compared	O
to	O
0.040	O
mm	O
.	O

The	O
framework	O
is	O
applicable	O
for	O
gold	O
standard	O
setup	O
on	O
any	O
rigid	O
anatomy	O
,	O
provided	O
that	O
the	O
acquired	O
images	O
contain	O
spatially	O
grouped	O
fiducial	O
markers	O
.	O

The	O
gold	O
standard	O
datasets	O
and	O
software	O
will	O
be	O
made	O
publicly	O
available	O
.	O

MicroRNA	O
101b	O
Is	O
Downregulated	O
in	O
the	O
Prefrontal	O
Cortex	O
of	O
a	O
Genetic	O
Model	O
of	O
Depression	O
and	O
Targets	O
the	O
Glutamate	O
Transporter	O
SLC1A1	O
(	O
EAAT3	O
)	O
in	O
Vitro	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
small	O
regulatory	O
molecules	O
that	O
cause	O
translational	O
repression	O
by	O
base	O
pairing	O
with	O
target	O
mRNAs	O
.	O

Cumulative	O
evidence	O
suggests	O
that	O
changes	O
in	O
miRNA	O
expression	O
may	O
in	O
part	O
underlie	O
the	O
pathophysiology	O
and	O
treatment	O
of	O
neuropsychiatric	O
disorders	O
,	O
including	O
major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
.	O

A	O
miRNA	O
expression	O
assay	B-P
that	O
can	O
simultaneously	O
detect	O
423	O
rat	O
miRNAs	O
(	O
miRBase	O
v.17	O
)	O
was	O
used	O
to	O
profile	B-P
the	O
prefrontal	O
cortex	O
(	O
PFC	O
)	O
of	O
a	O
genetic	O
rat	O
model	O
of	O
MDD	O
(	O
the	O
Flinders	O
Sensitive	O
Line	O
[	O
FSL	O
]	O
)	O
and	O
the	O
controls	O
,	O
the	O
Flinders	O
Resistant	O
Line	O
(	O
FRL	O
)	O
.	O

Gene	O
expression	O
data	O
from	O
the	O
PFC	O
of	O
FSL	O
/	O
FRL	O
animals	O
(	O
GEO	O
accession	O
no	O
.	O

GSE20388	O
)	O
were	O
used	O
to	O
guide	O
mRNA	O
target	O
selection	O
.	O

Luciferase	B-P
reporter	I-P
assays	I-P
were	O
used	O
to	O
verify	O
miRNA	O
targets	O
in	O
vitro	O
.	O

We	O
identified	O
23	O
miRNAs	O
that	O
were	O
downregulated	O
in	O
the	O
PFC	O
of	O
the	O
FSL	O
model	O
compared	O
with	O
controls	O
.	O

Interestingly	O
,	O
one	O
of	O
the	O
identified	O
miRNAs	O
(	O
miR-101b	O
)	O
is	O
highly	O
conserved	O
between	O
rat	O
and	O
human	O
and	O
was	O
recently	O
found	O
to	O
be	O
downregulated	O
in	O
the	O
PFC	O
of	O
depressed	O
suicide	O
subjects	O
.	O

Using	O
a	O
combination	O
of	O
in	O
silico	O
and	O
in	O
vitro	O
analyses	O
,	O
we	O
found	O
that	O
miR-101b	O
targets	O
the	O
neuronal	O
glutamate	O
transporter	O
SLC1A1	O
(	O
also	O
known	O
as	O
EAAC1	O
or	O
EAAT3	O
)	O
.	O

Accordingly	O
,	O
both	O
mRNA	O
and	O
protein	O
levels	O
of	O
SLC1A1	O
were	O
found	O
to	O
be	O
upregulated	O
in	O
the	O
PFC	O
of	O
the	O
FSL	O
model	O
.	O

Besides	O
providing	O
a	O
list	O
of	O
novel	O
miRNAs	O
associated	O
with	O
depression-like	O
states	O
,	O
this	O
preclinical	O
study	O
replicated	O
the	O
human	O
association	O
of	O
miR-101	O
with	O
depression	O
.	O

In	O
addition	O
,	O
since	O
one	O
of	O
the	O
targets	O
of	O
miR-101b	O
appears	O
to	O
be	O
a	O
glutamate	O
transporter	O
,	O
our	O
preclinical	O
data	O
support	O
the	O
hypothesis	O
of	O
a	O
glutamatergic	O
dysregulation	O
being	O
implicated	O
in	O
the	O
etiology	O
of	O
depression	O
.	O

Synthesis	O
and	O
Photophysical	O
Properties	O
of	O
Fluorescence	O
Molecular	O
Probe	O
for	O
Turn-ON-Type	B-P
Detection	I-P
of	O
Cytosine	O
Bulge	O
DNA	O
.	O

A	O
fluorescent	O
molecule	O
DANP	O
that	O
binds	O
to	O
cytosine	O
bulge	O
DNA	O
and	O
emits	O
characteristic	O
fluorescence	O
was	O
conjugated	O
to	O
pyrene	O
to	O
give	O
a	O
new	O
fluorescence	O
probe	O
PyDANP	O
.	O

Temperature	O
-	O
and	O
solvent	O
-dependent	O
absorption	O
changes	O
showed	O
that	O
DANP	O
and	O
pyrene	O
chromophores	O
stacked	O
at	O
room	O
temperature	O
in	O
an	O
aqueous	O
buffer	O
solution	O
and	O
quenched	B-P
fluorescence	I-P
.	O

Upon	O
binding	O
of	O
DANP	O
moiety	O
in	O
PyDANP	O
to	O
cytosine	O
bulge	O
DNA	O
,	O
the	O
fluorescence	O
from	O
DANP	O
bound	O
to	O
C-bulge	O
increased	O
by	O
∼12-fold	O
,	O
showing	O
that	O
PyDANP	O
is	O
a	O
turn-ON	B-P
probe	I-P
for	I-P
the	I-P
detection	I-P
of	O
C-bulge	O
DNA	O
.	O

Remitting	O
Seronegative	O
Symmetrical	O
Synovitis	O
With	O
Pitting	O
Edema	O
:	O
Appearance	O
on	O
FDG	B-P
PET/CT	I-P
.	O

Remitting	O
seronegative	O
symmetrical	O
synovitis	O
with	O
pitting	O
edema	O
(	O
RS3PE	O
)	O
is	O
a	O
rare	O
condition	O
in	O
the	O
elderly	O
and	O
can	O
appear	O
as	O
a	O
first	O
presentation	O
of	O
various	O
types	O
of	O
rheumatic	O
and	O
malignant	O
diseases	O
.	O

We	O
presented	O
a	O
62-	O
year	O
-old	O
man	O
with	O
the	O
diagnosis	O
of	O
RS3PE	O
based	O
on	O
the	O
clinical	O
sign	O
and	O
laboratory	O
data	O
.	O

Because	O
of	O
the	O
possibility	O
of	O
associated	O
malignancies	O
in	O
RS3PE	O
,	O
FDG	B-P
PET/CT	I-P
was	O
performed	O
to	O
exclude	O
occult	O
tumors	O
.	O

The	O
images	O
showed	O
multiple	O
,	O
symmetrically	O
,	O
diffusely	O
increased	O
F-FDG	O
uptake	O
in	O
the	O
soft	O
tissue	O
around	O
joints	O
and	O
bones	O
in	O
the	O
shoulders	O
,	O
hips	O
,	O
knees	O
,	O
and	O
ankles	O
.	O

The	O
opioid	O
antagonist	O
,	O
β-funaltrexamine	O
,	O
inhibits	O
lipopolysaccharide	O
-induced	O
neuroinflammation	O
and	O
reduces	O
sickness	O
behavior	O
in	O
mice	O
.	O

Brain	O
pathologies	O
such	O
as	O
neurodegenerative	O
diseases	O
,	O
infection	O
,	O
traumatic	O
brain	O
injury	O
,	O
and	O
mood	O
disorders	O
produce	O
enormous	O
personal	O
and	O
economic	O
burdens	O
.	O

It	O
is	O
well	O
established	O
that	O
neuroinflammation	O
plays	O
an	O
important	O
role	O
in	O
the	O
etiology	O
and/or	O
manifestation	O
of	O
such	O
disorders	O
.	O

Previously	O
,	O
we	O
discovered	O
that	O
beta-funaltrexamine	O
(	O
β-FNA	O
)	O
inhibits	O
inflammatory	O
signaling	O
in	O
human	O
astrocytes	O
in	O
vitro	O
,	O
resulting	O
in	O
reduced	O
expression	O
of	O
proinflammatory	O
cytokines	O
/	O
chemokines	O
.	O

The	O
present	O
study	O
examines	O
the	O
effects	O
of	O
peripherally	O
administered	O
β-FNA	O
on	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-induced	O
neuroinflammation	O
and	O
sickness	O
behavior	O
in	O
vivo	O
.	O

Adult	O
male	O
C57BL/6J	O
mice	O
were	O
administered	O
β-FNA	O
and	O
were	O
then	O
immediately	O
administered	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

At	O
24h	O
post-injections	O
,	O
sickness	O
behavior	O
was	O
assessed	O
in	O
an	O
open-field	O
test	O
.	O

Following	O
behavioral	O
analysis	O
plasma	O
and	O
brains	O
were	O
collected	O
.	O

Levels	O
of	O
interleukin-6	O
(	O
IL-6	O
)	O
,	O
interferon-γ	O
inducible	O
protein-10	O
(	O
CXCL10	O
)	O
,	O
and	O
monocyte	O
chemoattractant	O
protein-1	O
(	O
CCL2	O
)	O
were	O
determined	O
by	O
enzyme-linked	B-P
immunosorbant	I-P
assay	I-P
(	O
ELISA	B-P
)	O
.	O

At	O
24h	O
post-	O
LPS	O
injection	O
,	O
IL-6	O
,	O
CCL2	O
and	O
CXCL10	O
were	O
increased	O
in	O
the	O
plasma	O
,	O
whereas	O
,	O
only	O
CCL2	O
and	O
CXCL10	O
were	O
elevated	O
in	O
the	O
brain	O
.	O

β-FNA	O
significantly	O
inhibited	O
LPS	O
-induced	O
CXCL10	O
and	O
CCL2	O
expression	O
in	O
brain	O
,	O
but	O
minimally	O
or	O
not	O
at	O
all	O
in	O
the	O
plasma	O
.	O

LPS	O
-induced	O
sickness	O
behavior	O
,	O
as	O
indicated	O
by	O
a	O
reduction	O
in	O
distance	O
moved	O
,	O
was	O
prevented	O
by	O
β-FNA	O
.	O

Overall	O
,	O
CXCL10	O
expression	O
in	O
the	O
brain	O
was	O
most	O
positively	O
and	O
significantly	O
correlated	O
with	O
sickness	O
behavior	O
;	O
whereas	O
,	O
anxiety	O
-like	O
behavior	O
was	O
most	O
positively	O
and	O
significantly	O
correlated	O
with	O
IL-6	O
and	O
CCL2	O
levels	O
in	O
the	O
plasma	O
and	O
levels	O
of	O
CXCL10	O
and	O
CCL2	O
in	O
the	O
brain	O
.	O

The	O
reduction	O
in	O
sickness	O
behavior	O
may	O
be	O
in	O
part	O
due	O
to	O
decreased	O
chemokine	O
expression	O
in	O
the	O
brain	O
;	O
further	O
examination	O
of	O
the	O
anti-inflammatory	O
and	O
neuroprotective	O
effects	O
of	O
β-FNA	O
is	O
warranted	O
.	O

Inhibition	O
of	O
STEP61	O
ameliorates	O
deficits	O
in	O
mouse	O
and	O
hiPSC	O
-based	O
schizophrenia	O
models	O
.	O

The	O
brain	O
-	O
specific	O
tyrosine	O
phosphatase	O
,	O
STEP	O
(	O
STriatal-Enriched	O
protein	O
tyrosine	O
Phosphatase	O
)	O
is	O
an	O
important	O
regulator	O
of	O
synaptic	O
function	O
.	O

STEP	O
normally	O
opposes	O
synaptic	O
strengthening	O
by	O
increasing	O
N-methyl	O
D-aspartate	O
glutamate	O
receptor	O
(	O
NMDAR	O
)	O
internalization	O
through	O
dephosphorylation	O
of	O
GluN2B	O
and	O
inactivation	O
of	O
the	O
kinases	O
extracellular	O
signal-regulated	O
kinase	O
1	O
/	O
2	O
and	O
Fyn	O
.	O

Here	O
we	O
show	O
that	O
STEP61	O
is	O
elevated	O
in	O
the	O
cortex	O
in	O
the	O
Nrg1	O
(	O
+/-	O
)	O
knockout	O
mouse	O
model	O
of	O
schizophrenia	O
(	O
SZ	O
)	O
.	O

Genetic	O
reduction	O
or	O
pharmacological	O
inhibition	O
of	O
STEP	O
prevents	O
the	O
loss	O
of	O
NMDARs	O
from	O
synaptic	O
membranes	O
and	O
reverses	O
behavioral	O
deficits	O
in	O
Nrg1	O
(	O
+/-	O
)	O
mice	O
.	O

STEP61	O
protein	O
is	O
also	O
increased	O
in	O
cortical	O
lysates	O
from	O
the	O
central	O
nervous	O
system	O
-	O
specific	O
ErbB2	O
/	O
4	O
mouse	O
model	O
of	O
SZ	O
,	O
as	O
well	O
as	O
in	O
human	O
induced	O
pluripotent	O
stem	O
cell	O
(	O
hiPSC	O
)	O
-derived	O
forebrain	O
neurons	O
and	O
Ngn2	O
-	O
induced	O
excitatory	O
neurons	O
,	O
from	O
two	O
independent	O
SZ	O
patient	O
cohorts	O
.	O

In	O
these	O
selected	O
SZ	O
models	O
,	O
increased	O
STEP61	O
protein	B-P
levels	I-P
likely	O
reflect	O
reduced	O
ubiquitination	O
and	O
degradation	O
.	O

These	O
convergent	O
findings	O
from	O
mouse	O
and	O
hiPSC	O
SZ	O
models	O
provide	O
evidence	O
for	O
STEP61	O
dysfunction	O
in	O
SZ	O
.Molecular	O
Psychiatry	O
advance	O
online	O
publication	O
,	O
18	O
October	O
2016	O
;	O
doi:10.1038/mp.2016.163	O
.	O

Variant	O
2	O
of	O
KIAA0101	O
,	O
antagonizing	O
its	O
oncogenic	O
variant	O
1	O
,	O
might	O
be	O
a	O
potential	O
therapeutic	O
strategy	O
in	O
hepatocellular	O
carcinoma	O
.	O

Hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
is	O
one	O
of	O
the	O
most	O
lethal	O
malignant	O
tumors	O
worldwide	O
and	O
effective	O
therapies	O
,	O
including	O
molecular	O
therapy	O
,	O
remain	O
elusive	O
.	O

Our	O
previous	O
work	O
demonstrates	O
that	O
oncogenic	O
KIAA0101	O
transcript	O
variant	O
(	O
tv	O
)	O
1	O
promotes	O
HCC	O
development	O
and	O
might	O
be	O
a	O
HCC	O
therapeutic	O
target	O
.	O

However	O
,	O
the	O
function	O
of	O
another	O
KIAA0101	O
variant	O
,	O
KIAA0101	O
tv2	O
,	O
remains	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
reported	O
that	O
KIAA0101	O
tv2	O
was	O
highly	O
expressed	O
in	O
adjacent	O
non-tumorous	O
liver	O
tissues	O
(	O
NTs	O
)	O
compared	O
to	O
HCC	O
tissues	O
.	O

In	O
vivo	O
and	O
in	O
vitro	O
results	O
showed	O
that	O
KIAA0101	O
tv2	O
decreased	O
cell	O
survival	O
,	O
colony	O
formation	O
,	O
tumor	B-P
xenografts	I-P
,	O
migration	O
,	O
and	O
invasion	O
,	O
as	O
well	O
as	O
induced	O
cell	O
cycle	O
arrest	O
and	O
apoptosis	O
.	O

Interestingly	O
,	O
it	O
could	O
inhibit	O
the	O
function	O
of	O
KIAA0101	O
tv1	O
by	O
partially	O
down-regulating	O
KIAA0101	O
tv1	O
,	O
acting	O
similar	O
to	O
KIAA0101	O
tv1	O
short	O
hairpin	O
RNA	O
(	O
shRNA	O
)	O
.	O

Further	O
studies	O
illustrated	O
that	O
KIAA0101	O
tv2	O
could	O
increase	O
the	O
activity	O
of	O
p53	O
by	O
competing	O
with	O
KIAA0101	O
tv1	O
for	O
P53	O
binding	O
.	O

In	O
conclusion	O
,	O
KIAA0101	O
tv2	O
exerts	O
anti-tumor	O
activity	O
in	O
HCC	O
and	O
acts	O
as	O
an	O
endogenous	O
competitor	O
of	O
tumor-associated	O
KIAA0101	O
tv1	O
.	O

KIAA0101	O
tv2	O
has	O
a	O
potential	O
to	O
work	O
as	O
a	O
therapeutic	O
drug	O
targeting	O
the	O
KIAA0101	O
tv1	O
in	O
HCC	O
.	O

Stromal	O
alterations	O
in	O
ovarian	O
cancers	O
via	O
wavelength	O
dependent	O
Second	B-P
Harmonic	I-P
Generation	I-P
microscopy	I-P
and	O
optical	O
scattering	O
.	O

Ovarian	O
cancer	O
remains	O
the	O
most	O
deadly	O
gynecological	O
cancer	O
with	O
a	O
poor	O
aggregate	O
survival	O
rate	O
;	O
however	O
,	O
the	O
specific	O
rates	O
are	O
highly	O
dependent	O
on	O
the	O
stage	O
of	O
the	O
disease	O
upon	O
diagnosis	O
.	O

Current	O
screening	O
and	O
imaging	O
tools	O
are	O
insufficient	O
to	O
detect	O
early	O
lesions	O
and	O
are	O
not	O
capable	O
of	O
differentiating	O
the	O
subtypes	O
of	O
ovarian	O
cancer	O
that	O
may	O
benefit	O
from	O
specific	O
treatments	O
.	O

As	O
an	O
alternative	O
to	O
current	O
screening	O
and	O
imaging	O
tools	O
,	O
we	O
utilized	O
wavelength	O
dependent	O
collagen	O
-specific	O
Second	B-P
Harmonic	I-P
Generation	I-P
(	I-P
SHG	I-P
)	I-P
imaging	I-P
microscopy	I-P
and	O
optical	B-P
scattering	I-P
measurements	I-P
to	O
probe	O
the	O
structural	O
differences	O
in	O
the	O
extracellular	O
matrix	O
(	O
ECM	O
)	O
of	O
normal	O
stroma	O
,	O
benign	O
tumors	O
,	O
endometrioid	O
tumors	O
,	O
and	O
low	O
and	O
high-grade	O
serous	O
tumors	O
.	O

The	O
SHG	B-P
signatures	O
of	O
the	O
emission	O
directionality	O
and	O
conversion	O
efficiency	O
as	O
well	O
as	O
the	O
optical	O
scattering	O
are	O
related	O
to	O
the	O
organization	O
of	O
collagen	O
on	O
the	O
sub-micron	O
size	O
scale	O
and	O
encode	O
structural	O
information	O
.	O

The	O
wavelength	O
dependence	O
of	O
these	O
readouts	O
adds	O
additional	O
characterization	O
of	O
the	O
size	O
and	O
distribution	O
of	O
collagen	O
fibrils	O
/	O
fibers	O
relative	O
to	O
the	O
interrogating	O
wavelengths	O
.	O

We	O
found	O
a	O
strong	O
wavelength	O
dependence	O
of	O
these	O
metrics	O
that	O
are	O
related	O
to	O
significant	O
structural	O
differences	O
in	O
the	O
collagen	O
organization	O
and	O
are	O
consistent	O
with	O
the	O
dualistic	O
classification	O
of	O
type	O
I	O
and	O
II	O
serous	O
tumors	O
.	O

Moreover	O
,	O
type	O
I	O
endometrioid	O
tumors	O
have	O
strongly	O
differing	O
ECM	O
architecture	O
than	O
the	O
serous	O
malignancies	O
.	O

The	O
SHG	B-P
metrics	O
and	O
optical	B-P
scattering	I-P
measurements	I-P
were	O
used	O
to	O
form	O
a	O
linear	O
discriminant	O
model	O
to	O
classify	O
the	O
tissues	O
,	O
and	O
we	O
obtained	O
high	O
accuracy	O
(	O
>	O
90	O
%	O
)	O
between	O
high-grade	O
serous	O
tumors	O
from	O
the	O
other	O
tissue	O
types	O
.	O

High-grade	O
serous	O
tumors	O
account	O
for	O
~70	O
%	O
of	O
ovarian	O
cancers	O
,	O
and	O
this	O
delineation	O
has	O
potential	O
clinical	O
applications	O
in	O
terms	O
of	O
supplementing	O
histological	O
analysis	O
,	O
understanding	O
the	O
etiology	O
,	O
as	O
well	O
as	O
development	O
of	O
an	O
in	O
vivo	O
screening	O
tool	O
.	O

SHG	B-P
and	O
optical	B-P
scattering	I-P
measurements	I-P
provide	O
sub-resolution	O
information	O
and	O
when	O
combined	O
provide	O
superior	B-P
diagnostic	I-P
power	I-P
over	O
clinical	B-P
imaging	I-P
modalities	O
.	O

Additionally	O
the	O
measurements	O
are	O
able	O
to	O
delineate	O
the	O
different	O
subtypes	O
of	O
ovarian	O
cancer	O
and	O
may	O
potentially	O
assist	O
in	O
treatment	O
protocols	O
.	O

Understanding	O
the	O
altered	O
collagen	O
assembly	O
can	O
supplement	O
histological	O
analysis	O
and	O
provide	O
new	O
insight	O
into	O
the	O
etiology	O
.	O

These	O
methods	O
could	O
become	O
an	O
in	O
vivo	O
screening	O
tool	O
for	O
earlier	O
detection	O
which	O
is	O
important	O
since	O
ovarian	O
malignancies	O
can	O
metastasize	O
while	O
undetectable	O
by	O
current	O
clinical	B-P
imaging	I-P
resolution	O
.	O

Simultaneous	O
Bilateral	O
Cataract	O
Surgery	O
in	O
Outreach	O
Surgical	O
Camps	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
safety	O
and	O
visual	O
outcomes	O
of	O
simultaneous	O
bilateral	O
cataract	O
surgery	O
(	O
SBCS	O
)	O
with	O
intraocular	O
lens	O
implantation	O
performed	O
in	O
outreach	O
surgical	O
eye	O
camps	O
.	O

The	O
medical	O
records	O
of	O
47	O
consecutive	O
patients	O
who	O
underwent	O
simultaneous	O
bilateral	O
small-incision	O
cataract	O
surgery	O
between	O
January	O
2010	O
and	O
December	O
2015	O
in	O
outreach	O
surgical	O
camps	O
in	O
rural	O
Cameroon	O
were	O
reviewed	O
.	O

The	O
measures	O
included	O
postoperative	O
visual	O
outcomes	O
and	O
intraoperative	O
and	O
postoperative	O
complications	O
.	O

Data	O
from	O
94	O
eyes	O
of	O
47	O
participants	O
(	O
30	O
men	O
,	O
17	O
women	O
;	O
mean	O
age	O
:	O
60.93	O
±	O
13.58	O
years	O
,	O
range	O
:	O
45-80	O
years	O
)	O
were	O
included	O
in	O
this	O
study	O
.	O

The	O
presented	O
best	O
visual	O
acuity	O
(	O
VA	O
)	O
was	O
less	O
than	O
3/60	O
in	O
100	O
%	O
of	O
the	O
eyes	O
.	O

At	O
the	O
4-	O
week	O
follow-up	O
,	O
84.04	O
%	O
of	O
the	O
eyes	O
showed	O
increased	O
VA	O
of	O
1	O
line	O
or	O
more	O
(	O
P	O
=	O
.001	O
)	O
.	O

Of	O
these	O
,	O
71	O
(	O
75.53	O
%	O
)	O
achieved	O
good	O
VA	O
(	O
greater	O
than	O
6/18	O
)	O
.	O

Intraoperative	O
or	O
postoperative	O
complications	O
occurred	O
in	O
19	O
(	O
20.21	O
%	O
)	O
eyes	O
.	O

The	O
most	O
serious	O
intraoperative	O
complication	O
was	O
a	O
posterior	O
capsule	O
rupture	O
and	O
vitreous	O
loss	O
(	O
2	O
patients	O
,	O
2	O
eyes	O
)	O
.	O

The	O
postoperative	O
complications	O
included	O
a	O
transient	O
elevation	O
in	O
the	O
intraocular	O
pressure	O
(	O
6	O
eyes	O
)	O
,	O
chronic	O
corneal	O
oedema	O
(	O
5	O
eyes	O
)	O
,	O
iris	O
capture	O
(	O
3	O
eyes	O
)	O
,	O
lens	B-P
decentration	I-P
(	O
2	O
eyes	O
)	O
,	O
and	O
hyphema	O
(	O
1	O
eye	O
)	O
.	O

No	O
cases	O
of	O
postoperative	O
endophthalmitis	O
were	O
recorded	O
.	O

Under	O
the	O
strict	O
observation	O
of	O
endophthalmitis	O
prophylaxis	O
,	O
SBCS	O
is	O
an	O
option	O
to	O
reduce	O
the	O
cataract	O
blindness	O
backlog	O
in	O
rural	O
areas	O
of	O
developing	O
countries	O
.	O

The	O
evolutionary	O
history	O
of	O
bears	O
is	O
characterized	O
by	O
gene	O
flow	O
across	O
species	O
.	O

Bears	O
are	O
iconic	O
mammals	O
with	O
a	O
complex	O
evolutionary	O
history	O
.	O

Natural	O
bear	O
hybrids	O
and	O
studies	O
of	O
few	O
nuclear	O
genes	O
indicate	O
that	O
gene	O
flow	O
among	O
bears	O
may	O
be	O
more	O
common	O
than	O
expected	O
and	O
not	O
limited	O
to	O
polar	O
and	O
brown	O
bears	O
.	O

Here	O
we	O
present	O
a	O
genome	B-P
analysis	I-P
of	O
the	O
bear	O
family	O
with	O
representatives	O
of	O
all	O
living	O
species	O
.	O

Phylogenomic	O
analyses	O
of	O
869	O
mega	O
base	O
pairs	O
divided	O
into	O
18,621	O
genome	O
fragments	O
yielded	O
a	O
well-resolved	O
coalescent	O
species	O
tree	O
despite	O
signals	O
for	O
extensive	O
gene	O
flow	O
across	O
species	O
.	O

However	O
,	O
genome	B-P
analyses	I-P
using	O
different	O
statistical	O
methods	O
show	O
that	O
gene	O
flow	O
is	O
not	O
limited	O
to	O
closely	O
related	O
species	O
pairs	O
.	O

Strong	O
ancestral	O
gene	O
flow	O
between	O
the	O
Asiatic	O
black	O
bear	O
and	O
the	O
ancestor	O
to	O
polar	O
,	O
brown	O
and	O
American	O
black	O
bear	O
explains	O
uncertainties	O
in	O
reconstructing	O
the	O
bear	O
phylogeny	O
.	O

Gene	O
flow	O
across	O
the	O
bear	O
clade	O
may	O
be	O
mediated	O
by	O
intermediate	O
species	O
such	O
as	O
the	O
geographically	O
wide-spread	O
brown	O
bears	O
leading	O
to	O
large	O
amounts	O
of	O
phylogenetic	O
conflict	O
.	O

Genome-scale	B-P
analyses	I-P
lead	O
to	O
a	O
more	O
complete	O
understanding	O
of	O
complex	O
evolutionary	O
processes	O
.	O

Evidence	O
for	O
extensive	O
inter-specific	O
gene	O
flow	O
,	O
found	O
also	O
in	O
other	O
animal	O
species	O
,	O
necessitates	O
shifting	O
the	O
attention	O
from	O
speciation	O
processes	O
achieving	O
genome	O
-wide	O
reproductive	O
isolation	O
to	O
the	O
selective	O
processes	O
that	O
maintain	O
species	O
divergence	O
in	O
the	O
face	O
of	O
gene	O
flow	O
.	O

Chemisorption	O
of	O
Perfluorooctanoic	O
Acid	O
on	O
Powdered	O
Activated	O
Carbon	O
Initiated	O
by	O
Persulfate	O
in	O
Aqueous	O
Solution	O
.	O

Perfluorooctanoic	O
acid	O
(	O
PFOA	O
)	O
is	O
a	O
perfluorocarboxylic	O
acid	O
that	O
is	O
difficult	O
to	O
treat	O
by	O
most	O
conventional	O
methods	O
.	O

As	O
a	O
result	O
,	O
it	O
is	O
often	O
removed	O
from	O
solution	O
by	O
adsorption	B-P
on	O
powdered	O
activated	O
carbon	O
(	O
PAC	O
)	O
,	O
followed	O
by	O
incineration	O
of	O
the	O
spent	O
carbon	O
.	O

To	O
provide	O
a	O
new	O
approach	O
for	O
treatment	O
,	O
PFOA	O
was	O
exposed	O
to	O
sulfate	O
radicals	O
(	O
SO4	O
(	O
-•	O
)	O
)	O
produced	O
by	O
thermolysis	O
of	O
persulfate	O
(	O
S2O8	O
(	O
2-	O
)	O
)	O
in	O
the	O
presence	O
of	O
PAC	O
.	O

Under	O
acidic	O
conditions	O
,	O
thermal	O
activation	O
of	O
persulfate	O
resulted	O
in	O
transformation	O
of	O
PFOA	O
to	O
shorter-chain-length	O
perfluorinated	O
compounds	O
,	O
as	O
previously	O
reported	O
.	O

However	O
,	O
when	O
thermolysis	O
of	O
persulfate	O
occurred	O
under	O
circumneutral	O
pH	O
conditions	O
in	O
the	O
presence	O
of	O
PAC	O
,	O
a	O
new	O
removal	O
pathway	O
for	O
PFOA	O
was	O
observed	O
.	O

Under	O
these	O
conditions	O
,	O
the	O
removal	O
of	O
PFOA	O
was	O
attributable	O
to	O
chemisorption	O
,	O
a	O
process	O
in	O
which	O
PAC	O
catalyzed	O
persulfate	O
decomposition	O
and	O
reacted	O
with	O
the	O
transformation	O
products	O
to	O
produce	O
covalently	O
bound	O
PFOA	O
.	O

At	O
PAC	O
concentrations	O
between	O
200	O
and	O
1000	O
mg/L	O
and	O
an	O
initial	O
PFOA	O
concentration	O
of	O
0.5	O
μM	O
,	O
covalent	O
bonding	O
resulted	O
in	O
removal	O
of	O
10-40	O
%	O
of	O
the	O
PFOA	O
.	O

Under	O
these	O
conditions	O
,	O
the	O
process	O
resulted	O
in	O
removal	O
of	O
more	O
than	O
half	O
of	O
a	O
more	O
hydrophilic	O
perfluoroalkyl	O
acid	O
(	O
i.e.	O
,	O
perfluorobutanoic	O
acid	O
,	O
PFBA	O
)	O
,	O
which	O
was	O
greater	O
than	O
the	O
amount	O
of	O
PFBA	O
removed	O
by	O
physical	O
adsorption	B-P
on	O
PAC	O
.	O

Although	O
the	O
high	O
reaction	O
temperatures	O
(	O
i.e.	O
,	O
80	O
°C	O
)	O
and	O
relatively	O
high	O
doses	O
of	O
PAC	O
used	O
in	O
this	O
study	O
may	O
be	O
impractical	O
for	O
drinking	O
water	O
treatment	O
,	O
this	O
process	O
may	O
be	O
applied	O
to	O
the	O
treatment	O
of	O
these	O
recalcitrant	O
compounds	O
in	O
industrial	O
wastewater	O
,	O
reverse	O
osmosis	O
concentrate	O
,	O
and	O
other	O
waters	O
that	O
contain	O
high	O
concentrations	O
of	O
PFOA	O
and	O
other	O
perfluorocarboxylic	O
acids	O
.	O

Ulnar	O
Osteotomy	O
with	O
2-Pin	O
Unilateral	O
Gradual	O
Distraction	O
for	O
Treatment	O
of	O
Chronic	O
Monteggia	O
Fracture	O
:	O
A	O
Case	O
Report	O
.	O

Missed	O
Monteggia	O
fracture	O
leading	O
to	O
chronic	O
radial	O
head	O
dislocation	O
is	O
a	O
known	O
complication	O
.	O

The	O
surgical	O
treatment	O
options	O
remain	O
challenging	O
.	O

The	O
aim	O
of	O
treatment	O
is	O
to	O
reduce	O
the	O
radial	O
head	O
and	O
to	O
maintain	O
the	O
stability	O
of	O
the	O
elbow	O
in	O
all	O
ranges	O
of	O
motion	O
.	O

A	O
few	O
surgical	B-P
techniques	I-P
have	O
been	O
described	O
with	O
complications	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
13	O
years	O
old	O
boy	O
with	O
chronic	O
radial	O
head	O
dislocation	O
as	O
a	O
result	O
of	O
an	O
unrecognised	O
Monteggia	O
fracture	O
-	O
dislocation	O
for	O
eight	O
years	O
.	O

We	O
successfully	O
reduced	O
the	O
radial	O
head	O
and	O
corrected	O
the	O
cubital	O
valgus	O
from	O
45	O
degrees	O
to	O
10	O
degrees	O
with	O
a	O
proximal	O
ulna	O
osteotomy	O
and	O
gradual	O
distraction	O
with	O
2-pin	O
Monotube	O
external	O
fixator	O
.	O

The	O
correction	O
was	O
uneventful	O
with	O
good	O
functional	O
outcome	O
.	O

Personalized	O
Medicine	O
Approaches	O
in	O
Prostate	O
Cancer	O
Employing	O
Patient	O
Derived	O
3D	O
Organoids	O
and	O
Humanized	O
Mice	O
.	O

Prostate	O
cancer	O
(	O
PCa	O
)	O
is	O
the	O
most	O
common	O
malignancy	O
and	O
the	O
second	O
most	O
common	O
cause	O
of	O
cancer	O
death	O
in	O
Western	O
men	O
.	O

Despite	O
its	O
prevalence	O
,	O
PCa	O
has	O
proven	O
very	O
difficult	O
to	O
propagate	O
in	O
vitro	O
.	O

PCa	O
represents	O
a	O
complex	O
organ-like	O
multicellular	O
structure	O
maintained	O
by	O
the	O
dynamic	O
interaction	O
of	O
tumoral	O
cells	O
with	O
parenchymal	O
stroma	O
,	O
endothelial	O
and	O
immune	O
cells	O
,	O
and	O
components	O
of	O
the	O
extracellular	O
matrix	O
(	O
ECM	O
)	O
.	O

The	O
lack	O
of	O
PCa	O
models	O
that	O
recapitulate	O
this	O
intricate	O
system	O
has	O
hampered	O
progress	O
toward	O
understanding	O
disease	O
progression	O
and	O
lackluster	O
therapeutic	O
responses	O
.	O

Tissue	O
slices	O
,	O
monolayer	B-P
cultures	I-P
and	O
genetically	O
engineered	O
mouse	O
models	O
(	O
GEMM	O
)	O
fail	O
to	O
mimic	O
the	O
complexities	O
of	O
the	O
PCa	O
microenvironment	O
or	O
reproduce	O
the	O
diverse	O
mechanisms	O
of	O
therapy	O
resistance	O
.	O

Moreover	O
,	O
patient	O
derived	O
xenografts	O
(	O
PDXs	O
)	O
are	O
expensive	O
,	O
time	O
consuming	O
,	O
difficult	O
to	O
establish	O
for	O
prostate	O
cancer	O
,	O
lack	O
immune	O
cell-tumor	O
regulation	O
,	O
and	O
often	O
tumors	O
undergo	O
selective	O
engraftments	O
.	O

Here	O
,	O
we	O
describe	O
an	O
interdisciplinary	O
approach	O
using	O
primary	O
PCa	O
and	O
tumor	O
initiating	O
cells	O
(	O
TICs	O
)	O
,	O
three-dimensional	O
(	O
3D	O
)	O
tissue	O
engineering	O
,	O
genetic	B-P
and	O
morphometric	B-P
profiling	I-P
,	O
and	O
humanized	O
mice	O
to	O
generate	O
patient	O
-	O
derived	O
organoids	O
for	O
examining	O
personalized	O
therapeutic	O
responses	O
in	O
vitro	O
and	O
in	O
mice	O
co-engrafted	O
with	O
a	O
human	O
immune	O
system	O
(	O
HIS	O
)	O
,	O
employing	O
adaptive	O
T-cell-	O
and	O
chimeric	O
antigen	O
receptor-	O
(	O
CAR	O
)	O
immunotherapy	O
.	O

The	O
development	O
of	O
patient	O
specific	O
therapies	O
targeting	O
the	O
vulnerabilities	O
of	O
cancer	O
,	O
when	O
combined	O
with	O
antiproliferative	O
and	O
immunotherapy	O
approaches	O
could	O
help	O
to	O
achieve	O
the	O
full	O
transformative	O
power	O
of	O
cancer	O
precision	O
medicine	O
.	O

The	O
value	O
of	O
lacrimal	B-P
scintillography	I-P
in	O
the	O
assessment	O
of	O
patients	O
with	O
epiphora	O
.	O

PurposeTo	O
assess	O
the	O
influence	O
of	O
dacryoscintillography	B-P
(	O
DSG	B-P
)	O
on	O
the	O
treatment	O
decision	O
for	O
patients	O
with	O
epiphora	O
and	O
clinically	O
patent	O
non-functioning	O
lacrimal	O
systems	O
.MethodsA	O
retrospective	O
3-year	O
review	O
.	O

Inclusion	O
:	O
patients	O
having	O
DSG	B-P
for	O
epiphora	O
with	O
delayed	O
tear	O
clearance	O
,	O
lacrimal	O
system	O
patency	O
on	O
syringing	O
,	O
and	O
no	O
visible	O
external	O
cause	O
for	O
watering	O
.	O

On	O
the	O
basis	O
of	O
regurgitation	O
during	O
syringing	O
,	O
tear	O
ducts	O
were	O
divided	O
into	O
freely	O
patent	O
(	O
FP	O
≤20	O
%	O
)	O
or	O
stenosed	O
.	O

The	O
DSG	B-P
results	O
were	O
examined	O
for	O
correlation	O
with	O
symptoms	O
and	O
clinical	O
examination	O
,	O
the	O
influence	O
on	O
decision	O
to	O
proceed	O
to	O
dacryocystorhinostomy	O
(	O
DCR	O
)	O
,	O
and	O
the	O
ability	O
to	O
predict	O
the	O
surgical	O
outcome	O
.ResultsA	O
total	O
of	O
242	O
eyes	O
were	O
examined	O
.	O

The	O
clinical	B-P
diagnosis	I-P
was	O
FP	O
in	O
45.5	O
%	O
,	O
nasolacrimal	O
duct	O
stenosis	O
(	O
NLDS	O
)	O
in	O
26.4	O
%	O
,	O
and	O
other	O
in	O
3.3	O
%	O
.	O

The	O
DSG	B-P
was	O
normal	O
in	O
30.9	O
%	O
of	O
FP	O
and	O
18.7	O
%	O
of	O
NLDS	O
eyes	O
.	O

Of	O
the	O
asymptomatic	O
eyes	O
,	O
46.7	O
%	O
had	O
an	O
abnormal	O
DSG	B-P
.	O

DSG	B-P
sensitivity	O
was	O
73.6	O
%	O
and	O
specificity	O
53.3	O
%	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
DSG	B-P
results	O
in	O
those	O
with	O
FP	O
or	O
NLDS	O
.	O

DCR	O
was	O
recommended	O
in	O
39.1	O
%	O
of	O
the	O
symptomatic	O
eyes	O
with	O
abnormal	O
DSG	B-P
.	O

DCR	O
surgery	O
was	O
considered	O
inappropriate	O
in	O
all	O
46	O
eyes	O
with	O
normal	O
DSG	B-P
.	O

DCR	O
was	O
successful	O
in	O
76.5	O
%	O
,	O
however	O
,	O
the	O
DSG	B-P
result	O
did	O
not	O
affect	O
the	O
success	O
of	O
surgery	O
.Conclusion	O
DSG	B-P
has	O
severe	O
limitations	O
due	O
to	O
lack	O
of	O
correlation	O
with	O
symptoms	O
and	O
clinical	O
examination	O
,	O
inability	O
to	O
separate	O
lacrimal	O
duct	O
narrowing	O
from	O
lacrimal	O
pump	O
function	O
,	O
and	O
inability	O
to	O
predict	O
the	O
results	O
of	O
surgery	O
.	O

DSG	B-P
can	O
at	O
best	O
provide	O
limited	O
guidance	O
on	O
whether	O
to	O
proceed	O
to	O
DCR	O
surgery	O
.Eye	O
advance	O
online	O
publication	O
,	O
3	O
March	O
2017	O
;	O
doi:10.1038/eye.2017.20	O
.	O

Subcutaneous	O
cardioverter	O
defibrillator	O
has	O
longer	O
time	O
to	O
therapy	O
but	O
is	O
less	O
cardiotoxic	O
than	O
transvenous	O
cardioverter	O
defibrillator	O
.	O

Study	O
carried	O
out	O
in	O
a	O
preclinical	O
porcine	O
model	O
.	O

Totally	O
subcutaneous	O
implantable	O
cardioverter	O
defibrillator	O
(	O
S-ICD	O
)	O
delivers	O
higher	O
shock	O
energy	O
and	O
can	O
have	O
longer	O
time	O
to	O
therapy	O
compared	O
to	O
transvenous	O
implantable	O
cardioverter	O
defibrillator	O
(	O
T-ICD	O
)	O
.	O

Aim	O
of	O
the	O
study	O
was	O
to	O
compare	O
time	O
to	O
therapy	O
and	O
to	O
investigate	O
cardiac	O
,	O
cerebral	O
and	O
systemic	O
injuries	O
of	O
S-ICD	O
and	O
T-ICD	O
shocks	O
delivered	O
after	O
ventricular	O
fibrillation	O
(	O
VF	O
)	O
induction	O
.	O

Fourteen	O
pigs	O
were	O
randomly	O
implanted	O
with	O
a	O
S-ICD	O
(	O
n	O
=	O
7	O
)	O
or	O
a	O
T-ICD	O
(	O
n	O
=	O
7	O
)	O
.	O

Five	O
VF	O
episodes	O
were	O
induced	O
in	O
each	O
pig	O
.	O

For	O
each	O
VF	O
episode	O
,	O
up	O
to	O
two	O
shocks	O
could	O
be	O
delivered	O
by	O
the	O
T-ICD	O
or	O
the	O
S-ICD	O
to	O
terminate	O
the	O
arrhythmia	O
.	O

Cardiac	O
,	O
systemic	O
,	O
and	O
cerebral	O
toxicity	O
were	O
monitored	O
.	O

Mean	O
time	O
to	O
therapy	O
was	O
longer	O
in	O
the	O
S-ICD	O
group	O
compared	O
to	O
the	O
T-ICD	O
group	O
(	O
19	O
[	O
18	O
;	O
23	O
]	O
s	O
vs.	O
9	O
[	O
7	O
;	O
10	O
]	O
s	O
;	O
P	O
=	O
0.001	O
,	O
respectively	O
)	O
.	O

High-sensitivity	B-P
troponin	I-P
T	I-P
levels	O
were	O
significantly	O
higher	O
in	O
the	O
T-ICD	O
group	O
from	O
1	O
to	O
24	O
h	O
after	O
the	O
procedure	O
(	O
P	O
≤	O
0.02	O
)	O
.	O

Creatine	O
phosphokinase	O
activity	O
levels	O
were	O
significantly	O
higher	O
in	O
the	O
S-ICD	O
group	O
,	O
at	O
3	O
,	O
6	O
,	O
and	O
24	O
h	O
after	O
the	O
procedure	O
(	O
P	O
≤	O
0.05	O
)	O
.	O

Lactate	O
levels	O
were	O
not	O
significantly	O
different	O
between	O
groups	O
.	O

S100	O
protein	O
level	O
was	O
similar	O
in	O
both	O
groups	O
at	O
1	O
h	O
after	O
the	O
procedure	O
and	O
then	O
decreased	O
in	O
the	O
T-ICD	O
group	O
compared	O
to	O
the	O
S-ICD	O
group	O
(	O
P	O
=	O
0.04	O
)	O
.	O

Time	O
to	O
therapy	O
in	O
S-ICD	O
was	O
twice	O
as	O
long	O
as	O
for	O
T-ICD	O
,	O
but	O
did	O
n't	O
induce	O
relevant	O
brain	O
injury	O
.	O

Conversely	O
,	O
S-ICD	O
shocks	O
were	O
less	O
cardiotoxic	O
than	O
T-ICD	O
shocks	O
.	O

Two-stage	O
reconstructive	O
overlapping	O
stent	O
LEO+	O
and	O
SILK	O
for	O
treatment	O
of	O
intracranial	O
circumferential	O
fusiform	O
aneurysms	O
in	O
the	O
posterior	O
circulation	O
.	O

Intracranial	O
circumferential	O
fusiform	O
aneurysms	O
of	O
the	O
posterior	O
circulation	O
involving	O
arterial	O
branches	O
or	O
perforating	O
vessels	O
are	O
difficult	O
to	O
treat	O
.	O

This	O
article	O
shows	O
an	O
endovascular	O
reconstruction	O
technique	O
not	O
yet	O
described	O
,	O
using	O
a	O
telescoping	O
self-expandable	O
stent	O
(	O
LEO+	O
)	O
and	O
flow-diverter	O
device	O
(	O
SILK	O
)	O
at	O
different	O
surgical	O
times	O
.	O

Two	O
patients	O
with	O
circumferential	O
fusiform	O
aneurysm	O
,	O
one	O
being	O
an	O
aneurysm	O
of	O
the	O
segments	O
P2	O
and	O
P3	O
of	O
the	O
posterior	O
cerebral	O
artery	O
,	O
diagnosed	O
after	O
a	O
headache	O
,	O
and	O
the	O
other	O
a	O
partially	O
thrombosed	O
aneurysm	O
of	O
the	O
lower	O
basilar	O
artery	O
,	O
diagnosed	O
following	O
ischemia	O
of	O
the	O
brain	O
stem	O
.	O

Endovascular	O
treatment	O
was	O
performed	O
by	O
means	O
of	O
a	O
vascular	O
reconstruction	O
technique	O
that	O
used	O
at	O
different	O
surgical	O
times	O
:	O
overlapping	O
;	O
a	O
telescoped	O
self-expandable	O
stent	O
,	O
LEO+	O
;	O
and	O
a	O
flow-diverter	O
device	O
,	O
SILK	O
.	O

Angiographic	B-P
control	O
was	O
carried	O
out	O
at	O
6	O
and	O
12	O
months	O
,	O
to	O
evaluate	O
arterial	O
patency	O
,	O
flow	O
maintenance	O
in	O
the	O
arterial	O
branches	O
and	O
perforating	O
vessels	O
,	O
and	O
thrombosis	O
of	O
the	O
aneurysm	O
.	O

The	O
combined	O
use	O
at	O
different	O
surgical	O
times	O
of	O
the	O
self-expandable	O
stent	O
and	O
flow-diverter	O
device	O
was	O
technically	O
successful	O
in	O
both	O
patients	O
.	O

There	O
were	O
no	O
complications	O
during	O
the	O
procedure	O
,	O
nor	O
in	O
the	O
long-term	O
follow-up	O
with	O
full	O
arterial	O
vascular	O
reconstruction	O
,	O
maintenance	O
of	O
cerebral	O
perfusion	O
and	O
complete	O
aneurysm	O
occlusion	O
at	O
the	O
6-	O
and	O
12-	O
month	O
angiographic	B-P
follow-up	O
.	O

There	O
was	O
no	O
aneurysm	O
recanalization	O
nor	O
intra-stent	O
stenosis	O
.	O

Circumferential	O
fusiform	O
aneurysm	O
of	O
the	O
posterior	O
circulation	O
involving	O
arterial	O
branches	O
or	O
perforating	O
vessels	O
to	O
the	O
brain	O
stem	O
may	O
be	O
treated	O
with	O
this	O
arterial	O
reconstruction	O
technique	O
at	O
different	O
surgical	O
times	O
,	O
using	O
the	O
self-expandable	O
stent	O
called	O
LEO+	O
and	O
the	O
flow-diverter	O
device	O
SILK	O
,	O
minimizing	O
the	O
risk	O
of	O
complications	O
and	O
failure	O
of	O
the	O
endovascular	O
technique	O
,	O
with	O
the	O
potential	O
for	O
arterial	O
reconstruction	O
with	O
thrombosis	O
of	O
the	O
aneurysmatic	O
sac	O
,	O
as	O
well	O
as	O
flow	O
maintenance	O
in	O
the	O
eloquent	O
arteries	O
,	O
in	O
this	O
type	O
of	O
cerebral	O
aneurysm	O
.	O

Famous	O
faces	O
and	O
voices	O
:	O
Differential	O
profiles	O
in	O
early	O
right	O
and	O
left	O
semantic	O
dementia	O
and	O
in	O
Alzheimer	O
's	O
disease	O
.	O

Famous	O
face	O
and	O
voice	O
recognition	O
is	O
reported	O
to	O
be	O
impaired	O
both	O
in	O
semantic	O
dementia	O
(	O
SD	O
)	O
and	O
in	O
Alzheimer	O
's	O
Disease	O
(	O
AD	O
)	O
,	O
although	O
more	O
severely	O
in	O
the	O
former	O
.	O

In	O
AD	O
a	O
coexistence	O
of	O
perceptual	O
impairment	O
in	O
face	O
and	O
voice	O
processing	O
has	O
also	O
been	O
reported	O
and	O
this	O
could	O
contribute	O
to	O
the	O
altered	O
performance	O
in	O
complex	O
semantic	O
tasks	O
.	O

On	O
the	O
other	O
hand	O
,	O
in	O
SD	O
both	O
face	O
and	O
voice	O
recognition	O
disorders	O
could	O
be	O
related	O
to	O
the	O
prevalence	O
of	O
atrophy	O
in	O
the	O
right	O
temporal	O
lobe	O
(	O
RTL	O
)	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
twofold	O
:	O
(	O
1	O
)	O
to	O
investigate	O
famous	O
faces	O
and	O
voices	O
recognition	O
in	O
SD	O
and	O
AD	O
to	O
verify	O
if	O
the	O
two	O
diseases	O
show	O
a	O
differential	O
pattern	O
of	O
impairment	O
,	O
resulting	O
from	O
disruption	O
of	O
different	O
cognitive	O
mechanisms	O
;	O
(	O
2	O
)	O
to	O
check	O
if	O
face	O
and	O
voice	O
recognition	O
disorders	O
prevail	O
in	O
patients	O
with	O
atrophy	O
mainly	O
affecting	O
the	O
RTL	O
.	O

To	O
avoid	O
the	O
potential	O
influence	O
of	O
primary	O
perceptual	O
problems	O
in	O
face	O
and	O
voice	O
recognition	O
,	O
a	O
pool	O
of	O
patients	O
suffering	O
from	O
early	O
SD	O
and	O
AD	O
were	O
administered	O
a	O
detailed	O
set	O
of	O
tests	O
exploring	O
face	O
and	O
voice	O
perception	O
.	O

Thirteen	O
SD	O
(	O
8	O
with	O
prevalence	O
of	O
right	O
and	O
5	O
with	O
prevalence	O
of	O
left	O
temporal	O
atrophy	O
)	O
and	O
25	O
CE	O
patients	O
,	O
who	O
did	O
not	O
show	O
visual	O
and	O
auditory	O
perceptual	O
impairment	O
,	O
were	O
finally	O
selected	O
and	O
were	O
administered	O
an	O
experimental	O
battery	O
exploring	O
famous	O
face	O
and	O
voice	O
recognition	O
and	O
naming	O
.	O

Twelve	O
SD	O
patients	O
underwent	O
cerebral	O
PET	B-P
imaging	I-P
and	O
were	O
classified	O
in	O
right	O
and	O
left	O
SD	O
according	O
to	O
the	O
onset	O
modality	O
and	O
to	O
the	O
prevalent	O
decrease	O
in	O
FDG	O
uptake	O
in	O
right	O
or	O
left	O
temporal	O
lobe	O
respectively	O
.	O

Correlation	O
of	O
PET	B-P
imaging	I-P
and	O
famous	O
face	O
and	O
voice	O
recognition	O
was	O
performed	O
.	O

Results	O
showed	O
a	O
differential	O
performance	O
profile	O
in	O
the	O
two	O
diseases	O
,	O
because	O
AD	O
patients	O
were	O
significantly	O
impaired	O
in	O
the	O
naming	O
tests	O
,	O
but	O
showed	O
preserved	O
recognition	O
,	O
whereas	O
SD	O
patients	O
were	O
profoundly	O
impaired	O
both	O
in	O
naming	O
and	O
in	O
recognition	O
of	O
famous	O
faces	O
and	O
voices	O
.	O

Furthermore	O
,	O
face	O
and	O
voice	O
recognition	O
disorders	O
prevailed	O
in	O
SD	O
patients	O
with	O
RTL	O
atrophy	O
,	O
who	O
also	O
showed	O
a	O
conceptual	O
impairment	O
on	O
the	O
Pyramids	O
and	O
Palm	O
Trees	O
test	O
more	O
important	O
in	O
the	O
pictorial	O
than	O
in	O
the	O
verbal	O
modality	O
.	O

Finally	O
,	O
in	O
12	O
SD	O
patients	O
in	O
whom	O
PET	B-P
was	O
available	O
,	O
a	O
strong	O
correlation	O
between	O
FDG	O
uptake	O
and	O
face-to-name	O
and	O
voice-to-name	O
matching	O
data	O
was	O
found	O
in	O
the	O
right	O
but	O
not	O
in	O
the	O
left	O
temporal	O
lobe	O
.	O

The	O
data	O
support	O
the	O
hypothesis	O
of	O
a	O
different	O
cognitive	O
basis	O
for	O
impairment	O
of	O
face	O
and	O
voice	O
recognition	O
in	O
the	O
two	O
dementias	O
and	O
suggest	O
that	O
the	O
pattern	O
of	O
impairment	O
in	O
SD	O
may	O
be	O
due	O
to	O
a	O
loss	O
of	O
semantic	O
representations	O
,	O
while	O
a	O
defect	O
of	O
semantic	O
control	O
,	O
with	O
impaired	O
naming	O
and	O
preserved	O
recognition	O
might	O
be	O
hypothesized	O
in	O
AD	O
.	O

Furthermore	O
,	O
the	O
correlation	O
between	O
face	O
and	O
voice	O
recognition	O
disorders	O
and	O
RTL	O
damage	O
are	O
consistent	O
with	O
the	O
hypothesis	O
assuming	O
that	O
in	O
the	O
RTL	O
person	O
-specific	O
knowledge	O
may	O
be	O
mainly	O
based	O
upon	O
non-verbal	O
representations	O
.	O

Water	O
pollution	O
causes	O
ultrastructural	O
and	O
functional	O
damages	O
in	O
Pellia	O
neesiana	O
(	O
Gottsche	O
)	O
Limpr	O
.	O

The	O
aim	O
of	O
this	O
work	O
is	O
to	O
evaluate	O
the	O
effects	O
of	O
freshwater	O
pollution	O
in	O
the	O
heavily	O
contaminated	O
Sarno	O
River	O
(	O
Campania	O
,	O
South	O
Italy	O
)	O
,	O
using	O
Pellia	O
neesiana	O
(	O
Pelliaceae	O
Metzgeriales	O
)	O
in	O
order	O
to	O
propose	O
this	O
liverwort	O
as	O
a	O
potential	O
bioindicator	O
,	O
able	O
to	O
record	O
the	O
effects	O
of	O
water	O
pollution	O
,	O
particularly	O
the	O
one	O
related	O
to	O
metal	O
(	O
loid	O
)	O
contamination	O
.	O

Samples	O
of	O
P.	O
neesiana	O
in	O
nylon	O
bags	O
were	O
disposed	O
floating	O
for	O
one	O
week	O
on	O
the	O
waters	O
of	O
Sarno	O
River	O
in	O
three	O
sites	O
characterised	O
by	O
an	O
increasing	O
pollution	O
.	O

As	O
control	O
,	O
some	O
specimens	O
were	O
cultured	B-P
in	O
vitro	O
in	O
Cd	O
-	O
and	O
Pb	O
-added	O
media	O
,	O
at	O
the	O
same	O
pollutants	O
'	O
levels	O
as	O
measured	O
in	O
the	O
most	O
polluted	O
site	O
.	O

P.	O
neesiana	O
cell	O
ultrastructure	O
was	O
modified	O
and	O
severe	O
alterations	O
were	O
observed	O
in	O
chloroplasts	O
from	O
samples	O
exposed	O
in	O
the	O
most	O
polluted	O
site	O
,	O
and	O
Cd	O
-	O
and	O
Pb	O
-	O
cultured	B-P
samples	I-P
.	O

Concurrently	O
,	O
a	O
strong	O
increase	O
in	O
the	O
occurrence	O
of	O
Heat	O
shock	O
proteins	O
70	O
(	O
HSP70	O
)	O
was	O
detected	O
in	O
gametophytes	O
following	O
the	O
pollution	O
gradient	O
.	O

In	O
conclusion	O
,	O
ultrastructural	O
damages	O
can	O
be	O
directly	O
related	O
to	O
HSP	O
70	O
occurrence	O
in	O
liverwort	O
tissues	O
,	O
and	O
proportional	O
to	O
the	O
degree	O
of	O
pollution	O
present	O
in	O
the	O
river	O
;	O
thus	O
our	O
study	O
suggests	O
P.	O
neesiana	O
as	O
an	O
affordable	O
bioindicator	O
of	O
freshwaters	O
pollution	O
.	O

PRESENCE	O
OF	O
CITRININ	O
IN	O
GRAINS	O
AND	O
ITS	O
POSSIBLE	O
HEALTH	O
EFFECTS	O
.	O

Citrinin	O
is	O
a	O
mycotoxin	O
produced	O
by	O
several	O
species	O
of	O
the	O
genera	O
Aspergillus	O
,	O
Penicillium	O
and	O
Monascus	O
and	O
it	O
occurs	O
mainly	O
in	O
stored	O
grain	O
.	O

Citrinin	O
is	O
generally	O
formed	O
after	O
harvest	O
and	O
occurs	O
mainly	O
in	O
stored	O
grains	O
,	O
it	O
also	O
occurs	O
in	O
other	O
plant	O
products	O
.	O

Often	O
,	O
the	O
co-occurrence	O
with	O
other	O
mycotoxins	O
is	O
observed	O
,	O
especially	O
ochratoxin	O
A	O
,	O
which	O
is	O
usually	O
associated	O
with	O
endemic	O
nephropathy	O
.	O

At	O
the	O
European	O
Union	O
level	O
,	O
systematic	O
monitoring	O
of	O
Citrinin	O
in	O
grains	O
began	O
with	O
the	O
aim	O
of	O
determining	O
its	O
highest	O
permissible	O
amount	O
in	O
food	O
.	O

Thus	O
,	O
far	O
the	O
systematic	O
monitoring	O
of	O
the	O
above	O
mentioned	O
mycotoxin	O
in	O
Croatia	O
is	O
yet	O
to	O
begin	O
.	O

The	O
main	O
goal	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
presence	O
of	O
Citrinin	O
in	O
grains	O
sampled	O
in	O
the	O
area	O
of	O
Međimurje	O
,	O
Osijek-Baranja	O
,	O
Vukovar-Srijem	O
and	O
Brod-Posavina	O
County	O
.	O

For	O
the	O
purpose	O
of	O
identification	O
and	O
quantification	O
of	O
citrinin	O
,	O
high	B-P
performance	I-P
liquid	I-P
chromatograph	I-P
(	I-P
HPLC	I-P
)	I-P
with	I-P
fluorescence	I-P
was	O
used	O
(	O
Calibration	O
curve	O
k	O
>	O
0.999	O
;	O
Intra	O
assay	O
CV	O
=	O
2.1	O
%	O
;	O
Inter	O
assay	O
CV	O
=	O
4.3	O
%	O
;	O
LOQ	O
<	O
1	O
μg/kg	O
)	O
.	O

From	O
the	O
area	O
of	O
Međimurje	O
County	O
,	O
10	O
samples	O
of	O
corn	O
and	O
10	O
samples	O
of	O
wheat	O
were	O
analyzed	O
.	O

None	O
of	O
the	O
samples	O
contained	O
Citrinin	O
(	O
<	O
1	O
μg/kg	O
)	O
.	O

From	O
the	O
area	O
of	O
Osijek-Baranja	O
and	O
Vukovar-Srijem	O
County	O
,	O
15	O
samples	O
from	O
each	O
County	O
were	O
analyzed	O
.	O

The	O
mean	O
value	O
for	O
the	O
samples	O
of	O
Osijek-Baranja	O
County	O
was	O
19.63	O
μg/kg	O
(	O
median	O
=15.8	O
μg/kg	O
)	O
,	O
while	O
for	O
Vukovar-Srijem	O
County	O
the	O
mean	O
value	O
of	O
citrinin	O
was	O
14,6	O
μg/kg	O
(	O
median	O
=1.23	O
μg/kg	O
)	O
.	O

From	O
5	O
analyzed	O
samples	O
from	O
Brod-Posavina	O
County	O
,	O
one	O
of	O
the	O
samples	O
contained	O
citrinin	O
in	O
the	O
amount	O
of	O
23.8	O
μg/kg	O
,	O
while	O
the	O
registered	O
amount	O
s	O
in	O
the	O
other	O
samples	O
were	O
<	O
1	O
μg/kg	O
.	O

The	O
results	O
show	O
that	O
grains	O
from	O
several	O
Counties	O
contain	O
certain	O
amounts	O
of	O
Citrinin	O
possibly	O
indicating	O
a	O
significant	O
intake	O
of	O
citrinin	O
in	O
humans	O
.	O

It	O
must	O
be	O
stated	O
that	O
grains	O
and	O
grain-based	O
products	O
are	O
the	O
basis	O
of	O
everyday	O
diet	O
of	O
all	O
age	O
groups	O
,	O
especially	O
small	O
children	O
,	O
where	O
higher	O
intake	O
of	O
citrinin	O
can	O
occur	O
.	O

Consequently	O
,	O
we	O
emphasize	O
the	O
need	O
for	O
systematic	O
analysis	O
of	O
larger	O
amount	O
of	O
samples	O
,	O
from	O
both	O
large	O
grains	O
and	O
small	O
grains	O
,	O
especially	O
in	O
the	O
area	O
of	O
Brod-Posavina	O
County	O
,	O
in	O
order	O
to	O
obtain	O
more	O
realistic	O
notion	O
of	O
citrinin	O
contamination	O
of	O
grains	O
and	O
to	O
asses	O
the	O
health	O
risk	O
in	O
humans	O
.	O

Transforming	O
Growth	O
Factor	O
Beta	O
1	O
(	O
TGF-β1	O
)	O
in	O
Thyroid	O
Cancer	O
Patients	O
:	O
a	O
View	O
from	O
the	O
Peripheral	O
Blood	O
.	O

Transforming	O
growth	O
factor	O
beta	O
(	O
TGF-β	O
)	O
plays	O
an	O
important	O
role	O
in	O
many	O
pathophysiological	O
conditions	O
,	O
including	O
cancer	O
.	O

The	O
level	O
of	O
TGF-β	O
in	O
patients	O
with	O
differentiated	O
thyroid	O
cancer	O
(	O
DTC	O
)	O
has	O
not	O
been	O
examined	O
so	O
far	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
measure	O
TGF-β	O
concentration	O
in	O
serum	O
samples	O
and	O
in	O
PHA	O
-	O
stimulated	O
whole	O
blood	O
culture	B-P
in	O
vitro	O
and	O
to	O
analyze	O
possible	O
associations	O
of	O
TGF-β1	O
levels	O
with	O
leukocyte	O
,	O
lymphocyte	O
and	O
platelets	O
counts	B-P
,	O
the	O
histological	O
type	O
of	O
thyroid	O
cancer	O
,	O
and	O
stage	B-P
of	I-P
disease	I-P
.	O

TGF-β1	O
was	O
measured	O
in	O
22	O
DTC	O
patients	O
and	O
20	O
healthy	O
controls	O
using	O
the	O
duoSet	O
ELISA	O
Development	O
kit	O
for	O
human	O
TGF-β1	O
.	O

The	O
concentration	O
of	O
TGF-β1	O
in	O
serum	O
samples	O
from	O
both	O
groups	O
correlated	O
positively	O
with	O
the	O
platelet	O
counts	B-P
.	O

There	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
the	O
serum	O
concentrations	O
of	O
TGF-β1	O
between	O
DTC	O
patients	O
and	O
control	O
subjects	O
,	O
but	O
PHA	O
stimulated	O
whole	O
blood	O
cultures	B-P
of	O
DTC	O
patients	O
produced	O
less	O
TGF-β1	O
than	O
those	O
from	O
controls	O
.	O

Additional	O
studies	O
are	O
needed	O
to	O
determine	O
the	O
significance	O
of	O
these	O
in	O
vitro	O
findings	O
.	O

Suicidal	O
thoughts	O
and	O
behaviors	O
in	O
psychiatrically	O
referred	O
young	O
children	O
.	O

Despite	O
increased	O
awareness	O
of	O
the	O
prevalence	O
and	O
seriousness	O
of	O
mental	O
health	O
problems	O
in	O
early	O
childhood	O
,	O
there	O
have	O
been	O
few	O
empirical	O
studies	O
of	O
suicidal	O
thoughts	O
and	O
behaviors	O
in	O
this	O
age	O
group	O
.	O

This	O
study	O
examined	O
suicidal	O
thoughts	O
and	O
behaviors	O
in	O
360	O
preschool-aged	O
children	O
(	O
ages	O
3	O
to	O
7	O
years	O
)	O
presenting	O
to	O
a	O
psychiatric	O
day	O
treatment	O
program	O
.	O

A	O
semi-structured	B-P
diagnostic	I-P
interview	I-P
(	O
conducted	O
with	O
primary	O
caregivers	O
)	O
was	O
used	O
to	O
assess	O
for	O
child	O
suicidal	O
thoughts	O
and	O
behaviors	O
and	O
psychiatric	O
disorders	O
.	O

Participating	O
mothers	O
also	O
reported	O
on	O
their	O
own	O
psychological	O
distress	O
and	O
family	O
psychiatric	O
history	O
.	O

Forty-eight	O
children	O
(	O
13	O
%	O
)	O
were	O
reported	O
to	O
have	O
suicidal	O
thoughts	O
and	O
behaviors	O
,	O
with	O
suicidal	O
plans	O
or	O
attempts	O
endorsed	O
for	O
2-3	O
%	O
of	O
the	O
sample	O
.	O

Suicidal	O
thinking	O
and	O
behavior	O
was	O
associated	O
with	O
older	O
child	O
age	O
and	O
with	O
higher	O
rates	O
of	O
concurrent	O
depression	O
,	O
oppositional	O
defiant	O
disorder	O
,	O
and	O
posttraumatic	O
stress	O
disorder	O
in	O
univariate	O
analyses	O
,	O
with	O
age	O
and	O
depression	O
remaining	O
as	O
significant	O
predictors	O
in	O
a	O
multivariate	O
logistic	O
regression	O
model	O
.	O

Findings	O
suggest	O
that	O
suicidal	O
thoughts	O
and	O
behaviors	O
are	O
a	O
significant	O
clinical	O
concern	O
for	O
young	O
children	O
presenting	O
with	O
early	O
psychopathology	O
,	O
particularly	O
depression	O
,	O
with	O
implications	O
for	O
early	O
childhood	O
psychiatric	B-P
assessment	I-P
and	O
treatment	O
.	O

Formation	O
of	O
an	O
Intraretinal	O
Fluid	O
Barrier	O
in	O
Cavitary	O
Optic	O
Disc	O
Maculopathy	O
.	O

Cavitary	O
optic	O
disc	O
maculopathy	O
develops	O
when	O
fluctuating	O
pressure	O
gradients	O
along	O
anomalous	O
communications	O
in	O
the	O
optic	O
nerve	O
head	O
induce	O
migration	O
of	O
fluid	O
into	O
the	O
adjacent	O
retinal	O
tissue	O
.	O

We	O
sought	O
to	O
determine	O
whether	O
carefully	O
titrated	O
laser	O
photocoagulation	O
combined	O
with	O
vitrectomy	O
and	O
gas	O
tamponade	O
can	O
safely	O
create	O
an	O
effective	O
intraretinal	O
barrier	O
to	O
fluid	O
egress	O
from	O
the	O
optic	O
disc	O
cavitation	O
.	O

Retrospective	O
interventional	O
case	O
series	O
.	O

We	O
retrospectively	O
evaluated	O
medical	O
records	O
and	O
imaging	B-P
studies	I-P
of	O
22	O
consecutive	O
patients	O
with	O
cavitary	O
disc	O
maculopathy	O
evaluated	O
by	O
a	O
single	O
surgeon	O
between	O
1991	O
and	O
2014	O
.	O

Patients	O
requiring	O
surgery	O
underwent	O
carefully	O
titrated	O
juxtapapillary	O
laser	O
photocoagulation	O
followed	O
immediately	O
by	O
vitrectomy	O
and	O
gas	O
tamponade	O
.	O

Main	O
outcome	O
measures	O
were	O
change	O
in	O
visual	O
acuity	O
,	O
macular	O
fluid	O
resolution	O
,	O
and	O
recurrence	O
of	O
maculopathy	O
.	O

Eleven	O
patients	O
(	O
11	O
eyes	O
)	O
had	O
undergone	O
vitreous	O
surgery	O
and	O
were	O
included	O
in	O
the	O
study	O
.	O

No	O
preoperative	O
evidence	O
for	O
vitreous	O
traction	O
on	O
the	O
optic	O
disc	O
or	O
macula	O
was	O
seen	O
in	O
any	O
eye	O
.	O

Nine	O
patients	O
underwent	O
a	O
single	O
surgery	O
and	O
2	O
patients	O
required	O
additional	O
procedures	O
to	O
resolve	O
the	O
macular	O
fluid	O
.	O

Mean	O
length	O
of	O
follow-up	O
after	O
the	O
last	O
surgery	O
was	O
48.2	O
months	O
(	O
range	O
,	O
4-143	O
months	O
)	O
.	O

All	O
11	O
patients	O
(	O
100	O
%	O
)	O
had	O
complete	O
resolution	O
of	O
macular	O
fluid	O
,	O
with	O
an	O
average	O
time	O
to	O
resolution	O
of	O
8.5	O
months	O
(	O
range	O
,	O
1-18	O
months	O
)	O
.	O

Only	O
1	O
of	O
11	O
patients	O
(	O
9	O
%	O
)	O
had	O
recurrence	O
of	O
macular	O
fluid	O
(	O
14	O
months	O
postoperatively	O
)	O
.	O

The	O
average	O
preoperative	O
visual	O
acuity	O
of	O
20/125	O
(	O
logMAR	O
0.81	O
,	O
standard	O
deviation	O
[	O
SD	O
]	O
=	O
0.36	O
)	O
improved	O
by	O
nearly	O
4	O
lines	O
to	O
an	O
average	O
final	O
visual	O
acuity	O
of	O
20/57	O
(	O
logMAR	O
0.45	O
,	O
SD	O
=	O
0.37	O
)	O
(	O
P	O
=	O
.0072	O
)	O
.	O

A	O
possible	O
laser	O
-	O
induced	O
central	O
scotoma	O
was	O
suspected	O
in	O
only	O
1	O
patient	O
who	O
had	O
undergone	O
extensive	O
prior	O
laser	O
treatments	O
.	O

An	O
effective	O
intraretinal	O
barrier	O
to	O
fluid	O
migration	O
from	O
cavitary	O
optic	O
disc	O
anomalies	O
can	O
be	O
safely	O
achieved	O
in	O
most	O
patients	O
with	O
carefully	O
titrated	O
juxtapapillary	O
laser	O
photocoagulation	O
combined	O
with	O
vitrectomy	O
and	O
gas	O
tamponade	O
.	O

Once	O
achieved	O
,	O
the	O
barrier	O
facilitates	O
resolution	O
of	O
macular	O
fluid	O
and	O
long-term	O
avoidance	O
of	O
recurrent	O
maculopathy	O
.	O

The	O
nanocomposite	O
nature	O
of	O
bone	O
drives	O
its	O
strength	O
and	O
damage	O
resistance	O
.	O

In	O
human	O
bone	O
,	O
an	O
amorphous	O
mineral	O
serves	O
as	O
a	O
precursor	O
to	O
the	O
formation	O
of	O
a	O
highly	O
substituted	O
nanocrystalline	O
apatite	O
.	O

However	O
,	O
the	O
precise	O
role	O
of	O
this	O
amorphous	O
mineral	O
remains	O
unknown	O
.	O

Here	O
,	O
we	O
show	O
by	O
using	O
transmission	B-P
electron	I-P
microscopy	I-P
that	O
100-300	O
nm	O
amorphous	O
calcium	O
phosphate	O
regions	O
are	O
present	O
in	O
the	O
disordered	O
phase	O
of	O
trabecular	O
bone	O
.	O

Nanomechanical	O
experiments	O
on	O
cylindrical	O
samples	O
,	O
with	O
diameters	O
between	O
250	O
nm	O
and	O
3,000	O
nm	O
,	O
of	O
the	O
bone	O
's	O
ordered	O
and	O
disordered	O
phases	O
revealed	O
a	O
transition	O
from	O
plastic	O
deformation	O
to	O
brittle	O
failure	O
and	O
at	O
least	O
a	O
factor-of-2	O
higher	O
strength	O
in	O
the	O
smaller	O
samples	O
.	O

We	O
postulate	O
that	O
this	O
transition	O
in	O
failure	O
mechanism	O
is	O
caused	O
by	O
the	O
suppression	O
of	O
extrafibrillar	O
shearing	O
in	O
the	O
smaller	O
samples	O
,	O
and	O
that	O
the	O
emergent	O
smaller	O
-is-	O
stronger	O
size	O
effect	O
is	O
related	O
to	O
the	O
sample-size	O
scaling	O
of	O
the	O
distribution	O
of	O
flaws	O
.	O

Our	O
findings	O
should	O
help	O
in	O
the	O
understanding	O
of	O
the	O
multi-scale	O
nature	O
of	O
bone	O
and	O
provide	O
insights	O
into	O
the	O
biomineralization	O
process	O
.	O

Challenging	O
Achievement	O
of	O
Bidirectional	O
Block	O
After	O
Linear	O
Ablation	O
Affects	O
the	O
Rhythm	O
Outcome	O
in	O
Patients	O
With	O
Persistent	O
Atrial	O
Fibrillation	O
.	O

It	O
is	O
not	O
clear	O
whether	O
bidirectional	O
block	O
(	O
BDB	O
)	O
of	O
linear	O
ablations	O
reduces	O
atrial	O
fibrillation	O
(	O
AF	O
)	O
recurrence	O
after	O
radiofrequency	O
catheter	O
ablation	O
.	O

We	O
hypothesized	O
that	O
BDB	O
of	O
linear	O
ablation	O
has	O
prognostic	O
significance	O
after	O
radiofrequency	O
catheter	O
ablation	O
for	O
persistent	O
AF	O
.	O

Among	O
1793	O
consecutive	O
patients	O
in	O
the	O
Yonsei	O
AF	O
ablation	O
cohort	O
,	O
this	O
observational	O
cohort	O
study	O
included	O
398	O
patients	O
with	O
persistent	O
AF	O
(	O
75.6	O
%	O
male	O
;	O
age	O
,	O
59.8±10.3	O
years	O
)	O
who	O
underwent	O
catheter	O
ablation	O
with	O
a	O
consistent	O
ablation	O
protocol	O
of	O
the	O
Dallas	O
lesion	O
set	O
:	O
circumferential	O
pulmonary	O
vein	O
isolation	O
;	O
cavotricuspid	O
isthmus	O
ablation	O
(	O
CTI	O
)	O
;	O
roof	O
line	O
(	O
RL	O
)	O
;	O
posterior-inferior	O
line	O
(	O
PIL	O
)	O
;	O
and	O
anterior	O
line	O
(	O
AL	O
)	O
.	O

BDB	O
rates	O
of	O
de	O
novo	O
ablation	O
lines	O
were	O
100	O
%	O
in	O
circumferential	O
pulmonary	O
vein	O
isolation	O
,	O
100	O
%	O
in	O
CTI	O
,	O
84.7	O
%	O
in	O
RL	O
,	O
44.7	O
%	O
in	O
PIL	O
,	O
and	O
63.6	O
%	O
in	O
AL	O
.	O

During	O
29.0±18.4	O
months	O
of	O
follow-up	O
,	O
31.7	O
%	O
(	O
126/398	O
)	O
of	O
the	O
patients	O
showed	O
clinical	O
recurrence	O
.	O

Left	O
atrial	O
posterior	O
wall	O
(	O
LAPW	O
)	O
isolation	O
(	O
BDBs	O
of	O
RL	O
and	O
PIL	O
)	O
was	O
independently	O
associated	O
with	O
lower	O
clinical	O
AF	O
/	O
atrial	O
tachycardia	O
recurrence	O
(	O
hazard	O
ratio	O
,	O
0.68	O
;	O
95	O
%	O
CI	O
,	O
0.47-0.98	O
;	O
P=0.041	O
;	O
log-rank	O
,	O
P=0.017	O
)	O
,	O
whereas	O
BDBs	O
of	O
RL	O
or	O
AL	O
were	O
not	O
(	O
log-rank	O
,	O
P=0.178	O
for	O
RL	O
;	O
P=0.764	O
for	O
AL	O
)	O
.	O

Among	O
52	O
patients	O
who	O
underwent	O
repeat	O
procedures	O
(	O
23.0±16.1	O
months	O
after	O
de	B-P
novo	I-P
procedure	I-P
)	O
,	O
the	O
BDB	O
maintenance	O
rates	O
for	O
CTI	O
,	O
RL	O
,	O
PIL	O
,	O
and	O
AL	O
were	O
94.2	O
%	O
(	O
49	O
of	O
52	O
)	O
,	O
63.5	O
%	O
(	O
33	O
of	O
47	O
)	O
,	O
62.1	O
%	O
(	O
18	O
of	O
29	O
)	O
,	O
and	O
61.8	O
%	O
(	O
21	O
of	O
34	O
)	O
,	O
respectively	O
.	O

Although	O
PIL	O
crosses	O
the	O
esophageal	O
contact	O
area	O
,	O
LAPW	O
isolation	O
is	O
important	O
for	O
better	O
clinical	O
outcome	O
in	O
catheter	O
ablation	O
with	O
a	O
linear	O
ablation	O
strategy	O
for	O
patients	O
with	O
persistent	O
AF	O
.	O

Quercetin	O
attenuates	O
high	O
fructose	O
feeding	O
-	O
induced	O
atherosclerosis	O
by	O
suppressing	O
inflammation	O
and	O
apoptosis	O
via	O
ROS	O
-	O
regulated	O
PI3K/AKT	O
signaling	O
pathway	O
.	O

Quercetin	O
is	O
a	O
dietary	O
flavonoid	O
compound	O
extracted	O
from	O
various	O
plants	O
,	O
such	O
as	O
apple	O
and	O
onions	O
.	O

Previous	O
studies	O
have	O
revealed	O
its	O
anti-inflammatory	O
,	O
anti-cancer	O
,	O
antioxidant	O
and	O
anti-apoptotic	O
activities	O
.	O

This	O
study	O
investigated	O
the	O
ability	O
of	O
quercetin	O
to	O
inhibit	O
high	O
fructose	O
feeding	O
-	O
or	O
LPS	O
-	O
induced	O
atherosclerosis	O
through	O
regulating	O
oxidative	O
stress	O
,	O
apoptosis	O
and	O
inflammation	O
response	O
in	O
vivo	O
and	O
in	O
vitro	O
experiments	O
.	O

50	O
and	O
100mg/kg	O
quercetin	O
were	O
used	O
in	O
our	O
study	O
,	O
showing	O
significant	O
inhibitory	O
role	O
in	O
high	O
fructose	O
-	O
induced	O
atherosclerosis	O
via	O
reducing	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
levels	O
,	O
Caspase-3	O
activation	O
,	O
inflammatory	O
cytokines	O
releasing	O
,	O
the	O
number	O
of	O
terminal	O
deoxynucleotidyl	O
transferase	O
-mediated	O
dUTP	O
nick	O
end-labeling	O
(	O
TUNEL	O
)	O
-	O
positive	O
cells	O
and	O
collagen	O
contents	O
as	O
well	O
as	O
modulating	O
apoptosis	O
-	O
and	O
inflammation	O
-related	O
proteins	O
expression	O
.	O

We	O
also	O
explored	O
the	O
protective	O
effects	O
of	O
quercetin	O
on	O
atherosclerosis	O
by	O
phosphatidylinositide	O
3-kinases	O
(	O
PI3K	O
)	O
/	O
Protein	O
kinase	O
B	O
(	O
AKT	O
)	O
-associated	O
Bcl-2	O
/	O
Caspase-3	O
and	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF-κB	O
)	O
signal	O
pathways	O
activation	O
,	O
promoting	O
AKT	O
and	O
Bcl-2	O
expression	O
and	O
reducing	O
Caspase-3	O
and	O
NF-κB	O
activation	O
.	O

Quercetin	O
reduced	O
the	O
atherosclerotic	O
plaque	O
size	O
in	O
vivo	O
in	O
high	O
fructose	O
feeding	O
-	O
induced	O
mice	O
assessed	O
by	O
oil	B-P
red	I-P
O	I-P
.	O

Also	O
,	O
in	O
vitro	O
experiments	O
,	O
quercetin	O
displayed	O
inhibitory	O
role	O
in	O
LPS	O
-	O
induced	O
ROS	O
production	O
,	O
inflammatory	O
response	O
and	O
apoptosis	O
,	O
which	O
were	O
linked	O
with	O
PI3K	O
/	O
AKT	O
-	O
regulated	O
Caspase-3	O
and	O
NF-κB	O
activation	O
.	O

In	O
conclusion	O
,	O
our	O
results	O
showed	O
that	O
quercetin	O
inhibited	O
atherosclerotic	O
plaque	O
development	O
in	O
high	O
fructose	O
feeding	O
mice	O
via	O
PI3K	O
/	O
AKT	O
activation	O
regulated	O
by	O
ROS	O
.	O

Impact	O
of	O
Abnormal	O
DNA	O
Methylation	O
of	O
Imprinted	O
Loci	O
on	O
Human	O
Spontaneous	O
Abortion	O
.	O

Currently	O
,	O
there	O
is	O
a	O
growing	O
concern	O
regarding	O
the	O
safety	O
of	O
assisted	O
reproductive	O
technology	O
(	O
ART	O
)	O
due	O
to	O
increased	O
risk	O
of	O
spontaneous	O
abortion	O
(	O
SA	O
)	O
and	O
imprinting	O
disorders	O
in	O
ART	O
-	O
conceived	O
offspring	O
.	O

Early	O
investigations	O
suggested	O
that	O
aberrant	O
genetic	O
imprinting	O
may	O
be	O
related	O
to	O
pregnancy	O
loss	O
;	O
however	O
,	O
few	O
studies	O
have	O
used	O
human	O
tissue	O
specimens	O
.	O

Here	O
the	O
DNA	O
methylation	O
patterns	O
of	O
3	O
imprinted	O
genes	O
,	O
including	O
maternally	O
inherited	O
GRB10	O
and	O
the	O
paternally	O
inherited	O
IGF2	O
and	O
PEG3	O
genes	O
,	O
were	O
evaluated	O
in	O
human	O
chorionic	O
villus	O
samples	O
by	O
pyrosequencing	B-P
and	O
bisulfite	O
sequencing	O
polymerase	O
chain	O
reaction	O
.	O

The	O
samples	O
were	O
divided	O
into	O
4	O
groups	O
:	O
(	O
1	O
)	O
SA	O
of	O
natural	O
conception	O
(	O
NC	O
;	O
n	O
=	O
84	O
)	O
,	O
(	O
2	O
)	O
induced	O
abortion	O
of	O
NC	O
(	O
n	O
=	O
94	O
)	O
,	O
(	O
3	O
)	O
SA	O
after	O
ART	O
(	O
n	O
=	O
73	O
)	O
,	O
and	O
(	O
4	O
)	O
fetal	O
reduction	O
after	O
ART	O
(	O
n	O
=	O
86	O
)	O
.	O

The	O
methylation	O
levels	O
and	O
the	O
percentages	O
of	O
abnormal	O
methylation	O
of	O
the	O
IGF2	O
,	O
GRB10	O
,	O
and	O
PEG3	O
genes	O
between	O
the	O
ART	O
group	O
and	O
the	O
NC	O
group	O
showed	O
no	O
significant	O
difference	O
.	O

Both	O
IGF2	O
and	O
GRB10	O
genes	O
showed	O
higher	O
methylation	O
levels	O
in	O
the	O
SA	O
group	O
compared	O
to	O
the	O
non-SA	O
group	O
.	O

Additionally	O
,	O
determining	O
the	O
single-nucleotide	O
polymorphisms	O
of	O
4	O
loci	O
,	O
including	O
IGF2	O
rs3741205	O
,	O
rs3741206	O
,	O
rs3741211	O
,	O
and	O
GRB10	O
rs2237457	O
,	O
showed	O
that	O
the	O
TC+CC	O
genotype	O
of	O
IGF2	O
rs3741211	O
had	O
a	O
1.91-fold	O
increased	O
risk	O
of	O
SA	O
after	O
ART	O
.	O

However	O
,	O
there	O
was	O
no	O
association	O
between	O
the	O
mutant	O
genotype	O
of	O
IGF2	O
rs3741211	O
and	O
the	O
methylation	O
levels	O
of	O
IGF2	O
and	O
H19	O
,	O
and	O
ART	O
might	O
not	O
affect	O
the	O
distribution	O
of	O
the	O
abovementioned	O
genotypes	O
.	O

It	O
provides	O
support	O
for	O
the	O
opinion	O
that	O
genetic	O
imprinting	O
defects	O
may	O
be	O
associated	O
with	O
SA	O
,	O
which	O
might	O
not	O
be	O
due	O
to	O
ART	O
treatments	O
.	O

Anterior	O
single	O
implants	O
with	O
different	O
neck	O
designs	O
:	O
5	O
Year	O
results	O
of	O
a	O
randomized	O
clinical	O
trial	O
.	O

The	O
design	O
of	O
the	O
implant	O
neck	O
might	O
be	O
significant	O
for	O
preservation	B-P
of	O
marginal	O
bone	O
.	O

To	O
compare	O
the	O
5-year	O
radiographic	O
and	O
clinical	O
outcome	O
of	O
single	O
anterior	O
implants	O
provided	O
with	O
a	O
smooth	O
neck	O
,	O
a	O
rough	O
neck	O
or	O
a	O
scalloped	O
rough	O
neck	O
.	O

93	O
Patients	O
with	O
a	O
missing	O
anterior	O
tooth	O
in	O
the	O
maxilla	O
were	O
included	O
.	O

At	O
random	O
,	O
patients	O
received	O
an	O
implant	O
with	O
a	O
1.5	O
mm	O
smooth	O
neck	O
(	O
``	O
smooth	O
group	O
``	O
)	O
,	O
a	O
rough	O
neck	O
with	O
grooves	O
(	O
``	O
rough	O
group	O
``	O
)	O
or	O
a	O
scalloped	O
rough	O
neck	O
with	O
grooves	O
(	O
``	O
scalloped	O
group	O
``	O
)	O
.	O

Implants	O
were	O
installed	O
in	O
healed	O
sites	O
.	O

Follow-up	O
visits	O
were	O
conducted	O
after	O
final	O
crown	O
delivery	O
and	O
1	O
year	O
and	O
5	O
years	O
later	O
.	O

Scalloped	O
implants	O
showed	O
significantly	O
more	O
initial	O
marginal	O
bone	O
resorption	O
.	O

The	O
total	O
amount	O
of	O
bone	O
loss	O
was	O
1.26	O
±	O
0.90	O
mm	O
in	O
the	O
smooth	O
group	O
,	O
1.20	O
±	O
1.1	O
mm	O
in	O
the	O
rough	O
group	O
and	O
2.28	O
±	O
0.97	O
mm	O
in	O
the	O
scalloped	O
group	O
(	O
P	O
<	O
.05	O
)	O
.	O

Survival	O
rates	O
were	O
96.2	O
%	O
for	O
the	O
smooth	O
and	O
scalloped	O
group	O
and	O
100	O
%	O
for	O
the	O
rough	O
group	O
.	O

Scalloped	O
implants	O
showed	O
deeper	O
pocket	O
depths	O
,	O
more	O
bleeding	O
and	O
more	O
technical	O
complications	O
.	O

There	O
were	O
no	O
differences	O
in	O
esthetic	O
outcome	O
nor	O
in	O
patient	O
satisfaction	O
.	O

For	O
anterior	O
single	O
tooth	O
replacements	O
,	O
scalloped	O
implants	O
show	O
less	O
favorable	O
radiographic	O
and	O
clinical	O
outcome	O
compared	O
to	O
regular	O
implants	O
with	O
a	O
smooth	O
neck	O
or	O
rough	O
neck	O
.	O

How	O
do	O
wettability	O
,	O
zeta	O
potential	O
and	O
hydroxylation	O
degree	O
affect	O
the	O
biological	O
response	O
of	O
biomaterials	O
?	O
.	O

It	O
is	O
well	O
known	O
that	O
composition	O
,	O
electric	O
charge	O
,	O
wettability	O
and	O
roughness	O
of	O
implant	O
surfaces	O
have	O
great	O
influence	O
on	O
their	O
interaction	O
with	O
the	O
biological	O
fluids	O
and	O
tissues	O
,	O
but	O
systematic	O
studies	O
of	O
different	O
materials	O
in	O
the	O
same	O
experimental	O
conditions	O
are	O
still	O
lacking	O
in	O
the	O
scientific	O
literature	O
.	O

The	O
aim	O
of	O
this	O
research	O
is	O
to	O
investigate	O
the	O
correlations	O
between	O
some	O
surface	O
characteristics	O
(	O
wettability	O
,	O
zeta	O
potential	O
and	O
hydroxylation	O
degree	O
)	O
and	O
the	O
biological	O
response	O
(	O
protein	O
adsorption	O
,	O
blood	O
wettability	O
,	O
cell	O
and	O
bacterial	O
adhesion	O
)	O
to	O
some	O
model	O
biomaterials	O
.	O

The	O
resulting	O
knowledge	O
can	O
be	O
applied	O
for	O
the	O
development	O
of	O
future	O
innovative	O
surfaces	O
for	O
implantable	O
biomaterials	O
.	O

Roughness	O
was	O
not	O
considered	O
as	O
a	O
variable	O
because	O
it	O
is	O
a	O
widely	O
explored	O
feature	O
:	O
smooth	O
surfaces	O
prepared	O
by	O
a	O
controlled	O
protocol	O
were	O
compared	O
in	O
order	O
to	O
have	O
no	O
roughness	O
effects	O
.	O

Three	O
oxides	O
(	O
ZrO2	O
,	O
Al2O3	O
,	O
SiO2	O
)	O
,	O
three	O
metals	O
(	O
316LSS	O
steel	O
,	O
Ti	O
,	O
Nb	O
)	O
and	O
two	O
polymers	O
(	O
corona	O
treated	O
polystyrene	O
for	O
cell	B-P
culture	I-P
and	O
untreated	O
polystyrene	O
for	O
bacteria	B-P
culture	I-P
)	O
,	O
widely	O
used	O
for	O
biomedical	O
applications	O
,	O
were	O
considered	O
.	O

The	O
surfaces	O
were	O
characterized	O
by	O
contact	O
profilometry	O
,	O
SEM	B-P
-	O
EDS	B-P
,	O
XPS	B-P
,	O
FTIR	O
,	O
zeta	O
potential	O
and	O
wettability	O
with	O
different	O
fluids	O
.	O

Protein	O
adsorption	O
,	O
blood	O
wettability	O
,	O
bacterial	O
and	O
cell	O
adhesion	O
were	O
evaluated	O
in	O
order	O
to	O
investigate	O
the	O
correlations	O
between	O
the	O
surface	O
physiochemical	O
properties	O
and	O
biological	O
responses	O
.	O

From	O
a	O
methodological	O
standpoint	O
,	O
XPS	B-P
and	O
electrokinetic	O
measurements	O
emerged	O
as	O
the	O
more	O
suitable	O
techniques	O
respectively	O
for	O
the	O
evaluation	O
of	O
hydroxylation	O
degree	O
and	O
surface	O
charge	O
/	O
isoelectric	O
point	O
.	O

Moreover	O
,	O
determination	O
of	O
wettability	O
by	O
blood	O
appeared	O
a	O
specific	O
and	O
crucial	O
test	O
,	O
the	O
results	O
of	O
which	O
are	O
not	O
easily	O
predictable	O
by	O
using	O
other	O
type	O
of	O
tests	O
.	O

Hydroxylation	O
degree	O
resulted	O
correlated	O
to	O
the	O
wettability	O
by	O
water	O
,	O
but	O
not	O
directly	O
to	O
surface	O
charge	O
.	O

Wetting	O
tests	O
with	O
different	O
media	O
showed	O
the	O
possibility	O
to	O
highlight	O
some	O
differences	O
among	O
look-alike	O
materials	O
.	O

A	O
dependence	O
of	O
protein	O
absorption	O
on	O
hydroxylation	O
degree	O
,	O
charge	O
and	O
wettability	O
was	O
evidenced	O
and	O
its	O
maximum	O
was	O
registered	O
for	O
surfaces	O
with	O
low	O
wettability	O
in	O
both	O
water	O
based	O
and	O
protein	O
containing	O
media	O
and	O
a	O
moderate	O
surface	O
charge	O
.	O

As	O
far	O
as	O
bacterial	O
adhesion	O
is	O
concerned	O
,	O
no	O
effect	O
of	O
surface	O
charge	O
or	O
protein	O
adsorption	O
was	O
evidenced	O
,	O
while	O
the	O
presence	O
of	O
a	O
high	O
acid	O
component	O
of	O
the	O
surface	O
energy	O
appeared	O
significant	O
.	O

Finally	O
,	O
the	O
combination	O
of	O
hydroxylation	O
degree	O
,	O
wettability	O
,	O
surface	O
charge	O
and	O
energy	O
(	O
polar	O
component	O
)	O
emerged	O
as	O
a	O
key	O
parameter	O
for	O
cell	O
adhesion	O
and	O
viability	O
.	O

Immunoassays	B-P
for	O
riboflavin	O
and	O
flavin	O
mononucleotide	O
using	O
antibodies	O
specific	O
to	O
d-ribitol	O
and	O
d-ribitol-5-phosphate	O
.	O

Riboflavin	O
(	O
vitamin	O
B2	O
)	O
,	O
a	O
water-soluble	O
vitamin	O
,	O
plays	O
a	O
key	O
role	O
in	O
maintaining	O
human	O
health	O
.	O

Though	O
,	O
numerous	O
methods	O
have	O
been	O
reported	O
for	O
the	O
determination	B-P
of	O
total	B-P
riboflavin	I-P
(	I-P
TRF	I-P
)	I-P
content	I-P
in	O
foods	O
and	O
biological	O
samples	O
,	O
very	O
few	O
methods	O
are	O
reported	O
for	O
quantifying	O
riboflavin	O
and	O
its	O
coenzymes	O
[	O
flavin	O
mononucleotide	O
(	O
FMN	O
)	O
;	O
flavin	O
adenine	O
dinucleotide	O
(	O
FAD	O
)	O
]	O
individually	O
.	O

Recently	O
,	O
we	O
have	O
demonstrated	O
that	O
antibodies	O
specific	O
to	O
d-ribitol	O
and	O
d-ribitol-5-phosphate	O
also	O
recognize	O
riboflavin	O
and	O
FMN	O
,	O
respectively	O
,	O
and	O
not	O
vice-versa	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
evaluated	O
these	O
two	O
antibodies	O
for	O
the	O
analysis	O
of	O
riboflavin	O
and	O
FMN	O
by	O
indirect	O
competitive	O
ELISA	B-P
(	O
icELISA	B-P
)	O
in	O
selected	O
foods	O
and	O
pharmaceuticals	O
.	O

Under	O
the	O
optimal	O
assay	B-P
conditions	O
,	O
50	O
%	O
inhibition	O
concentration	O
(	O
IC50	O
)	O
and	O
limit	O
of	O
detection	O
(	O
LOD	O
,	O
IC10	O
)	O
were	O
3.41ng/mL	O
and	O
0.02ng/mL	O
for	O
riboflavin	O
,	O
and	O
7.84ng/mL	O
and	O
0.24ng/mL	O
for	O
FMN	O
,	O
respectively	O
,	O
with	O
detectable	O
concentration	O
range	O
between	O
0.1	O
and	O
100ng	O
of	O
analytes	O
and	O
<	O
0.1	O
%	O
cross-reactivity	O
with	O
other	O
water-soluble	O
vitamins	O
.	O

The	O
amounts	O
of	O
TRF	O
in	O
food	O
samples	O
,	O
as	O
analyzed	O
by	O
icELISA	B-P
using	O
ribitol	O
antibody	O
,	O
were	O
90-95	O
%	O
of	O
the	O
reported	O
values	O
in	O
the	O
literature	O
or	O
label	O
values	O
.	O

Quantification	O
of	O
individual	O
flavins	O
(	O
riboflavin	O
and	O
FMN	O
)	O
from	O
the	O
same	O
food	O
samples	O
showed	O
variation	O
in	O
their	O
values	O
compared	O
to	O
TRF	O
,	O
and	O
were	O
in	O
good	O
agreement	O
with	O
values	O
obtained	O
from	O
HPLC	B-P
and	O
AOAC	B-P
methods	O
.	O

Further	O
,	O
spiking	O
and	O
recovery	O
analysis	O
of	O
food	O
samples	O
and	O
pharmaceuticals	O
showed	O
no	O
significant	O
matrix	O
effects	O
.	O

The	O
immunoassays	B-P
were	O
validated	O
in	O
terms	O
of	O
accuracy	O
and	O
precision	O
using	O
inter-	B-P
and	O
intra-assays	B-P
.	O

The	O
immunoassays	B-P
developed	O
in	O
this	O
study	O
are	O
sensitive	O
and	O
appears	O
feasible	O
for	O
screening	O
a	O
large	O
number	O
of	O
samples	O
in	O
the	O
quantification	O
of	O
riboflavin	O
and	O
FMN	O
in	O
various	O
biological	O
samples	O
,	O
pharmaceuticals	O
and	O
natural	O
/	O
processed	O
foods	O
.	O

Neutrophil	O
gelatinase-associated	O
lipocalin	O
in	O
a	O
triphasic	O
rat	O
model	O
of	O
adenine	O
-	O
induced	O
kidney	O
injury	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
whether	O
NGAL	O
,	O
given	O
its	O
advantages	O
over	O
traditional	O
biomarkers	O
,	O
can	O
be	O
used	O
to	O
describe	O
the	O
dynamic	O
characteristics	O
of	O
the	O
renal	O
tubulointerstitial	O
insult	O
caused	O
by	O
adenine	O
.	O

Subsequently	O
,	O
it	O
will	O
be	O
possible	O
to	O
assess	O
NGAL	O
as	O
a	O
biomarker	O
of	O
any	O
acute	O
kidney	O
injury	O
,	O
on	O
top	O
of	O
chronic	O
interstitial	O
disease	O
,	O
if	O
NGAL	O
levels	O
are	O
stable	O
through	O
the	O
chronic	O
phase	O
of	O
our	O
adenine	O
model	O
.	O

Study	O
group	O
rats	O
were	O
fed	O
an	O
adenine	O
diet	O
,	O
and	O
control	O
group	O
rats	O
were	O
fed	O
a	O
regular	O
diet	O
only	O
.	O

Blood	O
and	O
urine	O
samples	O
for	O
urea	O
,	O
creatinine	O
and	O
NGAL	O
were	O
drawn	O
from	O
each	O
rat	O
at	O
the	O
beginning	O
of	O
the	O
study	O
and	O
after	O
1	O
,	O
3	O
,	O
4	O
,	O
5	O
,	O
6	O
,	O
7	O
and	O
8	O
weeks	O
.	O

Kidney	O
slices	O
from	O
these	O
rats	O
were	O
stained	B-P
with	O
Hematoxylin-eosin	B-P
(	O
HE	B-P
)	O
and	O
β-actin	O
stainings	B-P
.	O

Serum	O
urea	O
,	O
creatinine	B-P
and	O
NGAL	O
levels	O
and	O
urinary	O
NGAL/creatinine	O
ratio	O
in	O
the	O
study	O
group	O
were	O
higher	O
than	O
baseline	O
and	O
than	O
in	O
the	O
control	O
group	O
;	O
these	O
differences	O
were	O
statistically	O
significant	O
in	O
some	O
of	O
the	O
intervals	O
.	O

Tubulointerstitial	O
changes	O
and	O
adenine	O
crystals	O
were	O
evident	O
in	O
the	O
study	O
group	O
rats	O
.	O

In	O
the	O
rats	O
fed	O
adenine	O
,	O
serum	O
urea	O
,	O
creatinine	B-P
and	O
NGAL	O
levels	O
and	O
urinary	O
NGAL/creatinine	O
ratio	O
followed	O
a	O
triphasic	O
pattern	O
of	O
kidney	O
injury	O
:	O
an	O
acute	O
phase	O
while	O
on	O
the	O
adenine	O
diet	O
,	O
a	O
partial	O
recovery	O
phase	O
after	O
switching	O
to	O
the	O
regular	O
diet	O
and	O
a	O
chronic	O
kidney	O
disease	O
phase	O
after	O
stabilization	O
of	O
renal	O
function	O
.	O

NGAL	O
can	O
serve	O
a	O
biomarker	O
for	O
acute	O
kidney	O
injury	O
and	O
possibly	O
for	O
chronic	O
kidney	O
disease	O
in	O
the	O
tubulointerstitial	O
rat	O
model	O
.	O

Prevalence	O
of	O
high-risk	O
human	O
papillomavirus	O
infection	O
among	O
women	O
in	O
Shaanxi	O
province	O
of	O
China	O
:	O
A	O
hospital	O
-based	O
investigation	O
.	O

This	O
study	O
aimed	O
to	O
investigate	O
the	O
characteristics	O
of	O
female	O
high-risk	O
human	O
papillomavirus	O
(	O
HR-HPV	O
)	O
infection	O
in	O
Shaanxi	O
province	O
of	O
China	O
.	O

A	O
total	O
of	O
14	O
111	O
women	O
were	O
enrolled	O
for	O
HPV	O
genotyping	B-P
test	I-P
,	O
and	O
a	O
cytology	B-P
,	O
and/or	O
cervix	B-P
biopsy	I-P
were	O
performed	O
in	O
partial	O
women	O
.	O

Of	O
these	O
women	O
,	O
the	O
HPV	O
infection	O
rate	O
was	O
30.21	O
%	O
,	O
and	O
26.73	O
%	O
were	O
caused	O
by	O
HR-HPV	O
.	O

The	O
most	O
common	O
HR-HPV	O
genotypes	O
were	O
HPV-16	O
,	O
HPV-58	O
,	O
HPV-52	O
,	O
HPV-18	O
,	O
and	O
HPV-31	O
.	O

The	O
prevalence	O
of	O
HR-HPV	O
among	O
women	O
older	O
than	O
50	O
years	O
was	O
significantly	O
higher	O
than	O
the	O
other	O
groups	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
main	O
carcinogenic	O
genotypes	O
were	O
HPV-16	O
,	O
HPV-18	O
,	O
HPV-58	O
,	O
HPV-52	O
,	O
and	O
HPV-31	O
.	O

HPV-16	O
and	O
HPV-18	O
combined	O
caused	O
80.79	O
%	O
of	O
cervical	O
cancer	O
cases	O
.	O

The	O
infection	O
with	O
multiple	O
HR-HPVs	O
was	O
not	O
a	O
risk	O
factor	O
for	O
cervical	O
lesions	O
.	O

In	O
conclusion	O
,	O
HPV	O
infection	O
was	O
common	O
among	O
women	O
in	O
Shaanxi	O
province	O
.	O

Women	O
older	O
than	O
50	O
years	O
were	O
a	O
high-risk	O
group	O
for	O
HR-HPV	O
infection	O
and	O
cervical	O
cancer	O
.	O

HPV-16	O
and	O
HPV-18	O
were	O
the	O
main	O
carcinogenic	O
genotypes	O
in	O
this	O
region	O
.	O

Response	O
of	O
microbial	O
communities	O
colonizing	O
salt	O
marsh	O
plants	O
rhizosphere	O
to	O
copper	O
oxide	O
nanoparticles	O
contamination	O
and	O
its	O
implications	O
for	O
phytoremediation	O
processes	O
.	O

This	O
study	O
aimed	O
to	O
investigate	O
Cu	O
oxide	O
nanoparticles	O
(	O
CuO	O
NP	O
)	O
effect	O
on	O
microbial	O
communities	O
associated	O
with	O
salt	O
marsh	O
plants	O
(	O
Halimione	O
portulacoides	O
and	O
Pragmites	O
australis	O
)	O
rhizosphere	O
and	O
its	O
implications	O
for	O
phytoremediation	O
processes	O
.	O

Experiments	O
were	O
conducted	O
,	O
under	O
controlled	O
conditions	O
,	O
over	O
one	O
week	O
.	O

Rhizosediment	O
soaked	O
in	O
the	O
respective	O
elutriate	O
(	O
a	O
simplified	O
natural	O
medium	O
)	O
with	O
or	O
without	O
plants	O
,	O
was	O
doped	O
with	O
CuO	O
NP	O
or	O
with	O
Cu	O
in	O
ionic	O
form	O
.	O

Microbial	O
community	O
in	O
rhizosediments	O
was	O
characterized	O
in	O
terms	O
of	O
abundance	O
(	O
by	O
DAPI	O
)	O
and	O
structure	O
(	O
by	O
ARISA	O
)	O
.	O

Metal	O
uptake	O
by	O
plants	O
was	O
evaluated	O
by	O
measuring	O
Cu	O
in	O
plant	O
tissues	O
(	O
by	O
atomic	B-P
absorption	I-P
spectroscopy	I-P
)	O
.	O

Results	O
revealed	O
significant	O
metal	O
uptake	O
but	O
only	O
in	O
plant	O
roots	O
,	O
which	O
was	O
significantly	O
lower	O
(	O
H.	O
portulacoides	O
)	O
or	O
not	O
significant	O
(	O
P.	O
australis	O
)	O
when	O
the	O
metal	O
was	O
in	O
NP	O
form	O
.	O

Microbial	O
community	O
structure	O
was	O
significantly	O
changed	O
by	O
the	O
treatment	O
(	O
absence	O
/	O
presence	O
of	O
Cu	O
,	O
ionic	O
Cu	O
or	O
CuO	O
NP	O
)	O
as	O
showed	O
by	O
multivariate	O
analysis	O
of	O
ARISA	O
profiles	O
and	O
confirmed	O
by	O
analysis	O
of	O
similarities	O
(	O
Global	O
test	O
-	O
one	O
way	O
ANOSIM	O
)	O
.	O

Moreover	O
,	O
in	O
P.	O
australis	O
rhizosediments	O
microbial	O
abundance	O
,	O
bacterial	O
richness	O
and	O
diversity	O
indexes	O
were	O
significantly	O
affected	O
(	O
increased	O
or	O
decreased	O
)	O
due	O
to	O
metal	O
presence	O
whereas	O
in	O
H.	O
portulacoides	O
rhizosediment	O
microbial	O
abundance	O
showed	O
a	O
significant	O
decrease	O
,	O
particularly	O
when	O
the	O
metal	O
was	O
in	O
NP	O
form	O
.	O

Accordingly	O
,	O
Cu	O
presence	O
affected	O
the	O
response	O
of	O
the	O
rhizosphere	O
microbial	O
community	O
and	O
in	O
some	O
cases	O
that	O
response	O
was	O
significantly	O
different	O
when	O
Cu	O
was	O
in	O
NP	O
form	O
.	O

The	O
response	O
of	O
the	O
microbial	O
communities	O
to	O
Cu	O
NP	O
might	O
also	O
contribute	O
to	O
the	O
lower	O
metal	O
accumulation	O
by	O
plants	O
when	O
the	O
metal	O
was	O
in	O
this	O
form	O
.	O

So	O
,	O
Cu	O
NP	O
may	O
cause	O
disturbances	O
in	O
ecosystems	O
functions	O
,	O
ultimately	O
affecting	O
phytoremediation	O
processes	O
.	O

These	O
facts	O
should	O
be	O
considered	O
regarding	O
the	O
use	O
of	O
appropriate	O
salt	O
marshes	O
plants	O
to	O
remediate	O
moderately	O
impacted	O
areas	O
such	O
as	O
estuaries	O
,	O
where	O
NPs	O
can	O
be	O
found	O
.	O

Associations	O
between	O
human	O
breast	O
milk	O
hormones	O
and	O
adipocytokines	O
and	O
infant	O
growth	O
and	O
body	O
composition	O
in	O
the	O
first	O
6	O
months	O
of	O
life	O
.	O

Much	O
is	O
to	O
be	O
learnt	O
about	O
human	O
breast	O
milk	O
(	O
HBM	O
)	O
.	O

The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
extend	O
our	O
knowledge	O
of	O
HBM	O
by	O
investigating	O
the	O
role	O
of	O
maternal	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
,	O
sex	O
and	O
stage	O
of	O
lactation	O
(	O
month	O
1	O
vs.	O
6	O
)	O
on	O
HBM	O
insulin	O
,	O
glucose	O
,	O
leptin	O
,	O
IL-6	O
and	O
TNF-α	O
and	O
their	O
associations	O
with	O
infant	O
body	O
composition	O
.	O

Thirty-seven	O
exclusively	O
breastfeeding	O
infants	O
(	O
n	O
=	O
37	O
;	O
16♀	O
,	O
21♂	O
)	O
,	O
and	O
their	O
mothers	O
(	O
19-47	O
kg	O
m	O
(	O
-2	O
)	O
)	O
were	O
studied	O
at	O
1	O
and	O
6	O
months	O
of	O
lactation	O
.	O

Infants	O
had	O
body	O
composition	O
measured	O
(	O
using	O
dual-energy	B-P
X-ray	I-P
absorptiometry	I-P
)	O
and	O
HBM	O
collected	O
.	O

A	O
significant	O
interaction	O
between	O
maternal	O
BMI	O
and	O
infant	O
sex	O
on	O
insulin	B-P
levels	I-P
(	O
p	O
=	O
0.0322	O
)	O
was	O
observed	O
such	O
that	O
insulin	O
was	O
229	O
%	O
higher	O
in	O
obese	O
mothers	O
nursing	O
female	O
infants	O
than	O
in	O
normal	O
weight	O
mothers	O
nursing	O
female	O
infants	O
and	O
179	O
%	O
higher	O
than	O
obese	O
mothers	O
nursing	O
male	O
infants	O
.	O

For	O
leptin	O
,	O
a	O
significant	O
association	O
with	O
BMI	O
category	O
was	O
observed	O
(	O
p	O
<	O
0.0001	O
)	O
such	O
that	O
overweight	O
and	O
obese	O
mothers	O
had	O
96.5	O
%	O
and	O
315.1	O
%	O
higher	O
leptin	O
levels	O
than	O
normal	O
weight	O
mothers	O
,	O
respectively	O
.	O

Leptin	O
was	O
also	O
found	O
to	O
have	O
a	O
significant	O
(	O
p	O
=	O
0.0004	O
)	O
33.7	O
%	O
decrease	O
from	O
months	O
1	O
to	O
6	O
,	O
controlling	O
for	O
BMI	O
category	O
and	O
sex	O
.	O

A	O
significant	O
inverse	O
relationship	O
between	O
month	O
1	O
leptin	O
levels	O
and	O
infant	O
length	O
(	O
p	O
=	O
0.0257	O
)	O
,	O
percent	O
fat	O
(	O
p	O
=	O
0.0223	O
)	O
,	O
total	O
fat	O
mass	O
(	O
p	O
=	O
0.0226	O
)	O
and	O
trunk	O
fat	O
mass	O
(	O
p	O
=	O
0.0111	O
)	O
at	O
month	O
6	O
was	O
also	O
found	O
.	O

No	O
associations	O
or	O
interactions	O
were	O
observed	O
for	O
glucose	O
,	O
TNF-α	O
or	O
IL-6	O
.	O

These	O
data	O
demonstrate	O
that	O
maternal	O
BMI	O
,	O
infant	O
sex	O
and	O
stage	O
of	O
lactation	O
affect	O
the	O
compositional	O
make-up	O
of	O
insulin	O
and	O
leptin	O
.	O

Evaluation	O
of	O
Spontaneous	O
Bone	O
Regeneration	O
after	O
Enucleation	O
of	O
Large	O
Cysts	O
of	O
the	O
Jaws	O
using	O
Radiographic	O
Computed	B-P
Software	O
.	O

Spontaneous	O
regeneration	O
of	O
bone	O
is	O
commonly	O
seen	O
in	O
the	O
small	O
surgical	O
defects	O
caused	O
by	O
enucleation	O
of	O
cysts	O
.	O

However	O
,	O
in	O
case	O
of	O
large	O
surgical	O
defects	O
caused	O
by	O
the	O
enucleation	O
,	O
spontaneous	O
regeneration	O
of	O
bone	O
is	O
a	O
rare	O
phenomenon	O
and	O
it	O
depends	O
on	O
factors	O
,	O
such	O
as	O
age	O
of	O
the	O
patient	O
,	O
intact	O
periosteum	O
,	O
and	O
proper	O
stabilization	O
.	O

The	O
study	O
included	O
16	O
patients	O
,	O
who	O
reported	O
to	O
the	O
department	O
of	O
oral	O
and	O
maxillofacial	O
surgery	O
with	O
the	O
complaint	O
of	O
pain	O
and	O
swelling	O
in	O
the	O
jaws	O
diagnosed	O
as	O
cyst	O
.	O

The	O
sample	O
included	O
equal	O
numbers	O
of	O
male	O
and	O
female	O
subjects	O
aged	O
between	O
15	O
and	O
40	O
years	O
.	O

Panoramic	B-P
radiographs	I-P
were	O
taken	O
pre-	O
and	O
postoperatively	O
on	O
day	O
2	O
of	O
the	O
enucleation	O
.	O

The	O
dimensions	O
of	O
the	O
cyst	O
were	O
evaluated	O
on	O
the	O
radiograph	B-P
according	O
to	O
the	O
proforma	O
.	O

Subsequent	O
radiographs	B-P
were	O
taken	O
at	O
regular	O
intervals	O
of	O
1.5	O
,	O
3	O
,	O
and	O
6	O
months	O
using	O
standard	O
parameters	O
and	O
were	O
analyzed	O
using	O
MCID™	O
analysis	O
software	O
of	O
imaging	B-P
research	I-P
.	O

Mean	O
reduction	O
was	O
seen	O
in	O
up	O
to	O
39	O
and	O
60	O
%	O
in	O
the	O
cystic	O
cavity	O
size	O
and	O
increase	O
in	O
the	O
mean	O
density	O
up	O
to	O
59	O
and	O
90.2	O
%	O
at	O
3	O
and	O
6	O
months	O
intervals	O
respectively	O
.	O

Spontaneous	O
bone	O
regeneration	O
was	O
seen	O
even	O
after	O
primary	O
closure	O
of	O
the	O
large	O
cystic	O
defect	O
without	O
the	O
need	O
for	O
placement	O
of	O
foreign	O
substances	O
or	O
grafts	O
and	O
it	O
also	O
eliminated	O
the	O
complications	O
resulting	O
from	O
placement	O
of	O
foreign	O
substance	O
.	O

Further	O
studies	O
are	O
required	O
in	O
a	O
larger	O
sample	O
with	O
longer	O
follow-up	O
durations	O
to	O
confirm	O
the	O
outcome	O
of	O
the	O
present	O
work	O
for	O
the	O
benefit	O
of	O
patients	O
.	O

The	O
present	O
study	O
depicted	O
that	O
spontaneous	O
bone	O
regeneration	O
can	O
occur	O
with	O
accepted	O
results	O
after	O
simple	O
enucleation	O
of	O
jaw	O
cyst	O
without	O
the	O
aid	O
of	O
any	O
graft	O
material	O
.	O

Hence	O
,	O
simple	O
enucleation	O
may	O
be	O
considered	O
as	O
a	O
first	O
line	O
of	O
treatment	O
modality	O
for	O
cystic	O
lesion	O
of	O
the	O
jaws	O
.	O

This	O
simplifies	O
the	O
surgical	O
procedure	O
,	O
decreases	O
the	O
economic	O
and	O
biologic	O
costs	O
,	O
and	O
reduces	O
the	O
risk	O
of	O
postoperative	O
complications	O
.	O

Follow-up	O
is	O
necessary	O
along	O
with	O
patient	O
's	O
compliance	O
for	O
the	O
success	O
of	O
treatment	O
.	O

Utilization	O
and	O
Outcomes	O
of	O
Sentinel	B-P
Lymph	I-P
Node	I-P
Biopsy	I-P
for	O
Vulvar	O
Cancer	O
.	O

To	O
examine	O
the	O
use	O
and	O
predictors	O
of	O
sentinel	B-P
node	I-P
biopsy	I-P
in	O
women	O
with	O
vulvar	O
cancer	O
.	O

The	O
Perspective	O
database	O
,	O
an	O
all-payer	O
database	O
that	O
collects	O
data	O
from	O
more	O
than	O
500	O
hospitals	O
,	O
was	O
used	O
to	O
perform	O
a	O
retrospective	O
cohort	O
study	O
of	O
women	O
with	O
vulvar	O
cancer	O
who	O
underwent	O
vulvectomy	O
and	O
lymph	B-P
node	I-P
assessment	I-P
from	O
2006	O
to	O
2015	O
.	O

Multivariable	O
models	O
were	O
used	O
to	O
determine	O
factors	O
associated	O
with	O
sentinel	B-P
node	I-P
biopsy	I-P
.	O

Length	O
of	O
stay	O
and	O
cost	O
were	O
compared	O
between	O
women	O
who	O
underwent	O
sentinel	B-P
node	I-P
biopsy	I-P
and	O
lymphadenectomy	O
.	O

Among	O
2,273	O
women	O
,	O
sentinel	B-P
node	I-P
biopsy	I-P
was	O
utilized	O
in	O
618	O
(	O
27.2	O
%	O
)	O
and	O
1,655	O
(	O
72.8	O
%	O
)	O
underwent	O
inguinofemoral	O
lymphadenectomy	O
.	O

Performance	O
of	O
sentinel	B-P
node	I-P
biopsy	I-P
increased	O
from	O
17.0	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
12.0-22.0	O
%	O
)	O
in	O
2006	O
to	O
39.1	O
%	O
(	O
95	O
%	O
CI	O
27.1-51.0	O
%	O
)	O
in	O
2015	O
.	O

In	O
a	O
multivariable	O
model	O
,	O
women	O
treated	O
more	O
recently	O
were	O
more	O
likely	O
to	O
have	O
undergone	O
sentinel	B-P
node	I-P
biopsy	I-P
,	O
whereas	O
women	O
with	O
more	O
comorbidities	O
and	O
those	O
treated	O
at	O
rural	O
hospitals	O
were	O
less	O
likely	O
to	O
have	O
undergone	O
the	O
procedure	B-P
.	O

The	O
median	O
length	O
of	O
stay	O
was	O
shorter	O
for	O
those	O
undergoing	O
sentinel	B-P
node	I-P
biopsy	I-P
(	O
median	O
2	O
days	O
,	O
interquartile	O
range	O
1-3	O
)	O
compared	O
with	O
women	O
who	O
underwent	O
inguinofemoral	O
lymphadenectomy	O
(	O
median	O
3	O
days	O
,	O
interquartile	O
range	O
2-4	O
)	O
.	O

The	O
cost	O
of	O
sentinel	B-P
node	I-P
biopsy	I-P
was	O
$	O
7,599	O
(	O
interquartile	O
range	O
$	O
5,739-9,922	O
)	O
compared	O
with	O
$	O
8,095	O
(	O
interquartile	O
range	O
$	O
5,917-11,281	O
)	O
for	O
lymphadenectomy	O
.	O

The	O
use	O
of	O
sentinel	B-P
node	I-P
biopsy	I-P
for	O
vulvar	O
cancer	O
has	O
more	O
than	O
doubled	O
since	O
2006	O
.	O

Sentinel	B-P
lymph	I-P
node	I-P
biopsy	I-P
is	O
associated	O
with	O
a	O
shorter	O
hospital	O
stay	O
and	O
decreased	O
cost	O
compared	O
with	O
inguinofemoral	O
lymphadenectomy	O
.	O

The	O
Therapeutic	O
Effect	O
of	O
Berberine	O
in	O
the	O
Treatment	O
of	O
Nonalcoholic	O
Fatty	O
Liver	O
Disease	O
:	O
A	O
Meta-Analysis	O
.	O

Aim	O
.	O

To	O
assess	O
the	O
efficacy	O
of	O
berberine	O
in	O
the	O
treatment	O
of	O
nonalcoholic	O
fatty	O
liver	O
disease	O
through	O
meta-analysis	O
.	O

Method	O
.	O

We	O
searched	O
Embase	O
,	O
Pubmed	O
,	O
Cochrane	O
Library	O
,	O
and	O
so	O
forth	O
,	O
until	O
March	O
2016	O
for	O
randomized	O
controlled	O
trials	O
using	O
berberine	O
to	O
treat	O
NAFLD	O
.	O

Result	O
.	O

Six	O
randomized	O
controlled	O
trials	O
involving	O
501	O
patients	O
were	O
included	O
in	O
this	O
study	O
.	O

The	O
results	O
showed	O
that	O
the	O
efficacy	O
of	O
reducing	O
TC	O
,	O
LDL	O
,	O
ALT	O
,	O
2hPG	O
,	O
and	O
HbA1c	O
in	O
NAFLD	O
patients	O
of	O
the	O
berberine	O
group	O
were	O
significantly	O
higher	O
than	O
that	O
of	O
control	O
group	O
.	O

The	O
subgroup	O
analyses	O
on	O
TG	O
,	O
AST	O
,	O
and	O
FBG	B-P
indicated	O
that	O
treatment	O
combined	O
with	O
berberine	O
decreased	O
TG	O
level	O
in	O
NAFLD	O
patients	O
significantly	O
.	O

Compared	O
with	O
other	O
drugs	O
,	O
berberine	O
alone	O
decreased	O
TG	O
level	O
in	O
NAFLD	O
patients	O
significantly	O
.	O

We	O
also	O
conducted	O
a	O
descriptive	O
analysis	O
on	O
insulin	O
resistance	O
and	O
radiography	B-P
results	O
that	O
berberine	O
can	O
improve	O
NAFLD	O
patients	O
'	O
insulin	O
resistance	O
and	O
fatty	O
liver	O
.	O

Conclusion	O
.	O

According	O
to	O
analysis	O
result	O
,	O
berberine	O
has	O
positive	O
efficacy	O
on	O
blood	O
lipids	O
,	O
blood	O
glucose	O
,	O
liver	O
function	O
,	O
insulin	O
resistance	O
,	O
and	O
fatty	O
liver	O
condition	O
of	O
NAFLD	O
patients	O
.	O

However	O
,	O
due	O
to	O
the	O
limitation	O
of	O
number	O
and	O
quality	O
of	O
trials	O
included	O
,	O
more	O
clinical	O
randomized	O
controlled	O
trials	O
with	O
high	O
quality	O
are	O
needed	O
for	O
further	O
verification	O
of	O
the	O
efficacy	O
of	O
berberine	O
on	O
NAFLD	O
patients	O
.	O

The	O
clinical	O
and	O
economic	O
burden	O
of	O
significant	O
bleeding	O
during	O
lung	O
resection	O
surgery	O
:	O
A	O
retrospective	O
matched	O
cohort	O
analysis	O
of	O
real	O
-	O
world	O
data	O
.	O

The	O
objective	O
of	O
this	O
retrospective	O
study	O
was	O
to	O
quantify	O
the	O
clinical	O
and	O
economic	O
burden	O
of	O
significant	O
bleeding	O
in	O
lung	O
resection	O
surgery	O
in	O
the	O
US	O
.	O

This	O
study	O
utilized	O
2009-2012	O
data	O
from	O
the	O
Premier	O
Perspective	O
Database	O
(	O
TM	O
)	O
.	O

Adult	O
patients	O
with	O
primary	O
pulmonary	O
lobectomy	O
or	O
segmentectomy	O
procedures	O
were	O
categorized	O
by	O
the	O
surgical	O
approach	O
(	O
VATS	O
vs	O
open	O
)	O
and	O
primary	O
diagnosis	O
(	O
primary	B-P
or	O
metastatic	B-P
lung	I-P
cancer	I-P
vs	O
non-lung	B-P
cancer	I-P
)	O
.	O

Patients	O
requiring	O
≥3	O
units	O
of	O
blood	O
products	O
with	O
at	O
least	O
1	O
unit	O
of	O
PRBCs	O
:	O
``	O
significant	O
bleeding	O
``	O
cohort	O
;	O
those	O
requiring	O
<	O
3	O
units	O
:	O
``	O
non-significant	O
bleeding	O
``	O
cohort	O
;	O
and	O
those	O
not	O
requiring	O
blood	O
products	O
:	O
``	O
no	O
bleeding	O
``	O
cohort	O
.	O

A	O
matched	O
cohort	O
analysis	O
was	O
performed	O
between	O
the	O
``	O
significant	O
bleeding	O
``	O
and	O
the	O
``	O
no	O
bleeding	O
cohort	O
``	O
using	O
matching	O
variables	O
:	O
hospital	O
,	O
lung	B-P
cancer	I-P
diagnosis	I-P
,	O
year	O
of	O
surgery	O
,	O
APR-DRG	O
severity	O
score	O
,	O
procedure	O
type	O
and	O
approach	O
,	O
age	O
,	O
and	O
gender	O
.	O

The	O
``	O
All	O
-	O
patient	O
``	O
cohort	O
comprised	O
21,429	O
patients	O
:	O
213	O
``	O
significant	O
bleeding	O
``	O
;	O
2,780	O
``	O
non-significant	O
bleeding	O
``	O
;	O
and	O
18,436	O
``	O
no	O
bleeding	O
``	O
.	O

Overall	O
incidence	O
of	O
significant	O
chest	O
bleeding	O
was	O
0.99	O
%	O
.	O

Patients	O
from	O
``	O
significant	O
bleeding	O
``	O
cohort	O
and	O
``	O
non-significant	O
bleeding	O
``	O
cohort	O
had	O
2.5	O
days	O
and	O
2	O
days	O
(	O
p	O
<	O
0.0001	O
)	O
longer	O
length	O
of	O
stay	O
in	O
the	O
hospital	O
compared	O
to	O
those	O
in	O
the	O
``	O
no	O
bleeding	O
``	O
cohort	O
,	O
respectively	O
.	O

Overall	O
,	O
hospital	O
costs	O
for	O
``	O
significant	O
bleeding	O
``	O
cohort	O
were	O
higher	O
than	O
``	O
no	O
bleeding	O
``	O
cohort	O
for	O
those	O
who	O
were	O
covered	O
under	O
Medicare	O
(	O
$	O
59,871	O
vs	O
$	O
23,641	O
)	O
,	O
were	O
≥76	O
years	O
of	O
age	O
(	O
$	O
64,010	O
vs	O
$	O
24,243	O
)	O
,	O
had	O
greater	O
severity	O
of	O
illness	O
(	O
$	O
97,813	O
vs	O
$	O
51,871	O
)	O
and	O
underwent	O
open	O
segmentectomy	O
(	O
$	O
74,220	O
vs	O
$	O
21,903	O
)	O
.	O

Hospital	O
costs	O
for	O
``	O
significant	O
bleeding	O
``	O
cohort	O
and	O
``	O
non-significant	O
bleeding	O
``	O
were	O
significantly	O
higher	O
(	O
$	O
11,589	O
and	O
$	O
5,280	O
,	O
respectively	O
,	O
p	O
<	O
0.0001	O
)	O
than	O
no	O
bleeding	O
cohort	O
.	O

Although	O
significant	O
bleeding	O
during	O
lung	O
resection	O
surgery	O
is	O
rare	O
,	O
patients	O
with	O
such	O
complication	O
could	O
stay	O
longer	O
at	O
the	O
hospital	O
and	O
cost	O
an	O
average	O
of	O
$	O
13,103	O
more	O
than	O
those	O
without	O
.	O

Global	O
Strategy	O
for	O
the	O
Diagnosis	O
,	O
Management	O
,	O
and	O
Prevention	O
of	O
Chronic	O
Obstructive	O
Lung	O
Disease	O
2017	O
Report	O
.	O

GOLD	O
Executive	O
Summary	O
.	O

This	O
Executive	O
Summary	O
of	O
the	O
Global	O
Strategy	O
for	O
the	O
Diagnosis	O
,	O
Management	O
,	O
and	O
Prevention	O
of	O
COPD	O
,	O
Global	O
Initiative	O
for	O
Chronic	O
Obstructive	O
Lung	O
Disease	O
(	O
GOLD	O
)	O
2017	O
report	O
focuses	O
primarily	O
on	O
the	O
revised	O
and	O
novel	O
parts	O
of	O
the	O
document	O
.	O

The	O
most	O
significant	O
changes	O
include	O
:	O
(	O
1	O
)	O
the	O
assessment	O
of	O
chronic	O
obstructive	O
pulmonary	O
disease	O
has	O
been	O
refined	O
to	O
separate	O
the	O
spirometric	B-P
assessment	I-P
from	O
symptom	O
evaluation	O
.	O

ABCD	O
groups	O
are	O
now	O
proposed	O
to	O
be	O
derived	O
exclusively	O
from	O
patient	O
symptoms	O
and	O
their	O
history	O
of	O
exacerbations	O
;	O
(	O
2	O
)	O
for	O
each	O
of	O
the	O
groups	O
A	O
to	O
D	O
,	O
escalation	O
strategies	O
for	O
pharmacologic	O
treatments	O
are	O
proposed	O
;	O
(	O
3	O
)	O
the	O
concept	O
of	O
deescalation	O
of	O
therapy	O
is	O
introduced	O
in	O
the	O
treatment	O
assessment	O
scheme	O
;	O
(	O
4	O
)	O
nonpharmacologic	O
therapies	O
are	O
comprehensively	O
presented	O
;	O
and	O
(	O
5	O
)	O
the	O
importance	O
of	O
comorbid	O
conditions	O
in	O
managing	O
chronic	O
obstructive	O
pulmonary	O
disease	O
is	O
reviewed	O
.	O

Clinical	O
and	O
angiographic	B-P
correlation	O
of	O
high-sensitivity	O
C-reactive	O
protein	O
with	O
acute	O
ST	O
elevation	O
myocardial	O
infarction	O
.	O

Vascular	O
inflammation	O
and	O
associated	O
ongoing	O
inflammatory	O
responses	O
are	O
considered	O
as	O
the	O
critical	O
culprits	O
in	O
the	O
pathogenesis	O
of	O
acute	O
atherothrombotic	O
events	O
such	O
as	O
acute	O
coronary	O
syndrome	O
(	O
ACS	O
)	O
and	O
myocardial	O
infarction	O
(	O
MI	O
)	O
.	O

ST	O
segment	O
elevation	O
myocardial	O
infarction	O
(	O
STEMI	O
)	O
is	O
considered	O
as	O
one	O
of	O
the	O
prominent	O
clinical	O
forms	O
of	O
ACS	O
.	O

Moreover	O
,	O
C-reactive	O
protein	O
(	O
CRP	O
)	O
is	O
an	O
important	O
acute	O
phase	O
prsotein	O
,	O
which	O
may	O
be	O
estimated	O
using	O
high-sensitivity	B-P
methods	I-P
(	O
hs-CRP	B-P
)	O
,	O
and	O
its	O
elevated	O
level	O
in	O
body	O
fluids	O
reflects	O
chronic	O
inflammatory	O
status	O
.	O

The	O
circulating	O
hs-CRP	B-P
level	O
has	O
been	O
proposed	O
as	O
a	O
promising	O
inflammatory	O
marker	O
of	O
coronary	O
artery	O
disease	O
(	O
CAD	O
)	O
.	O

The	O
present	O
study	O
investigated	O
the	O
correlation	O
of	O
hs-CRP	B-P
level	O
with	O
clinical	O
and	O
angiographic	B-P
features	O
of	O
STEMI	O
,	O
various	O
other	O
traditional	O
risk	O
factors	O
,	O
complications	O
of	O
myocardial	O
infarction	O
and	O
angiographically	O
significant	O
CAD	O
.	O

Out	O
of	O
190	O
patients	O
with	O
STEMI	O
that	O
were	O
analyzed	O
,	O
the	O
interval	O
between	O
symptom	O
onset	O
and	O
reperfusion	O
therapy	O
(	O
window	O
period	O
)	O
varied	O
from	O
0.5	O
to	O
24	O
h.	O
The	O
hs-CRP	B-P
value	O
was	O
found	O
to	O
be	O
higher	O
in	O
non-diabetic	O
patients	O
(	O
0.61	O
mg/dl	O
)	O
compared	O
with	O
diabetic	O
patients	O
(	O
0.87	O
mg/dl	O
)	O
.	O

Moreover	O
,	O
a	O
significant	O
correlation	O
between	O
hs-CRP	B-P
and	O
hs-troponin	B-P
T	I-P
was	O
also	O
recorded	O
(	O
P	O
<	O
0.001	O
)	O
.	O

However	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
mean	O
hs-CRP	B-P
values	O
in	O
patients	O
with	O
or	O
without	O
mortality	O
.	O

It	O
is	O
considered	O
that	O
the	O
present	O
study	O
will	O
increase	O
the	O
understanding	O
of	O
atherosclerosis	O
in	O
general	O
and	O
may	O
also	O
have	O
clinical	O
applications	O
in	O
the	O
targeting	O
of	O
therapy	O
for	O
this	O
harmful	O
disease	O
.	O

The	O
prognostic	O
value	O
of	O
cytotoxic	O
T-lymphocyte	O
antigen	O
4	O
in	O
cancers	O
:	O
a	O
systematic	O
review	O
and	O
meta-analysis	O
.	O

The	O
outcomes	O
of	O
studies	O
analyzing	O
the	O
prognostic	O
role	O
of	O
CTLA-4	O
in	O
cancers	O
are	O
controversial	O
.	O

Therefore	O
,	O
the	O
aim	O
of	O
our	O
meta-analysis	O
was	O
to	O
clarify	O
the	O
correlation	O
between	O
CTLA-4	O
expression	O
and	O
OS	O
in	O
different	O
cancer	O
cases	O
.	O

Relevant	O
literature	O
was	O
searched	O
using	O
PubMed	O
,	O
EMBASE	O
,	O
Web	O
of	O
Science	O
,	O
and	O
the	O
Cochrane	O
Library	O
.	O

The	O
clinicopathological	O
features	O
,	O
hazard	O
ratio	O
(	O
HR	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
CI	O
)	O
were	O
collected	O
from	O
these	O
studies	O
and	O
were	O
analyzed	O
using	O
Stata	O
version	O
12.0	O
software	O
.	O

The	O
pooled	O
HR	O
values	O
showed	O
no	O
significant	O
correlation	O
between	O
CTLA-4	O
expression	O
levels	O
and	O
OS	O
in	O
relation	O
to	O
tumors	O
(	O
HR	O
:	O
1.24	O
,	O
95	O
%	O
CI	O
:	O
0.98-1.56	O
,	O
I2	O
=	O
71.7	O
%	O
,	O
P	O
=	O
0.000	O
)	O
.	O

Further	O
subgroup	O
analyses	O
were	O
conducted	O
and	O
categorized	O
by	O
experimental	O
methods	O
,	O
CTLA-4	O
sources	O
and	O
cancer	O
types	O
.	O

The	O
survey	O
showed	O
a	O
significant	O
correlation	O
(	O
HR	O
:	O
1.47	O
,	O
95	O
%	O
CI	O
:	O
1.14-1.89	O
)	O
between	O
high	O
expression	O
of	O
CTLA-4	O
and	O
OS	O
in	O
the	O
SNP	O
subgroup	O
,	O
and	O
subgroups	O
analyzing	O
by	O
PCR	O
(	O
HR	O
:	O
1.50	O
,	O
95	O
%	O
CI	O
:	O
1.20-1.86	O
)	O
and	O
flow	B-P
cytometry	I-P
(	O
HR	O
:	O
2.76	O
,	O
95	O
%	O
CI	O
:	O
1.49-5.14	O
)	O
.	O

In	O
addition	O
,	O
our	O
analysis	O
observed	O
significant	O
differences	O
between	O
patients	O
and	O
controls	O
in	O
in	O
CTLA-4+	O
CD4+	O
lymphocytes	O
,	O
sur	O
CTLA-4+	O
CD4+	O
lymphocytes	O
,	O
in	O
CTLA-4+	O
CD8+	O
lymphocytes	O
,	O
and	O
sur	O
CTLA-4+	O
CD8+	O
lymphocytes	O
.	O

Knowledge	O
of	O
the	O
effects	O
of	O
CTLA-4	O
could	O
potentially	O
be	O
used	O
to	O
effectively	O
guide	O
appropriate	O
prognosis	O
and	O
therapeutic	O
strategies	O
in	O
cancer	O
patients	O
.	O

Directed	O
Functional	O
Networks	O
in	O
Alzheimer	O
's	O
Disease	O
:	O
Disruption	O
of	O
Global	O
and	O
Local	O
Connectivity	O
Measures	O
.	O

Techniques	O
available	O
in	O
graph	O
theory	O
can	O
be	O
applied	O
to	O
signals	O
recorded	O
from	O
human	O
brain	O
.	O

In	O
network	O
analysis	O
of	O
EEG	B-P
signals	O
,	O
the	O
individual	O
nodes	O
are	O
EEG	B-P
sensor	O
locations	O
and	O
the	O
edges	O
correspond	O
to	O
functional	O
relations	O
between	O
them	O
that	O
are	O
extracted	O
from	O
EEG	B-P
time	O
series	O
.	O

In	O
this	O
work	O
,	O
we	O
study	O
EEG	B-P
-based	O
directed	O
functional	O
networks	O
in	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O

To	O
this	O
end	O
,	O
directed	O
connectivity	O
matrices	O
of	O
25	O
AD	O
patients	O
and	O
26	O
healthy	O
subjects	O
are	O
processed	O
and	O
a	O
number	O
of	O
neurophysiologically	O
meaningful	O
graph	O
theory	O
metrics	O
are	O
studied	O
.	O

Our	O
data	O
show	O
that	O
functional	O
networks	O
of	O
AD	O
brains	O
have	O
significantly	O
reduced	O
global	O
connectivity	O
in	O
alpha	O
and	O
beta	O
bands	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
AD	O
brains	O
have	O
significantly	O
higher	O
local	O
connectivity	O
than	O
healthy	O
controls	O
in	O
alpha	O
and	O
beta	O
bands	O
.	O

This	O
decreased	O
profile	O
in	O
global	O
connectivity	O
can	O
be	O
linked	O
to	O
compensatory	O
increased	O
local	O
connectivity	O
as	O
a	O
result	O
of	O
widespread	O
decline	O
in	O
the	O
long-range	O
connections	O
.	O

We	O
also	O
study	O
resiliency	O
of	O
brain	O
networks	O
against	O
targeted	O
attack	O
to	O
hub	O
nodes	O
and	O
find	O
that	O
AD	O
networks	O
are	O
less	O
resilient	O
than	O
healthy	O
brains	O
in	O
alpha	O
and	O
beta	O
bands	O
.	O

High	O
molecular	O
weight	O
PEGylation	O
of	O
human	O
pancreatic	O
polypeptide	O
at	O
position	O
22	O
improves	O
stability	O
and	O
reduces	O
food	O
intake	O
in	O
mice	O
.	O

Human	O
pancreatic	O
polypeptide	O
(	O
hPP	O
)	O
is	O
known	O
to	O
suppress	O
appetite	O
and	O
food	O
intake	O
,	O
thereby	O
representing	O
a	O
potential	O
therapeutic	O
approach	O
against	O
obesity	O
and	O
associated	O
metabolic	O
disorders	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
improve	O
hPP	O
stability	O
by	O
covalent	O
PEGylation	O
with	O
diverse	O
molecular	O
weight	O
polyethylene	O
glycols	O
(	O
PEGs	O
)	O
at	O
two	O
positions	O
using	O
promising	O
lead	O
structures	O
while	O
maintaining	O
target	O
activity	O
.	O

Modified	O
peptides	O
were	O
synthesized	O
by	O
combined	O
solid-phase	O
and	O
solution-phase	O
peptide	O
synthesis	O
.	O

Their	O
potency	O
was	O
investigated	O
in	O
constitutively	O
expressing	O
human	O
epithelial	O
cells	O
and	O
isolated	O
human	O
colonic	O
mucosa	O
as	O
well	O
as	O
receptor-transfected	O
artificial	O
cell	O
lines	O
.	O

Human	O
blood	O
plasma	O
and	O
porcine	O
liver	O
homogenates	O
were	O
used	O
to	O
examine	O
the	O
in	O
vitro	O
stability	O
of	O
the	O
analogues	O
.	O

The	O
most	O
promising	O
variants	O
were	O
injected	O
s.c.	O
in	O
C57BL/6JRj	O
mice	O
to	O
monitor	O
fasting-induced	O
food	O
intake	O
and	O
bioavailability	O
.	O

In	O
human	O
epithelia	O
and	O
colonic	O
mucosal	O
preparations	O
,	O
activity	O
of	O
the	O
modified	O
hPP	O
peptides	O
depended	O
on	O
the	O
core	O
sequence	O
and	O
latency	O
of	O
the	O
peptides	O
was	O
related	O
to	O
PEG	O
size	O
.	O

Peptides	O
modified	O
with	O
a	O
22	O
kDa	O
PEG	O
(	O
PEG22	O
)	O
remained	O
intact	O
in	O
blood	O
plasma	O
and	O
on	O
incubation	B-P
with	O
liver	O
homogenates	O
for	O
more	O
than	O
96	O
h.	O
Finally	O
,	O
hPP2-36	O
,	O
[	O
K	O
(	O
22	O
)	O
(	O
PEG22	O
)	O
]	O
hPP2-36	O
and	O
[	O
K	O
(	O
22	O
)	O
(	O
PEG22	O
)	O
,	O
Q	O
(	O
34	O
)	O
]	O
hPP	O
significantly	O
reduced	O
cumulative	O
food	O
intake	O
in	O
mice	O
over	O
16	O
h	O
after	O
s.c.	O
administration	O
.	O

Modification	O
with	O
PEG22	O
at	O
position	O
22	O
stabilizes	O
hPP	O
significantly	O
while	O
extending	O
its	O
biological	O
activities	O
and	O
could	O
be	O
used	O
in	O
drug	O
development	O
prospectively	O
.	O

Systems	O
Toxicology	O
:	O
Real	O
World	O
Applications	O
and	O
Opportunities	O
.	O

Systems	O
Toxicology	O
aims	O
to	O
change	O
the	O
basis	O
of	O
how	O
adverse	O
biological	O
effects	O
of	O
xenobiotics	O
are	O
characterized	O
from	O
empirical	O
end	O
points	O
to	O
describing	O
modes	O
of	O
action	O
as	O
adverse	O
outcome	O
pathways	O
and	O
perturbed	O
networks	O
.	O

Toward	O
this	O
aim	O
,	O
Systems	O
Toxicology	O
entails	O
the	O
integration	O
of	O
in	O
vitro	O
and	O
in	O
vivo	O
toxicity	O
data	O
with	O
computational	O
modeling	O
.	O

This	O
evolving	O
approach	O
depends	O
critically	O
on	O
data	O
reliability	O
and	O
relevance	O
,	O
which	O
in	O
turn	O
depends	O
on	O
the	O
quality	O
of	O
experimental	O
models	O
and	O
bioanalysis	O
techniques	O
used	O
to	O
generate	O
toxicological	O
data	O
.	O

Systems	O
Toxicology	O
involves	O
the	O
use	O
of	O
large-scale	O
data	O
streams	O
(	O
``	O
big	O
data	O
``	O
)	O
,	O
such	O
as	O
those	O
derived	O
from	O
omics	O
measurements	O
that	O
require	O
computational	O
means	O
for	O
obtaining	O
informative	O
results	O
.	O

Thus	O
,	O
integrative	O
analysis	O
of	O
multiple	O
molecular	O
measurements	O
,	O
particularly	O
acquired	O
by	O
omics	B-P
strategies	I-P
,	O
is	O
a	O
key	O
approach	O
in	O
Systems	O
Toxicology	O
.	O

In	O
recent	O
years	O
,	O
there	O
have	O
been	O
significant	O
advances	O
centered	O
on	O
in	O
vitro	O
test	O
systems	O
and	O
bioanalytical	B-P
strategies	I-P
,	O
yet	O
a	O
frontier	O
challenge	O
concerns	O
linking	O
observed	O
network	O
perturbations	O
to	O
phenotypes	O
,	O
which	O
will	O
require	O
understanding	O
pathways	O
and	O
networks	O
that	O
give	O
rise	O
to	O
adverse	O
responses	O
.	O

This	O
summary	O
perspective	O
from	O
a	O
2016	O
Systems	O
Toxicology	O
meeting	O
,	O
an	O
international	O
conference	O
held	O
in	O
the	O
Alps	O
of	O
Switzerland	O
,	O
describes	O
the	O
limitations	O
and	O
opportunities	O
of	O
selected	O
emerging	O
applications	O
in	O
this	O
rapidly	O
advancing	O
field	O
.	O

Systems	O
Toxicology	O
aims	O
to	O
change	O
the	O
basis	O
of	O
how	O
adverse	O
biological	O
effects	O
of	O
xenobiotics	O
are	O
characterized	O
,	O
from	O
empirical	O
end	O
points	O
to	O
pathways	O
of	O
toxicity	O
.	O

This	O
requires	O
the	O
integration	O
of	O
in	O
vitro	O
and	O
in	O
vivo	O
data	O
with	O
computational	O
modeling	O
.	O

Test	O
systems	O
and	O
bioanalytical	B-P
technologies	I-P
have	O
made	O
significant	O
advances	O
,	O
but	O
ensuring	O
data	O
reliability	O
and	O
relevance	O
is	O
an	O
ongoing	O
concern	O
.	O

The	O
major	O
challenge	O
facing	O
the	O
new	O
pathway	O
approach	O
is	O
determining	O
how	O
to	O
link	O
observed	O
network	O
perturbations	O
to	O
phenotypic	O
toxicity	O
.	O

Synthesis	O
,	O
EGFR	O
inhibition	O
and	O
anti-cancer	O
activity	O
of	O
new	O
3,6-dimethyl-1-phenyl-4-	O
(	O
substituted-methoxy	O
)	O
pyrazolo	O
[	O
3,4-d	O
]	O
pyrimidine	O
derivatives	O
.	O

A	O
new	O
series	O
of	O
hybrid	O
pyrazolo	O
[	O
3,4-d	O
]	O
pyrimidine	O
scaffold	O
with	O
a	O
heteroaryl	O
moiety	O
as	O
pyrazole	O
,	O
oxadiazole	O
,	O
triazole	O
or	O
phthalimide	O
moiety	O
(	O
14a-f	O
,	O
16	O
,	O
17	O
,	O
19	O
,	O
20	O
)	O
was	O
synthesized	O
and	O
biologically	O
evaluated	O
for	O
the	O
cytotoxicity	O
against	O
human	O
liver	O
cancer	O
cell	O
line	O
(	O
HEPG-2	O
)	O
,	O
human	O
breast	O
cancer	O
cell	O
line	O
(	O
MCF-7	O
)	O
and	O
human	O
colon	O
cancer	O
cell	O
line	O
(	O
HCT-116	O
)	O
.	O

While	O
the	O
pyrazolo	O
hybrid	O
compounds	O
(	O
14a-f	O
)	O
showed	O
good	O
activity	O
against	O
HEPG-2	O
,	O
MCF-7	O
and	O
HCT-116	O
cell	O
lines	O
(	O
IC50	O
=	O
3.65	O
-	O
39.98	O
,	O
1.45	O
-	O
54.19	O
and	O
2.00	O
-	O
50.6	O
µM	O
respectively	O
)	O
in	O
comparison	O
with	O
doxorubicin	O
(	O
IC50	O
=	O
5.66	O
,	O
2.60	O
and	O
8.48	O
µM	O
respectively	O
)	O
,	O
the	O
triazolo	O
derivatives	O
(	O
17	O
,	O
19	O
)	O
showed	O
considerable	O
potency	O
(	O
IC50	O
=	O
22.20	O
-	O
54.61	O
,	O
14.98	O
-	O
88.78	O
,	O
and	O
10.79	O
-	O
53.40	O
µM	O
respectively	O
)	O
,	O
the	O
oxadiazolo	O
hybrid	O
compound	O
(	O
16	O
,	O
IC50	O
=	O
149.91	O
,	O
115.89	O
and	O
110.07	O
µM	O
respectively	O
)	O
and	O
phthalimido	O
hybrid	O
compound	O
(	O
20	O
,	O
IC50	O
=	O
96.02	O
,	O
131.19	O
and	O
120.36	O
µM	O
respectively	O
)	O
showed	O
low	O
potency	O
.	O

The	O
pyrazolo	O
derivative	O
(	O
14d	O
,	O
IC50	O
=	O
3.65	O
,	O
1.45	O
and	O
2.00	O
µM	O
)	O
was	O
the	O
most	O
potent	O
among	O
all	O
compounds	O
against	O
HEPG-2	O
,	O
MCF-7	O
and	O
HCT-116	O
cell	O
lines	O
respectively	O
.	O

Also	O
,	O
the	O
hybrid	O
pyrazolo	O
[	O
3,4-d	O
]	O
pyrimidine	O
derivatives	O
were	O
evaluated	O
for	O
their	O
inhibitory	O
activity	O
to	O
epidermal	O
growth	O
factor	O
receptor	O
tyrosine	O
kinase	O
(	O
EGFR-TK	O
)	O
and	O
they	O
showed	O
a	O
good	O
inhibitory	O
activity	O
(	O
IC50	O
=	O
8.27	O
-	O
19.03	O
µM	O
)	O
.	O

With	O
the	O
exception	O
of	O
the	O
pyrazolo	O
derivative	O
(	O
14c	O
,	O
IC50	O
=	O
18.82	O
µM	O
)	O
,	O
the	O
inhibitory	O
activity	O
against	O
EGFR-TK	O
was	O
consistent	O
with	O
the	O
in	O
vitro	O
cytotoxic	O
activity	O
against	O
HEPG-2	O
,	O
MCF-7	O
and	O
HCT-116	O
cell	O
lines	O
.	O

Moreover	O
,	O
molecular	O
docking	O
studies	O
were	O
performed	O
and	O
the	O
results	O
were	O
in	O
agreement	O
with	O
that	O
obtained	O
from	O
the	O
in	O
vitro	O
inhibition	B-P
assays	I-P
.	O

Extract	O
of	O
Caulis	O
Spatholobi	O
,	O
a	O
novel	O
blocker	O
targeting	O
tumor	O
cell	O
‑induced	O
platelet	O
aggregation	O
,	O
inhibits	O
breast	O
cancer	O
metastasis	O
.	O

Metastasis	O
of	O
breast	O
cancer	O
is	O
the	O
vital	O
step	O
for	O
malignant	O
progression	O
.	O

During	O
such	O
a	O
process	O
,	O
hematogenous	O
metastasis	O
is	O
an	O
indispensable	O
approach	O
for	O
the	O
dissemination	O
of	O
cancer	O
cells	O
.	O

A	O
platelet	O
,	O
contributes	O
to	O
hypercoagulable	O
state	O
,	O
and	O
is	O
also	O
identified	O
the	O
crucial	O
factor	O
in	O
the	O
coagulation	O
system	O
for	O
supporting	O
metastasis	O
.	O

Therefore	O
,	O
the	O
relationship	O
of	O
a	O
platelet	O
and	O
a	O
tumor	O
cell	O
plays	O
a	O
critical	O
role	O
in	O
tumor	O
cell	O
metastasis	O
.	O

Consequently	O
,	O
inhibiting	O
tumor	O
cell	O
‑induced	O
platelet	O
aggregation	O
(	O
TCIPA	O
)	O
is	O
recongnized	O
as	O
a	O
crucial	O
target	O
on	O
suppression	O
of	O
tumor	O
metastasis	O
such	O
as	O
aspirin	O
(	O
ASA	O
)	O
.	O

Under	O
such	O
circumstance	O
,	O
here	O
we	O
report	O
that	O
,	O
through	O
dissociating	O
the	O
tumor‑platelet	O
(	O
T‑P	O
)	O
complex	O
,	O
80	O
%	O
ethanol	O
extracts	O
of	O
Caulis	O
Spatholobi	O
(	O
SET	O
)	O
successfully	O
alleviated	O
the	O
hypercoagulation	O
state	O
,	O
thereby	O
reducing	O
tumor	O
metastasis	O
and	O
improving	O
the	O
prospects	O
of	O
survival	O
in	O
breast	O
cancer	O
cell	O
model	O
.	O

Through	O
MTT	B-P
and	O
anti‑aggregation	B-P
assay	I-P
stimulated	I-P
by	I-P
ADP	I-P
,	O
we	O
detected	O
the	O
optimum	O
treatment	O
time	O
and	O
the	O
optimum	O
dose	O
of	O
SET	O
.	O

By	O
using	O
confocal	B-P
microscopy	I-P
,	O
we	O
observed	O
that	O
SET	O
can	O
strongly	O
block	O
the	O
formation	O
of	O
T‑P	O
complex	O
i	O
n	O
vitro	O
.	O

The	O
result	O
was	O
further	O
quantified	O
and	O
confirmed	O
by	O
the	O
FACS	B-P
analysis	I-P
.	O

The	O
fluorescent	O
value	O
of	O
T‑P	O
complex	O
was	O
obviously	O
decreased	O
in	O
the	O
drug‑treated	O
groups	O
.	O

In	O
vivo	O
,	O
4T1	O
cells	O
were	O
injected	O
through	O
the	O
mouse	O
tail	O
vein	O
for	O
dynamic	B-P
visualization	I-P
by	O
small	O
animal	O
imaging	O
system	O
.	O

The	O
metastatic	O
intensity	O
was	O
quantified	O
and	O
the	O
survival	O
curve	O
was	O
analyzed	O
.	O

Additionally	O
,	O
general	O
observation	O
and	O
hematoxylin	B-P
and	I-P
eosin	I-P
(	I-P
H	I-P
&	I-P
E	I-P
)	I-P
staining	I-P
of	O
lung	O
tissue	O
was	O
performed	O
.	O

SET	O
exerted	O
an	O
obvious	O
effect	O
on	O
the	O
inhibition	O
of	O
metastasis	O
and	O
increasing	O
the	O
survival	O
rate	O
of	O
mice	O
.	O

For	O
the	O
molecular	O
mechanism	O
study	O
of	O
anti‑TCIPA	B-P
,	O
zymography	O
and	O
R	O
T‑PCR	O
assay	O
preliminarily	O
revealed	O
the	O
molecular	O
mechanism	O
of	O
SET	O
in	O
the	O
regulation	O
of	O
P	O
‑T	O
interaction	O
.	O

Collectively	O
,	O
through	O
drug	O
efficacy	O
identification	O
and	O
pharmacological	O
revealing	O
,	O
we	O
have	O
obtained	O
a	O
promising	O
candidate	O
for	O
the	O
interference	O
of	O
breast	O
metastasis	O
by	O
suppressing	O
TCIPA	O
,	O
which	O
will	O
be	O
beneficial	O
for	O
clinical	O
cancer	O
treatment	O
.	O

The	O
Use	O
of	O
a	O
Software	O
-	O
Assisted	O
Method	O
to	O
Estimate	O
Fetal	O
Weight	O
at	O
and	O
Near	O
Term	O
Using	O
Magnetic	B-P
Resonance	I-P
Imaging	I-P
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
apply	O
a	O
semi-automated	O
calculation	O
method	O
of	O
fetal	O
body	O
volume	O
and	O
,	O
thus	O
,	O
of	O
magnetic	O
resonance-estimated	O
fetal	O
weight	O
(	O
MR-EFW	O
)	O
prior	O
to	O
planned	O
delivery	O
and	O
to	O
evaluate	O
whether	O
the	O
technique	O
of	O
measurement	O
could	O
be	O
simplified	O
while	O
remaining	O
accurate	O
.	O

MR-EFW	O
was	O
calculated	O
using	O
a	O
semi-automated	O
method	O
at	O
38.6	O
weeks	O
of	O
gestation	O
in	O
36	O
patients	O
and	O
compared	O
to	O
the	O
picture	O
archiving	O
and	O
communication	O
system	O
(	O
PACS	O
)	O
.	O

Per	O
patient	O
,	O
8	O
sequences	O
were	O
acquired	O
with	O
a	O
slice	O
thickness	O
of	O
4-8	O
mm	O
and	O
an	O
intersection	O
gap	O
of	O
0	O
,	O
4	O
,	O
8	O
,	O
12	O
,	O
16	O
,	O
or	O
20	O
mm	O
.	O

The	O
median	O
absolute	O
relative	O
errors	O
for	O
MR-EFW	O
and	O
the	O
time	O
of	O
planimetric	O
measurements	O
were	O
calculated	O
for	O
all	O
8	O
sequences	O
and	O
for	O
each	O
method	O
(	O
assisted	O
vs.	O
PACS	O
)	O
,	O
and	O
the	O
difference	O
between	O
the	O
methods	O
was	O
calculated	O
.	O

The	O
median	O
delivery	O
weight	O
was	O
3,280	O
g.	O
The	O
overall	O
median	O
relative	O
error	O
for	O
all	O
288	O
MR-EFW	O
calculations	O
was	O
2.4	O
%	O
using	O
the	O
semi-automated	O
method	O
and	O
2.2	O
%	O
for	O
the	O
PACS	O
method	O
.	O

Measurements	O
did	O
not	O
differ	O
between	O
the	O
8	O
sequences	O
using	O
the	O
assisted	O
method	O
(	O
p	O
=	O
0.313	O
)	O
or	O
the	O
PACS	O
(	O
p	O
=	O
0.118	O
)	O
,	O
while	O
the	O
time	O
of	O
planimetric	O
measurement	O
decreased	O
significantly	O
with	O
a	O
larger	O
gap	O
(	O
p	O
<	O
0.001	O
)	O
and	O
in	O
the	O
assisted	O
method	O
compared	O
to	O
the	O
PACS	O
method	O
(	O
p	O
<	O
0.01	O
)	O
.	O

Our	O
simplified	O
MR-EFW	O
measurement	O
showed	O
a	O
dramatic	O
decrease	O
in	O
time	O
of	O
planimetric	O
measurement	O
without	O
a	O
decrease	O
in	O
the	O
accuracy	O
of	O
weight	O
estimates	O
.	O

